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DNA methylation is a major form of epigenetic modification and involves the addition of a 
methyl group covalently to the 5-position of the cytosine pyrimidine ring, mostly within the 
context of CpG dinucleotides in vertebrate somatic cells. Methylation of CpG dinucleotides 
at promoter regions is generally associated with transcriptional repression. In this context, 
the methyl-CpG binding proteins (MeCPs) that are capable of recognition of methylated 
CpG dinucleotides are proposed to play a central role in DNA methylation associated 
transcriptional repression. Methyl-CpG binding domain protein 4 (MBD4) is an MeCP that 
possesses a glycosylase domain at its C-terminal, which can excise and repair both G:T and 
G:U mutations derived from DNA deamination at CpG dinucleotides, in addition to its N-
terminal MBD binding domain. MBD4 has been associated with a number of pathways 
including DNA repair, apoptosis, transcriptional repression, and possibly DNA 
demethylation processes. However, the precise contribution of MBD4 to these processes 
remains unclear.  
To explore the functional repertoire of MBD4 I decided to undertake multiple 
protein interaction studies to identify potential partner proteins. I performed yeast 2-hybrid 
screens with an 11.5 day mouse embryonic cDNA library and multiple mass spectrometry of 
immunoprecipitates of tagged versions of MBD4 that were over-expressed in human cell 
lines. I detected ~380 potential interacting candidates with these assays. A significant 
number of candidates were detected in both assay systems. Chosen candidates were further 
validated by reciprocal co-IP of expressed partners and by immunofluorescence (IF) 
microscopy to determine their potential co-localisation in mouse and human cell lines. 
Subsequently, I identified the intervening domain of MBD4 as a novel protein interaction 
region for tested candidates. My analysis suggests that MBD4 can have a role in regulation 
of post-replication methyl-error repair/methylation machinery through its direct interaction 
with DNMT1 (previously shown), UHRF1 (novel) and USP7 (novel), as well as possible 
cross-talk to histone modification and chromatin remodelling pathways, through partners 
such as PRMT5 and ACF1. Interestingly the transcription regulatory components KAP1 and 
CFP1 not only interact with but also dramatically influence the stability of exogenously 
expressed MBD4 in human cells. In general positive validation by IP and IF demonstrates 
the robustness of the initial screens, and implies that MBD4 may impact upon several 
transcriptional and epigenetic networks along with a number of nuclear pathways that 
include transcriptional repression, DNA repair and RNA processing.  
 v 
To test for transcriptional aberration in the absence of Mbd4 function I profiled two 
independent mouse cell lines that lack MBD4 activity using Illumina MouseWG-6 v2.0 
Expression BeadChip arrays. A number of genes were identified that are significantly up- or 
down- regulated in both Mbd4-/- MEFs. This included mis-expression of insulin-like growth 
factor-binding proteins and two paternally imprinted genes Dio3 and H19. The cohort of 
genes that were mis-expressed in the Mbd4-/- MEFs overlap with genes that responsed to 
tamoxifen exposure in an ER-positive ZR-75-1 xenograft model. In response to this 
observation I identified a potential interaction between MBD4 and estrogen receptor α (ERα) 
by co-IP and IF co-localisation. This suggests that MBD4 might potentiate transcription of 
estrogen regulated genes via a direct interaction with ERα, supporting a possible link 
between replication repair remodelling and steroid/thyroid hormone receptor transcriptional 
regulation. Additionally I performed a pathway analysis by which several developmental 
genes including Sox9, Klf2 and Klf4, were prioritised as possible MBD4 targets. On this 
basis I propose a role for MBD4 in acquired diseases such as cancers and autoimmune 
diseases via transcriptional regulation. 
I also performed a comparison of MBD4 DNA binding activity with MBD4 
homologues from the Medaka fish (Oryzias latipes) and the amphibian, Xenopus laevis. I 
could show that DNA binding specificity to a series of methylated and mismatched probes is 
conserved regardless of the poor sequence conservation of the MBD domain of MBD4 
between the species. I conclude that MBD4 is integrated in multiple pathways in the nucleus 
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One definition of Epigenetics is that it is concerned with alterations in phenotype caused by 
changes in cellular properties that are inherited but do not represent an alteration in 
genotype. In vertebrate somatic cells, epigenetic regulation of gene expression is thought to 
reinforce stable expression states at different loci (Jaenisch and Bird, 2003). These are 
associated with particular molecular signatures of DNA and chromatin modifications 
connected with active and repressed chromatin states (Barski et al., 2007). Epigenetic 
signatures such as DNA methylation are developmentally regulated and are thought to define 
comparable tissues and differentiation states (Baranzini et al., 2010). In cancer, as well as in 
embryos generated through somatic cell nuclear transfer, normal patterns of DNA 
methylation are altered (Sproul et al., 2011, Beaujean et al., 2004). These changes are 
thought to underlie the molecular pathology of these ‘disease’ states (Illingworth et al., 2010, 
Illingworth and Bird, 2009, Beaujean et al., 2004).  
This chapter begins by introducing the epigenetic mark of DNA methylation, and the 
machinery and the biological functions of DNA methylation in vertebrates. The methyl-CpG 
binding proteins act as interpreter of DNA methylation and the possible link between DNA 
methylation, repair and the other epigenetic mechanisms that synchronise the transcriptional 
repression events are then discussed. Finally, the methyl-CpG binding DNA repair 
glycosylase MBD4 (also known as MED1) is discussed in detail, with a brief introduction of 
the only other mammalian thymine glycosylase TDG. At the end of the chapter, the aims of 
the research presented in Chapters 3 to 6 are outlined briefly. 
 
1.2.	  	  DNA	  methylation	  
 
5-methyl-dexycytidine (5mC) was described in DNA as early as in 1925 from the tubercle 
bacillus (Johnson and Coghill, 1925), and two decades later in calf thymus DNA (Hotchkiss, 
1948). However, the biological function of this cytosine modification was not illuminated at 
the time. In 1975, two papers (Holliday and Pugh, 1975, Riggs, 1975) proposed 5mC as an 
important epigenetic modification that could influence gene expression and this change the 
scientific community’s view on the importance of this ‘fifth nucleotide’ in eukaryotic 
biology (Doerfler, 2006). Now DNA methylation is generally agreed as a typical epigenetic 
mark, as it satisfies the stringent criterion of an epigenetic system, ‘mitotically and 
meiotically heritable’ proposed by Riggs (1996) (Russo et al., 1996), which was redefined 
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from the original term defined by Waddington (Waddington, 1942). In prokaryotes, 
methylation at both adenine and cytosine residues were found as part of the host restriction 
system that serves to protect the prokaryotic cell from foreign genetic material especially for 
the bacterial genome (Bickle and Kruger, 1993). However, in multicellular eukaryotes, DNA 
methylation occurs predominately but not exclusively at cytosine residues within a CpG 
dinucleotide (Bestor, 2000). 
In mammals, a major form of epigenetic information is carried by DNA methylation, 
which comes in the forms of 5-methylcytosine (5mC) and the more recently discovered 5-
hydroxymethylcytosine (5hmC) (Tahiliani et al., 2009, Kriaucionis and Heintz, 2009) 
(Figure. 1.1). For 5mC, a methyl group is added covalently to the 5-position of cytosine by 
DNA cytosine methyltransferases (DNMTs), mostly within the context of CpG dinucleotides 
in mouse somatic cells; however, non-CpG methylation also occurs at a high frequency in 
mouse and human embryonic stem (ES) cells (Lister et al., 2009, Ramsahoye et al., 2000). 
Interestingly, non-CpG methylation seems to be a feature of the pluripotent state, as it is 
present in induced pluripotent stem cells (iPS) generated by transduction of a non-pluripotent 
somatic cell with stem cell-associated genes, which results in reprogramming of the recipient 
cell’s epigenetic profile (Lister et al., 2009). A recent discovery is the identification of a 
second modification in vertebrate DNA, 5-hydroxymethylcytosine (5hmC), in Purkinje 
neurons and embryonic stem cells (Tahiliani et al., 2009, Kriaucionis and Heintz, 2009). 
5hmC is formed by adding a hydroxy group to the methyl-cytosine, in a reaction mediated 
by the Tet (Ten Eleven Translocation) family of enzymes (Tahiliani et al., 2009, Iyer et al., 
2009) (Figure 1.1). Its importance in epigenetics is that the hydroxymethyl group is 
suggested to alter the biological properties of methylated DNA. It is noteworthy that the 
methyl groups of both thymine and 5mC are susceptible to oxidation with 5mC being 
slightly more reactive resulting in the generation of 5hmC (Burdzy et al., 2002). 5hmC also 
presents a new experimental problem, as conventional techniques (with the exception of a 
5hmC specific antibody), cannot distinguish between 5mC and 5hmC in DNA (Nestor et al., 
2010, Huang et al., 2010b). Until this apparent anomaly is properly resolved, there will be 
some uncertainty in existing DNA methylation databases. Recent technical developments 
can now distinguish prominent 5hmC sites in the genome (Song et al., 2011a, Nestor et al., 
2012). However, it is clear that 5hmC is less abundant than 5mC, and the latter is still the 
most prominent modification in vertebrate DNA in many tissues (Wu and Zhang, 2011). 
5mC values are stable at a typical value of around 4.5% of all cytosine in tissues, whereas 
5hmC values vary significantly (Munzel et al., 2010). This suggests that 5hmC has a specific 
function that is not absolutely correlated with 5mC levels; initial analysis suggests that 5hmC 
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is predominantly associated with the gene bodies of highly expressed genes (Song et al., 
2011a). The replacement of a 5mC residue with 5hmC can inhibit the binding of methyl-
CpG binding proteins (MECPs), interfering with their functional roles in transcription (Jin et 
al., 2010). Moreover, in acute myeloid leukemia (AML), inhibition of TET function is 
associated with hypermethylation of a fraction of CpG islands (Figueroa et al., 2010). 
 
 
Figure.	   1.1.	   The	   three	   major	   forms	   of	   cytosine	   bases	   in	   mammalian	   DNA.	   A	   methyl	  
group	   can	   be	   added	   covalently	   to	   the	   5-­‐position	   of	   cytosine	   by	   DNA	   cytosine	  
methyltransferases	  (DNMTs)	  with	  co-­‐factor	  S-­‐adenosyl	  methionine	  (SAM),	  resulting	  in	  
the	  5-­‐methyl-­‐cytosine,	  mostly	  within	  the	  context	  of	  CpG	  dinucleotides	  in	  somatic	  cells.	  
In	  addition,	  5-­‐hydroxymethyl-­‐cytosine	  (5hmC)	   is	   formed	  by	  adding	  a	  methyl	  group	  to	  
cytosine	   and	   subsequently	   a	   hydroxy	   group,	   in	   a	   reaction	  mediated	   by	   the	   Tet	   (Ten	  
Eleven	  Translocation)	  family	  of	  enzymes,	  α-­‐keto	  gluterate	  (αKG)	  dioxygenases.	  
 
 
1.3.	  	  DNA	  methylation	  machinery	  
 
The presence of DNA methylation at regulatory sequences in somatic cells is generally 
associated with transcriptional repression and potentially has a long term impact on the 
stability of gene expression and on genome stability (Sharma et al., 2010). In humans, 
alterations in genomic methylation patterns are involved in the etiology of imprinting 
syndromes such as Beckwith-Wiedemann, Prader-Willi and Angelman, and have been 
implicated in a number of other disease conditions, especially cancers (Goll and Bestor, 
2005). The presence of the methyl group to 5-position of the cytosine does not interfere with 
the Watson–Crick base paring of DNA, and this additional modification can be efficiently 
detected by DNA-interacting proteins (Jurkowska et al., 2010). In general, DNA methylation 
of the gene promoter region that is usually CG-rich results in the repression of the gene 
activity (Lister et al., 2009, Laurent et al., 2010, Zhang et al., 2009), while active genes 
usually correlate with hypomethylation around the regions of transcriptional start site (TSS) 
and high levels of methylation in the gene body (Lister et al., 2009, Laurent et al., 2010, 
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Zhang et al., 2009). In mammals, the enzymes responsible for targeting and maintaining 
global DNA methylation are constructed from a complex set of functional modules, broadly 
divided into the N-terminal ‘regulatory’ domain and the C-terminal ‘catalytic’ domain 
(Figure. 1.2). The regulatory domain functions largely as an interaction module, allowing 
multiple protein-protein interactions, DNA binding and nuclear localization (Goll and 
Bestor, 2005). Conversely, the C-terminal domain comprises ten motifs responsible for the 
enzyme’s catalytic activity; six of these motifs are conserved in nearly all cytosine 
methyltransferases across the evolutionary spectrum from bacteria to mammals (Figure. 1.2). 
Three methyltransferase enzymes, DNMT1, DNMT3A and DNMT3B coordinate the 
establishment and maintenance of DNA methylation patterns in mammals (Figure 1.2). The 
‘de novo' methyltransferases, DNMT3A and DNMT3B, target cytosine methylation to 
previously unmethylated CpG dinucleotides, whereas the ‘maintenance’ enzyme, DNA 
methyltransferase-1 (DNMT1), preserves existing methylated sites (Goll and Bestor, 2005). 
DNMT3A and 3B are thought to be de novo methylases with an equal preference for 
hemimethylated and unmethylated DNA, which are necessary for de novo methylation of the 
genome during development and potentially newly integrated retroviral sequences (Okano et 
al., 1999, Okano et al., 1998). The N-terminal region interacts with many chromatin-
associated proteins including the de novo methyltransferases, methyl-CpG binding proteins 
(MECPs) and histone modifying enzymes. It also contains a nuclear localization signal, a 
PCNA (proliferating cell nuclear antigen)-interacting domain, a replication-targeting region 
and a cysteine-rich Zn2+-binding domain that can potentially bind non-methylated CG rich 
DNA. DNMT1 also contains a domain showing homology to the polybromo-1 protein and is 
thought to mediate protein–protein interactions. Many of these interactions are involved in 
transcriptional repression (Smallwood et al., 2007, Esteve et al., 2006). Recent structural 
analysis suggests an elegant model for the maintenance DNA methylation function of 
DNMT1 in which its CXXC domain specifically binds to unmethylated CpG containing 
DNA and resulting in a repositioning of the CXXC-BAH1 linker between the DNA and the 
active site of DNMT1, preventing de novo methylation (Song et al., 2011b). Furthermore, a 
loop projecting from the BAH2 domain interacts with the target recognition domain (TRD), 
stabilizing it in a retracted position, and preventing it from accessing the DNA major groove. 
In consequence only hemimethylated CpG dinucleotides that do not bind the CXXC domain 
can gain access to the active site. The multiple interactions of DNMT1 suggest that it can be 
a participant in multiple complex networks involved in gene regulation, epigenetic signalling 








































































































































































































































































































































































protein-protein interactions, protein-DNA interactions, subcellular localization, catalytic 
activity and its stability (Patel et al., 2010, Du et al., 2010b, Lee and Muller, 2009). The 
protein lysine methyltransferase SET7 regulates DNMT1 activity in mammalian cells by 
promoting degradation of DNMT1 and thus allows epigenetic changes via DNA 
demethylation (Esteve et al., 2009). The Lys-142 of DNMT1 can be specifically 
monomethylated by SET7 and this modification is mutually exclusive with its Ser-143 
phosphorylation; phosphorylated DNMT1 is more stable than methylated DNMT1 (Esteve et 
al., 2011).  
The respective N-terminal domains of DNMT3A and 3B are responsible for their 
targeting to chromatin via a PWWP domain, and impart differences in specificity. In this 
respect, it appears DNMT3B is specialised in methylation of specific regions of the genome, 
such as pericentromeric repeats and CpG islands on the inactive X-chromosome, whereas 
DNMT3A is required for maternal imprints of differentially methylated regions (DMRs), in 
addition to their general de novo roles (Kim et al., 2009a). The PWWP domain of DNMT3A 
specifically recognizes the histone 3 lysine 36 trimethylation mark and this may be important 
for its subnuclear localization (Dhayalan et al., 2010). This interaction may underlie co-
distribution of DNA methylation and H3K36me3 in chromatin (Hodges et al., 2009). Mouse 
embryos become hypomethylated during early development; reestablishment of global 
methylation depends on the de novo activity of DNMT3A and DNMT3B (Okano et al., 
1999). Once established, DNA methylation patterns are stably maintained over cell divisions 
by DNMT1 through its preference for hemimethylated DNA. In addition, deletion of 
DNMT3A in primordial germ cells disrupts paternal and maternal imprinting, where as 
DNMT3B is dispensable for mouse gametogenesis and imprinting (Kaneda et al., 2010, Kato 
et al., 2007). A rare chromosome breakage disease called the immunodeficiency, centromeric 
region instability, and facial anomalies syndrome (ICF) is associated with point mutations in 
the DNMT3B gene leading to hypomethylation of satellite DNA, this hypomethylation 
phenotype can be recapitulated in a mouse model (Velasco et al., 2010, Xu et al., 1999). 
Protein interaction domains in the regulatory N-terminal of DNMT3A and 
DNMT3B also mediate binding to transcriptional co-repressors (Qiu et al., 2002). DNMT3B 
is associated with SIN3A, SUMO1/UBC9, condensin and the chromatin remodeling enzyme 
hSNF2H, while DNMT3A has been shown to bind the co-repressor RP58 and the oncogenic 
factor PML-RAR (Goll and Bestor, 2005). Both also interact with DNMT1, histone 
deacetylases (HDAC) and multiple transcription factors (Hervouet et al., 2009). Thus, the 
cooperative function between DNMTs provides a way of passing on and maintaining 
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epigenetic information between successive cell generations and this is reinforced through 
interaction with chromatin modifiers. Unlike DNMT1 and DNMT3A/B, the DNA 
methyltransferase DNMT2 has only weak methyltransferase activity in vitro, and its absence 
causes no discernable effects in global CpG methylation levels nor results in a 
developmental phenotype (Goll and Bestor, 2005). A cofactor, DNMT3L (DNMT3-Like), is 
expressed only in germ and ES cells. It is not a methyltransferase but enhances de novo 
methyl transferase activity in ES cells (Ooi et al., 2010).  
In addition to a role in gene silencing, 5mC is a prominent source of mutations as its 
mutation to thymine (T) is 10–50-fold higher than other transitions (Duncan and Miller, 
1980). Both DNMT3A and 3B can interact with repair enzymes, thymine DNA glycosylase 
(TDG) and methyl-CpG binding domain protein 4 (MBD4), that have evolved to counteract 
the mutagenic effect of methylcytosines (Boland and Christman, 2008, Li et al., 2007, 
Hendrich et al., 1999). This implies a mechanistic link between DNA repair at sites affected 
by 5mC deamination and subsequent re-methylation. 
 
1.4.	   DNA	   methylation,	   RNA	   interference,	   histone	  
modifications	  and	  repression	  
 
The presence of DNA methylation (5mC) at CG rich promoters clearly acts as a deterrent to 
transcription. Known targets include imprinted genes, transposons, the XIST gene and CpG 
islands (CGIs) genes on the inactive X-chromosome. However, the extent to which promoter 
methylation regulates developmental and tissue specific gene expression is unresolved. In 
general, repression by DNA methylation is considered to occur downstream of other 
epigenetic or trans-acting factors that signal the initial inactivation event. For example, in the 
case of the pluripotency factor POU5F1 (previously known as OCT3/4), initial repression 
during differentiation is mediated by sequence-specific repressors such as GCNF followed 
by conversion from an active to an inactive histone modification signature and lastly by the 
deposition of DNA methylation at the promoter (Cedar and Bergman, 2009, Feldman et al., 
2006). Genome wide sequencing analysis suggests that the number of potential genes that can 
be directly regulated by DNA methylation in a tissue and developmental specific manner may 
be quite small corresponding to 100–200 of annotated CGI’s in somatic cells (Meissner et al., 
2008). However, this may be an underestimate, as new data suggests there are approximately 
23,000 and 25,500 CGIs in the mouse and human genomes respectively, about half of which 
are associated with annotated transcription start sites for mainly constitutively expressed 
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genes (Illingworth et al., 2010) (Figure. 1.3). As with previous estimates, around 2.5% of the 
annotated CGI’s are methylated in somatic tissues and may be directly regulated by DNA 
methylation. In contrast the non-annotated or ‘orphan’ CGI’s show higher levels of tissue 
specific methylation (14-20%) and lack marks of active transcription; histone H3 tri-
methylation on lysine 4 (H3K4me3) and RNA polymerase II occupancy (Illingworth et al., 
2010) (Figure. 1.3). These may be directly regulated by DNA methylation in different tissues 
and developmental stages. The importance of the preservation of these patterns is suggested 
by the abnormal silencing of annotated tumor suppressor genes by unscheduled de novo 
methylation of their promoter CGIs, which can contribute to unchecked proliferation in 
neoplastic cells (Sharma et al., 2010). In addition, tumor-specific CGI methylation differed 
from that in normal tissues by not being preferentially targeted to orphans CGIs (Illingworth 
et al., 2010). At the same time as de novo methylation of CGIs, global methylation levels 
associated with satellite repeats and retroposons are reduced in cancers. This may permit 
activation of typically silent transposons and contribute to genomic instability through 
illegitimate recombination events (Sharma et al., 2010).  
 RNA interference is a conserved process by which sequence-specific long double-
stranded RNA (dsRNA) is converted into short fragments of ~20 nucleotides that are called 
siRNAs (small interfering RNA), which can induce gene silencing via two pathways: post-
transcriptional gene silencing and transcriptional gene silencing (TGS) (Hamilton and 
Baulcombe 1999, Matzke et al., 2001). In plants, RNNA-directed DNA methylation (RdDM) 
has been shown by genetic and biochemical approaches, in which sequence-specific DNA 
methylation can be established by small interfering RNAs (siRNAs) guided de novo DNA 
methyltransferases (Chinnusamy and Zhu, 2009, Law and Jacobsen, 2010, Matzke et al., 
2007, Wassenegger et al., 1994, Zhang and Zhu, 2011). TGS is well documented in plants 
but less so in mammals (Matzke et al., 2001). It has been demonstrated that promoter-
targeted siRNAs can induce silencing of simian immunodeficiency virus (SIV) replication by 
induction of methylation at a CpG site within the SIV promoter region following siRNA-
induced suppression (Lim et al., 2008, Suzuki et al., 2005). Different classes of small RNAs 
differ in their origin, biogenesis, expression pattern, and utilization. MicroRNAs (miRNA) 
are single-stranded RNA molecules approximately 21–23 nucleotides in length that can 
silence by binding to target mRNAs. It has been suggested that miRNAs are also directly 
involved in the maintenance of genomic integrity through global repression of transposable 
elements (TEs) and indirectly through regulation of DNA and histone modifying enzymes 
(Shalgi et al., 2010, Das et al., 2010). Interestingly, a noncoding RNA has been identified 














































































































































































































































































































































































































































































































































































































































































































































































recruitment of DNMT3B and subsequent silencing of ribosomal RNA genes (Schmitz et al., 
2010). 
While DNA methylation plays an important part in overall transcriptional repression, 
it is clear that animal cells also utilize additional networks to mediate gene silencing. In ES 
cells that lack all three active DNA methyltransferases, a relatively small percentage of 
genes become reactivated (Fouse et al., 2008). This contrasts with inhibition of Dnmt1 
function in somatic cell (Jackson-Grusby et al., 2001). Eukaryotic DNA is packaged with 
histone and non-histone proteins into chromatin and this has two important consequences. 
Firstly, it allows the packaging and compaction of ~1.8 m of DNA into a nucleus typically 5-
20 µm in diameter. Secondly, it promotes the regulation of essential cellular events including 
transcription, lineage specification, DNA replication and cell division. The fundamental unit 
of chromatin is the nucleosome, which is composed of an octamer of the four core histones 
(H2A, H2B, H3 and H4) around which 147 bp of DNA is super-helically coiled 1.65 times 
(Khorasanizadeh, 2004). The repressive effect of nucleosomes on transcription can be 
enhanced or reduced by combinations of histone modifications (Lee et al., 2010, Shilatifard, 
2006). The major effect of histone modifications is to regulate transcription by creating a 
docking site for non-histone effector proteins to modify chromatin structure. However in 
some cases, strongly charged modifications can alter chromatin structure directly, through 
disrupting the DNA-histone interaction. A diverse range of histone modifications have been 
reported including: acetylation, methylation, phosphorylation, ubiquitination, sumoylation, 
formylation, deimination, ADP ribosylation, and proline isomerization. Covalent post-
translational modifications to the tails of histone proteins can reversibly affect gene 
expression by modifying their interaction with DNA and other nuclear proteins. These 
modifications can have either activating or repressive effects on the expression of 
surrounding genes, depending upon which histone residue receives the particular 
modification. The combination of these modifications and the resulting effect on gene 
expression is referred to as the “Histone Code” (Turner, 2007). 
For example, trimethylation of lysine 4 on histone H3 (H3K4me3) is enriched at 
transcriptionally active gene promoters, whereas trimethylation of H3K9 (H3K9me3) and 
H3K27 (H3K27me3) is present at gene promoters that are transcriptionally repressed. The 
latter two modifications together constitute the two main silencing mechanisms in 
mammalian cells, H3K9me3 working in concert with DNA methylation and H3K27me3 
largely working exclusive of DNA methylation. Genome-wide studies showing distinct 
localization and combinatorial patterns of these histone marks in the genome have 
significantly increased our understanding of how these diverse modifications act in a 
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cooperative manner to regulate global gene expression patterns (Sharma et al., 2010). The 
polycomb complex (PRC), which mediates tri-methylation of lysine 27 on histone H3 
(H3K27me3) appears to be targeted specifically to genes involved in development and 
differentiation (Mikkelsen et al., 2007). DNA methylation and specific histone modifications 
can also influence each other during mammalian development and it is noteworthy that many 
of the components from each system interact such that histone H3 methylation at lysine 9 
(H3K9me2/3) can help to direct DNA methylation patterns, and DNA methylation might 
serve as a template for some histone modifications after DNA replication (Lee et al., 2010, 
Cedar and Bergman, 2009). Heterochromatin protein (HP1) binds H3K9me2/3 containing 
chromatin through its chromodomain and at the same time acts like a nuclear ‘Velcro’ protein 
through multiple interactions with protein partners via its chromoshadow domain (Dialynas et 
al., 2008). H3K9me2/3 is generated by a multitude of histone methyltransferases including 
SUVAR39H1, G9a and GLP. Interaction partners for HP1 include DNMT1, SUVAR39H1 
and G9a (Smallwood et al., 2007, Esteve et al., 2006). HP1 can inhibit preinitiation complex 
(PIC) assembly in vitro by blocking key subunits of the TFIID and Mediator coactivator 
complexes. Notably, binding of HP1 inhibited the Sp1-regulated survivin gene in vivo upon 
DNA damage-induced silencing (Smallwood et al., 2008). Loss of HP1 proteins causes 
chromosome segregation defects and lethality in some organisms and a reduction in levels of 
HP1 family members is associated with cancer progression in humans (Dialynas et al., 
2008). 
In contrast, histone H3 methylation at lysine 27 may be mutually exclusive with the 
presence of DNA methylation (Weber et al., 2007). Genes targeted by polycomb actually 
undergo repression through a process of heterochromatinization. Binding of the PRC2 
complex to specific genes brings about local tri-methylation of histone H3K27 by means of 
the histone methyltransferase EZH2 contained in these complexes (Morey and Helin, 2010). 
These methyl groups then serve as a ligand for the chromodomain protein, CBX2, that is part 
of the PRC1 complex, and this generates a heterochromatin-like structure and gene 
repression. However polycomb target genes in ES cells can have a bivalent chromatin 
signature, being marked by both H3K27me3 and the activating modification H3K4me3 
(Mikkelsen et al., 2007, Barski et al., 2007). As development proceeds, the polycomb 
complex is removed in a gene and cell-type specific manner, thus activating or maintaining 
the silencing of those genes as required through development (Mikkelsen et al., 2007, Boyer 
et al., 2006). Like DNA methylation, gene silencing via histone modification can be maintained 
in vivo through multiple cell divisions. One possibility is that this occurs through the simple 
rebinding of repressor molecules following DNA replication. 
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It has been reported that CGIs that are aberrantly methylated in neoplastic cells 
coincide with sites targeted by polycomb in human ES cells (Schlesinger et al., 2007). 
Approximately 16% of all CGIs are H3K27me3 positive in human ES cells and these sites 
are not over-represented among the CGIs methylated in blood, cerebellum or normal colon 
(Illingworth et al., 2010). In contrast, 56% of tumor-specifically methylated CGIs are 
derived from CGIs that were H3K27 trimethylated in embryonic cells (Illingworth et al., 
2010). These findings emphasize the distinction between tumor-specific CGI methylation 
and that found in normally developing human somatic tissues and reinforce the possible link 
between polycomb complexes and tumor-specific CGI methylation. Loss of the Swi/Snf 
chromatin remodeler component SNF5 in malignant rhabdoid tumors leads to elevated 
expression of EZH2 (Wilson et al., 2010). Consequently, Polycomb targets are broadly 
H3K27-trimethylated and repressed in SNF5-deficient fibroblasts and cancers. Normally 
there is antagonism between SNF5 and EZH2 in the regulation of stem cell-associated 
programs so that SNF5 loss deregulates these programs.  
	  
1.5.	   	   Methyl-­‐CpG	   binding	   proteins	   -­‐	   interpreters	   of	   DNA	  
methylation	  
 
The methylation mark can be specifically recognised by a group of methyl-CpG binding 
proteins (MECPs), which may mediate an alternative mechanism for transcriptional 
regulation. In general, the MECPs may ‘read’ the established methylated sequences, recruit 
histone modifying complexes, together with which regulate higher order chromatin structure, 
maintain genome integrity, and stabilize patterns of gene expression. At present three major 
families of mammalian MECPs have been characterized (Ballestar and Wolffe, 2001) 
(Figure. 1.4). 1. Methyl-CpG binding domain proteins (MBDs) including MBD1, MBD2, 
MBD3, MBD4 and MeCP2; 2. The structurally unrelated methyl-CpG binding zinc-finger 
proteins of Kaiso family including KAISO/ZBTB33, ZBTB4 and ZBTB38; and 3. Methyl-
CpG binding SRA domain proteins of UHRF family including UHRF1 and very similar 
UHRF2. The first family of MBDs, with the exception of MBD3, all specifically recognize 
methyl-CpG through their novel methyl-CpG binding domain (MBD). In contrast, KAISO 
family proteins bind methylated DNA through a zinc finger motif. The third family of UHRF 
proteins recognize methylated DNA via a SRA domain and contain an ubiquitin-like motif, a 




























































































































































































































































































































































































 MECPs have binding affinity specifically to symmetrical 5-methyl-CpG (5meCpG) 
but some of them have additional binding preferences. The MBD domain of MBD1 
recognizes methylated CpGs within TCGCA and TGCGCA sequence context more 
efficiently and CXXC motifs of MBD1 can recognise and bind to unmethylated DNA 
(Clouaire et al., 2010). The MBD of chicken MBD2 (96% identical to human MBD2) is 
shown to bound to methyl-CpG in a single orientation, which suggests its sequence 
specificity for bases outside of the symmetric methyl-CpG (Scarsdale et al., 2011). MeCP2 
requires an A/T run adjacent to the methyl-CpG for efficient DNA binding, which were 
shown by in vitro binding assays (Klose et al., 2005). Mammalian MBD3 contains a well-
conserved MBD domain but it does not recognize methylated DNA, owing to amino acid 
substitutions within its MBD domain.  Instead, MBD3 is an essential subunit of the Mi-
2/NuRD chromatin remodelling complex, which have been shown to function as a 
transcriptional repressor complex both in vitro and in cell culture assays. In addition, two 
proteins MBD5 and MBD6 were identified based on their domain similarity to the MBDs, 
but no methylated DNA binding affinity was demonstrated (Laget et al., 2010). In the second 
MECP family, the zinc finger domain of KAISO proteins is responsible for the methyl-CpG 
binding, and has a binding preference to two methyl-CpG motifs in close proximity, 
preferably in tandem (Filion et al., 2006, Prokhortchouk et al., 2001, Ruzov et al., 2004). The 
third MECP family proteins UHRF proteins recognise methylated DNA through their SRA 
domain. UHRF1 is reported to bind hemi-methylated DNA at symmetrical methylated CpGs. 
By a distinct flipping mechanism similar to that of DNMT1, the SRA domain of UHRF1 can 
recognise and bind to hemi-methylated DNA, and is involved in the maintenance of DNA 
methylation with DNMT1 (Avvakumov et al., 2008, Arita et al., 2008). The other protein in 
the family UHRF2 has an SRA domain with 75% similarity to that of UHRF1 and has been 
shown to have a similar binding preference to hemi-methylated DNA in vitro (Pichler et al., 
2011). As there are a large number of proteins containing zinc finger or SRA domains in the 
genome, it is very possible more methyl-CpG binding proteins may be identified with 
distinct binding specificities. 
Almost all the MECPs have been demonstrated to be associated with transcriptional 
repressors and induce transcriptional repression, suggesting an elaborate link between DNA 
methylation and transcriptional repression. In addition to the direct mechanism in which 
DNA methylation alters the transcription binding sites, interfering the binding of 
transcriptional factors such as E2F or CREB, thereby preventing transcriptional activation 
(Campanero et al., 2000, Iguchi-Ariga and Schaffner, 1989), MECPs can read and interpret 
the epigenetic mark of methylation and associate with various chromatin modifiers to 
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establish a repressive chromatin environment (Fuks et al., 2003, Jones et al., 1998, Nan et al., 
1998, Wade et al., 1999). One of the examples is the founding MECP protein MeCP2; In 
addition to the binding specificity of methylated DNA, MeCP2 has been demonstrated to 
associate with various co-repressor complexes such as Sin3A, NCoR, through its 
transcription-repression domain (TRD) (Kokura et al., 2001, Jones et al., 1998). MeCP2 was 
demonstrated to target to promoter DNA and cause strong transcriptional repression, and 
inhibition of HDACs in the Sin3A complex by trichostatin A (TSA) relieves MeCP2-
mediated silencing, suggesting that MeCP2 may serve as a global transcriptional silencer 
(Nan et al., 1998, Jones et al., 1998). However, only subtle changes in gene expression were 
identified by the global transcriptional profiling of MeCP2-/- mice brains (Tudor et al., 2002), 
suggesting other MECPs may compensate the functional defects caused by the lacking of 
MeCP2 activity. In response to this hypothesis, mice lacking three of the MECPs MeCP2, 
MBD2 and KAISO have been generated (Martin Caballero et al., 2009). All of these three 
MeCPs have been shown to be involved in the transcriptional repression. The phenotype of 
these mice is still viable and fertile with neurological abnormalities, which is very similar to 
mice lacking MeCP2 alone. It is noteworthy that the closest relative protein of MeCP2 
within the MECPs, MBD4, was not included in this multiple knockout, as MBD4 was 
demonstrated mainly as a repair protein in the group at the time (Hendrich and Tweedie, 
2003). In addition, there might be more MECP proteins which have not been identified so 
far, thus the mild phenotype of the triple-knockout mice only suggests that the chosen three 
proteins do not compensate for each other, in terms of their activities of transcriptional 
repression (Bartke et al., 2010). In addition, the MeCP2 interaction with the Sin3A 
chromatin remodelling complex is not stable, suggesting MeCP2 may engage a more diverse 
range of cofactors for its repressive function (Klose and Bird, 2004). Indeed, MeCP2 has 
been demonstrated to interact with other chromatin-associated complexes such as nuclear co-
repressor complex N-CoR (Kokura et al., 2001), and the core ATPase of the SWI/SNF ATP-
dependent chromatin remodeling complex, Brm (Hu et al., 2006, Harikrishnan et al., 2005). 
The functional role of these associations is not clear yet, but interacting convergence of these 
repressive complexes implicated from several other MECPs such as KAISO and MBD2 
implicates the importance of these associations. Moreover, the MBD domain of MBD4 is 
most similar to that of MeCP2, with common MBD ancestor shared based on the 
evolutionary primary sequence analysis (Figure. 1.7). Due to the special glycosylase domain 
property of MBD4, it was thought mainly as a repair protein. The possible repressive 
function of MBD4 at its regulatory N-terminal may have been underestimated.  
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1.6.	  	  Cellular	  response	  to	  epigenetic	  perturbation	  
 
The utilization of epigenetic regulatory mechanisms in disease states can contribute to the 
molecular pathology by altering gene expression states that support progression and inhibit 
defense pathways such as tumor suppressor genes (Sharma et al., 2010). For example, 
epigenetic inactivation of hMLH1 is a major cause of microsatellite instability in sporadic 
colorectal cancers, likewise epigenetic alteration of genes involved in the induction of 
senescence is often associated with cancers showing mutations in the Ras signaling pathway 
(Toyota and Suzuki, 2010). Hypomethylation of short and long interspersed repetitive 
elements has been reported in cancer, and hypomethylation of the genome has been observed 
in ICF syndrome (Jin et al., 2010, Tao et al., 2002). Since epigenetic mechanisms are deeply 
embedded in regulating developmental gene expression programs, it is not surprising that 
loss of components of the epigenetic toolbox during development results in severely 
impaired or embryonic lethal phenotype. The cellular response is not governed just by 
transcriptome changes but also specific activation of signaling cascades that usually respond 
to DNA damage. Despite obvious differences in biology and early developmental strategies, 
inhibition of dnmt1 function in Xenopus laevis embryos shows remarkable similarity with 
mouse Dnmt1−/− mutants as indicated by the presence of axial defects, failure to form a 
neural tube, and improper patterning of the somites (Stancheva and Meehan, 2000, Lei et al., 
1996, Li et al., 1992). Underlying the phenotype in both species is activation of p53-
mediated apoptosis (Stancheva et al., 2001, Jackson-Grusby et al., 2001). One generalization 
from the analysis of DNMT1 depletion or inhibition is that it is not essential for the survival 
of embryonic cells during early cleavage stages. Instead the effect of disrupting DNMT1 
function only becomes apparent during and past gastrulation when loss of DNMT1 provides 
a signal through p53, to initiate apoptosis. Although reduction of Dnmt1 levels has been 
associated with the maintenance of pancreatic cell identity (Dhawan et al., 2011, Oghamian 
et al., 2011, Anderson et al., 2009), which possibly depends on an event of DNA 
methylation-mediated repression of pancreatic cell lineage determination genes (Dhawan et 
al., 2011), this does not preclude the possibility of an impaired apoptosis pathway through 
p53 (Ruzov et al., 2009b). Recently it has also been reported that mutations in DNMT1 cause 
autosomal dominant cerebellar ataxia, deafness and narcolepsy (Winkelmann et al., 2012), 
but the underlying molecular mechanism(s) remain unidentified. 
Like DNMTs, inactivation of many histone-modifying enzymes in ES cells does not 
result in cell lethality but is detrimental to embryo development (Tachibana et al., 2005, 
Tachibana et al., 2002, Peters et al., 2001). The H3K9 methyltransferases G9a, GLP and 
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Suvar39h1/2 are required for early embryo development, although mortality of G9a and GLP 
deficient embryos occurs earlier (by E8.5) than Suvar39h1/2 mutants (E14.5) (Tachibana et 
al., 2005, Tachibana et al., 2002, Peters et al., 2001). The G9a and GLP mutants are very 
similar and TUNEL assays indicate that abundant apoptosis occurs in G9a−/− embryos, 
whereas very few cells were positive in wild-type embryos (Tachibana et al., 2002). The 
mechanistic basis of this apoptotic activation is unclear, however G9a−/− derived MEFs are 
viable despite having an extensive gene mis-expression profile, which suggests there is a 
developmental specific checkpoint (as for DNMT1) that is activated upon G9a inactivation 
in early embryos (Sampath et al., 2007). By contrast, Suv39h double mutants exhibited 
genomic instability in a subpopulation of cells, which did not trigger extensive apoptosis 
(Peters et al., 2001). This suggests that repeat DNA associated Suv39h-dependent H3-K9 
methylation is important for maintaining a stringent higher-order structure at pericentric 
heterochromatin, which is required to protect genomic stability. Absence of Suv39h HMTase 
does not trigger cell death pathways. Similarly loss of the Polycomb components has not 
been reported to trigger apoptosis (Morey and Helin, 2010). However, the S-
adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A (DZNep) induces efficient 
apoptotic cell death in cancer cells but not in normal cells by depleting cellular levels of the 
PRC2 components EZH2, SUZ12, and EED (Tan et al., 2007). This reduced H3K27me2/3 
levels but not H3K9me2/3. In this case preferential reactivation of a novel apoptosis effector, 
FBXO32, by DZNep, may be responsible for inducing apoptosis in the cancer context. This 
would be consistent with a cancer specific phenotype in which epigenetic mechanisms have 
been co-opted to selectively repress genes that are antagonistic to transformation either by 
inhibiting cellular proliferation and promoting either senescence or apoptosis (Wu et al., 
2010). 
A recent report suggests that DNA methyltransferases are essential for maintaining 
the memory of a genotoxic insult that persists after γ-radiation exposure (Rugo et al., 2011). 
Mouse embryonic stem cells exposed to γ-radiation harbour the effects of the insult for 
weeks and conditioned media from the progeny of exposed cells can induce DNA damage 
and homologous recombination in naive cells. Experiments in ES cells suggest that the 
molecular pathway that underlies the memory of the insult requires Dnmt1 and Dnmt3a but 
not Dnmt3b (Rugo et al., 2011). These exciting data suggests a potential molecular pathway 
for persistent bystander effects associated with exposing cells to of DNA-damaging agents.   
Ubiquitin-like, containing PHD and RING finger domains, 1, also known as UHRF1 
or Np95, binds methylated CpG through its SET and RING finger-associated (SRA) domain 
(Sharif et al., 2007). It localizes to replicating heterochromatin and is dependent on the 
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presence of hemi-methylated DNA (Figure. 1.6 B). Np95 forms complexes with Dnmt1 and 
is essential in vivo to maintain global and local DNA methylation. Np95−/− embryos 
exhibited growth retardation and various malformations such as neural tube closure defect, 
small branchial arches and failure in outgrowth of allantois. Like Dnmt1-/- embryos they exhibit 
excess apoptosis that may be independent of the transcriptional changes associated with DNA 
hypomethylation. 
Recent work demonstrates that complete inactivation of DNMT1 function in human 
cancer cells results in cell death, but this decrease in viability occurs with minimal changes 
in global DNA methylation (Chen et al., 2007). This observation supports the hypothesis that 
DNMT1 possesses essential functions independent of its role as a maintenance 
methyltransferase and links its absence with activation of a cellular checkpoint response. 
Partial reduction in xDnmt1p levels without changes in DNA methylation levels is sufficient 
to activate a cell death program in Xenopus embryos (Dunican et al., 2008). This contrasts 
with Dnmt1−/− ES cells, which proliferate normally in culture unless they are induced to 
differentiate, but notably they exhibit high rates of micro-satellite instability and DNMT1 
(but not the de novo methyltransferases) can be recruited to sites of DNA damage via PCNA 
(Mortusewicz et al., 2005, Guo et al., 2004). A possible mechanism for DNMT1 recruitment 
and signaling apoptosis is through the mismatch repair pathway (MMR). The methyl-CpG 
binding protein, MBD4 (MED1) has been shown to function as a thymine glycosylase and 
interacts with the MMR protein MLH1. An important function of MMR proteins is to sense 
DNA damage and mediate the decision to repair the lesion or to induce apoptosis in somatic 
cells (Palii et al., 2008). The levels of several MMR proteins are reduced in Mbd4−/− mouse 
embryonic fibroblasts, which can account for the diminished apoptotic response of these cells to 
DNA damaging agents (Sansom et al., 2003, Cortellino et al., 2003). In wild type cells, DNA-
damage recognition by MMR factors is sufficient to trigger cell-cycle arrest and apoptosis 
through direct interaction with signaling kinases such as ATM, ATR, CHK1, CHK2, which 
ultimately activates p53 (Luo et al., 2004). MBD4 can interact directly with both DNMT1 
and MLH1 leading to recruitment of all three components at DNA damage sites (Ruzov et 
al., 2009). The co-localization of DNMT1, MBD4 and MLH1 suggests that they may 
participate in a cellular checkpoint that monitors potential DNA hypomethylation events by 
detecting the presence or absence of the maintenance methyltransferase, perhaps at or 
adjacent to the replication fork. The recruitment of these components in response to localized 
DNA damage suggests that they can have a role in the cellular decision whether to repair the 
lesion or activate apoptosis (Ruzov et al., 2009). Double depletion experiments in Xenopus 
laevis suggest that both MBD4 and MLH1 are required for the embryonic lethal phenotype 
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of associated with DNMT1 depletion. Inhibition of p53, MBD4 or MLH1 alleviates 
phenotypic consequences DNMT1 inactivation in frogs. This suggests in this model system 
that it is the absence of DNMT1 at cellular checkpoint that triggers apoptosis by releasing 
MLH1/MBD4 to activate downstream DNA damage kinases such as ATM, which activate 
p53 and subsequent apoptosis. In agreement with this, over-expression of either MLH1 or 
MBD4 in MEFs resulted in activation of an apoptotic response and the glycosylase catalytic 
activity of MBD4 is not required for this (Ruzov et al., 2009b). In contrast, over-expression 
of MBD4 did not induce apoptosis in HCT116 cells, which lack functional MLH1, whereas 
over-expression of GFP-MLH1 did. This model suggests that the maintenance of genome 
integrity through DNA repair mechanisms includes preservation of epigenetic signatures, 
requiring the participation of DNA and histone modifying enzymes in repair pathways. 
In general, the propagation and preservation of epigenetic signatures in development 
is essential for normal transcription programs. The consequences of loss of these systems can 
contribute to susceptibility to disease and increased phenotypic variation (Whitelaw et al., 
2010, Sharma et al., 2010). Loss of this transcriptional ‘dampening’ system is detected by 
cellular surveillance systems that in many cases can result in activation of intrinsic and 
extrinsic apoptotic pathways if the epigenetic alterations are detrimental to cell viability. 
 
1.7.	  	  Methyl-­‐CpG	  binding	  domain	  protein	  4	  
 
MBD4 is the only methyl-CpG binding DNA protein that associated with repair 
function within the MECPs group. It has two significant domains identified by homology 
and functional analysis: a highly conserved glycosylase domain (60% conservation between 
species) at the C-terminus, and a less well conserved methyl-CpG binding (MBD) domain 
(37% conservation between species) at the N-terminus (Bellacosa et al., 1999, Hendrich and 
Bird, 1998) (Figure. 1.5). The N-terminal MBD domain of MBD4 is able to discriminate 
between methylated and unmethylated double stranded DNA (Hendrich and Bird, 1998a). 
The C-terminal glycosylase domain of MBD4 was shown in vitro to recognise and repair the 
mismatched products from deamination including thymine and uracil (Hendrich and Bird, 
1998, Wong et al., 2002). MBD4 is proposed to be involved in the repair of mismatches 
resulting from cytosine deamination. Spontaneous hydrolytic deamination of methylated 
cytosine causes C to T transitions at methylated CpG, and C to U mutation at non-
methylated CpG. MBD4 was shown to excise and repair both T and U mutations at 
methylated and non-methylated CpGs via its glycosylase domain. The methyl-CpG binding 
domain of MBD4 binds preferentially to methylated CpG:TpG mismatches, the primary  
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Figure.	   1.5.	   Functional	   domains	   of	   methyl-­‐CpG	   binding	   domain	   protein	   4	   (MBD4).	   A	  
schematic	   highlighting	   the	   two	   domains	   of	   MBD4;	   an	   N-­‐terminal	   MBD	   domain	   that	  
binds	   methyl-­‐CpG	   containing	   duplexes	   including	   mis-­‐matches	   and	   a	   C-­‐terminal	  
Glycosylase	   domain,	   which	   can	   excise	   and	   repair	   both	   thymine	   and	   uracil	  mutations	  
that	   result	   from	   deamination	   of	   methyl-­‐cytosine	   and	   unmethylated	   cytosine.	   The	  
glycosylase	   domain	   of	  MBD4	   is	  well	   conserved,	   about	   114	   amino	   acids	   long,	   sharing	  
70.2%	   identical	   sites	   between	   species	   from	  Medaka	   Fish	   to	   Human.	   In	   contrast,	   the	  
MBD	  domain	  of	  MBD4	  has	  poor	  conservation,	  the	  70	  amino	  acids	  that	  constitute	  MBD	  
domain	  sharing	  only	  31.6%	   identical	   sites.	  The	   intervening	  region	   is	  a	  domain	  desert	  
and	   highly	   variable	   in	   sequence.	   It	   is	   noteworthy	   that	   a	   50	   amino	   acid	   region	   right	  
ahead	   of	   the	   glycosylase	   domain	   is	   conserved	   between	   species.	   This	   region	   interacts	  
with	   several	   important	   protein	   partners,	   including	   MLH1	   and	   FADD.	   Sequence	  
alignments	  of	   the	  MBD	  domain,	   the	   intervening	  region	  and	   the	  glycosylase	  domain	  of	  
MBD4	  protein	  were	  generated	  with	  clustalX	  module	  of	  Geneious	  pro	  software.	  
 
 
product of deamination at methyl-CpG. MBD4 can repress several methylated reporter genes 
(Fukushige et al., 2006, Kondo et al., 2005), However, the global genomic targets of MBD4 
have not been characterised. Mbd4-/- mice are both viable and fertile, and show only mild 
physiological defects (Millar et al., 2002). However, morpholino knock-down of xMbd4 in 
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Xenopus laevis shows serious developmental defects and fails to develop to tadpole. Re-
introduction of mouse Mbd4 mRNA can rescue the phenotype (Ruzov et al., 2009). Novel 
interacting partners of MBD4 include MLH1 and Fas-associated death domain (FADD) 
proteins, suggesting a potential link between genome surveillance and apoptosis (Screaton et 
al., 2003, Hendrich and Bird, 1998) (Figure. 1.6 D). Consistent with these observations, 
reduced apoptosis occurs in the small intestine of Mbd4−/− mice in response to a variety of 
DNA-damaging agents, and increased tumorigenicity was observed in Mbd4−/− mice with a 
tumor-susceptible Apc min background (Millar et al., 2002, Wong et al., 2002, Hendrich et al., 
1999). 
 It has been proposed that MBD4 proteins arose as a fusion protein between MBD 
and glycosylase domain ancestors in the vertebrate lineage (Hendrich and Tweedie, 2003). 
MBD2/3 represents the ancestral methyl-CpG binding protein. Interestingly, a prototypical 
MBD4 protein and its putative ancestor MBD2/3 were both identified outside vertebrates in 
the cephalochordate amphioxus (Branchiostoma floridae) (Albalat, 2008). A putative MBD4 
was predicted in the Ciona intestinalis genome, but it lacks an MBD domain. The finding of 
a putative MBD4 protein in this invertebrate-vertebrate transition model organism pushes 
back the origin of MBD4 proteins in evolutionary time (Albalat, 2008a). The MBD domain 
of MBD4 is most similar to that of MeCP2 in primary sequence, binds specifically to 
methylated DNA (Hendrich and Bird, 1998, Ballestar and Wolffe, 2001). MeCP2 has been 
described in several molecular roles including transcriptional repression, activation of 
transcription, nuclear organization, and splicing, whereas the role of MBD4 remains largely 
unknown apart from functions in DNA repair and apoptosis (Sasai and Defossez, 2009). 
Noticeably, the primary sequence of the MBD domain of MBD4 proteins in vertebrates 
diverges much more than that of MeCP2, while important residues responsible for DNA 
binding and Rett syndrome mutations are well conserved (Chapter 6). 
MBD4 (NM_003925) is a gene of 9060bp coded by 8 exons from 129158852 to 
129149792 according to GRCh37 human genome assembly v37 by IGB browser. The 
longest human MBD4 protein has 580 amino acids, at approximately 66 kDa. MBD4 gene 
mutations were found in tumors that exhibit genomic instability associated with defective 
DNA mismatch repair (MMR); termed primary microsatellite-instability (MSI). A characteristic 
of MSI tumors is frequent silencing of MLH1 and down-regulation of MMR target genes, 
such as MRE11 and MBD4 (Miquel et al., 2007). The somatic MBD4 mutations in these 
tissues are likely a consequence of MMR deficiency. Accumulated evidences have shown 
that MBD4 and several MMR proteins fall in the same base excision repair (BER) pathway. 




Figure.	   1.6.	   Model	   illustration	   of	   the	   maintenance	   of	   DNA	   methylation	   and	   the	  
involvement	   of	   protein	   complexes.	   (A-­‐B)	   The	   preferential	   substrate	   for	   the	  
maintenance	   cytosine	   methyltransferase,	   DNMT1,	   is	   hemi-­‐methylated	   CpG	   sites	  
resulting	  from	  newly	  synthesized	  DNA	  in	  somatic	  cells.	  DNMT1	  can	  be	  localised	  at	  the	  
replication	  fork,	  and	  functions	  with	  the	  help	  of	  partner	  proteins	  including	  UHRF1	  and	  
PCNA	  (Proliferating	  cell	  nuclear	  antigen).	  (C)	  At	  post-­‐replication,	  DNMT1	  and	  a	  methyl-­‐
CpG	  binding	  protein	  MBD4	  can	  be	  localized	  together	  at	  DNA	  damage	  sites	  and	  may	  be	  
part	   of	   cellular	   pathway	   that	   activates	   apoptosis.	   MBD4	   interacts	   directly	   with	   both	  
DNMT1	  and	  MLH1	  leading	  to	  recruitment	  of	  all	  three	  at	  DNA	  damage	  sites.	  (D)	  MBD4	  
has	   also	   been	   shown	   to	   recruit	   Fas-­‐associated	   death	   domain	   protein	   (FADD),	   which	  
bridges	  death	  receptors	  with	  initiator	  caspases.	  FADD	  may	  also	  be	  an	  apoptotic	  effector	  
via	  MBD4.	   (E)	   Several	   active	  DNA	  demethylation	  models	   have	   been	   proposed.	  MBD4	  
was	   reported	   to	   execute	   active	   DNA	   demethylation	   at	   the	   CYP27B1	   promoter	   in	  
response	   to	   PTH	   (Parathyroid	   Hormone)	   signaling.	   Similarly	   TDG	   (Thymine	   DNA	  
glycosylase)	   can	   also	   interact	   with	   DNMT3A	   and	   DNMT3B	   and	   function	   as	   5mC	  
glycosylase	   against	   hemi-­‐methylated	   DNA	   with	   the	   same	   weak	   excision	   activity	   as	  
MBD4.	   In	   zebrafish	   embryos,	   Aid,	   Mbd4	   and	   the	   DNA	   repair	   protein	   Gadd45a	   may	  
cooperate	  to	  induce	  demethylation.	  Thymine	  glycosylases	  such	  as	  TDG	  and	  MBD4	  may	  
function	  on	  deamination	  of	  5-­‐methyl-­‐cytosine	  by	  repairing	  the	  resulting	  mismatch.	  (F)	  
TET1	   is	   capable	   of	   acting	   on	   both	   fully	   methylated	   and	   hemi-­‐methylated	   DNA,	  
producing	   5-­‐hydroxymethylcytosine	   (5hmC)	   in	   DNA,	  which	  may	   also	   act	   in	   signaling	  
pathways	  associated	  with	  turnover	  and	  maintenance	  of	  the	  epigenome.	  
 
 
in Mbd4−/− MEFs (Cortellino et al., 2003). Although Mbd4 inactivation did not increase 
mini-satellite instability (MSI) in the mouse genome, it did result in a 2- to 3-fold increase in 
C to T transition mutations at CpG sequences in splenocytes and epithelial cells of the small 
intestinal mucosa (Millar et al., 2002). The change in the gastrointestinal cancer phenotype 
was associated with an increase in somatic C to T mutations at CpG sites within the coding 
region of the wild-type Apc allele. These studies indicate that Mbd4 inactivation may alter 
the mutation spectrum in cancer cells and modify the cancer predisposition phenotype. A C-
terminal truncation of MBD4 containing its MBD domain was detected in the HCA7 cell 
line (colon cancer cell line) (Bader et al., 1999). Frequent MBD4 mutations were reported in 
MSI tumours in sporadic colon cancers and in hereditary non-polyposis colorectal cancer 
(HNPCC) tumours. The frequency of MBD4 mutations was correlated with MSH2/MLH1 
germline mutations (Riccio et al., 1999). In human, frame-shift mutation of MBD4 occurs in 
up to 43% of microsatellite unstable colon cancers. A frame-shift in a polyadenine tract due 
to an MMR defective background resulted in a mutated form of MBD4 that occurs naturally 
in human colon cancers (Abdel-Rahman et al., 2008). This leads to a premature truncation of 
the MBD4 protein, which has an intact MBD domain but lacks of the whole glycosylase 
domain. It has been suggested that this truncated form of MBD4 acts in a dominant negative 
way, competitively inhibiting normal glycosylase activity of wild type MBD4, and increases 
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mutation frequency when overexpressed in cells (Bader et al., 2007). The frameshift 
mutations in MBD4 appear to be selected for in MSI tumour cells, as similar coding 
polyadenine repeats in other tested genes are rarely altered in this panel of 56 primary MSI 
tumours (Riccio et al., 1999). Over-expression of MBD4tru in Big Blue (lacI)-transfected, 
MSI human colorectal carcinoma cells doubled the mutation frequency, indicating that the 
modest dominant negative effect on DNA repair can occur in living cells in short-term 
experiments. Intriguingly, the whole mutation spectrum was increased, not only at CpG sites, 
suggesting that truncated MBD4 has a more widespread effect on genomic stability. This 
demonstration of a dominant negative effect may be of significance in tumour progression 
and acquisition of drug resistance (Abdel-Rahman et al., 2008, Bader et al., 2007). 
Regarding tumor prognosis, reduced expression of MBD4 correlated with poorly 
differentiated tumors in hepatocarcinomas (HCC) (Saito et al., 2001). In an investigation 
using 24 paired colorectal cancer samples, MBD4 was found to be a significant prognostic 
factor for patient survival by Kaplan-Meier survival analysis (Xi et al., 2008). In addition, 
expression levels of MBD4 and MBD3 correlated with the grade of malignancy in human 
gliomas both in vivo and in vitro (Schlegel et al., 2002). It is not surprising that a defect in 
this system results contributes to disease pathology, for example by increasing the mutation 
rate at a second site in the two hits (Knudsen) cancer model. 
MBD4 is proposed to be a candidate involved in DNA demethylation activity. This 
activity might be stimulated in partnership with DNMT3A and DNMT3B, as the enzymatic 
excision activity of MBD4 is 30–40-fold lower than its T•G mismatch glycosylase activity 
(Wu and Zhang, 2010). Similarly the only other mammalian thymine glycosylase TDG 
(Thymine DNA glycosylase) was also reported to interact with DNMT3A and DNMT3B and 
act as a 5meC glycosylase activity against hemimethylated DNA with the same weak excision 
activity as MBD4 (Wu and Zhang, 2010) (Figure. 1.6 E). In addition to the possible 
demethylation activity of MBD4 at specific promoter, zebrafish mbd4 has been proposed to 
be a candidate protein that is involved in DNA demethylation activity in zebrafish (Rai et al., 
2008). Rai and colleagues showed that MBD4 removes G:T mismatch-specific thymines, 
which results from 5mC deamination, via the coupling of certain enzymes in the cytidine 
deaminase family (Activation Induced deaminase (AID) and apolipo-protein B RNA-editing 
catalytic component (Apobec) (Rai et al., 2008b). Interestingly, deamination activity by 
AID/Apobec may not occur unless MBD4 and/or other possible factor are present and/or 
activated, and a catalytically inactive hMBD4 derivative (D560A) stabilized the putative G:T 
intermediate and prevented rapid thymine removal (Rai et al., 2008b). MBD4 was also 
reported to interact with Xenopus DNMT1 to promote p53 dependent apoptosis (Ruzov et al., 
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2009b), and DNMT3b, which is proposed to methylate cytosine and to deaminate 5-meC, 
relying on an inefficient deaminase activity (Metivier et al., 2008, Kangaspeska et al., 2008). 
Recent studies in mice have implicated TDG in active DNA demethylation, interacting with 
the deaminase AID and the damage response protein GADD45a. These findings suggest a 
two-step mechanism for DNA demethylation in mammals, whereby 5-methylcytosine and 5-
hydroxymethylcytosine are first deaminated by AID to thymine and 5-hydroxymethyluracil, 
respectively, followed by TDG-mediated thymine and 5-hydroxymethyluracil excision repair 
(Cortellino et al., 2011a, Cortazar et al., 2011). It is possible that MBD4 may make a 
contribution to this process (Figure. 1.6 F). 
Both TDG and MBD4 have been shown to be capable of removing guanine 
(G):uracil (U) mispair and guanine (G):thymine (T) mispair, products from deamination of 
the exocyclic amino group in cytosine and 5-methylcytosine. These two coexisting 
glycosylases seem redundant for a system targeting mismatched thymine and uracil. Their 
evolutionary timeline is very different (Figure. 1.7). Both glycosylase ancestors of MBD4 
and TDG were found in Bacteria. Glycosylase ancestors of MBD4 were also found in 
Archaea, whereas only a hypothetical protein TDG Archaea ortholog was identified. Both 
glycosylase ancestors of MBD4 and TDG were identified in plants and fungi. In contrast, the 
earliest MBD domain ancestors exist in plants but not in fungi. Most importantly, whereas 
the TDG protein was found in almost all the species throughout evolution, full length MBD4 
emerges as a fusion protein only from Chordates onwards, the representative of Invertebrate-
Vertebrate transition. This suggests that in a more complex system such as vertebrates, an 
additional glycosylase like MBD4 is required to maintain genome integrity and MBD4 may 
possess some special roles such as apoptosis signaling, where fatal mismatches cannot be 
repaired. Interestingly, according to the evolutionary rate, the proportion of CG sites in 
vertebrates is far less than that of lower organisms, due to the accumulation of evolutionary 
repair events of spontaneous deamination. The additional glycosylase system aiming at a 
lower proportion of CG sites may result in more precise genome surveillance, which is a 
requirement in higher animals. Alternatively, there might be other functions the additional 
glycosylase possesses, in order to precisely regulate the system such as the epigenetic 
transcriptional repression. Recently it has been demonstrated that TDG is essential for early 
mouse development and the embryonic lethal phenotype of Tdg-/- mice includes mis-
expression of developmental genes, suggesting it may have a structural role in maintaining 
sites of active gene expression (Cortazar et al., 2011, Cortellino et al., 2011a). There was 
some evidence that TDG might also function to erase aberrant methylation at normally  
 27 
 
Figure.	  1.7.	  Evolutionary	  timeline	  of	  the	  two	  mammalian	  thymine	  glycosylase	  proteins:	  
methyl-­‐CpG	   binding	   domain	   protein	   4	   and	   thymine-­‐DNA	   glycosylase	   (TDG).	   The	  
ortholog	  of	  proteins	   including	  the	  MBD	  domain	  and	  the	  glycosylase	  domain	  of	  human	  
MBD4	   and	   full	   length	   human	   TDG	  were	   inferred	   initially	   by	   reciprocal	   best	   BLASTP	  
searches	   against	   the	   non-­‐redundant	   protein	   sequences	   database,	   and	   confirmed	   by	  
phylogenetic	   reconstructions.	   Neighbor-­‐joining	   (NJ)	   phylogenetic	   trees	   were	  
constructed	   for	   domains	   of	   MBD4	   and	   full	   length	   TDG.	   Maximum	   likelihood	   (ML)	  
analyses	   were	   performed	   using	   the	   PHYML	   module	   from	   Geneious	   pro	   software,	  
following	   the	   JTT	  model	   of	   amino	   acid	   substitution.	   Protein	   domains	  were	   identified	  
using	   InterProScan	   and	   conserved	   domains	   servers.	   Published	   procedures	   for	   this	  
bioinformatic	  approach	  were	  followed	  (Albalat,	  2008).	  Glycosylase	  ancestors	  for	  MBD4	  
and	  TDG	  can	  be	   found	   in	  Bacteria.	  Glycosylase	  ancestors	  of	  MBD4	  were	  also	   found	   in	  
Archaea,	   whereas	   only	   a	   hypothetical	   TDG	   Archaea	   ortholog	   was	   identified.	   Both	  
glycosylase	  ancestors	  of	  MBD4	  and	  TDG	  were	  found	  in	  Plants	  and	  Fungi,	  in	  contrast,	  the	  
earliest	  MBD	  domain	  ancestors	  were	  in	  plants	  and	  not	  in	  Fungi.	  TDG	  protein	  was	  found	  
in	  almost	  all	  the	  species	  throughout	  evolution,	  the	  full	  length	  MBD4	  though,	  emerges	  as	  




methylation free CpG island promoters. A bisulfite deep sequencing approach of TDG 
mutant embryos may address this possibility more fully, with the caveat that the sites may be 
5-hydroxymethylated and not 5mC modified. MBD4 was also reported to interact with 
Xenopus DNMT1 in response to DNA damage and DNMT3b (Ruzov et al., 2009b, Boland 
and Christman, 2008a, Metivier et al., 2008, Kangaspeska et al., 2008) (Figure. 1.6 C). 
Controversially DNMT3b was proposed to methylate cytosine and to deaminate 5-meC, 
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relying on an intrinsic inefficient deaminase activity as part of a gene activation program 
(Ruzov et al., 2009b, Metivier et al., 2008, Kangaspeska et al., 2008). Thymine glycosylases 
such as TDG and MBD4 may function on deamination of 5-methyl-cytosine by repairing the 
mismatch.  
In sum, MBD4 is a special MeCP protein which possesses a MBD binding domain 
and a distinct glycosylase domain. It has been associated with a number of pathways 
including DNA repair, apoptosis, transcriptional repression, and possibly DNA 
demethylation processes. However, the precise contribution of MBD4 to these processes 
remains unclear. This led me to undertake the investigation of novel roles of MBD4 as my 
PhD project. 
 
1.8.	  	  Research	  aims	  
 
The aim of the research presented in this thesis was to functionally analyse the methyl-CpG 
binding domain protein MBD4. Four principal areas of research were investigated: 
 
i) High-throughput screens to identify the interacting protein partners of MBD4 
(Chapter 3). The yeast two-hybrid and affinity purification followed by mass 
spectrometry assays were performed. Additionally, functional annotation of the 
candidates were used to identify the significant clusters and to select the most 
robust MBD4 interacting candidates for the further validations. 
ii) Validate and character the interactions between MBD4 and the selected protein 
candidates (Chapter 4). Reciprocal IP and immunocytochemistry was used to 
analyse the interactions and intracellular localisation of candidates, and the 
dependence of candidate localisations on MBD4. Additionally, the domains of 
MBD4 responsible for the interactions were identified. 
iii) The biological significance of Mbd4 (Chapter 5). The biological significance of 
MBD4 was investigated by bioinformatic analysis of the gene expression 
changes of two independent MEFs cell lines that lack Mbd4 activity in parallel 
with Tdg, the only other thymine glycosylase in mammals. The potential direct 
interaction between Mbd4 and estrogen receptor alpha (ERα) was also 
investigated. 
iv) The in vitro binding specificity of MBD domain of MBD4 (Chapter 6). The in 
vitro EMSA assay was used to determine the evolutionary binding specificity of 
MBD domain of Xenopus and medaka (Fish) MBD4 on a variety of probes, 
including unmethylated, methylated, hydroxymethylated, and mismatched 
DNAs. 
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Chapter	  2:	  Materials	  and	  Methods	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2.1.	  	  Microbiological	  techniques	  
 
2.1.1.	  	  Transformation	  of	  bacteria	  
 
Chemically competent DH5α Escherichia coli (E. coli)(Invitrogen) were mixed with an 
appropriate 10-100ng (1-5ul) of plasmid and incubated on ice for 30min.  The transformation 
mixture was heat shocked in water bath at 42°C for 45sec, immediately placed on ice for 
2min, then 500µl S.O.C. media (Invitrogen) of room temperature was added, and the mixture 
was incubated at 37°C with shaking for 1 hour. Different amount (usually 40ul, 100ul, and 
the rest all) of transformed cells were aseptically spread onto L-agar plates supplemented 
with the appropriate antibiotic. The L-agar plates were made in batch by HGU technical 
services, and the antibiotics concentrations were ampicillin at 50mg/ml; kanamycin at 
50mg/ml; chloramphenicol at 13mg/ml. For blue/white selection 80µl X-gal (25mg/ml) was 
spread onto the agar plates and dried prior to bacterial plating. Streaked plates were inverted 
and incubated at 37°C overnight.  
 
2.1.2.	  	  Growth	  of	  bacteria	  and	  isolation	  of	  plasmid	  DNA	  
 
For the preparation of plasmid DNA, single colonies of transformed bacteria from the 
selection plate were picked and used to inoculate 3-5ml LB (Luria-Bertani) broth (prepared 
by HGU technical services) supplemented with the appropriate antibiotic at the 
concentrations supplied above. The mixed LB broth was incubated at 37°C overnight with 
shaking at >225rpm. For maxi-preparations, 1.5ml of this culture was used as pre-culture to 
inoculate 150ml of LB supplemented with appropriate antibiotics and incubated for a further 
16hr.  'Nucleospin Plasmid' kit for 3ml cultures (Machery-Nagal) or 'GenElute HP 
Endotoxin-free Maxiprep Kit' for 150ml cultures (Sigma) were used for plasmid DNA 
isolation according to manufacturer's instructions.  
 
2.2.	  	  DNA	  preparation	  and	  manipulation	  
2.2.1.	  	  Polymerase	  chain	  reaction	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Specific DNA molecules were amplified from a DNA template by the polymerase chain 
reaction (PCR) as described by (Mullis et al., 1986).  
Routine PCR protocol         
50µL reaction 
10xPCR buffer 5µL 
Forward Primer 5 µL 
Reverse Primer 5 µL 
MgCl2 1.5 µL 
dNTPs 1 µL 
Taq 0.5 µL 
Template DNA 1 µL 
ddH2O X µL 
1. 95°C  4’ 
2. 94°C  30” 
3. 57°C  45” 
4. 72°C  50” 
5. go to 2. 29 times 




2.2.2.	  	  Restriction	  digest	  of	  DNA	  
 
Restriction digests contained 4U restriction enzyme (Roche)/µg DNA and the appropriate 
reaction buffer, and were supplemented with 100µg/ml BSA if required. Restriction digests 
were incubated at the appropriate temperature for the restriction enzyme (usually 37°C) for a 
minimum of 2 hours. Digested DNA was resolved on a 2% agarose gel, stained using 
ethidium bromide according to the manufacturer's instructions, then visualised by UV trans-
illumination. 
 
2.2.3.	  	  Agarose	  gel	  electrophoresis	  and	  DNA	  extraction	  from	  agarose	  
 
The separation of DNA on the basis of molecular weight was achieved by agarose gel 
electrophoresis using the Sub-cell system (Bio-Rad). 0.8-2% (w/v) agarose gels were used 
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depending on the molecular weight of the DNA fragment(s) of interest. Agarose gels were 
prepared with TAE or TBE and contained 0.5µg/ml ethidium bromide, a DNA intercalating 
agent that fluoresces in ultraviolet (UV) light. DNA samples and100bp DNA ladder 
(Promega) in Blue/Orange 6X loading dye were loaded into the wells of the gel. Agarose 
gels were run at constant voltage (50-125Vdepending on the size of the gel) in TAE or TBE 
electrophoresis buffer, then DNA was visualised under UV light. If a DNA fragment was to 
be purified from the gel to be cloned, the exposure to UV light was kept to a minimum. DNA 
fragments required for cloning were resolved by agarose gel electrophoresis and were 
purified using the NucleoSpin Extract II kits according to the manufacturer’s instructions.  
 
2.2.4.	  	  Phenol-­‐chloroform	  extraction	  and	  ethanol	  precipitation	  
 
At least 200µl of sample was used for the DNA isolation using an equal volume of 25:24:1 
phenol:chloroform:isoamyl alcohol (Sigma), then mixed, allowed to settle followed by 
centrifuged at 16,000g for 15min at room temperature. The mixture appears aqueous and 
organic components divided into phases and the top aqueous layer was the DNA-containing 
aqueous phase, and was carefully taken. An equal volume of chloroform was added followed 
by pulse vortex and centrifuged at 16,000g for 5 minutes at room temperature. The top 
aqueous phase was carefully taken to remove residual phenol. 1/10 volume of 3M sodium 
acetate (Sigma) and 2.5 volumes of ice cold ethanol were added into the aqueous phase to 
precipitate DNA and incubating for 5min at room temperature or longer at -20°C if required. 
1µl of glycoblue (15mg/ml, Ambion) was added when precipitating limiting quantities of 
DNA according to manufacturer's instructions.  Precipitated material was centrifuged at 
16,000g for 20min at room temperature and the pellet was washed at least once in 75% 
ethanol to remove salts. The washed pellet was resuspended in distilled ultra-filtered water 
(MilliQ water). 
 
2.2.5.	  	  DNA	  quantification	  and	  assessment	  
 
The concentration of purified nucleic acids was quantified using in a Nanodrop 
spectrophotometry.  The 'Nanodrop ND-1000' was used to measure the A260 and A260/A230 
and A260/A280 ratios of DNA samples for quantifying both dsDNA and ssRNA samples.  The 
A260 was used to calculate the concentration of the sample (as an OD of 1 at 260nm = 
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50µg/ml of dsDNA).  A260/A230 and A260/A280 ratios were for estimating the purity of nucleic 
acids.   
	  
2.2.6.	  	  pGEM-­‐T	  Easy	  cloning	  
 
Because Taq polymerases often leave a dA 3' overhang on the end of PCR products, PCR 
products can be cloned into pGEM T Easy vector (Promega) that has 5' dT overhangs.  PCR 
products were ligated with pGEM T Easy vector according to the manufacturer's instructions 
except 4°C overnight incubation was adopted to get maximum efficiency of ligation. 
 
2.2.7.	  	  DNA	  ligation	  
 
DNA ligation reactions for target vectors were performed in a 20µl volume, and contained 5 
Weiss units T4 DNA ligase, Rapid ligation buffer (Roche) and 50ng vector DNA. A 3-5:1 
molar ratio of insert DNA to vector DNA was present in each reaction. DNA ligation 
reactions were incubated for 5mins at room temperature, and then 5µl was transformed into a 
200µl aliquot of competent bacterial cells. 
 
2.2.8.	  	  DNA	  sequencing	  
 
Plasmid DNA to be sequenced was purified using a NucleoSpin Extract II kit according to 
the manufacturer’s instructions. DNA sequencing was performed using the BigDye 
Terminator v3.1 Cycle Sequencing kit (ABI). DNA sequencing reactions contained 2µl 
BigDye Terminator v3.1, 3.2pmol primer and 50-300ng DNA template in a 10µl volume, 
and were incubated under the following conditions: initial DNA denaturation at 96°C for 
1min, then 25 cycles of DNA denaturation at 96°C for 10s,primer annealing at 50°C for 5s, 
and DNA polymerase extension at 60°C for 4min.Sequencing reactions were cleaned up and 
were run on an ABI capillary sequencer by the MRC Human Genetics Unit Sequencing 
Service.  
 
2.2.9	  in	  vitro	  methylation	  
 
 34 
Plasmids were mixed with the appropriate bacterial methylase and buffer (NEB) 
supplemented with 160µM S-Adenosyl methionine (SAM) or 32µM SAM for HhaI 
methylase at 37°C for 2 hrs. Fresh SAM was often added after 2hrs and the sample incubated 
for a further 1hr at 37°C. The reaction was stopped by adding the breakdown product of 
SAM, S-adenosyl-L-homocysteine (SAH), to inhibit the methyltransferase reaction. 
Phenol/chloroform extraction was used to purify the products. For confirmation of the in 
vitro methylation, the purified products were digested with the methyl-sensitive enzyme 
HpaII and its methyl- insensitive isoschizomer MspI. 
 
2.2.10.	  	  Site-­‐directed	  mutagenesis	  
 
The QuikChange® II XL Site-Directed Mutagenesis Kit (Stratagene) was used according to 
the manufacturer's instructions to introduce base changes/insertions in the sequence of 
plasmid DNA templates. Mutagenic oligonucleotide primers were designed by Stratagene 
online program available at http://www.stratagene.com/qcprimerdesin. Reactions were set up 
at 50µl volume and either 10ng or 50ng of dsDNA template were used. The reactions were 
then cycled through the following temperature cycles in a thermal cycler: 
Segment Cycles Temperature Time 
1 1 95°C 1 minute 
2 18 95°C 50 seconds 
60°C 50 seconds 
68°C 1 minute/kb of plasmid 
length + 2 minutes 
3 1 68°C 7 minutes 
4  4°C  
On completion of the thermal cycling program, 1µl of Dpn I restriction enzyme (10 U/µl) 
was added directly to each amplification reaction, then reactions were gently mixed and 
incubated at 37°C for 1 hour. Either 2 or 10µl of the digested mixture was used to transform 
XL10-Gold ultracompetent cells provided by the kit. Transformed clones were selected on 
agar plates containing appropriate antibiotics, and then plasmid DNA was prepared and 
checked by sequencing for the required nucleotide sequence alteration. 
 
2.3.	  	  RNA	  preparation	  and	  analysis	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2.3.1.	  	  Isolation	  of	  RNA	  from	  mammalian	  cells	  
 
'Trizol' reagent (Invitrogen) was used for RNA isolation from mammalian cells and tissues 
according to manufacturer's instructions. This is usually suitable for the occasion where cell 
numbers were not limiting (>1 x 104). Briefly, Trizol was added to adherent cells directly 
onto the culture surface (after removing media) to minimise chance of RNA degradation. 
Usually per 25cm2 of culture surface for mouse embryonic fibroblasts at >70% confluence, 
1ml of Trizol was added. The samples were then incubated for 2 minutes at room 
temperature to disrupt nucleoprotein complexes, and then 1/10 volume of 
bromochloropropane (BCP) was added. After mixed vigorously by hand, the mixture was 
allowed to briefly settle down, and immediately centrifuged at 12,000g for 15min at 4°C. 
The centrifuged sample contains separated organic, inter- and aqueous phases. The top 
RNA-containing aqueous phase was carefully transferred to a fresh RNase free eppendorf 
and precipitated with an equal volume of isopropanol (if RNA quantity is limited, 1ul 
glycoblue (Ambion) was added) for 10 minutes at room temperature. The sample was 
pelleted by centrifugation at 12,000g for 10 mins at 4°C, and then washed in 75% ethanol. 
The washed pellet was resuspended in RNase-free water (DEPC treated water - Sigma), and 
a portion of RNA was taken for determining the concentration by spectrophotometry using 
Nanodrop ND-1000 on RNA settings, and the RNA integrity by ethidium bromide agarose 
gel electrophoresis for the abundant ribosomal RNA fragments or by Bioanalyser RNA1000 
chip (Agilent) for accurate integrity accessment (Bioanalyser analysis performed by HGU 
technical services). The rest portion of resuspended sample was stored at –80°C for long-
term storage. Generally, the utmost care is needed for handling RNA.  Clean gloves, pipettes 
and bench surfaces were required. Where possible, the working spaces were rinsed with 
RNase Zap (Ambion), and RNase-free filtered pipette tips, eppendorf tubes and water were 
used throughout.   
 
2.3.2.	  	  Preparation	  of	  cDNA	  
 
Where possible, all RNA samples were DNase treated with Turbo DNA-free DNase 
(Ambion) according to the manufacturers instructions for the generation of complimentary 
DNA (cDNA). When RNA quantities were limiting, the DNase step was not performed 
occasionally, but very top RNA-containing aqueous phase was carefully transferred to 
ensure there is no DNA contamination, and in subsequent reactions negative controls are 
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required such as -RT (no reverse transcriptase). Where possible, 2-5ug RNA was used in 
each DNase reaction as a template for cDNA (complimentary DNA) synthesis. The reverse 
transcription reaction was primed by random heximers (Promega) using SuperscriptII or 
SuperscriptIII (Invitrogen) according to manufacturer's instructions, and RNase inhibitor 
(RNaseIn - Promega) was supplemented to the reaction to ensure no degradation of the RNA 
template in the early stages of the reaction. Negative control of cDNA reactions without the 
addition of the reverse transcriptase was performed to ensure there are no DNA and aerosol 
contamination, and in downstream experiments non-intron-spanning primers were used. 
cDNA was stored at -20°C, and -70°C for long-term storage. 
 
2.3.3.	  	  RT-­‐PCR	  
 
RT-PCR using cDNA as a template was performed to semi-quantitatively assess the specific 
genes in steady-state cellular RNA transcription level. 'Primer3' program 
(http://frodo.wi.mit.edu/primer3/) was used for primer desig (Table 2.1). Brifly, the default 
settings were adopted, usually a Ta (annealing temperature) of 55°C, a product size of 
<400bp and skipping a large intron where possible were used to avoid genomic DNA 
contamination.  RT-PCR was performed with 1x PCR buffer (Invitrogen), 2mM MgCl2, 
dNTPs (0.5mM each), 150nM each primer, 0.6u Taq (Thermus aquaticus) DNA polymerase 
(Invitrogen) and an appropriate volume of cDNA. Reactions were incubated in a 
thermocycler using the following program: 
Segment Cycles Temperature Time 
1 1 95°C 2 minute 
2 18-35 94°C 15 seconds 
56°C 20 seconds 
72°C 25 seconds 
3 1 72°C 10 minutes 
4  4°C  
PCR products were run by agarose gel electrophoresis and visualised using ethidium 
bromide staining and UV trans-illumination. 
 
 
2.4.	  	  Protein	  preparation	  and	  analysis	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2.4.1.	  	  Cell	  extracts	  
 
Whole cell protein extracts were prepared by adding an appropriate volume of Lammelli 
buffer in PBS washed cells (60mM Tris pH6.8; 10% glycerol; 2% SDS w/v; 0.01% 
bromphenol blue w/v; 10mM DTT). The mixture was sonicated briefly using an 'Soniprep 
150' probe sonicator (MSE)(3 pulses of 30s at 10µm amplitude), centrifuged to remove 
debris (5min at 20,000g at room temperature) to sheer chromatin and boiled for 5 minutes at 
95°C to denature proteins. The supernatant was taken and glycerol added to a 10% final 
concentration, before storage at –20°C. 
 
2.4.2.	  	  SDS-­‐PAGE	  
 
The separation of proteins on the basis of molecular weight was achieved by denaturing SDS 
polyacrylamide gel electrophoresis (SDS PAGE) according to the method of Laemmli 
(1970), using the vertical electrophoresis Mini-PROTEAN system (Bio-Rad). The 
polyacrylamide separating gels were between 8% and 15% (w/v) depending on the 
molecular weight of the protein(s) of interest. 5% (w/v) polyacrylamide stacking gels were 
used. Protein samples were mixed with 2X SDS PAGE loading buffer and Pre-stained 
protein marker (Protein Loading Buffer Pack, Fermentas ), were incubated at 95°C for 4 min 
and then put on ice, before being loaded into the wells of the stacking gel. SDS PAGE gels 
were run at constant current (200V) in Tris-glycine electrophoresis buffer. SDS PAGE gels 
were stained by incubating in GelCode Blue Stain Reagent (Thermo) with shaking for 1 hour 
in room temperature or in cold room overnight. Gels were washed in diswater until protein 
bands were clearly visible. The stained gels were dried if a permanent record was required. 
 
2.4.3.	  	  Western	  blotting	  
 
Proteins were transferred from SDS PAGE gels onto Hybond-ECL Nitrocellulose membrane 
(Amersham) using a GENIE® Electrophoretic Transfer Blotter (ideascientific) and fresh 
Methanol-Tris-Glycine transfer buffer. Blotting was performed at 15V 2.7A constant current 
(TELEX AC.DC power supply) for 45 mins depending on the surface area of the gels. Non-
specific binding sites on the western blot were blocked by incubation in 5%(w/v) Marvel 
milk powder in 0.5% TBST at 4°C o/n, or for at least 1h on a shaking platform at r/t. All 
subsequent steps were also performed on a shaking platform at r/t. The blot was washed 2 
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times 15 mins 0.5% PBST and then incubated with a primary antibody in 0.5% PBST for 2h 
or in cold room overnight. After 3 times 5 mins washes in PBST, the blot was then incubated 
with either an Alkaline Phosphatase Conjugated or a horseradish peroxidase (HRP)-
conjugated secondary antibody in 5% (w/v) milk in 0.5% PBST for 1h, then washed 2 times 
15 mins 0.5% PBST and 2 times 15 mins PBS washes. The blots were incubated either by 
Immun-StarTM AP Substrate (Bio-Rad) for 5 mins or Equal volumes of ECL solutions 1 and 
2 were mixed, and the composite ECL solution was incubated with the blot for 1min with 
gentle shaking. The blot was placed in a developing cassette, covered with Saran wrap and 
exposed to Hyperfilm ECL (GE Healthcare) for 10 mins (AP) or 30s(ECL), then for shorter 
or longer periods of time as required. Films were developed by a SRX-101A tabletop film 
processor (Konica Minolta). Primary and secondary AP-, HRP-conjugated antibody dilutions 
were based on recommendations from the antibody supplier(s) and on empirical 
observations. 
 
2.4.4.	  	  Purification	  of	  recombinant	  protein	  
 
Ni-NTA agarose purification of His-tagged proteins produced in E.coli were purified by 
nickel agarose chromatography. Ni-NTA beads (Invitrogen) were prepared according to 
manufacture's instructions, and then mixed with the cleared supernatant from the lysed cells. 
Bacterial cell lysates were incubated with the nickel agarose beads on a roller at 4°C for 1 
hour to allow binding of His-tagged proteins to the resin. After binding, the lysates with 
beads were transferred to a reusable Polyprep Chromatography Column and the lysates were 
loaded at least 3 times.  The beads were then washed once in 10 times beads volume 
Washing Buffer A, PH8.0. Proteins were eluted from the column by appropriate volumes of 




2.5.	  	  Mammalian	  cell	  culture	  
 
2.5.1.	  	  Culture	  of	  mouse	  embryonic	  fibroblasts	  
 
Prior to defrosting mammalian cells, the appropriate cell culture medium was prewarmed to 
37°C. The stock of frozen cells was quickly thawed in a 37°C water bath. 5ml medium was 
added drop-wise to the cells, and the cell suspension was incubated at r/t for 2min. A further 
10ml medium was added drop-wise. The cells were then pelleted by centrifugation at 
1,000rpm for 4min. A single cell suspension was prepared in fresh medium and transferred 
to a T75 cell culture flask (12ml medium/T75 flask). The volume of medium and the 
diameter of the flask used were determined by the amount of cells in the stock. Flasks were 
incubated at 37°C in 5%CO2. When the cells were confluent, the plate was washed with 
PBS before being incubated with trypsin-EDTA (2ml/T75 Flask) for 2 mins. Trypsin is 
aserine protease that can mediate the detachment of cells from the cell culture plate surface. 
After cell dissociation from the surface, fresh medium (10ml/T75 plate) was added, and a 
single cell suspension was prepared. The cells were divided by either 1/6 or 1/8 and were 
resuspended in fresh medium. The required volume of the cell suspension was transferred 
into a new cell culture flask with an appropriate volume of additional medium. As commonly 
used mammalian adherent cell lines divide approximately once every 24h, and cells were 
routinely passaged to 12.5-25% confluency, passaging was carried out once every 2-
4d.When preparing a stock of frozen cells, cells were trypsinised and spun down as 
described above. The cell pellet was then resuspended in cell culture medium containing 
10% (v/v) DMSO (cells from a T75 flask were resuspended in3ml total volume). The 
presence of DMSO increases the percentage of cells that survive freezing and thawing by 
minimising the formation of ice crystals within the cells. The cell stocks were stored at 
−20°C for 1h, then at −70°C o/n, before being transferred to a liquid N2 cryostore for 
indefinite storage. 
 
2.5.2	  DNA	  transfection	  
 
HEK293T, CMT93, or MEFs Cells were seeded at appropriate number at least 24hrs prior to 
transfection in culture media lacking antibiotics and grown to a confluence up to 70-80%. 
Lipofectamine 2000 (Invitrogen) was used in accordance with manufacturer’s instructions. 
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Briefly, plasmid DNA and lipofectamine were added in separated appropriate volume of 
Opti-mem (Gibco) for 5 minutes and then combined together with gentle mixing. The 
combined solution containing DNA and lipofectamine in Opti-mem was incubated for a 
further 25 minutes before being added directly to cells (up to 30 minutes). Appropriate 
amount of Lipofectamine 2000 was used according to manufacturer’s instructions. 
 
	  
2.6.	  	  Experimental	  procedures	  
2.6.1	  Yeast	  Two	  Hybrid	  Mating	  Procedure	  
 
Reference: Bendixen et al. (1994) Nucl. Acids Res. 22 (9):1778-1779 See also in Figure. 3.2 
1. Start an overnight culture of 30 ml of SD –Trp from a single yeast colony containing 
GAL4 BD-Bait construct (pGBKT7). Use a colony less than 3 weeks old for best 
results. Shake at 30°C. 
2. The next day, ~24 hours after inoculation, use the 30 ml culture to inoculate a 2 X 
300 ml culture of SD –Trp (i.e. 270 ml of YNB 30 mls of SD –Trp) with 150 ul and 
300 ul, respectively. Shake overnight at 30°C. 
3. The next day in the morning measure the OD600 and choose the culture closest to 
0.7 to 0.9 to continue with. 
4. Take a frozen aliquote of the library cDNA and resuspend directly with 1 ml of YPD 
(pipetting up and down) and add to 50 ml of YPD. Incubate at 30°C for 30 minutes. 
5. Mix library (50ml) with 300 ml culture and rinse the library flask several times with 
liquid from the 300 ml culture. Collect cells on filters (0.22 mm GS (millipore)) in 
screwtop bottle top by syringing through the cells in 20 ml aliquotes. Follow with a 
syringe of 10 ml YPD and a syringe to push through air until there is no more liquid. 
6. Place the filter discs, cell side up, on YPD plates (place 4 discs on each 15cm YPD 
(+Ade) plate) and incubate at 30 c for 5 hours. 
7. Resuspend cells on filters by placing them in a sterile petri and rincing up and down 
with 2 X 750-1000 ul of YNB (depends on number of plates). Pool all the washes in 
one 50 ml falcon. 
8. Plate 1-1.2 mls of resuspended cells per 24cm X 24 cm library plate which is SD-
Trp -Leu and –His (2 mM AT-3) use glass beads to spread and incubate at 30 c for 5 
days. Colonies should appear by then. 
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9. As a control dilute 100 ul of resuspended cells in 1ml of YNB for a 1/10 dilution and 
make 1/200 and 1/4000 from that dilution using YNB. Then plate 100 ul of 1/10 and 
1/200 dilution on SD-Trp and SD-Leu plates and 1/200 and 1/4000 on SD-Trp/-Leu 
(gives idea of efficiency of the mating). In 2 days you should have colonies. 
10. After 5 –6 days pick any yeast colonies that grow and replate on SD-Ade, SD-His 
and SD-Ade/His plates containing 2 mM AT. Good colonies should grow on all 
three. Interaction can also be tested by increasing concentration of AT to 5 mM, 
which select for only strong interactors. Do this by picking a colony into 50-100 ul 
of dH2O and laying a drop of about 3-5 uls on each plate (use matching grids). 
Add 2 ml of AT per litre of agar and 100 mls of SD to give SD-Ade/His then add either 1 
ml/100ml of His (2mg/ml) or Ade (10 mg/ml) for –Ade or –His, respectively (note: SD is –
Trp/Leu/His/Ade to begin with). 
 
2.6.2	  IP	  and	  MS	  of	  MBD4-­‐Containing	  Molecular	  Complexes	  
 
HEK293T cells were seeded to fifty 10cm tissue-culture plates. When the cells grow up to 
70% confluence, the cells were transfected with FLAG tagged expression vector. About 48 
hr posttransfection, cells were lysed with a hypotonic lysis buffer (0.05% NP-40, 10 mM 
HEPES, 1.5 mM MgCl2, 10 mM KCl, 5 mM EDTA, and complete protease inhibitor 
cocktail (Roche), pH 7.4, 30x106 cells/ml), and were incubated on ice for 15 min. Cytosolic 
fraction was discarded and the separated cell nuclei were incubated on ice for 1 hr in a 
nuclear extract buffer (20 mM HEPES, 300 mM NaCl, 20 mM KCl, EDTA-free complete 
protease inhibitor cocktail (Roche) and MNase (Nuclease S7; Roche), pH 7.4, 30x106 
cells/ml). a final concentration of 5mM EDTA was used to stop the chromatin digestion, and 
the sample was centrifuged at 20,000g for 30 minutes twice to get post nuclear supernatants. 
50ul Sepharose beads covalently conjugated to Flag- specific mAb (Sigma) or were added to 
Samples and were incubated for 2 hours with rotation at 4°C. Beads were washed (3x) with 
ice-cold PBS containing 0.05% NP40, and once with pure ice-cold PBS. Bound proteins 
were eluted by boiling for 5 min in sample buffer, and the eluted samples were loaded on a 
large 10% SDS-PAGE (BioRad) and separated. Gels were stained with Colloidal Blue 
(NuPAGE, Invitrogen) Reference: (Abramson et al., 2010). Several chunks of bands of 
diverse molecular weights were excised from the experimental and control lane of a 
corresponding molecular weights. The gel chunks were sent to St. Andrews Mass Spec 
services for analysis. 
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2.6.3	  Electrophoretic	  mobility	  shift	  assay	  (EMSA)	  	  
 
All oligonucleotides were synthesized by Sigma- Aldrich and purified by desalting. Double 
stranded probes for EMSA assays were generated by annealing a reversed single stranded 
oligonucleotide to the appropriate forward single stranded oligonucleotide. The resulting 
probes were purified by 8% none denature polyacrylamide gel, and eluted by Maxam and 
Gilbert elution buffer. The purified probes were then methylated with M.Sss1 
methyltransferase to obtain methylated probes with a single methylated CpG (m+). The 
double stranded probes were purified by Phenol-chloroform extraction and end labelled with 
T4 polynucleotide kinase (Promega) in the presence of gamma 32P labelled ATP. EMSA 
reactions were assembled in 20 µl reaction volumes at room temperature by pre-incubating 
500 ng poly(dG-dC)•poly (dG-dC) (Sigma) or Ecoli (Sigma) competitor DNA and 
recombinant protein in binding buffer (8 % ficoll, 20 mM HEPES pH 7.9, 150 mM KCl, 
1mM EDTA, and 0.5mM DTT) for 10 min.  In each EMSA recombinant proteins were 
usually used from 100nM to 1000nM (from 100nM at a 2X increasing progressively manner, 
for example, 100nM, 200nM, 400nM, etc) (Figure. 2.1). Labelled probe DNA containing 
bromophenol blue as a migration marker was added and the reaction which was allowed to 
continue for a further 25 minutes at room temperature.  The binding reaction was loaded on 
to a 6 % or 8 % non-denaturing polyacrylamide that had been pre run for 1 hour at 250 V in 
0.5X TBE at 4 °C.   The samples were electrophoresed at 250 V for 2hours, until the 
bromophenol blue dye front had migrated 10 cm into the gel.  The gel was transferred to 3 
mm Whatman paper and covered by Saran, and then dried at 80 °C for 2 hour.  Dried gels 






Figure.	   2.1.	   EMSA	   assay	   optimisation	   with	   and	   without	   E.coli	   competitor	   (1μg),	  
demonstrating	  the	  robust	  preferential	  binding	  specificity	  of	  xl.MeCP2	  to	  the	  methylated	  
probes	   containing	   CpG	   dinucleotides	   than	   the	   responsive	   unmethylated	   ones.	   A.	  
Without	   competitor,	   binding	   of	   the	   duplex	   probes	   containing	   5-­‐methylcytosine	  
(5mC)(left)	  or	   the	  responsive	  unmethylated	  cytosines	   (right)	   in	   the	  context	  of	  CpG	  to	  
varying	   concentrations	   of	   the	   methyl-­‐binding	   domain	   (MBD)	   of	   xl	   (Xenopus	   laevis)	  
MeCP2	  from	  1&5.	  Free	  probe;	  2&6.	  100	  nM;	  3&7.	  200nM;	  4&8.	  400nM;	  sequence	  of	  Sm	  
duplex	   is	   listed,	   M	   indicates	   the	   methylated	   cytosine	   base.	   B.	   With	   1μg	   E.coli	  
competitor,	  increasing	  amount	  of	  xl.MeCP2	  from	  50nM	  (Lane	  1&8),	  100nM	  (Lane	  2&9),	  
etc.	  to	  1600nM	  (lane	  6&13,	  excess	  amount)	  were	  co-­‐shifted	  with	  methylated	  U6	  probe	  
(left),	  and	  unmethylated	  U6	  probe	  (right,	  a	  probe	  without	  AT	  run	  in	  comparison	  to	  S1	  
and	   S2	   probes,	   see	   chapter	   6).	   In	   general,	   from	   both	   essays	   with	   and	   without	  
competitor,	   preferential	   binding	   specificity	   of	   xl.MeCP2	   to	   methylated	   probes	  
containing	  CpG	  dinucleotides	  can	  be	  clearly	  observed.	  The	  assays	  with	  competitors	  are	  
cleaner	  and	  clear	  binds	  without	   smear	  migrant	  are	  usually	  observed.	   It	   also	  excludes	  
the	  non-­‐specific	  binding	  possibility	  in	  the	  assays	  without	  competitors.	  
 
2.6.4.	  	  Quantitative	  polymerase	  chain	  reaction	  (qPCR)	  
 
Quantitative real-time polymerase chain reaction (qPCR) was used for quantification of 
cDNA. Reactions were performed in duplicate in white 96-well plates (Eurogentec) in 
LightCycler (Roche). 10µl of '2x Brilliant II qPCR master mix' (Agilent) was used and 
supplemented with 150nM each primer, DNA or cDNA template in MilliQ dH20 for a total 
20ul. The program used for the reactions was: 95°C for 5min, then cycles of 94°C for 15sec, 
55°C for 20sec and 72°C for 20sec, followed by a melt curve ramping from 60-95°C. Roche 
LightCycler 480 qPCR machine was used and fluorescence signal of the SYBR green dye 
was measured after each cycle of PCR.  Primers was designed with an annealing temperature 
of 55°C and a product size of <150bp, and to span a large intron where possible to avoid 
genomic DNA contamination using the 'Primer3' program (http://frodo.wi.mit.edu/primer3/) 
(Table 2.1). A standard curve was generated by 10-fold serial dilution of a cDNA sample, 
and housekeeping genes, such as actb and gapdh, was used to normalise for loading and 
overall efficiency of the cDNA synthesis reaction. Technical or biological replicates were 
performed all the time, the qPCR error (error between the two qPCR replicates) was ignored 
and the standard error was calculated between the technical or biological replicates. Error 
bars denote the standard error of the mean (S.E.M) for each sample.   
 
2.6.5.	  	  Immunofluorescence	  of	  fixed	  cells	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Mouse colon cancer cells CMT93 were seeded on gelatinised glass coverslips at a density of 
2*105 cells per well of a 6-well plate and cultured for 24hr.  The co-transfection with vectors 
expressing epitope- tagged (GFP or FLAG) full length Mbd4 with epitope-tagged (GFP, 
Cherry, or FLAG) interacting candidate proteins. After washed twice in PBS the cells were 
then fixed in 4% formaldehyde (v/v in PBS)(Sigma) for 10min at room temperature with 
gentle rocking. Cells were rinsed 3 times in PBS to remove formaldehyde and then 0.1% 
TritonX-100 (v/v in PBS)(Sigma) was added for 5min at room temperature for cell 
permealisation followed by 2 rinses in PBS.  100µl of block solution (PBS; 0.5% BSA w/v; 
0.1% Tween20 v/v (Sigma); 10% goat serum v/v) was added, and the coverslips were kept in 
a humidified box and and incubated for 30min at room temperature. The primary and 
secondary antibodies were diluted in Goat serum as the secondary antibodies used were 
raised in goat, for minimising background signal produced by secondary antibody binding.  
Primary antibodies (Antibody table 2.2) were diluted 1:100-1:1000 in block solution and 
100µl was added to coverslips.  Clean parafilm tailored to thin plastic strips were used to 
cover the coverslips to prevent them drying. The coverslips were kept in humid box and 
incubated overnight at 4°C.  The second day, coverslips were washed 3 times for 5min in 
PBS with 0.1% Tween20 v/v (Sigma).  Secondary antibodies (Goat α-rabbit IgG-Alexafluor 
Red conjugate (Invitrogen); Goat α-mouse IgG-Alexafluor Green conjugate (Invitrogen)) 
were diluted 1:1000 in block solution added to coverslips in the dark for 1hr at room 
temperature. Coverslips were then washed 3 times for 5min in PBS with 0.1% Tween20 v/v 
(Sigma), and care need to be taken to minimise the light exposure. Coverslips were mounted 
in 'Vectashield' mounting media (Vector Laboratories) (250ng/ml DAPI pre-mixed) and 
viewed using 2 or 3 colour fluorescence microscopy using defined exposure settings.  
Fluorescence images were taken using a Hamamatsu Orca AG CCD camera (Hamamatsu 
Photonics), Zeiss Axioplan II fluorescence microscope with Plan-neofluar objectives and 
Chroma #83000 triple band pass filter set (Chroma Technology), and  'IP Lab' software was 
used for image analysis. 
 
2.6.6.	  	  Protein	  extraction	  from	  E.	  coli	  
 
Standard expression conditions for protein extraction and elution are as follows. 
1. Grow a 5-ml overnight culture at 37°C in BL21-CodonPlus®(DE3)-RIPL cells in Luria-
Bertani (LB) broth supplemented with 50µg/ml ampicillin. 
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2. Subculture this 1:100 into prewarmed 400 ml LB/ampicillin in a baffled 2-liter flask and 
shake at 37° at 250 rpm for 3 h (to mid/late exponential phase, OD600=0.6 to 0.8). Lower 
temperatures can also be used to promote protein solubility; we have used 18, 25, and 30° 
depending on the individual protein. 
3. Add isopropyl-β-d-thiogalactoside (IPTG) to 0.4mM and continue shaking for 4–6 h. The 
IPTG concentration and length of induction can also be varied to optimize the yield of the 
soluble protein.  
4. Harvest cells and resuspend in either 20 ml BugBuster® Protein Extraction Reagent 
(Novagen) with 1µl/ml Benzonase Nuclease (Novagen), or buffer A [50 mM 
Na2HPO4/NaH2PO4, pH 7.4, 300 mM NaCl, 10 mM imidazole, 10 mM 2-mercaptoethanol 
(2-ME), 30% glycerol] containing 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride 
(AEBSF).  The cells were then lysed by sonication (3× 1-min bursts on ice with a microtip) 
or without sonication if use BugBuster reagent. Recover the soluble fraction after 
centrifugation for 30 min at 15,000g at 4°C. 
5. Purify the his-tagged protein by a standard protocol of Nickel agarose purification. 
Proteins are generally eluted with either a Tris- or a phosphate-based buffer containing 200 
mM imidazole, 150–300 mM NaCl, 1 mM 2-ME, and glycerol if required. 
6. After SDS–PAGE analysis to judge yield and purity, dialyze the eluted protein against 
dialysis buffer (50 mM Tris- or phosphate-based buffer, pH 8.0, containing 150–300 mM 
NaCl and 1 mM 2-ME, and glycerol as necessary) to remove imidazole.  
 
2.6.7	  Immunohistochemistry	  on	  human	  primary	  cancer	  tissues	  
 
Tissue microarray (TMA) slides were prepared at 4µm sections, and were deparaffinised in 
xylene and rehydrated in 99%, 80% and 50% ethanol. For antigen retrieval, 0.15mM Sodium 
Citrate, pH6.0 buffer was used. Microwave pressure cooker was used for heat induced 
antigen retrieval for 5min. The sections were cooled down for 10 minutes, followed by rinse 
in 0.05% phosphate buffered saline (PBS, OXOID, #BR0014G)-Tween (Tween20, BIO-
RAD, #170-6531). The sections were blocking in 3% Hydrogen peroxide for 10 minutes and 
serum free protein block (Dako, #X0909) for 10min. The antibody was diluted in antibody 
diluent (Dako, #S0809) with 1:100-1:4000 dilution to determine the optimum concentration. 
The sections were incubated with primary antibodies for either 1 h at room temperature or 
overnight at 4°C. Dako REAL EnvisonTM Detection system (Dako, #K5007) was used for 
staining, which consists of Envision/HRP solution, diaminobenzidine (DAB chromogen) and 
substrate buffer containing hydrogen peroxide. The EnvisionTM/HRP was added onto the 
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sections for 30 min at room temperature, followed by DAB diluted in substrate buffer at a 1 
in 50 dilution for 10 min. The sections were then counterstained in Haematoxylin and Scott’s 
tap substitute. Negative control that has no primary antibody was performed 
 
2.6.8	  Immunofluorescence	  on	  human	  primary	  cancer	  tissues	  
 
The procedures before the incubation of primary antibody were exactly same as described 
above. Slides were then incubated with primary antibodies along with pan-cytokeratin 
(Mouse anti-pan cytokeratin or Rabbit anti-pan cytokeratin) diluted in antibody diluent 
(Dako, #S0809) for 1 h at room temperature  or overnight at 4°C. After rinsing in 0.05% 
PBST, the secondary antibodies (Alexa 555–conjugated goat anti-mouse or goat anti-rabbit 
antibody diluted 1:100 which have conjugated with horseradish peroxidise HRP, Dako, 
#K4001, #K4003) were added and incubated for 1 h at room temperature. The sections were 
then incubated with TSA conjugated with Cyanine 5 (Perkin Elmer, #NEL745) for 10 min to 
visualize the target protein. The sections were mounted with mounting medium (Invitrogen, 
#P36931) containing (DAPI, Invitrogen, #P36931). The slides were dried overnight, and 
then were sealed with nail polish. For long-term storage, slides were kept in dark box at 4°C. 
 
2.6.9	  Expression	  microarray	  
 
Total RNA was extracted from each cell line at four time points in two weeks for biological 
replicates. The Bioanalyzer 2100 (Agilent) quantitative on-chip electrophoresis was used for 
confirmation of the integrity of RNA samples. For mouse Ref-6 v2 Expression BeadChips 
(Illumina), biotinylated cRNA for hybridisation was generated using the TotalPrep RNA 
Amplification kit (Illumina) according to the manufactures instructions. 500ng total RNA 
was used to synthesise double stranded DNA (dsDNA). Biotin labelled cRNA was generated 
using purified dsDNA as a template from 6 hours at 37°C in vitro transcription. The 
biotinylated cRNA was purified and before apply them onto illunina arrays; another 
confirmation of integrity using the Bioanalyzer 2100 was performed. The application of 





2.7.	  	  Bioinformatic	  analyses	  and	  data	  processing	  
 
In general, two methods of the Illumina Beadstudio gene expression module v3.4 and  
Matlab bioinformatics toolbox were used for the bioinformatics analysis and data processing  
in this section. 
 
2.7.1	  Microarray	  analysis	  
 
Beadstudio Gene Expression Module v3.4 (Illumina) was used to analysis the raw data 
generated from microarray. Average normalization and/or quantile normalization were 
adopted with background removal (a set of quantile normalization plottings were in Figure. 
2.2 & 2.3 & 2.4 to show the data plottings before and after normalizations). Bar and line 
charts were drawn in Matlab and Microsoft Excel with error bars representing standard error 
of the mean. MAXY plots were drawn in Matlab.  Boxplots were drawn in Matlab using the 
default settings for whisker length and box height. T-test error model with multiple testing 
corrections using Benjamini and Hochberg false discovery rate was adopted for analysis of 
differential expression. In this occasion, two-tailed Student's T-test was performed to test if 
independent samples are equally large for small numbers of samples or where normality 
could be assumed. For the non-transformed MBD4 knockout cell line, only two pairs of 
samples were microarrayed because of limited cost, and Mann-Whitney-U (MWU) test was 
performed. Mann-Whitney-U (MWU) test (also known as Wilcoxon-Rank-Sum test) is a 
non-parametric test that was used to test if two independent samples are equally large.  
MWU test was used where sample size was sufficiently large and a normal distribution of 
samples could not be assumed.  
For very high-stringent criterion, a primary filter of >5-fold expression change 
threshold was set to determine genes most significantly differentially expressed between 
samples. The detection p- value in the raw data is calculated based on their relative signals to 
negative controls and the genes that have detection p-values of p <0.05 can be considered 
statistically true detected. The expression fold-changes of all the genes (in gene ranking 
table) and probes (in probe ranking table) whose detection p-values <0.05 were ranked. The 
genes that expression fold change larger than 5 fold in both MBD4 knockout cell lines were 
considered as most robust gene candidates. In addition, a 2-fold change stringent was also 






Figure	   2.2.	   Data	   before	   and	   after	   Quantile	   normalisation.	   Boxplots	   of	   the	   log2	  
transformed	  signal	  intensities	  are	  shown	  for	  each	  replicate	  (Vt_WT:	  virus	  transformed	  
cell	   line,	   wildtype;	   Vt_KO:	   virus	   transformed	   cell	   line,	   Mbd4	   knockout;	   Nt_WT:	   non-­‐
transformed	  cell	  line,	  wildtype;	  Nt_KO:	  non-­‐transformed	  cell	  line,	  Mbd4	  knockout).	  The	  
Quantile	   normalisations	   rank	   the	   data	   for	   each	   array,	   take	   the	   average	   value	   at	   each	  
rank	   and	   then	   for	   each	   array	   replace	   the	   expression	   values	   with	   their	   rank	   average	  
value.	   The	   upshot	   of	   this	   is	   that	   the	   data	   in	   each	   array	   then	   has	   exactly	   the	   same	  
distribution.	   Note	   there	   are	   differences	   in	   intensities	   between	   samples	   on	   the	   same	  
chip	   and	   samples	   on	   different	   chips.	   The	   first	   BeadChip,	   containing	   samples	  
Vt_WT&Vt_KO1&2,	   and	   Nt_WT&Nt_KO1,	   seems	   to	   be	   slightly	   more	   variable	   than	   the	  
second	   BeadChip	   containing	   samples	   Vt_WT&Vt_KO3&4,	   and	   Nt_WT&Nt_KO2.	   After	  





Figure.	  2.3.	  MA	  and	  XY	  plots	  showing	  pairwise	  comparison	  of	  the	  arrays	  on	  a	  BeadChip	  
before	  and	  after	  Quantile	  normalization.	  The	  MA	  plots	  for	  all	  pairwise	  comparisons	  are	  
in	  the	  upper-­‐right	  corner.	  In	  the	  lower-­‐left	  corner	  are	  the	  XY	  plots	  of	  the	  comparisons.	  
On	  an	  MA	  plot,	  the	  average	  of	  the	  expression	  levels	  of	  two	  arrays	  ‘A’	  are	  plotted	  on	  the	  x	  
axis,	  and	  the	  difference	  in	  the	  measurement	  ‘M’	  on	  the	  y	  axis.	  An	  XY	  plot	  is	  a	  scatter	  plot	  
of	   one	   array	   against	   another.	   The	   expression	   boxplots	   and	   MAXY	   plots	   reveal	   that,	  
there	   are	  differences	   in	   expression	   levels	  within	   chips	   and	  between	   chips;	  hence,	   the	  








































































































































































































































































































































2.7.2 Gene ontology (GO) and IPA pathway analysis 
 
The program Database for Annotation, Visualization, and Integrated Discovery (DAVID) 
2007 (Dennis et al. 2003) was used for identification of significant gene clusters. Default 
parameters were adopted, and the background was normalised to Illumina BeadChip v2 Ref-
6. Ingenuity Pathway Analysis (IPA) system (Ingenuity Systems, Mountain View, CA, USA, 
www.ingenuity.com) was used for the pathway analysis and visualisation. The datasets 
containing differently expressed genes with their values of fold change were uploaded to the 
application.  
1. Network Generation. Data sets containing gene identifiers and corresponding 
expression values or protein identifiers for protein interactions were uploaded 
respectively into in the application. Each identifier was mapped to its 
corresponding object in the Ingenuity® Knowledge Base. Cutoffs of differential 
gene expression value were not set as the identify molecules whose expression 
were pre-processed and the cutoffs were pre-decided before the upload. These 
molecules, called Network Eligible molecules, were overlaid onto a global 
molecular network developed from information contained in the Ingenuity 
Knowledge Base. Networks of Network Eligible Molecules were then 
algorithmically generated based on their connectivity. 
2. Functional Analysis of an Entire Data Set. The Functional Analysis identified 
the biological functions and/or diseases that were most significant to the data set. 
Molecules were associated with biological functions and/or diseases in the 
Ingenuity Knowledge Base were considered for the analysis. Right‐tailed 
Fisher’s exact test was used to calculate a p‐value determining the probability 
that each biological function and/or disease assigned to that data set is due to 
chance alone. 
3. Functional Analysis of a Network. The Functional Analysis of a network 
identified the biological functions and/or diseases that were most significant to 
the molecules in the network. The network molecules associated with biological 
functions and/or diseases in the Ingenuity Knowledge Base were considered for 
the analysis. Right‐tailed Fisher’s exact test was used to calculate a p‐value 
determining the probability that each biological function and/or disease assigned 
to that network is due to chance alone. 
4. Canonical Pathway Analysis of Entire Data Set. Canonical pathways analysis 
identified the pathways from the IPA library of canonical pathways that were 
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most significant to the data set. Molecules from the data set were associated with 
a canonical pathway in the Ingenuity Knowledge Base were considered for the 
analysis. The significance of the association between the data set and the 
canonical pathway was measured in 2 ways: 1) A ratio of the number of 
molecules from the data set that map to the pathway divided by the total number 
of molecules that map to the canonical pathway is displayed. 2) Fisher’s exact 
test was used to calculate a p‐value determining the probability that the 
association between the genes in the dataset and the canonical pathway is 
explained by chance alone. 
5. Network/My Pathways/ Path Designer Graphical Representation. A network/My 
Pathways is a graphical representation of the molecular relationships between 
molecules. Molecules are represented as nodes, and the biological relationship 
between two nodes is represented as an edge (line). All edges are supported by 
at least one reference from the literature, from a textbook, or from canonical 
information stored in the Ingenuity Knowledge Base. Human, mouse, and rat 
orthologs of a gene are stored as separate objects in the Ingenuity Knowledge 
Base, but are represented as a single node in the network. The intensity of the 
node color indicates the degree of up‐ (red) or down‐ (green) regulation. 
Nodes are displayed using various shapes that represent the functional class of 
the gene product. Edges are displayed with various labels that describe the 
nature of the relationship between the nodes (e.g., P for phosphorylation, T for 

















BL21-CodonPlus®(DE3)-RIPL cells Stratagene 
XL10-Gold Stratagene 
BL21 Gen-X Competent E.coli Genlantis 
 
Table	  2.2.	  Synthetic	  Oligonucleotides	  used	  
Name Reference 5'→3' Sequence 
MedakaMBD4_forward This Report CCTGGGATCCATGAAAAATCACAAAGATGA 
MedakaMBD4_reverse This Report CCTGCTCGAGCAGTGGGAGTGCTTCTGAGG 
xlMBD4_forward This Report CCTGGGATCCAATGTAGATGACAAAAATTC 
xlMBD4_reverse This Report CCTGCTCGAGGTCTCTGTCCTCATCTTCCC 
XlMeCP2_forward This Report CCTGGGATCCAGAGACAGGGGTCCCATGTA 
XlMeCP2_reverse This Report CCTGCTCGAGAGGCTTTTTCGGTTGCTTCT 
MedakaMBD4_New_forward This Report CCTGGGATCCGCCTGCTTTAAAGAACTGAC 
MedakaMBD4_New_reverse This Report CCTGCTCGAGTCTCCTCTGCTTTTGACTCA 
xlMBD4_New_forward This Report CCTGGGATCCGAAAAGAGCCAACTACAAGA 
XlMeCP2_New_forward This Report CCTGGGATCCGCTGTTCCTGAATCTTCTGC 
mMBD4_New_forward This Report CCTGGGATCCGTGATAAGCAGTGAGCGCAG 
mMBD4_New_reverse This Report CCTGCTCGAGCTGCAGGGAAGTCAGAGCTG 
MedakaMBD4_stop_reverse This Report CCTGCTCGAGTCATCTCCTCTGCTTTTGACTCA 
xlMBD4_stop_reverse This Report CCTGCTCGAGTCAGTCTCTGTCCTCATCTTCCC 
XlMeCP2_stop_reverse This Report CCTGCTCGAGTCAAGGCTTTTTCGGTTGCTTCT 
mMBD4_stop_reverse This Report CCTGCTCGAGTCACTGCAGGGAAGTCAGAGCTG 
xlmbd4_full_forward This Report CCTGGGATCCATGGCTGCTCCTGTGCCGGA 






mMBD4_27aahmecp2_f This Report CCTGGGATCCGCTGTGCCGGAAGCTTCTGCCTCCCCCAAACAG
CGGCGCTCCATCATCCGTGACCGGGGACCCATGTATGATGACC
CCACCGTCCCGTGTGGATGGGAAA 
medMBD4_27aahmecp2_f This Report CCTGGGATCCGCTGTGCCGGAAGCTTCTGCCTCCCCCAAACAG
CGGCGCTCCATCATCCGTGACCGGGGACCCATGTATGATGACC
CCACCATGCCTCCAGGCTGGATTA 




Oligos for Y2H 
mMBD4_Y2H_forward This Report CCTGCCATGGGTGATAAGCAGTGAGCGCAG 
mMBD4_Y2H_reverse1 This Report CCTGGGATCCCTGCAGGGAAGTCAGAGCTG 
mMBD4_Y2H_reverse2 This Report CCTGGTCGACCTGCAGGGAAGTCAGAGCTG 
mMBD4_Y2H_newF This Report CCTGCCATGGATGGTGATAAGCAGTGAGCGCAGCTCC 
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mMBD4_Y2H_newR1 This Report CCTGGGATCCTCACTGCAGGGAAGTCAGAGCTGCC 
mMBD4_Y2H_newR2 This Report CCTGGTCGACTCACTGCAGGGAAGTCAGAGCTGCC 
mMBD4_Y2H_fullF1 This Report CCTGCATATGGAGAGCCCAAACCTTGGGGACA 
mMBD4_Y2H_fullR1 This Report CCTGGTCGACTCAAGATAGACTTAATTTTTCATGA 
mMBD4_Y2H_fullF2 This Report CCTGGAATTCATGGAGAGCCCAAACCTTGGGGACA 
mMBD4_Y2H_fullR2 This Report CCTGGGATCCTCAAGATAGACTTAATTTTTCATGA 
 
Oligos for repression test 
pcDNA31_mMBD_F This Report CCTGGGATCCATGGTGATAAGCAGTGAGCGCAGCTCC 
pcDNA31_mMBD_R This Report CCTGCTCGAGTCACTGCAGGGAAGTCAGAGCTGCC 
pcDNA31_mMBD4full_F1 This Report CCTGGCTAGCATGGAGAGCCCAAACCTTGGGGAC 
pcDNA31_mMBD4full_F2 This Report CCTGGGATCCATGGAGAGCCCAAACCTTGGGGAC 
pcDNA31_mMBD4full_R1 This Report CCTGAAGCTTTCAAGATAGACTTAATTTTTCATG 
pcDNA31_mMBD4full_R2 This Report CCTGCTCGAGTCAAGATAGACTTAATTTTTCATG 
pcDNA31_mMBD4full_R3 This Report CCTGGAATTCTCAAGATAGACTTAATTTTTCATG 
mMBD4_repress_fullF1 This Report CCTGAGATCTATGGAGAGCCCAAACCTTGGGGACA 
mMBD4_repress_fullR1 This Report CCTGCTCGAGTCAAGATAGACTTAATTTTTCATGA 
mMBD4_repress_fullF2 This Report CCTGGAATTCATGGAGAGCCCAAACCTTGGGGACA 
mMBD4_repress_fullR2 This Report CCTGCTCGAGTCAAGATAGACTTAATTTTTCATGA 
mMBD4_repress_mbdF1 This Report CCTGAGATCTGTGATAAGCAGTGAGCGCAGC 
mMBD4_repress_mbdR1 This Report CCTGCTCGAGTCACTGCAGGGAAGTCAGAGCTGCC 
mMBD4_repress_mbdF2 This Report CCTGGAATTCGTGATAAGCAGTGAGCGCAGC 
mMBD4_repress_mbdR2 This Report CCTGCTCGAGTCACTGCAGGGAAGTCAGAGCTGCC 
xlMBD4_repress_fullF1 This Report CCTGAGATCTATGGCTGCTCCTGTGCCGGAGAGCCC 
xlMBD4_repress_fullR1 This Report CCTGCTCGAGTCAGTTGAGGCCAAGCTTCTTGTG 
xlMBD4_repress_fullF2 This Report CCTGGAATTCATGGCTGCTCCTGTGCCGGAGAGCCC 
xlMBD4_repress_fullR2 This Report CCTGCTCGAGTCAGTTGAGGCCAAGCTTCTTGTG 
xlMBD4_repress_mbdF1 This Report CCTGAGATCTGAAAAGAGCCAACTACAAGACAGC 
xlMBD4_repress_mbdR1 This Report CCTGCTCGAGTCAGTCTCTGTCCTCATCTTCCCCC 
xlMBD4_repress_mbdF2 This Report CCTGGAATTCGAAAAGAGCCAACTACAAGACAGC 
xlMBD4_repress_mbdR2 This Report CCTGCTCGAGTCAGTCTCTGTCCTCATCTTCCCCC 
 
Oligos for mutagenesis 
ins_18nt_after_455 This Report CTTTAAGAAGGAGATATACATATGCATCATCATCATCATCATC
AAGTTTCAGTTGAAACCACTCAA 
ins_18nt_after_455_antisense This Report TTGAGTGGTTTCAACTGAAACTTGATGATGATGATGATGATGC
ATATGTATATCTCCTTCTTAAAG 
 
Oligos for sequencing 
TF_forward This Report GGAATTCCATATGCAAGTTTCAGTTGAAAC 
TF_reverse This Report GAGCTGATGAACCAGCAGGCGGGATCCCG 
TF_right_reverse This Report CGGGATCCCGCCTGCTGGTTCATCAGCTC 
TF_right1_175 This Report CATAACGCTGAGCGACGATA 
TF_right2_151 This Report TCGGTACTTTGCCTTTACGG 
TF_right3_69 This Report GCTGTCAGCAGCGATTGTAA 
TF_right4_391 This Report CAACAACCGGCTTTTCAACT 
mMBD4_Seq_forward This Report GTGATAAGCAGTGAGCGCAG 
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mMBD4_Seq_reverse This Report CTGCAGGGAAGTCAGAGCTG 
mMBD4_Seq_lprimer545 This Report CTTCAGAGTCGCCAGAAAGC 
mMBD4_Seq_lprimer1056 This Report ACAGGATGGCTCTGAAATGC 
xlMBD4_116R_seq_primer This Report CATTGCCGTATTTGCC 
xlMBD4_559R_seq_primer This Report GTGAAGGTATCAACGTC 
xlMBD4_958R_seq_primer This Report CTACAAACAGTGCTTC 
pcdna3.1_BGH This Report TAGAAGGCACAGTCGAGG 
T7terminator This Report CTAGTTATTGCTCAGCG 
T7_reversed This Report TAATACGACTCACTATA 
 
Probes for EMSAs 
S1(63) (Klose et al., 
2005b) 
GCAGCACGGTGGGGGGCCGGAGTTAAGGACTCGTTGTC 
S2(48) (Klose et al., 
2005b) 
CCAAGGTTGGTCGACCCCGGAGATAACGAAGCTCGGTG 
S3(11) (Klose et al., 
2005b) 
CAAGGAGGGATAGTAGCCGGACAGAAGAAATCTCTGGG 
S4(60) (Klose et al., 
2005b) 
GCTTGACTACCCAGACCCGGGGCGATCAATTACCGTTG 
S5(83) (Klose et al., 
2005b) 
CACTCTGGAAGATACGCCGGGAGTAAGCGAGCTGTAGG 
U6(64B) (Klose et al., 
2005b) 
GCGGTGTTAGGGTCCCCCGGTGCGCCAATGGCTGCTGA 
U7(58B) (Klose et al., 
2005b) 
CGCTCGGGGGGTTGGCCCGGATCCCTGGCACCTCTAGT 
S1reverse  (Klose et al., 
2005b) 
GACAACGAGTCCTTAACTCCGGCCCCCCACCGTGCTGC 
S2reverse  (Klose et al., 
2005b) 
CACCGAGCTTCGTTATCTCCGGGGTCGACCAACCTTGG 
S3reverse  (Klose et al., 
2005b) 
CCCAGAGATTTCTTCTGTCCGGCTACTATCCCTCCTTG 
S4reverse  (Klose et al., 
2005b) 
CAACGGTAATTGATCGCCCCGGGTCTGGGTAGTCAAGC 
S5reverse  (Klose et al., 
2005b) 
CCTACAGCTCGCTTACTCCCGGCGTATCTTCCAGAGTG 
U6reverse  (Klose et al., 
2005b) 
TCAGCAGCCATTGGCGCACCGGGGGACCCTAACACCGC 
U7reverse  (Klose et al., 
2005b) 
ACTAGAGGTGCCAGGGATCCGGGCCAACCCCCCGAGCG 
Sm probe duplex (Prokhortcho




RT-PCR for checking Mbd4 and Tdg knockouts 
F_M4exon3internal (Fiona MacDougall, 2007) TCAAGACACGAAGCAAGTGG 
R_ M4exon3internal (Fiona MacDougall, 2007) CCCTTTCTGTCTCCCTTCG 
F_M4exon2 (Fiona MacDougall, 2007) TACCACAGCGACAGAAGGC 
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R_M4exon4 (Fiona MacDougall, 2007) CTTGTGTCCGTGGGATGC 
M4JF (Fiona MacDougall, 2007) AAGGTGGCACCTAGAGCTGTCG 
M4JR (Fiona MacDougall, 2007) GGATATTCGGTGCTGTCGCTCG 
mTdgEx5 (Fiona MacDougall, 2007) CGGATTCACCAACATGGTGG 
mTdgEx6L (Fiona MacDougall, 2007) GTTTCTGCACCAGGATGCG 
M4KO_F_p1 (Millar et al., 2002b) CGGCTCAGTGGTTTGAGTTGAGTTGTGTTT 
M4KO_R_p3R (Millar et al., 2002b) CACCTTCTGAACCACAGATGCTCTT 
M4KO_p1/2 (Millar et al., 2002b) CTTGGGATCGCTGCAAGGAAGATA 
M4KO_p2 (Millar et al., 2002b) AGTACCACAGCGACAGAAGGCCACAAG 
 
For Mass Spec 
hMBD4mbd_mass_F This Report CCTGGAATTCATGAAAAGAAGCAGTGAATGTAA 
hMBD4mbd_mass_R This Report CCTGGCGGCCGCTAGATGGGATGTCAGG 
hMBD4full_mass_F This Report CCTGGAATTCATGGGCACGACTGGGCTGGAGAG 
hMBD4full_mass_R This Report CCTGGCGGCCGCAGATAGACTTAATTTTTCATG 
mMBD4mbd_mass_F This Report CCTGGCTAGCGTGATAAGCAGTGAGCGCAG 
mMBD4full_mass_F This Report CCTGGCTAGCGAGAGCCCAAACCTTGGGGA 
mMBD4full_mass_R This Report CCTGCTCGAGTCATCAAGATAGACTTAATTTTTC 
 
For MBD4  interaction domain 
hMBD4_F_1_156   This Report CCTGGGATCCggcacgactgggctggagag 
hMBD4_R_1_156   This Report CCTGCTCGAGtttatatcttgacttgatac 
hMBD4_R_1_408   This Report CCTGCTCGAGctgtgttcgtgggatggtat 
hMBD4_F_408_580   This Report CCTGGGATCCcagatagaaagaaggaaaac 
hMBD4_R_408_580   This Report CCTGCTCGAGagatagacttaatttttcat 
hMBD4_F_156_455   This Report CCTGGGATCCaaagactgcagcatggcagc 
hMBD4_R_156_455   This Report CCTGCTCGAGatcatgaaaaagtgtttctt 
 
Primers used for expression analysis from cDNA (all are intergenic) 
RT_Igfbp4_F This Report GAGAAGCCCCTGCGTACAT 
RT_Igfbp4_R This Report GTTGGGATGTTCGCTCTCAT 
RT_Gfpt1_F This Report GAGCTCACCCTCGCTTCTG 
RT_Gfpt1_R This Report CCAAGATTTCTCGTCTTGTTCG 
RT_ Cryl1_F This Report GGGGTGGTGATCGTAGGC 
RT_ Cryl1_R This Report TTTCCAGGGCGTCTGTTATC 
RT_ Dio3_F This Report AGGTTGGTGGTCGGAGAAG 
RT_ Dio3_R This Report AACAGCACGAGGCACGAG 
RT_ Odz4_F This Report GTACTGGAGCCTGGGAACC 
RT_ Odz4_R This Report TCTCTCAGCCTCAGACTGTCC 
RT_ Sdpr_F This Report TGTCCAGGTGAAGAGACTGG 
RT_ Sdpr_R This Report TGGCTCCTTCACAAACACAC 
RT_ Wnt4_F This Report CCTGCGACTCCTCGTCTTC 
RT_ Wnt4_R This Report CTCTGGATCAGGCCTTTGAG 
RT_ C1qtnf3_F This Report TTGCTTTTCCTCCCATTTTG 
RT_ C1qtnf3_R This Report CCTTGGTAACCACGAAATCC 
RT_ Anxa4_F This Report AGACTGGGCGGGTCCTATC 
RT_ Anxa4_R This Report CATGCTGTAGCTCACGTTCAG 
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RT_ Cp_F This Report AGCCTTGGCAAGAGATAAGC 
RT_ Cp_R This Report CGATCTGGACCATTTTGAAG 
RT_ Emb_F This Report TACCCGCTCCTCCTTCTATG 
RT_ Emb_R This Report AAGGTTTGAGTATTTCGCCATC 
RT_ Gjb2_F This Report TTCAGACCTGCTCCTTACCG 
RT_ Gjb2_R This Report GAGGATGCTCTGGAGTGTGC 
RT_ Ifitm1_F This Report GGATCCTAGGCCTTTCCATC 
RT_ Ifitm1_R This Report TCGCAGAAGTTGAGATGTGG 
RT_ Igfbp5_F This Report TTTGCCTCAACGAAAAGAGC 
RT_ Igfbp5_R This Report GAAGACCTTGGGGGAGTAGG 
RT_ Il17d(1-2)_F This Report CAAGTCTGGAAAGCATCACG 
RT_ Il17d(1-2)_R This Report GAGCTGCAGCGTGTGGTG 
RT_ Mtap2_F This Report TTCTTTCCCTCGTTTCTTCG 
RT_ Mtap2_R This Report GAAACTTGGAGCACACAGCA 
RT_ Pcsk6_F This Report CGCACGGCTACCTCAACT 
RT_ Pcsk6_R This Report GGGTCCATTCTGAGGAAGGT 
RT_ Tox_F This Report GCTTGATGTGAGAGTGAAATGG 




Custom oligonucleotides for PCR or DNA sequencing were purchased from Sigma- Aldrich. An 
oligonucleotide stock solution was prepared by the resuspension of lyophilised oligonucleotides in 
dH2O to 100pmol/µl. This stock solution was diluted in dH2O to give a 25pmol/µl PCR primer 
solution or a 1pmol/µl DNA sequencing primer solution. Resuspended oligonucleotides were stored at 
−20°C. 
 
Oligonucleotides used as EMSA assay substrates 
 
Custom oligonucleotides for use as EMSA assay substrates were purchased from Sigma- Aldrich. An 
oligonucleotide stock solution was prepared the same as PCR primers above. 
 
Table	  2.3.	  Plasmids	  used	  
 





Amp Thapa, et al. 2008 
pET21b(-)-6histag-TF-
UB_6histag (atupstream and 
downstream) 
Amp This Report 
pHUE Amp Baker, et al. 2005 
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pHUsp2-cc Amp Baker, et al. 2005 
pHUE-H6‐  
Ub‐M‐GSTP1 
Amp Baker, et al. 2005 
 
For Y2H 
pGBKT7 Kan Clontech 
 
MBD Domain Cloning 
medaka Amp Ruzov, et al. 2009 
xlMBD4 Amp Ruzov, et al. 2009 
xlMeCP2 Amp Ruzov, et al. 2009 
mMBD4 Amp Ruzov, et al. 2009 
 
Repression assay 
PCS2p+eGFPbgl2seq Amp This Report 
PCS2p+nls_eGFPbgl2seq Amp This Report 
pGL3-b-Tex19(+224,-56) Amp This Report 
TK-Renilla Amp Promega 
pCDNA3.1(+) Amp Molecularlab 
IOM20218-pDEST26 Amp imaGenes 
IOM20218-pDEST27 Amp imaGenes 
IOM20218-pdEYFP-C1amp Amp imaGenes 
IOM20218-pT-Rex-DEST31 Amp imaGenes 
pGemT-Easy Amp Promega 
 
Table	  2.4.	  Cell	  culture	  conditions	  and	  genotypes.	  
 
Cell type Genotype Culture Media Passaged 
MEF p53-/- DMEM; 15% FCS; 1xNEAA; 2mM L-Glutamine; 1mM Na Pyruvate; 
1000U/ml Pen; 650µg/ml Strep 
1 in 8 
pMEF WT DMEM; 15% FCS; 1xNEAA; 2mM L-Glutamine; 1mM Na Pyruvate; 
1000U/ml Pen; 650µg/ml Strep 
1 in 6 
293T WT DMEM; 10% FCS; 1000U/ml Pen; 650µg/ml Strep 1 in 10 
CMT93 WT DMEM; 10% FCS; 1000U/ml Pen; 650µg/ml Strep 1 in 10 
MEF Mbd4-/- DMEM; 10% FCS; 1xNEAA; 2mM L-Glutamine; 1mM Na Pyruvate; 
1000U/ml Pen; 650µg/ml Strep 
1 in 10 (virus 
transformed); 
1 in 4 (non-
transformed) 
ES WT, E14 GMEM; 15% FCS; 1xNEAA; 2mM L-Glutamine; 1mM Na Pyruvate; 
0.1mM ß-Mecaptoethanol: 1000U/ml LIF; 1000U/ml Pen; 650µg/ml Strep 
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3.1.	  	  Introduction	  
 
MBD4 has been linked to the mismatch repair pathway as part of a demethylation process (It 
has been implicated as a glycosylase to excise the thymine mismatches generated by 
deaminases); apoptosis signalling and transcriptional repression (Meng et al., 2011). Most of 
these findings started from insights of MBD4 interacting proteins and the relevant potential 
functions of MBD4 were then confirmed and further investigated. For example, a yeast two-
hybrid screen (Y2H) using MLH1 as bait identified MBD4 as candidate interacting protein 
and the subsequent validations and functional investigations confirmed that MBD4 is 
involved in the mismatch repair pathway (MMR) (Bellacosa et al., 1999). Another example 
comes from co-immunoprecipitation of MBD4, where several deaminases such as AID and 
APOBECs were suggested to co-immunoprecipitate with MBD4 in zebrafish tissues, and the 
further investigations implicated MBD4 as a possible component of the demethylation 
process in zebrafish (Rai et al., 2008). MBD4 has a fusion-like domain structure, with an 
MBD domain and a glycosylase domain separated by a ‘desert’ region that exhibits poor 
conservation of amino acid sequence (Figure. 3.1). The fusion-like domain property of 
MBD4 implies that it may perform functions in addition to its activity as a glycosylase. It is 
noteworthy that there were published Y2H studies using MBD4 as bait, however, only a few 
candidates were identified (Millar, 2002), most of which were related to the 
glycosylase/repair function of MBD4. This may be due to a limitation of the cDNA library 
and low-sensitivity Y2H system that was used. For example, Millar chose a mouse brain 
cDNA library as the pool for prey (Millar, 2002),  but the expression of MBD4 in brain is 
very low (based on the BioGPS, www.biogps.org). This suggests that the library is not very 
suitable and that MBD4 interacting proteins that are not expressed in brain could be missed. 
Most of the known MBD4 interacting proteins bind at the C-terminal domain of MBD4 
(Figure. 3.1), with little known about the N-terminal regulatory part of MBD4. Our lab has 
previously identified DNMT1 as a key partner of MBD4, and showed that the N-terminal 
portion containing the MBD domain of MBD4 can account for the association (Ruzov et al., 
2009). In addition, several other MBD4 partners that interact with MBD4 at its N-terminal 
domain have been identified by affinity purification of MBD4 complex, including the afore 
mentioned deaminases and several transcriptional repressors including SIN3a and HDAC1 
(Fukushige et al., 2006, Kondo et al., 2005) (Figure. 3.1). To date, a systematic screen for 
MBD4 interacting protein partners is lacking, which could lead to a better understanding of 




Figure.	  3.1.	  MBD4	  interacting	  proteins	  from	  literature	  review.	  If	  known,	  the	  minimum	  
region	   of	   MBD4	   involved	   in	   the	   interaction	   is	   shown	   below	   each	   protein	   name.	   The	  
proteins	  in	  green	  interact	  with	  MBD4	  at	  its	  N-­‐terminal	  MBD	  domain	  or	  its	  intervening	  




High-throughput methods such as Y2H screening and affinity purification of 
complexes followed by mass spectrometry analysis (AP/MS) are the two most frequently 
used methods for interactomics research (Brückner et al., 2009). Y2H is a well-established 
genetic in vivo approach that allows detection of interacting proteins in living yeast cells 
(Fields and Song, 1989). In Y2H system, interaction of bait protein and prey protein 
activates delicately designed reporter genes, which allow mated yeasts to be screened by 
either chemical or colour selection. Y2H can be performed with high-throughput on a 
genome-wide scale, and the expense is relatively low compared with an equivalent AP/MS 
based method (Brückner et al., 2009). More recently AP/MS has become a powerful tool for 
high-throughput screening of protein interactions (Gloeckner et al., 2007). MS coupled to 
single- or double affinity purification is now routinely applied to identify proteolytic 
fragments of proteins or protein complexes (Fenn et al., 1989). Single step purification such 
as Flag- and Strep- tag can be used for affinity purifications. However, two-step purification 
using the TAP (tandem affinity purification) approach was shown to be more efficient 
(Gloeckner et al., 2007). The idea of TAP is that it contains a fusion of two affinity tags 
partitioned by a protease cleavage site allowing each tag to be used sequentially to purify the 
protein of interest and interacting proteins (Gloeckner et al., 2007). Followed by 
computational analysis of MS data, the background/noise can be dramatically reduced 
compared to single tag purification (Brückner et al., 2009). 
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Y2H and AP/MS approaches detect complementary kinds of protein interactors 
(Brückner et al., 2009). Both approaches may detect binary direct interactions. However, 
Y2H may detect transient and very weak interaction that may be missed in AP/MS, while 
AP/MS may determine all the components of a large complex, which may not be direct 
interactions, and thus could not be identified by Y2H. Both screens may have their own 
limitations and advantages, in terms of their coverage, false-positives, and sensitivities. It is 
noteworthy that a combination of both approaches followed by well-designed bioinformatics 
analysis may lead to a fairly complete interactome data and may therefore facilitate a better 
biological understanding of the targeted proteins. 
To explore the functional repertoire of MBD4 I decided to undertake multiple 
protein interaction studies to determine its potential partner proteins. I performed Y2H with 
an 11.5-day mouse embryonic cDNA library and multiple AP/MS experiments using tagged 
versions of MBD4 that were over-expressed in human cell lines. I detected ~ 380 potential 
interacting candidates with these assays. A significant number of candidates were detected in 
both assay systems. In general, further validations and functional studies of these candidates 
demonstrated the robustness of my initial screens, and suggest that MBD4 may impact 
several transcriptional and epigenetic networks along with a number of nuclear pathways 
that include DNA repair, transcriptional repression through histone and chromatin 
remodellers, and possibly RNA processing. 
 
3.2.	  	  Results	  
 
3.2.1.	  	  Yeast	  two-­‐hybrid	  screens	  with	  full	  length	  and	  MBD	  domain	  of	  MBD4	  
 
Most of the previously suggested MBD4 interacting proteins interact with MBD4 at or near 
its C-terminal glycosylase domain. Specifically, there are ~30-50 amino acids immediately 
upstream of its C-terminal glycosylase domain identified as the minimum interacting region 
for most of the previously suggested MBD4 interactions. It has been previously shown that 
MBD4 interacts directly with both DNMT1 and MLH1, leading to recruitment of all three 
proteins at DNA damage sites (Ruzov et al., 2009). The region that is thought to be 
responsible for the interaction of MBD4 and DNMT1 within MBD4 is its N-terminus MBD 
domain (Ruzov et al., 2009), which suggests that the MBD domain of MBD4 may act as an 
interaction domain in addition to its methyl-CpG binding capability. Thus, initially I 
hypothesised that MBD4 may possess additional functions that are independent of its role as 
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a glycosylase DNA repair protein. The MBD domain of MBD4 may be a region that recruit 
other partners. Herein I started to perform yeast two-hybrid screens using the MBD domain 
and full length Mbd4 protein as baits. 
I chose to work with Clontech Matchmaker™ library construction & screening 
system with a mouse 11.5 days embryo cDNA library. The reason why I used this library is 
that the 11.5 days mouse embryo has passed the early developmental stage which MBD4 
may have less significance as the mice lacking Mbd4 are viable, while the library has 
enriched cDNAs representing the ongoing development of the circulatory system, intestinal 
tract, urogenital system, central nervous system and external form (The Edinburgh Mouse 
Atlas, http://www.emouseatlas.org/). MBD4 is expressed ubiquitously during the mouse 
development and different tissues and organs, suggesting this 11.5 days mouse embryo 
cDNA of late developmental stage might give me potential hits in addition to what has been 
done previously with brain library. I cloned full-length mouse Mbd4 and the MBD domain of 
mouse Mbd4 into the bait vector, pGBKT7. The fusion bait vectors were then transformed 
into yeast-109 strain. The pre-transformed 11.5 days mouse embryo cDNA library for the 
screen was pre-transformed into yeast-187 stain and was commercially available (Clontech). 
The bait protein was expressed as a fusion to the Gal4 DNA-binding domain (DNA-BD), 
while prey proteins in the pre-transformed library are expressed as fusions to the Gal4 
activation domain (AD). When bait and prey proteins interact, the transcription of four 
reporter genes (ADE2, HIS3, MEL1, and LacZ) can be activated, as the Gal4 DNA-BD and 
AD are brought into close proximity. In addition, the bait vector pGBKT7 has TRP1 
sequence, whereas the library vector has LEU2 sequence. This means in theory only diploid 
cells containing bait and prey of positive interacting candidate could grow on the selection 
plates lacking histidine, adenine, leucine and tryptophan. They also express a-galactosidase 
(MEL1), turning blue in the presence of the chromagenic substrate X-α-Gal.  
I performed control experiments first, and confirmed there were no autoactivation 
and toxicity in my baits. I chose quadruple-dropout (SD/-Ade/-His/-Leu/-Trp/X-α-Gal), the 
most stringent selection, for my initial screen, and followed a modified mating protocol to 
increase the mating efficiency (Figure. 3.2). Over 2000 positive colonies of MBD4 full 
length screen grew and turned blue on selection plates, and ~150 positive colonies from 
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Figure.	   3.2.	   Yeast	   two-­‐hybrid	   flow	   chart	   for	   detecting	   MBD4’s	   potential	   interacting	  
partners.	  Picture	  parts	  are	  adapted	  from	  the	  reference	  indicated.	  
 
MBD domain screen. I next performed quality control and identification of cDNA hits. The 
positive colonies showing deepest blue (1440 from MBD4 full length screen, 144 from MBD 
domain screen) were picked out, and were restreaked onto fresh quadruple-dropout selection 
plates for further confirmation of their phenotypes (Figure. 3.3.1). The restreaking can 
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eliminate the false positive colonies on the initial selection plates to increase the chance of 
rescuing the positive prey plasmid, as there may be a mixture of blue and white colonies 
indicating segregation of positive interactors (blue) from non-interactors (white). Colonies 
that have been confirmed by restreaking were picked to perform yeast colony PCRs. I 
decided to directly purify the PCR products and perform sequencing to identify the inserts. 
The majority of interaction candidates were identified by this colony PCR-purification-
sequencing approach. Plasmid-rescue was performed for the positive colonies that failed to 
be sequenced (n=257 (18%) in full length MBD4 screen; n=17 (11%) in MBD domain 
screen) (Figure. 3.3.2). These rescued plasmids were then sequenced. Using a combination 
of these methods, prey cDNAs were identified from all positive colonies (Figure. 3.3.2). The 
cDNA inserts were identified using the sequence search module of Geneious Pro software. 
In total, 230 individual candidates were identified using full-length mouse MBD4 as bait 
(Figure. 3.4) and 29 candidates were identified using the MBD domain as bait (Figure. 3.5). 
Of the 29 candidates found using the MBD domain, 20 candidates (69%) overlap with the 
full-length screen (Suppl Table. 3.1.1 & 3.1.2). This high percentage of overlapping between 
the two Y2H screens demonstrates the technical robustness of the assay. Moreover, Many of 
the candidates received multiple hits, which implies robustness of the screens. For example, 
the top candidate, SRSF2 (also known as SC35) has 116 hits in the MBD4 full length screen, 
as well as 41 hits in the MBD domain screen, suggesting it is a suitable candidate for the 
further validation (Figure. 3.4 & Figure. 3.5). Lastly, I performed a functional annotation of 
these candidates by comparison of both full length and MBD domain screens, and annotated 
them into functional groups. Instead of annotating these candidates using GO terms tool for 
enrichments, I manually classified them into functional groups based on their molecular 
function and biological process in the latest curated Panther classification system. This 
avoids the well-known lack of non-specific annotations in the GO term annotations, as the 
proteins in the Panther system are classified by expert biologists by functions, enabling me to 
look in-depth at the candidates. Interestingly, the proportions of functional groups of MBD 
domain and full-length screens are very similar (Figure. 3.6), and the top biological functions 
include signalling and transcriptional regulation, suggesting that the MBD domain of MBD4 
might have a role that is independent from its glycosylase domain through its association 
proteins. In total over 3000 colony PCRs followed by sequencing, and over 500 plasmid 





























































































































































Figure.	   3.3.2.	   Quality	   control	   and	   identification	   of	   Y2H	   hits.	   There	   are	   in	   total	   1440	  
positive	   colonies	   selected	   from	   the	  MBD4	   full-­‐length	   screen,	   and	   144	   from	   the	  MBD	  
domain	  only	  screen,	  all	  of	  which	  showed	  blue	  phenotype	  on	  the	  initial	  selection	  plates.	  
Many	  colonies	  did	  not	  grow	  when	  re-­‐streaked	  on	  selective	  plates	  (blue	  segments)	  and	  
therefore	   were	   excluded.	   The	   remaining	   colonies	   were	   processed	   by	   colony	   PCRs	  
followed	  by	  sequencing.	  Most	  of	  the	  candidates	  were	  successfully	  identified	  using	  this	  
method	   (red	   and	   purple	   segments).	   The	   colonies	   that	   could	   not	   identified	   using	   this	  
method	  were	   subjected	   to	  plasmid	   rescue	   (green	  and	  yellow	   segments).	   In	   total,	   230	  
individual	   candidates	  were	   identified	   from	   the	  MBD4	   full-­‐length	   screen,	   and	  29	   from	  





Figure.	  3.4.	  Interacting	  candidates	  (gene	  names)	  from	  MBD4	  full	  length	  Y2H	  screen.	  The	  
numbers	   on	   the	   proportional	   pie	   chart	   indicate	   the	   number	   of	   hits	   received	   for	   each	  
prey	  protein.	  The	  genes	  indicated	  only	  by	  GenBank	  accession	  ID	  are	  the	  ones	  that	  have	  






Figure.	   3.5.	   Interacting	   candidates	   (gene	   names)	   from	  MBD	   domain	   Y2H	   screen.	   The	  
numbers	   on	   the	   proportional	   pie	   chart	   indicate	   the	   number	   of	   hits	   received	   for	   each	  
prey	  protein.	  The	  genes	  indicated	  only	  by	  GenBank	  accession	  ID	  are	  the	  ones	  that	  have	  













Figure.	   3.6.	   Functional	   annotations	   of	   MBD4	   interacting	   candidates	   from	   Y2H.	   The	  
candidates	   from	  both	  Mbd4	   full	   length	   Screen	   (A)	   and	  MBD	  domain	   screen	   (B)	  were	  
manually	   curated	   into	   functional	   classes	   based	   on	   the	   Panther	   classification	   system.	  
The	  proportions	  of	  each	  functional	  group	  in	  both	  screens	  are	  similar,	  and	  MBD4	  seems	  
to	   impact	   a	   number	   of	   pathways.	   (C)A	   venn	   diagram	   showing	   that	   most	   of	   the	  
candidates	   from	  the	  MBD	  domain	  screen	  were	  overlapping	  with	  the	  ones	   from	  MBD4	  
full-­‐length	  screen.	  
 
3.2.2.	   	   Identification	   of	   MBD4-­‐associated	   proteins	   by	   co-­‐immunoprecipitation	  
followed	  by	  MS	  analysis	  
 
The large number of potential interacting candidates of MBD4 from my Y2H screens 
representing a diverse of pathways was unexpected, as MBD4 was thought mainly as a repair 
glycosylase protein. The large number of candidates with the possible functional diversity 
indicate that MBD4 might involve in a number of nuclear pathways. An immediate question 
was which candidates I should choose for further validation. Affinity purification followed 
by mass spectrometry (AP/MS) is a quick and efficient way to identify associated proteins 
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(Brückner et al., 2009). Moreover, AP/MS is a complementary approach to Y2H for 
identifying the protein complexes that MBD4 associates with (Brückner et al., 2009). 
Additionally the complete datasets from both high-throughput screens enabled accurate 
functional annotation and network analysis, as the protein-protein databases include curated 
protein associations from both assays of direct interactions and protein complexes. 
I chose to undertake multiple co-immunoprecipitations (co-IPs) followed by MS 
analyses using HEK293T cells as they show high transfection efficiency using standard 
DNA delivery techniques (Abramson et al., 2010). As discussed in section 3.1, the 
development of the tandem affinity purification (TAP) technique increases the efficiency and 
accuracy of large-scale purification of native protein complexes. I decided to use a TAP 
vector called SF-TAP, which combines a tandem Strep-tag II with a FLAG-tag (Gloeckner et 
al., 2007). The advantage of this system is that the size of the TAP (SF-TAP) tag is reduced 
to 4.6 kDa, which is very efficient for cleavage, in comparison with the original 21-kDa TAP 
tag (Gloeckner et al., 2007). I cloned human full length MBD4 into SF-TAP, and 
overexpressed this fusion protein in HEK293T cells. Initially, I followed a two-step protocol; 
the SF-tagged MBD4 and SF-TAP tag protein alone as control were eluted under native 
conditions using desthiobiotin in the first step and the FLAG octapeptide in the second step. 
Bound proteins were then loaded on SDS-PAGE gels and stained with coomassie blue. In 
TAP-tagged MBD4-expressing lanes, more bands were visible than the corresponding 
control lanes (Figure 3.7 B, C and E). The strongest band was observed in the TAP-tagged 
MBD4 expressing lane at expected size of 80–85 kDa (arrows in Figure 3.7 B, C and E) and 
absent from the control lane. This suggests that TAP-tagged MBD4 was successfully 
immunoprecipitated together with a number of partner proteins. Gel slices containing 
individual bands showing a clear difference in the presence or absence of MBD4 were 
excised from both MBD4 expressing lanes and the corresponding control lane (Figure. 3.7 B 
C E brackets and numbers indicated), and were sent to St. Andrews Mass Spec Services for 
MS analysis. Each gel slice identified several protein candidates. Importantly, MBD4 was 
the most abundant protein from the 80–85 kDa band, an indication that the approach was 
successful. The two-step TAP approach resulted in 4 robust hits including PRMT5 (Figure. 
3.7 E), however, it may also remove many real hits due to the stringency of two IPs. As I 
have got a cohort of candidates from Y2H screens, I decided to perform single Flag- and 
single Strep- IP for additional screens, to inclease the IP screen coverage for overlapping 
candidates in both Y2H and AP/MS screens.  
The combined raw data sets of the three single- and double- tagged experiments 
yielded a large number of putative MBD4-associated protein candidates (192 in total). To 
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focus on the most robust candidates and to eliminate false positives, I removed the proteins 
that were also detected in the relevant control lane as well as the proteins that were 
corresponding to known contaminants/false positives (Abramson et al., 2010). Removing 
these proteins yielded ~150 candidates of MBD4 interacting partners from the AP/MS 
screens (Suppl Table 3.2. ~150 candidates). Ten (6.7%) of these candidates overlap with 
Y2H screen. In the MS analysis, the MudPIT (Multidimensional Protein Identification 
Technology) scoring is the standard protein scoring method which calculates the sum of the 
ions scores but exclude the scores for duplicate matches, while the matched query number 
indicates how many non-redundant peptides identified from MS match in the peptide 
databases (Yates et al., 2009). Among the MBD4 associated candidates from the AP/MS, I 
identified 50 protein candidates that stood out with both high-confident MudPIT scores and 
the significant number of queries matched (Figure. 3.8). These 50 significant candidates did 
not only have significant MudPIT scores (Figure. 3.8 all 150 candidates, upper gray bar 
chart), but also were detected by more matched queries than their similar MudPIT 
neighbours (Figure. 3.8 lower blue bar chart). They are indicated in their names and light 
gray bars in the middle of Figure. 3.8.  
The large number of candidates (93.3%) did not overlap with the Y2H screen. This 
is not surprising as Y2H and AP/MS screens detect complementary kind of protein 
interactors as discussed in the introduction section, as well as the system diversity that would 
be expected between the mouse embryo cDNA library and IP host HEK293T kidney derived 
cells. The robustness of these putative associations was then verified by validations of 
selected candidates by reciprocal co-IPs and cellular co-localisation experiments that will be 
discussed in Chapter 4.  An immediate question was whether this set of proteins could imply 
significant functional pathways that MBD4 may impact upon, which would be testable 
direction(s) for further investigation? 
 
3.2.3.  Functional clustering of putative MBD4-interacting proteins by systemic network 
analysis 
 
By the complementary high-throughput screens of Y2H and AP/MS, I have identified a large 
set of potential Mbd4 interacting candidates (n=380), including its possible direct partners 
and protein complex components. The high-percentage of positives in my further validation 
in Chapter 4 and the hits of previously suggested Mbd4 interacting proteins in my screen 




Figure.	   3.7.	   Identification	   of	   Mbd4	   -­‐associated	   proteins	   by	   IP/MS	   screens.	   (A)	   The	  
schematic	  representation	  of	  the	  human	  MBD4	  full	  length	  protein	  fused	  with	  SF-­‐TAP	  at	  
its	  C-­‐terminal.	   (B)	  One	   step	   purification	   using	   FLAG-­‐tag,	   or	   (C)	   Strep-­‐tag	   II.	   (D)	   Flow	  
chart	  of	  the	  SF-­‐TAP	  procedure.	  (E)	  Two	  step	  purification.	  Arrows	  in	  (B)	  (C)	  (E)	  indicate	  
the	  MBD4	  bands.	  The	  representative	  protein	  candidates	   identified	   in	  each	   fraction	  by	  













































































































































































































































































































































































































































































MBD4 associations. Many of the MBD4-associated candidates were indeed previously 
reported to interact with each other. For example, it has been suggested that USP7 and 
UHRF1 interact with and control ubiquitination and stability of the maintenance DNA 
methyltransferase DNMT1 (Felle et al., 2011, Khoronenkova et al., 2011, Du et al., 2010). 
Interestingly, the former two proteins USP7 and UHRF1 were also identified from my 
screens and we have previously shown DNMT1 interacts with MBD4 directly (Ruzov et al., 
2009). I mapped all the protein candidates into existing protein-protein interaction databases, 
prioritised the candidates based on proximity and identified the most valuable ones and/or 
the central hub protein candidates for the further investigations. However, my candidate list 
will inevitably contain a large number of false positives. The Ingenuity knowledge base is a 
repository of biological interactions and functional annotations created from manually 
curated and individually modelled relationships between proteins, genes, complexes, in the 
context of cells and tissues, metabolites, drugs and diseases. I decided to perform a 
functional and network clustering analysis using the Ingenuity Pathway Analysis (IPA) to 
understand the pathways that MBD4 might impact on, as well as to identify the potential 
‘hub’ protein candidates for further investigation. I recognise the cohort of the false positives 
existing in my candidate list may perturb the accuracy of the IPA analysis, however, these 
annotation results are still capable of targeting to the functional role of MBD4 where 
carefully considered with the previously suggested phenotype and functions of MBD4 (I will 
discuss this in the section below). I combined interatomic data from both screens together 
with previously reported MBD4 interacting proteins, and then mapped them into the IPA 
protein-protein interaction database, to identify significant biological functions and canonical 
pathways that MBD4 may involve in (Ingenuity Systems, www.ingenuity.com). The 
function annotations and network clustering are shown in Figure. 3.9 and Supple Figure. 3.1, 





Figure.	   3.9.	   Functional	   annotations	   of	   MBD4	   interacting	   candidates	   from	   Y2H	   and	  
AP/MS	   screens.	   All	   the	   candidates	   from	   both	   screens	   together	   with	   known	   MBD4	  
partners	   were	   mapped	   into	   IPA	   databases.	   Bar	   charts	   represent	   the	   p-­‐value	  
significance,	  in	  which	  Fisher’s	  exact	  test	  was	  used	  to	  calculate	  a	  p‐value	  determining	  
the	  probability	  that	  the	  association	  between	  the	  genes	  in	  the	  dataset	  and	  the	  canonical	  
pathway	   is	   explained	   by	   chance	   alone.	   (the	   bigger	   number	   at	   the	   –log(p-­‐value)	   scale	  
above	   represents	   the	  more	   significant	   category	   group	   in	   the	   cluster,	   a	   threshold	   line	  
was	  automatically	  calculated	  by	   the	  software	   labelled	  by	   the	  yellow	  vertical	   line)	  The	  
yellow	  dots	  in	  (B)	  represent	  the	  ratio	  of	  the	  number	  of	  molecules	  from	  the	  data	  set	  that	  
map	  to	  the	  pathway	  divided	  by	  the	  total	  number	  of	  molecules	  that	  map	  to	  the	  canonical	  
pathway	  whose	  scale	  is	  at	  below.	  
 
 
3.3.	  	  Discussion	  
 
In this chapter I have reported the identification of ~380 potential interacting protein 
candidates of MBD4 by complementary approaches of Y2H and AP/MS. The top candidates 
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in either screen and the overlapping candidates from both screens can be thought as MBD4 
candidate partners for further investigations. In addition, functional analysis of these protein 
candidates imply that MBD4 may impact several transcriptional and epigenetic networks 
along with a number of nuclear pathways that include DNA repair, histone modification and 
chromatin remodeling, and RNA processing.  
MBD4 has been suggested to be involved in many cellular function including DNA 
repair, apoptosis, DNA demethylation and transcriptional repression. However, the precise 
molecular function of MBD4 in these processes remains unknown. My screens provide 
protein candidates for further investigation. Regarding its role in DNA replication, 
recombination and repair, a group of protein candidates are very interesting (Figure. 3.9 A). 
These can be mainly divided into two significant protein clusters (Figure. 3.10. A&B); the 
repair protein cluster (Figure. 3.10 A), and the histone modification and chromatin 
remodeling protein cluster (Figure. 3.10. B). Particularly, the link between the latter cluster 
of candidates with MBD4 is largely unknown. Thus it will be very interesting to look into 
the ‘hub’ candidates in the context of histone modification and chromatin remodeling, to 
investigate if MBD4 has a role in recruiting co-regulators and altering the chromosomal 
organisations to form a suitable local micro-environment for the efficient repair, or 
independent from its repair function (Figure. 3.9 B). This led to our decision to choose a 
number of protein candidates within this cluster including PRMT5, UHRF1, and TRIM28 
for the further validations in chapter 4. Moreover, I tested two independent methods of Y2H 
and AP/MS for detection of Mbd4 associations, in addition to the well-designed controls and 
baits such as MBD domain and full length of MBD4 in Y2H. These enabled me to choose 
the most reliable candidates from these overlapping lists for further validations (See table 
4.1). For example the candidates DEK, SETD1a and USP7, which were identified in both 
Y2H and AP/MS, and SRSF2 which was the top candidate from both MBD domain and full 
length screen in Y2H.  
It is noteworthy that there may be a number of false positives within my screen 
candidates. This may be due to the technical limitations of the Y2H, as well as the less 
stringent threshold I chose in my AP/MS. However, there are three reasons I decided to use 
this set of non-validated protein candidates to perform the IPA pathway analysis for 
prediction of MBD4 functions. Firstly, although the overlapping candidates from both 
screens may be thought as most robust ones for the further investigation, inevitably they lose 
the clues regarding the connections of the individual MBD4 functions, considering the 
pathways MBD4 may involved in are functionally relevant to each other. Thus a systemic 
functional analysis using all these MBD4 screening candidates may take account of all these 
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functional links in the prediction of MBD4 functions. Secondly, in comparison to the protein 
interaction knowledge bases of the functional annotation programmes, which are unbiased 
and stochastic to MBD4 function, the datasets from my MBD4 screening indeed largely tend 
to be MBD4 associated and relevant to MBD4 functions. Thus the probability of identifying 
true biological processes and functional clusters that MBD4 may be involved in is much 
higher than that of false discovery. Thirdly, the existing protein-protein interaction datasets 
is a scale-free network by and large. This is partially because in the past research, ‘valuable’ 
proteins were investigated more extensively and are more well-understood than the others. In 
such context, the ‘hub’ candidates that stood out from the clustering analysis would more 
likely link MBD4 function to well studied pathways that may have significant biological 
relevance. On the other hand, the existing protein interaction datasets from the knowledge 
base of IPA is derived from the expert-curated data from the publications and/or verification 
of protein interaction databases, which may have less false positive data than those of 
predicted protein interaction databases and possibly GO term databases. A functional 
annotation and clustering using this IPA datasets could increase the chance to avoid the false 
positives that is part of the automatic analysis. However, the top ‘hub’ candidates need to be 
carefully validated (See Chapter 4) and the canonical pathways and biological functions 
suggested require thorough consideration together with additional analysis of the 
misregulated gene expression of Mbd4-/- cells and in specific tissue context(s), biological 
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4.1.	  	  Introduction	  
 
The protein associations of MBD4 are of interest as through them MBD4 may be involved in 
a number of pathways and/or they may regulate the activity of MBD4 in biological 
processes. A number of candidates from screens were selected for validation, and 
investigations of the interactions between MBD4 and the validated proteins are presented in 
this chapter. 
 
4.2.	  	  Results	  
 
4.2.1.	  	  Validation	  of	  MBD4	  Protein	  associations	  by	  Reciprocal	  co-­‐IP	  
 
In Chapter 3, I have identified a large number of candidates that potentially associate with 
MBD4. To confirm these associations I performed reciprocal coimmunoprecipitations (co-
IP) followed by western blotting. Since it was impossible for me to verify the interactions for 
all of the ~380 MBD4-associated candidates, I chose four candidates from my Y2H Screen 
and seven candidates from my AP/MS screens (of which three candidate proteins were 
overlapping the ones from Y2H list) (Table 4.1 & 4.2). Most of these chosen candidates have 
known functions that may be linked to transcriptional regulation of MBD4 function, 
including histone modification, chromatin remodelling and components of known repressor 
complexes. As I mentioned in discussion of chapter 3, a transcriptional repression function 
for MBD4 has been reported but the precise mechanism is largely unknown. In addition, my 
top candidate SRSF2 from Y2H might implicate for MBD4 in splicing, thus was also chosen 
because of its possible biological implications. I did not pick all the candidates that are 
overlapping between the screens of Y2H and AP/MS because many of their antibodies and 
plasmids are not immediately available. In addition, I also included three other candidates 
that were not in my screening lists but are the components of multi-protein complex of 
chosen candidates, or within the same domain group of my chosen candidates, including 
CFP1 (form complex with SETD1a), PRMT1 and PRMT3 (same domain group of PRMT5), 
because they are available when we requested plasmids for the potential candidates. And I 
thought they were also very good control in parallel of my validations, to test if the whole 
protein complex is associated with MBD4 or just the single components, or if the whole 
family proteins sharing significant domain structure interacts with MBD4 or just the protein 
identified in the screen. I chose MLH1 as my positive control, as it was the most robust 
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interacting protein of MBD4 in previous publications (Bellacosa et al., 1999, Ruzov et al., 
2009). To serve as negative control, I used empty vector and LEDGF/p75, which was in the 
same vector that my MBD4 was cloned into, and is not expected to associate with MBD4 
(Madapura et al., 2012). I chose to use overexpressed tagged proteins because there were no 
good antibodies for MBD4 at the time. Candidate proteins (tagged with a peptide sequence 
FLAG-, GFP-, or M-Cherry-) were co-transfected with tagged-MBD4 into HEK 293T cells, 
and were immunoprecipitated from whole lysates, followed by western blotting (WB) with 
an MBD4-tag-specific or candidate-tag-specific antibody. A summary of all the validated 
candidates can be found in Table 4.1. 
 
 







Figure.	   4.1.	   Confirmation	  of	  MBD4	  protein	   associations	  by	   reciprocal	   co-­‐IP.	  HEK293T	  
cells	   expressing	   FLAG-­‐	   or	   GFP-­‐	   tagged	   MBD4	   and	   a	   given	   candidate	   interactor,	  
expressed	  exogenously	  as	  an	  HA-­‐,	  FLAG-­‐,	  GFP-­‐,	  or	  Cherry-­‐	   tagged	  protein,	  were	   lysed	  
and	   their	   total	   cell	   extracts	  were	   IPed	  with	   an	   antibody	   directed	   at	   the	   candidate	   or	  
tagged	   MBD4.	   Associations	   between	   MBD4	   and	   the	   candidates	   were	   analysed	   by	  
sequential	  Western	  blotting	  using	  indicated	  antibodies.	  (A)	  5	  candidates	  UHRF1,	  KAP1,	  
PRMT5,	   PRMT3,	   and	   PRMT1	   were	   confirmed	   by	   reciprocal	   co-­‐IP.	   (B)	   4	   candidates	  
USP7,	   ACF1,	   SETD1a,	   and	   CFP1	   were	   confirmed	   by	   one	   FLAG-­‐	   or	   GFP-­‐	   co-­‐IP.	   (C)	  
SRSF2(SC35)	  validation	  was	  negative.	  (D)	  MLH1	  was	  positive	  control,	  and	  LEDGF/P75	  
and	  GFP	  only	  were	  negative	  controls.	  	  
 
The positive control MLH1 showed a robust interaction with MBD4, and the 
negative control LEDGF/P75 were very clear negative in the IP lane, suggesting that my 
reciprocal co-IPs were technically reliable (Figure. 4.1 D). Nine out of eleven protein 
candidates tested showed positive associations with MBD4 by reciprocal co-IPs or single 
side co-IP (Figure. 4.1 A-B), suggesting that these proteins are true Mbd4-interactors (either 
direct or indirect). Among these nine validated protein candidates, five proteins including 
UHRF1, PRMT5, PRMT3, PRMT1, and KAP1 were validated by reciprocal co-IP. Among 
the four other proteins validated by single side co-IPs, USP7 showed robust binding with 
MBD4 in two independent co-IPs where MBD4 was tagged by FLAG or GFP. Another three 
protein candidates including SETD1a, CFP1, and ACF1 can be IPed from GFP- or FLAG- 
tagged MBD4, but failed to be detected in reciprocal IP. However, CFP1 did indeed affect 
the expression level and pattern of MBD4, which is shown later in this chapter and ACF1 did 
tightly colocalise with Mbd4 within nuclei, also shown later in this chapter, indicating their 
associations with MBD4 are true positive. In contrast, two protein candidates DEK and 
SRSF2/SC35 were negative in my co-IPs (Figure. 4.1 C). However, I noticed the FLAG-
DEK expression is pretty low in the input lane, and the GFP-DEK was undetectable under 
the fluorescent microscopy, suggesting it needs further investigation. In addition, 
SRSF2/SC35 was originally screened out from my Y2H, and was the top hit candidate for 
both full length and MBD domain Y2H screens. Due to the technical diversity between Y2H 
and IP, which I have discussed in Chapter 3, it is not unusual that the top hit candidate SC35 
could not be detected in IP validation, as the interaction between SRSF2/SC35 and MBD4 
may be transient or very weak. Notably SRSF2/SC35 did indeed inhibit the expression level 
of MBD4, which is shown in Chapter 4.2.3, indicating there is certain connection between 
SRSF2/SC35 and MBD4. All the co-IPs were repeated at least three times by different wash 
buffers, wash times, and with/without DNase, except ACF1, which was positive at the first 
time but negative at the second essay. However, its mutant GFP-ACF-^BAZ was negative 
(Figure. 4.1. C left), in parallel with its positive result (Figure. 4.1. B upper right), suggesting 
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ACF1 is a true positive MBD4 interacting candiate but further validation is required. In sum, 
the validations by reciprocal IP showed the overall robustness of my Y2H and IP/MS 
screens, and identified a cohort of significant MBD4 interacting proteins for further 
investigations. 
 
4.2.2.	   	   Subcellular	   localisations	  of	  MBD4-­‐Interacting	  Protein	   candidates	  with	   co-­‐
transfection	  of	  MBD4	  analysed	  by	  immunofluorescence	  microscopy	  
 
To test if the chosen candidates occupy the same cellular space with MBD4 (in 2 
dimensions), I performed co-transfection followed by immunofluorescent (IF) microscopy to 
determine their potential co-localisations and subcellular distributions in mouse CMT93 and 
human HEK293T cell lines. If the proteins are concentrated in the same cellular space, it 
would support the idea that they may form stable complexes with MBD4. 
Immunofluorescent microscopy was performed on fixed mouse CMT93 cells after transient 
transfection of FLAG- or GFP- tagged MBD4 and one of the chosen MBD4 interacting 
candidates. The MBD4 and its interacting candidates were either fused to GFP-, M-Cherry- 
fluorescent peptides, or FLAG- tagged which was detected by antibody against FLAG 
peptide and Texas Red- conjugated secondary antibody. A summary of IF microscopy for all 











changes when  
co-transfection 
with MBD4? 
UHRF1 Y N Y  Y 
PRMT5 Y /several spots Y N  Y 
PRMT3 Y Y Y   
PRMT1 Y Y Y /partially   
KAP1 Y Y N   
USP7 Y Y Y Y Y 
SETD1A Y Y /occasionally N  Y 
CFP1 Y Y Y /partially   
ACF1 Y N Y  Y 
DEK Y N Y /partially   
SC35 Y Y /occasionally Y /partially   
MLH1 Y Y Y Y Y 
Table	  4.2.	  List	  of	  MBD4	  associated	  protein	  candidates	  for	  IF	  co-­‐localisation.	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MBD4 and MLH1 
 
Overexpressed MBD4 protein, fused with either GFP or Flag tag, is localized to the 
nucleus, and exhibits concentrated signal at DAPI bright spots, resembling the endogenous 
MBD4 distribution  (Figure. 4.2) (Hendrich and Bird, 1998). The DAPI bright spots 
correspond to methylated satellite DNA, a natural ligand for MBD4 (Ruzov et al., 2009). 
Non-heterochromatic staining of GFP or Flag tagged MBD4 is also clearly observed in 
CMT93 cells. Transfection of MBD4 using vectors expressing GFP-, or FLAG- tagged full-
length mouse or human MBD4 results in the similar nucleus distribution (Figure. 4.2), 
except occasionally cytoplasmic expression can be observed for FLAG tagged human MBD4 
in CMT93 cells (Figure. 4.2 C). The bright staining of MBD4 was concentrated in areas of 
DAPI bright spots, consistent with the localization of MBD4 to heterochromatic regions of 
the nucleus (Ruzov et al., 2009). Co-localization experiments were conducted to characterize 
the associations between the nucleus distributions of MBD4 and its interacting candidates. 
The mouse CMT93 Cell line is a colon cancer cell line with intact heterochromatin sites, and 
was chosen to perform the co-transfection with vectors expressing epitope- tagged (GFP or 
FLAG) full length Mbd4 with epitope-tagged (GFP, M-Cherry, or FLAG) interacting 




Figure.	   4.2.	   MBD4	   localises	   to	   bright	   DAPI	   spots	   that	   are	   tightly	   associated	   with	  
heterochromatic	   condensed	   chromatins.	   A.	   Nuclear	   distribution	   of	   bright	   spots	  
containing	  GFP-­‐mMBD4	  was	   compared	  with	  DAPI	   staining	   in	  mouse	  CMT93	   cells.	   	   B.	  
Nucleus	  distribution	  of	  bright	  spots	  containing	  FLAG-­‐hMBD4	  was	  compared	  with	  DAPI	  
staining	  in	  CMT93	  cells.	  Vectors	  expressing	  FLAG	  tagged	  human	  MBD4	  fusion	  proteins	  
were	   transiently	   transfected	   into	  mouse	   CMT93	   cells,	   and	  were	   detected	   using	   anti-­‐
FLAG	   antibody	   and	   Texas	   Red-­‐	   conjugated	   secondary	   antibody.	   Fixed	   cells	   were	  
counterstained	  with	  DAPI.	  The	  nucleus	  distribution	  of	  overexpressed	  Mbd4	  resembles	  
that	   of	   endogenous	   mMBD4	   (Hendrich	   and	   Bird,	   1998).	   All	   the	   cells	   successfully	  
transfected	  vectors	  containing	  GFP-­‐mMBD4	  and	  almost	  all	  the	  FLAG-­‐hMBD4	  show	  this	  
pattern.	   C.	   Occasionally	   cytoplasmic	   expression	   of	   FLAG	   tagged	   hMBD4	   can	   be	  
observed,	   but	   the	   pattern	   of	   their	   nucleus	   expression	   is	   the	   same	   as	   the	   pattern	  
described	  above.	  
 
I used MLH1 protein as my positive control. In CMT93 cells, the single transfection 
of GFP-Mlh1 showed a diffused localisation pattern in the nucleus and some staining in the 
cytoplasm, and the DAPI bright spots were largely excluded from the distribution of MLH1, 
fitting with previously published results for MLH1 locolisation (Figure. 4.3 A) (Ruzov et al., 
2009). In contrast, after co-transfection of GFP-MLH1 with FLAG-hMBD4, GFP-MLH1 
exhibited a distinct distribution pattern. The distribution of MLH1 became condensed, and 
concentrated at DAPI bright spots, exactly colocalising with MBD4 bright dots in the 
nucleus, where was previously reported to be associated with heterochromatic chromatins 
(Figure. 4.3 B) (Ruzov et al., 2009). My IF results of the positive control MLH1 confirmed 
our previous finding that overexpressed MBD4 recruits MLH1 to DAPI bright 
heterochromatic sites in p53-/- cells (Ruzov et al., 2009), indicating my protocol for IF works 
well. In addition, the successful reproduction of the recruitment of MLH1 to heterochromatic 
chromatin by MBD4 in our new cell model of CMT93 cells served a excellent positive 
control for my IF protocol and cell model in my following observations. 
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Figure.	  4.3.	  MBD4	  recruits	  MLH1	  to	  bright	  DAPI	  spots	  that	  are	  tightly	  associated	  with	  
heterochromatic	   condensed	   chromatins.	   A.	   Diffused	   nucleus	   distribution	   pattern	   of	  
MLH1	   by	   itself	   where	   heavily	   stained	   DAPI	   spots	   were	   excluded	   from	   the	   MLH1	  
distribution.	   Vectors	   containing	   GFP-­‐mMLH1	   were	   transiently	   transfected,	   and	  
compared	  with	  DAPI	   staining	   in	   CMT93	   cells.	   B.	   Co-­‐transfection	   of	   FLAG-­‐hMBD4	  and	  
GFP-­‐MLH1	   into	  mouse	   CMT93	   cells	   results	   in	   the	   recruitment	   of	   GFP-­‐MLH1	   to	   DAPI	  
bright	   spots.	   Vectors	   expressing	   FLAG-­‐hMBD4	   and	   GFP-­‐MLH1	   were	   transiently	  
transfected	  into	  mouse	  CMT93	  cells,	  and	  were	  detected	  using	  anti-­‐FLAG	  antibody	  and	  
Texas	   Red-­‐	   conjugated	   secondary	   antibody.	   These	   results	   repeated	   our	   previous	  
findings	   in	   (Ruzov	  et	   al.,	   2009)	   and	   served	  as	  positive	   control.	  All	   the	   cells	   single-­‐	   or	  





USP7, UHRF1, and ACF1 
 
My MBD4 interacting protein candidate USP7 is M-Cherry tagged and exhibits a nuclear 
distribution (and some in the cytoplasm) that is similar to that of the positive control MLH1 
in both single transfection and co-transfection with MBD4. M-Cherry-USP7 by itself 
distributed a diffused pattern in the nucleus (Figure. 4.4 A), and when cotransfected with 
MBD4, it is clear that MBD4 recruits USP7 to DAPI bright spots (Figure. 4.4 B). This 




Figure.	  4.4.	  MBD4	  recruits	  USP7	   to	  bright	  DAPI	  Spots	   that	  are	   tightly	  associated	  with	  
condensed	   heterochromatic	   chromatins.	   A.	   Diffused	   nucleus	   distribution	   pattern	   of	  
USP7	   by	   itself	   where	   heavily	   stained	   DAPI	   spots	   were	   excluded	   from	   the	   USP7	  
distribution.	   Vectors	   containing	   Mcherry-­‐USP7	   were	   transiently	   transfected,	   and	  
compared	  with	   DAPI	   staining	   in	   CMT93	   cells.	   B.	   Co-­‐transfection	   of	   GFP-­‐mMBD4	   and	  
Mcherry-­‐USP7	  into	  mouse	  CMT93	  cells	  results	   in	  the	  recruitment	  of	  Mcherry-­‐USP7	  to	  
DAPI	  bright	  spots.	  Vectors	  expressing	  GFP-­‐mMBD4	  and	  Cherry-­‐USP7	  were	  transiently	  
transfected	  into	  mouse	  CMT93	  cells.	  All	  the	  cells	  single-­‐	  or	  double	  transfected	  show	  this	  
pattern	  (See	  supplementary	  Figures	  4.3_4.4	  B1&B2).	  
 
 The other MBD4 interacting protein candidate UHRF1 exhibited a nuclear 
distribution that was condensed and colocalised with DAPI bright dots when FLAG-UHRF1 
was overexpressed in CMT93 cells. This is similar to the subcellular distribution of the 
endogenous UHRF1 protein (Bostick et al., 2007) (Figure. 4.5 A). In the cells with a single 
transfection of FLAG-UHRF1, occasionally (one of seven in supplementary figure C1) some 
minor changes in the chromatin morphology is observed where UHRF1 accumulates can be 
observed in the nucleus. This is associated with a reduced DAPI bright spots but the size of 
the cells was normal. However, when FLAG-UHRF1 was co-transfected with GFP-MBD4, 
the chromatin where FLAG-UHRF1 and GFP-MBD4 accumulated exhibited dramatic 
changes (Figure. 4.5 B&C&D) (four of six in supplementary figure C2), and the DAPI bright 
dots were drastically reduced (all the double transfected cells). The size of the co-transfected 
cells was much bigger than the untransfected controls (four of six in supplementary figure 
C2), and the chromatins were either very condensed in a fragmented manner or a continued 
distribution. In both cases, MBD4 was tightly colocalised with UHRF1, and some of the 







Figure.	   4.5.	  MBD4	  colocalises	  with	  UHRF1	   causing	  dramatic	   changes	  of	   chromatins	  &	  
disappearance	  of	  DAPI	  bright	  spots.	  A.	  Nucleus	  distribution	  of	  bright	  spots	  containing	  
FLAG-­‐UHRF1	   was	   compared	   with	   DAPI	   staining	   in	   CMT93	   cells.	   Vectors	   expressing	  
FLAG	   tagged	  UHRF1	   fusion	   proteins	  were	   transiently	   transfected	   into	  mouse	   CMT93	  
cells.	  Fixed	  cells	  were	  counterstained	  with	  DAPI.	  B.	  Co-­‐transfection	  of	  GFP-­‐mMBD4	  and	  
FLAG-­‐UHRF1	   into	  mouse	   CMT93	   cells	   results	   in	   the	   significant	   changes	   at	   chromatic	  
sites	   (see	   C&D).	   Overexpressed	   MBD4	   and	   UHRF1	   tightly	   colocalise	   together,	   and	  
bright	   DAPI	   spots	   associated	   with	   heterochromatic	   chromatins	   disappeared.	   In	  
addition,	  the	  nucleus	  size	  of	  over	  half	  of	  all	  the	  double	  transfected	  cells	  are	  much	  bigger	  
than	   the	   single	   transfected	   cells	   containing	  MBD4	   or	   UHRF1	   (See	   C&D,	   and	   also	   see	  
supplementary	   Figure	   4.5_4.6	   C1&C2).	   	   Vectors	   expressing	   GFP-­‐mMBD4	   and	   FLAG-­‐
UHRF1	  were	  transiently	  transfected	  into	  mouse	  CMT93	  cells,	  and	  were	  detected	  using	  
anti-­‐FLAG	   antibody	   and	   Texas	   Red-­‐	   conjugated	   secondary	   antibody.	   All	   the	   single	  
transfected	   cells	   and	   over	   half	   of	   double	   transfected	   cells	   show	   this	   pattern	   (See	  
supplementary	   Figure.	   4.5_4.6	   C1&C2).	   Other	   double	   transfected	   have	   no	   change	   at	  
their	  nucleus	  size	  but	  cells	  also	  show	  significant	  chromatic	  changes	  (See	  supplementary	  
Figure.	  4.5_4.6	  C1&C2).	  	  	  
 
A third candidate ACF1 showed a tight co-localisation with MBD4 (Figure. 4.6). 
ACF1 co-localises with DAPI bright spots in the nucleus when singly overexpressed. In the 
cells co-transfected with ACF1 and MBD4, they were both concentrated and some of them 
(~70-80%) became larger condensed bight spots, colocalising with the DAPI bright regions, 
exhibiting a possible chromatin remodeling event happening at the heterochromatic sites. 
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Figure.	   4.6.	   MBD4	   colocalises	   with	   ACF1	   at	   DAPI	   bright	   spots	   showing	   a	   condensed	  
pattern	   of	   distribution.	   A.	   Nucleus	   distribution	   of	   speckles	   containing	   GFP-­‐ACF1	  was	  
compared	   with	   DAPI	   staining	   in	   CMT93	   cells.	   Vectors	   expressing	   GFP	   tagged	   ACF1	  
fusion	  proteins	  were	  transiently	  transfected	  into	  mouse	  CMT93	  cells.	  Fixed	  cells	  were	  
counterstained	   with	   DAPI.	   B.	   Co-­‐transfection	   of	   FLAG-­‐hMBD4	   and	   GFP-­‐ACF1	   into	  
mouse	   CMT93	   cells.	   Overexpressed	   MBD4	   and	   ACF1	   tightly	   colocalise	   together	   in	   a	  
condensed	   manner	   at	   bright	   DAPI	   spots.	   Vectors	   expressing	   FLAG-­‐hMBD4	   and	   GFP-­‐
ACF1	  were	   transiently	   transfected	   into	  mouse	   CMT93	   cells,	   and	  were	   detected	   using	  
anti-­‐FLAG	  antibody	  and	  Texas	  Red-­‐conjugated	  secondary	  antibody.	  ~70-­‐80%	  of	  single	  







KAP1, PRMT5, CFP1 and SETD1a 
 
In CMT93 cells, overexpressed FLAG-KAP1 exhibits a general diffused distribution in 
whole cell or only in the nucleus but it is excluded from the DAPI bright spots (Figure. 4.7 
A). This staining pattern of KAP1 can be observed in all the single FLAG-KAP1 transfection 
and the co-transfection of FLAG-KAP1 with GFP-MBD4. Occasionally several large 
condensed staining foci of FLAG-KAP1 can be observed in the cytoplasm and tightly 
attached to the nuclear membrane in both single- and co-transfection (1 of 5 in 
Supplementary Figures E1&E2). It is noteworthy that the KAP1 distribution was reported to 
be very dynamic depend on the cell differentiation stage, the cell types and endogenous or 
ectopic conditions, thus it is not surprising that the distribution of overexpressed KAP1 in 
CMT93 cells was very different and might be artificial. However, it is notable that KAP1 
distribution in all my essays was excluded from GFP-MBD4 and DAPI bright spots, but 
tightly surrounded them (Figure. 4.7 B&C), which is consistent with the previous 
observations that KAP1 was not seen concentrated at the visible domains of constitutive 
heterochromatin in differentiated mouse cells, even in cells where KAP1 is concentrated 






Figure.	  4.7.	  KAP1	  does	  not	  colocalise	  with	  MBD4	  and	  bright	  DAPI	  spots	  but	  its	  diffused	  
distribution	  tightly	  surrounds	  Mbd4	  and	  DAPI	  bright	  spots.	  However,	  it	  is	  noteworthy	  
that	   the	   unusual	   distribution	   of	   overexpressed	   KAP1	   may	   be	   artificial.	   A.	   Nucleus	  
distribution	   of	   KAP1	   was	   compared	   with	   DAPI	   counterstaining.	   Vectors	   containing	  
FLAG-­‐KAP1	   were	   transiently	   transfected	   into	   CMT93	   cells,	   and	   were	   detected	   with	  
anti-­‐FLAG	  antibody	  and	  Texas	  Red-­‐conjugated	  secondary	  antibody.	  The	  overexpressed	  
KAP1	  exhibits	  diffused	  general	  distribution	  in	  whole	  cell	  or	  only	  in	  nucleus.	  The	  bright	  
DAPI	  spots	  were	  excluded	  from	  such	  diffused	  distribution	  of	  KAP1.	  B.	  GFP-­‐mMBD4	  and	  
FLAG-­‐KAP1	   were	   transiently	   expressed	   together	   and	   compared	   with	   DAPI	   staining.	  
Overexpressed	  MBD4	  colocalises	  with	  DAPI	  bright	  spots,	  whereas	  KAP1	  shows	  diffused	  
general	  distribution	  in	  whole	  cell	  or	  in	  nucleus	  the	  same	  as	  controls,	  but	  excluded	  from	  
DAPI	   and	  MBD4	  bright	   spots.	   (See	  C)	  All	   the	   cells	   single-­‐	  or	  double	   transfected	   show	  
this	  pattern	  (See	  supplementary	  Figure.	  4.7_4.8	  E1&E2).	  
 
Consistent with the previous publication regarding the dynamic distribution of 
PRMT5 during development and in different cell types (Tee et al., 2010, Zhao et al., 2009), 
FLAG-PRMT5 in mouse CMT93 cells showed highly condensed spots in cytoplasm, but 
surrounded the nucleus tightly (Figure. 4.8 A). However, several single or twin bright spots 
of FLAG-PRMT5 are clearly located within nucleus in both single- and co-transfection with 
MBD4 (Figure. 4.8 A&B). The bright spots of FLAG-PRMT5 do not colocalise with MBD4 
and DAPI bright spots (Figure. 4.8 C), however, in about half of the co-transfected cells, 
dramatic changes were observed at the condensed chromatins where MBD4 and DAPI bright 
spots colocalised (See Supple Figure. F1&F2). Notably, in such regions within the nucleus, 
FLAG-PRMT5 spots were surrounded by MBD4 located chromatin, indicating a potential 
cross-talk between MBD4 and PRMT5 at the loci (Figure. 4.8 C). In contrast, Overexpressed 
FLAG tagged PRMT1 and PRMT3 showed a general diffused staining in both cytoplasm 
and nucleus but some of the bright DAPI spots were excluded (Figure. 4.9-4.10). In both 
single- and co-transfection with MBD4, FLAG tagged PRMT1 and PRMT3 partially 











Figure.	  4.8.	  Ectopic	  PRMT5	  mainly	  expresses	  in	  cytoplasm	  and	  does	  not	  colocalise	  with	  
MBD4	   and	   bright	   DAPI	   spots.	   Although	   a	   few	   PRMT5	   expressions	   does	   distribute	   as	  
spots	  in	  nucleus,	  they	  are	  clearly	  not	  colocalised	  with	  MBD4	  spots.	  However,	  half	  of	  the	  
double	   transfected	   cells	   show	   a	   pattern	   that	   the	   PRMT5	   spots	   in	   nucleus	   are	  
surrounded	  by	  MBD4	  expression,	  and	  dramatic	  changes	  in	  chromatin	  organisation	  can	  
be	  observed	  at	  MBD4	  expression	  sites	  (See	  C	  &	  also	  see	  supplementary	  Figure.	  4.7_4.8	  
F1&F2).	   	  A.	  Nucleus	  distribution	  of	  PRMT5	  was	  compared	  with	  DAPI	  counterstaining.	  
Vectors	   containing	   FLAG-­‐PRMT5	   were	   transiently	   transfected	   into	   CMT93	   cells,	   and	  
were	  detected	  with	  anti-­‐FLAG	  antibody	  and	  Texas	  Red-­‐conjugated	  secondary	  antibody.	  
The	   overexpressed	   PRMT5	   exhibits	   condensed	   distribution	   in	   cytoplasm	   attaching	  
nucleus,	  and	  several	  separated	  PRMT5	  spots	  are	  in	  nucleus.	  B.	  GFP-­‐mMBD4	  and	  FLAG-­‐
PRMT5	   were	   transiently	   expressed	   together	   and	   compared	   with	   DAPI	   staining.	  
Overexpressed	   MBD4	   colocalises	   with	   DAPI	   bright	   spots	   that	   are	   associated	   with	  
heterochromatic	  chromatins.	  About	  half	  of	  the	  double	  transfected	  cells	  show	  changes	  at	  
MBD4	  highly	  expressing	  chromatins,	  Surrounding	  the	  PRMT5	  spots	  in	  nucleus	  (See	  C	  &	  




Figure.	  4.9.	  PRMT3	  shows	  ubiquitous	  distribution	  in	  the	  whole	  cell	  body	  and	  colocalises	  
with	  MBD4	  and	  bright	  DAPI	  spots.	  A.	  Distribution	  of	  PRMT3	  was	  compared	  with	  DAPI	  
counterstaining.	   Vectors	   containing	   FLAG-­‐PRMT3	   were	   transiently	   transfected	   into	  
CMT93	   cells,	   and	   were	   detected	   with	   anti-­‐FLAG	   antibody	   and	   Texas	   Red-­‐conjugated	  
secondary	   antibody.	  The	  overexpressed	  PRMT3	  exhibits	   diffused	   general	   distribution	  
in	  whole	  cell.	  The	  bright	  DAPI	  spots	  were	  colocalised	  with	  such	  diffused	  distribution	  of	  
PRMT3.	   B.	   GFP-­‐mMBD4	   and	   FLAG-­‐PRMT3	   were	   transiently	   expressed	   together	   and	  
compared	  with	  DAPI	  staining.	  Overexpressed	  MBD4	  colocalises	  with	  DAPI	  bright	  spots,	  
whereas	   PRMT3	   shows	   diffused	   general	   distribution	   the	   same	   as	   controls,	   but	   No	  
bright	  spots	  of	  PRMT3	  were	  observed.	  All	  the	  cells	  single-­‐	  or	  double	  transfected	  show	  





Figure.	   4.10.	   PRMT1	   shows	   a	   diffused	   distribution	   in	   both	   cytoplasm	   and	   nucleus,	  
partially	   colocalises	  with	  MBD4	  and	  bright	  DAPI	   spots.	  A.	  Distribution	  of	  PRMT1	  was	  
compared	   with	   DAPI	   counterstaining.	   Vectors	   containing	   FLAG-­‐PRMT1	   were	  
transiently	   transfected	   into	  CMT93	   cells,	   and	  were	  detected	  with	   anti-­‐FLAG	   antibody	  
and	   Texas	   Red-­‐conjugated	   secondary	   antibody.	   The	   overexpressed	   PRMT1	   exhibits	  
diffused	   general	   distribution	   in	   the	   whole	   cell.	   The	   bright	   DAPI	   spots	   were	   partially	  
colocalised	  with	  such	  diffused	  distribution	  of	  PRMT1.	  B.	  GFP-­‐mMBD4	  and	  FLAG-­‐PRMT1	  
were	  transiently	  expressed	  together	  and	  compared	  with	  DAPI	  staining.	  Overexpressed	  
MBD4	   colocalises	   with	   DAPI	   bright	   spots,	   and	   PRMT1	   shows	   diffused	   distribution	  
mainly	   in	   the	  nucleus,	  and	  partially	   colocalises	  with	  DAPI	  and	  MBD4	  bright	   spots.	  All	  




Similar to their endogenous expression (Lee and Skalnik, 2002), overexpressed 
FLAG-CFP1 and FLAG-SETD1a proteins were localized to the nucleus in CMT93 cells and 
exhibits a punctate or sparkle distribution (Figure. 4.11-4.12 A). These speckles are 
concentrated in areas of DAPI light staining and are clearly excluded from the DAPI and 
MBD4 bright spots, consistent with their localizations to euchromatic regions of the nucleus 
(Lee and Skalnik, 2002). Some sparkles or dense staining of FLAG-CFP1 can be observed in 
cytoplasm, and the same was observed in several SETD1a transfected cells. Notably, their 
distribution only partially overlapped with co-transfected GFP-MBD4. The MBD4 
distribution was largely not affected when cotransfected with CFP1 or SETD1a in CMT93 
cells (Figure. 4.11-4.12 B). 
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Figure.	  4.11.	  CGBP	  (CFP1)	  localises	  to	  nucleus	  speckles	  in	  MBD4	  and	  DAPI	  light	  regions.	  
A.	   Nucleus	   distribution	   of	   sparkle	   pattern	   of	   FLAG-­‐CGBP	   fusion	   proteins	   (like	  
endogenous	  CGBP	  protein)	  was	  detected	  in	  CMT93	  cells	  using	  anti-­‐FLAG	  antibody	  and	  
Texas	  Red-­‐conjugated	  secondary	  antibody.	  Fixed	  cells	  were	  counterstained	  with	  DAPI	  
and	  observed	  by	   fluorescent	  microscopy.	  Vectors	  expressing	  FLAG-­‐tagged	  CGBP	  were	  
transiently	  transfected	  into	  CMT93	  cells.	  B.	  Nucleus	  distribution	  of	  speckles	  containing	  
GFP-­‐CGBP	   was	   compared	   with	   GFP-­‐mMBD4	   and	   DAPI	   staining	   in	   CMT93	   cells.	  
Overexpressed	   MBD4	   colocalises	   with	   DAPI	   bright	   spots,	   and	   CGBP	   shows	   sparking	  
distribution	  mainly	   in	  nucleuss,	   and	  partially	   colocalises	  with	  DAPI	   and	  MBD4	  bright	  
spots.	  All	  the	  cells	  single-­‐	  or	  double	  transfected	  show	  this	  pattern	  (See	  supplementary	  





Figure.	  4.12.	  SETD1a	  shows	  diffused	  distribution	  in	  nucleus,	  excluded	  from	  MBD4	  and	  
bright	  DAPI	  spots.	  A.	  Distribution	  of	  SETD1a	  was	  compared	  with	  DAPI	  counterstaining.	  
Vectors	   containing	   FLAG-­‐SETD1a	  were	   transiently	   transfected	   into	   CMT93	   cells,	   and	  
were	  detected	  with	  anti-­‐FLAG	  antibody	  and	  Texas	  Red-­‐conjugated	  secondary	  antibody.	  
The	  overexpressed	  SETD1a	  exhibits	  diffused	  general	  distribution	  in	  nucleus.	  The	  bright	  
DAPI	  spots	  were	  excluded	   from	  such	  diffused	  distribution	  of	  SETD1a.	  B.	  GFP-­‐mMBD4	  
and	   FLAG-­‐SETD1a	   were	   transiently	   expressed	   together	   and	   compared	   with	   DAPI	  
staining.	  Overexpressed	  MBD4	  colocalises	  with	  DAPI	  bright	  spots,	  and	  SETD1a	  shows	  
diffused	  distribution	  mainly	  in	  nucleus,	  and	  excluded	  from	  DAPI	  and	  MBD4	  bright	  spots	  




DEK and SRSF2/SC35 
 
Overexpressed FLAG-DEK and GFP-SC35 exhibit overall diffused distribution in nucleus, 
but with nucleoli excluded from their distribution. Most of the DAPI bright spots were 
excluded from the FLAG-DEK and GFP-SC35 distribution (Figure. 4.13-4.14 A). when co-
transfected with MBD4, a small fraction of MBD4-containing spots co-localized with the 
RNA splicing factor GFP-SC35 and oncogene FLAG-DEK. However, It is noteworthy that 
the overall distribution of MBD4 is clearly distinct from that of GFP-SC35 and FLAG-DEK 





Figure.	   4.13.	   DEK	   shows	   a	   diffused	   distribution	   in	   nucleus,	   partially	   overlaps	   with	  
MBD4	   and	   bright	   DAPI	   spots.	   A.	   Distribution	   of	   DEK	   was	   compared	   with	   DAPI	  
counterstaining.	   Vectors	   containing	   FLAG-­‐DEK	   were	   transiently	   transfected	   into	  
CMT93	   cells,	   and	   were	   detected	   with	   anti-­‐FLAG	   antibody	   and	   Texas	   Red-­‐conjugated	  
secondary	   antibody.	   The	   overexpressed	  DEK	   exhibits	   diffused	   general	   distribution	   in	  
nucleus.	  The	  bright	  DAPI	  spots	  were	  partially	  overlap	  with	  such	  diffused	  distribution	  of	  
DEK.	   B.	   GFP-­‐mMBD4	   and	   FLAG-­‐DEK	   were	   transiently	   expressed	   together	   and	  
compared	  with	  DAPI	  staining.	  Overexpressed	  MBD4	  colocalises	  with	  DAPI	  bright	  spots.	  
DEK	  shows	  diffused	  distribution	  in	  nucleus,	  and	  partially	  overlap	  with	  DAPI	  and	  MBD4	  
bright	   spots.	   All	   the	   cells	   single-­‐	   or	   double	   transfected	   show	   this	   pattern	   (See	  





Figure.	  4.14.	  SC35	  shows	  diffused	  distribution	  in	  nucleus,	  partially	  overlaps	  with	  MBD4	  
and	   bright	   DAPI	   spots.	   A.	   Distribution	   of	   SC35	   was	   compared	   with	   DAPI	  
counterstaining.	  Vectors	  containing	  GFP-­‐SC35	  were	  transiently	  transfected	  into	  CMT93	  
cells.	   The	   overexpressed	   SC35	   exhibits	   diffused	   general	   distribution	   in	   nucleus.	   The	  
bright	  DAPI	  spots	  were	  partially	  overlapping	  with	  such	  diffused	  distribution	  of	  SC35.	  B.	  
FLAG-­‐hMBD4	  and	  GFP-­‐SC35	  were	   transiently	   expressed	   together	   and	   compared	  with	  
DAPI	   staining.	   Overexpressed	   MBD4	   colocalises	   with	   DAPI	   bright	   spots,	   and	   SC35	  
shows	  diffused	  distribution	  with	  sparkling	  in	  nucleus,	  and	  partially	  overlap	  with	  DAPI	  
and	  MBD4	   bright	   spots.	   All	   the	   cells	   single-­‐	   or	   double	   transfected	   show	   this	   pattern	  
(See	  supplementary	  Figure.	  4.13_4.14	  L1&L2).	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4.2.3.	   	   Some	   MBD4-­‐associated	   Proteins	   affect	   the	   nucleus	   localization	   and	  
expression	  intensity	  of	  MBD4	  when	  over-­‐expressed	  
 
By IP and IF, I have validated several robust MBD4-interacting proteins such as UHRF1, 
USP7, and ACF1. However, there are some candidates in my validation list can be 
immunoprecipitated but their distribution patterns were largely distinct from that of MBD4. I 
then addressed if the expression level or pattern of MBD4 could be affected by co-
transfection of these candidates. I co-transfected GFP tagged MBD4 and the chosen 
candidates into HEK293T cells. Surprisingly, although the nucleus distribution of KAP1, 
CFP1 and SC35 were entirely distinct from that of MBD4 in mouse CMT293T cells, they 
did indeed affect both expression intensity and distribution pattern of GFP-MBD4 in 293T 
cells. Overexpressed KAP1 and CFP1 can largely increase the expression intensity of 
cotransfected GFP-MBD4, whereas overexpressed SC35 and USP7 decreases the intensity of 
GFP-MBD4 (Figure 4.15). The distribution patterns of MBD4 were completely changed by 
the cotransfections of FLAG tagged KAP1 and CFP1, concentrating at the nucleus periphery 
in cotransfection with KAP1, while becoming very condensed in the case of CFP1. It is 
noteworthy that my reciprocal co-IPs were performed in 293T cells. In CMT93 cells, I could 
not observe such changes. However, at least in 293T cells, it is very clear that these MBD4 
associated proteins including KAP1, CFP1, USP7, and SC35 affected the nuclear 








Figure.	  4.15.	  MBD4	  associated	  protein	  candidates	  can	  influence	  the	  expression	  intensity	  
and	  pattern	  of	  MBD4.	  The	  GFP-­‐tagged	  MBD4	  was	  transiently	  transfected	  into	  293T	  cells	  
singly	  (A.	  upper	  left)	  or	  co-­‐transfected	  with	  respective	  interacting	  candidates.	  (A.	  upper	  
right)	  SC35	  decreases	  the	  expression	   intensity	  of	  MBD4	  at	  ~26%,	   in	  contrast	  to	  CFP1	  
(A	  lower	  left,	  increase	  ~28%)	  and	  KAP1	  (A.	  lower	  right,	  increase	  ~15%)	  that	  increases	  
or	   stabilises	   MBD4	   expression.	   (B)	   Single	   transfection	   of	   MBD4	   shows	   a	   ubiquitous	  
expression	   within	   nucleuss	   in	   293T	   cells,	   with	   little	   bright	   spots	   inside	   (Left).	   In	  
contrast,	   co-­‐transfection	   of	   KAP1	   results	   in	   the	   accumulation	   of	  MBD4	   expression	   at	  
nucleus	   peripheral	   (middle),	   and	   MBD4	   shows	   a	   condensed	   distribution	   of	   MBD4	  
within	  nucleus	  when	  co-­‐transfected	  with	  CFP1	   (right).	   (C)	   In	   a	   certain	   concentration,	  
the	  intensity	  of	  MBD4	  can	  be	  influence	  dramatically	  by	  co-­‐transfection	  of	  its	  associating	  
protein	   candidates.	   In	   this	   batch	   of	   transfections,	   SC35	   decreases	   the	   expression	   of	  
MBD4	   at	   similar	   level	   (upper	   left),	   in	   contrast	   to	   KAP1	   that	   increases	   and	   stabilises	  
MBD4	  expression	  dramatically	  at	  this	  time	  at	  ~	  282%	  (lower	  right).	  Co-­‐transfections	  of	  
ERα	  (upper	  right)	  was	  similar	  to	  the	  single	  transfection	  of	  MBD4	  (A	  upper	  left).	  USP7	  
(lower	   left)	   decreased	  MBD4	  expression	   at	  ~33%.	  All	   the	  pictures	  were	   taken	   at	   full	  
confluence	  and	  where	  possible	  at	  the	  regions	  that	  no	  overlapping	  cells	  were	  observed.	  
Mean	  Intensities	  were	  calculated	  by	  ImageJ,	   in	  which	  the	  total	   intensity	  of	  the	  picture	  
was	  divided	  by	  the	  total	  area	  of	  the	  picture.	  All	  the	  mean	  intensities	  were	  normalised	  to	  
the	  picture	  of	  double	  transfection	  of	  MBD4	  and	  SC35.	  As	  I	  chose	  full	  confluence	  regions	  
in	  all	  the	  transfections	  to	  take	  picture,	  I	  assume	  the	  total	  number	  of	  cells	  in	  each	  picture	  
were	  roughly	  similar.	  Thus	  the	  ratios	  of	  intensity	  changes	  can	  be	  considered	  as	  a	  rough	  
measurement	   to	  give	  a	  brief	   idea	  how	  much	  changes	   in	  each	  pictures	  compared	  with	  
the	  GFP-­‐MBD4	  single	  transfection	  control	  (Millar,	  2002).	  
 
4.2.4.	  	  Identification	  of	  the	  interacting	  domains	  of	  MBD4	  responsible	  for	  candidate	  
binding	  by	  pull	  down	  assays.	  
 
In order to define the interacting domains within MBD4 responsible for its associations with 
the identified MBD4 interacting proteins, I made different mutants of MBD4 that were 
extracted and purified in vitro from E.coli. Subsequently I characterised the interacting 
domains of MBD4 responsible for the associations with the identified interacting proteins by 
reciprocal pull down assays. Four truncated versions of MBD4 (Figure. 4.16A) were 
generated and expressed in E.coli as HIS-tagged fusion proteins (Figure. 16B). The HIS-
tagged fusion mutants have a thermostable protein called trigger factor as well as ubiquitin at 
its upstream (Figure. 4.16B), which make the fusion proteins very soluble and stable in the 
following extraction and purification processes (Thapa et al., 2008). The four truncated 
mutants of MBD4 were designed to represent the MBD, interveining, and glycosylase 
domains of MBD4, and part of these mutants overlap with each other to minimise the 
interacting regions that were specifically responsible for the associations. The purified His-
MBD4 mutants were then reciprocally co-immunoprecipitated with the identified MBD4 
interacting proteins with FLAG- or GFP- tags that were overexpressed in HEK 293T cells. I 
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used MLH1 as the positive control, as it robustly associates with MBD4, and its interacting 
domains had been fine mapped (Millar, 2002). The interacting domains that were identified 
by my reciprocal pull downs were consistent with the previous findings, showing the 
robustness of my mutants pull down approach (amino acids (AAs) 410-455 from my assays 
in Figure. 4.16 D & AAs 415-420 from Catherine Millar Thesis (Millar, 2002), Adrain Bird 
Lab). Finally I identified the interacting domains within MBD4 responsible for its 
associations with UHRF1, PRMT5, and KAP1. Notably I characterised the interveining 
domain of MBD4 were largely responsible for the MBD4 associations of UHRF1, PRMT5, 
and KAP1. This region within MBD4 was previously reported as a function desert, my 
characterisation here elucidates that this interveining region may possess a significant role 
for protein interactions, which might be independent from its glycosylase repair and DNA 






Figure.	   4.16.	   Identification	   of	   interacting	   domains	   of	   MBD4	   responsible	   for	   the	  
associations	  with	   its	   confirmed	   interacting	  candidates	  UHRF1,	  PRMT5,	  and	  KAP1.	   (A)	  
The	  scheme	  of	  four	  mutants	  representing	  different	  domain	  of	  MBD4.	  (B)	  the	  schematic	  
representation	   of	   the	   fusion	   protein	  mutants	   of	   MBD4,	   and	   coomassie	   results	   of	   the	  
purified	  MBD4	  mutants	   fused	  with	   trigger	   factor	   and	  ubiquitin	   fusions	   (6His-­‐TF-­‐UB).	  
(C)	  Flow	  chart	  of	  the	  reciprocal	  co-­‐IP	  procedure.	  (D)	  Reciprocal	  co-­‐IPs	  for	  identification	  
of	  interacting	  regions	  of	  MBD4	  for	  its	  association	  with	  MLH1.	  the	  region	  labelled	  by	  red	  
square	   is	   the	   interacting	   domain	   identified,	   which	   correlates	   with	   the	   previous	  
reported	  GST	  pull	  down	  findings	  (Catherine	  Millar	  Thesis,	  Adrain	  Bird	  Lab),	  and	  served	  
as	   positive	   control.	   (E)	   (F)	   (G)	   the	   interacting	   domains	   of	  MBD4	   responsible	   for	   the	  




4.3.	  	  Discussion	  
 
In this chapter, I selected a number of MBD4 interacting protein candidates to verify their 
association with MBD4 by reciprocal co-IP and IF colocolisation. The majority of positive 
results not only confirmed the robustness of my Y2H and AP/MS screens, but also provided 
me with several robust MBD4 partners for future investigations. These include USP7, 
UHRF1, ACF1, PRMT5, and KAP1. Here I discuss the possible implications of these MBD4 
protein interactions, which include the regulation of DNA methyltransferases activity 
through ubiquitination and deubiquitination of UHRF1 and USP7; induction of 
transcriptional repression by chromatic remodelling of ACF1 and histone modification of 
PRMT5 and by recruiting transcriptional co-repressor KAP1. All of these may facilitate the 
functions of MBD4 in transcriptional repression, DNA repair, apoptosis, and in the possible 
active DNA demethylation pathways.  
 Here I need make it clear that the colocalisation experiments on over-expressed 
tagged proteins may “over-represent” protein interactions because the level of the proteins 
are not physiological. Thus the role of MBD4 in regulating DNA methylation (through 
UHRF1), remodelling (Through ACF1), repression (Through KAP1) etc. are really 
speculations/hypothesises which I would have tested had there been sufficient time, for 
example, the assays of methylation in Mbd4-/- cells using HPLC followed by next generation 
sequencing etc. 
4.3.1.	  Regulation	  of	  stability	  of	  DNA	  methylation:	  a	  possible	  role	  of	  MBD4	  through	  
its	  association	  with	  USP7	  &	  UHRF1?	  
 
USP7 (Ubiquitin specific peptidase 7, herpes virus-associated; also known as HAUSP) is a 
deubiquitinating enzyme, a member of the ubiquitin specific peptidase class of 
deubiquitinating enzymes (DUBs) (Qin et al., 2011). Depletion of Usp7 in mice results in 
arrest of embryonic development shortly after implantation (E6.5–7.5) (Kon et al., 2010), 
and its associating developmental factors and substrates including EBNA1 (Holowaty, 
2003), DAXX (Tang et al., 2006), FOXO4 (van der Horst et al., 2006), PTEN (Song et al., 
2008), and loss of their functions may contribute to this early embryonic lethal phenotype. 
USP7 takes part in the cellular stress responses by regulating the stability of p53 and MDM2 
through its deubiquitination activity (Li et al., 2002, Cummins and Vogelstein, 2004, 
Cummins et al., 2004, Meulmeester et al., 2005). It has been proposed that USP7 may have 
dual roles; In addition to a direct deubiquitylation of histones in chromatin remodelling, 
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USP7 may regulate the cellular levels of E3 ubiquitin ligases indirectly involved in histone 
ubiquitylation (Khoronenkova et al., 2011). In particular, the deubiquitination of histone 
H2B can be enhanced by the direct interaction of GMP-synthetase and USP7, which act as a 
transcriptional corepressor (van der Horst et al., 2006, van der Knaap et al., 2005, Sarkari et 
al., 2009). Furthermore, it has been shown that USP7 can modulate MDM2 cellular levels 
and significantly reduce chromatin DNA accessibility and the rate of repair of oxidative 
lesions, while no change of the levels or activity of base excision repair enzymes was 
observed in the USP7 transient siRNA knockdown. This suggests that USP7 may modulate 
chromatin remodeling that recruits a repressive chromatin environment suitable for efficient 
base excision repair (BER) of oxidative lesions (Khoronenkova et al., 2011). 
UHRF1 (Ubiquitin-like with PHD and ring finger domains 1; also known as ICBP90 
in human; NP95 in mouse) plays a central role in the maintenance of genomic DNA 
methylation. UHRF1 interacts with and recruits DNMT1 to hemi-methylated DNA in 
daughter DNA strands to faciltate their methylation. In addition, the SRA domain of UHRF1 
not only recognises and binds preferentially to hemi-methylated DNA, but also has a binding 
specificity to newly discovered 5-hydroxymethylcytosine (5hmC) probes with similar 
affinity to 5-methylcytosine probes by a putative flip mechanism (Frauer et al., 2011, 
Rajakumara et al., 2011, Sharif et al., 2007). DNMT1 has such flip mechanism as well (Song 
et al., 2012). UHRF1 also binds to di- and tri-methylated histone H3K9, as well as 
ubiquitination of histone H3, and associates with heterochromatin formation, suggesting an 
important role of UHRF1 in linking histone modifications, DNA methylation, and chromatin 
structure (Unoki et al., 2009). The UHRF1 complex includes a cohort of crucial 
developmental factors including HDAC1, Tip60, G9a, and maintenance and de novo 
DNMTs, thus it is not surprising that inactivation of mouse NP95 (mouse version of Uhrf1) 
was lethal to midgestation embryos (Muto, 2002). UHRF1 is upregulated in variety of 
cancers, which is probably associated with the the tumor suppressor p53, as it was shown 
that UHRF1 may be downregulated by p53, which is lacking in 50% of cancers, through up-
regulation of p21/WAF1 and subsequent deactivation of E2F1 (Unoki et al., 2009a, Unoki et 
al., 2009b). 
In this chapter, I have shown that MBD4 interacts with USP7 and UHRF1 directly 
by reciprocal co-IP and IF. Interestingly co-transfection of MBD4 dramatically changed the 
nucleus localisation of USP7, such that MBD4 recruits USP7 to heterochromatic sites, which 
coincide with the similar observation of our previous finding of the recruitment of MLH1 to 
micro-irradiated heterochromatic sites led by MBD4 (Ruzov et al., 2009). In addition, co-
introduction of MBD4 and UHRF1 not only co-localises tightly together in the nucleus, but 
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also causes chromatic changes, and induces the drastic reduction of the DAPI bright spots, 
where are generally associated with heterochromatic chromatins. It has been shown that a 
large macromolecular protein complex containing DNMT1, USP7, TIP60, UHRF1, HDAC1, 
and PCNA accumulates and binds at the DNA replication fork and the components of this 
complex co-ordinately regulate the functional availability of DNMT1 (Du et al., 2010, Qin et 
al., 2011, Felle et al., 2011). My findings of direct interactions between MBD4 and USP7 
and UHRF1 have suggested a previously unknown pathway that MBD4 might co-ordinately 
modulate the ubiquitination of DNMT1, and consequently regulates the stability and 
enzymatic activity of DNMT1 (Figure. 4.17). Furthermore, we have previously shown that 
MBD4 and DNMT1 could localise to sites of DNA damage, together with PCNA and MMR 
protein MLH1 (Ruzov et al., 2009). Additionally, recent work suggests that DNMT1 
participates in the MMR pathway and can be recruited to sites of DNA damage by PCNA 
(Loughery et al., 2011, Guo et al., 2004, Mortusewicz et al., 2005). These data suggest that 
the interaction of these partners on chromatin is influenced by DNA damage and that, while 
present at these lesions, it is possible that MBD4 and DNMT1 can participate in the decision 
to either repair the DNA damage, maintain the DNA methylation profile, or activate a cell 
death program (Ruzov et al., 2009). In general, at the initiation of DNA replication, MBD4 
might be involved in stabilizing the maintenance methyltransferases DNMT1, by firstly 
regulating the ubiquitination activity of UHRF1 to ubiquitinate DNMT1, thereby leading to 
proteasomal degradation, and subsequently recruits USP7 and HDAC1 to the established 
complex containing DNMT1 and UHRF1, and localise the macromolecular complex to the 
replication forks through the interaction with PCNA (Figure. 4.17. A). The components of 
the accumulating complex can be maintained at a proper level by the concerted actions of the 
ubiquitination and de-ubiquitination activities of UHRF1 and USP7, which may be regulated 
by MBD4, so that the methylation maintenance can be completed by the appropriate activity 
of DNMT1. In addition, during and after the cell cycle where DNA replication errors occur 
including the DNA damages and DNA methylation mismatches, MBD4 itself as a 
glycosylase, together with the MMR proteins such as MLH1, may recognise, excise and 
repair the DNA damages and maintain the DNA methylation profile, or induce apoptosis if 
the errors are fatal (Figure. 4.17. B). Finally, at the end of DNA replication when the entire 
hemi-methylated DNA is re-methylated, the excess amounts of DNMT1 can be sensed and 
ubiquitination-mediated proteasomal degradation of DNMT1 is triggered (Du et al., 2010). 
In this model, MBD4 may directly interact with the key components of the complex, and 
might regulate the sequential posttranslational events at the DNA replication fork, recruit a 
repressive chromatic environment and act as a co-repressor, repair and maintain the 
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methylation profile or trigger the apoptosis pathway, contributing to the regulation of 
DNMT1 stability during the cell cycle. Lastly, it is possible that the recently discovered 5-
hydroxymethylcytosine could be recognised and contribute to this process, as the SRA 
domain of UHRF1 in this complex may bind to the hydroxy-marks (Frauer et al., 2011), and 
MBD4 is a well-known glycosylase in the base excision repair pathway, which also interacts 
with MMR proteins such as MLH1. It is noteworthy that MBD4 by itself cannot bind to 
hydroxymethylated DNA at least in my in vitro EMSAs in chapter 6. However, it does not 
exclude the possibility that a glycosylase like MBD4 in a large protein complex containing 
some hydroxymethylation-binding proteins might be involved in this novel pathway, and/or 
MBD4 in such complex may recognise and excise other hydroxy-products of the possible 
DNA demethylation pathways (Hashimoto et al., 2012). My finding of their direct 
interaction suggests the complex containing MBD4, UHRF1 and DNMT1 may be an 
important candidate responsible for the putative demethylation process mediated by either 
the canonical model of thymine conversion by deamination of 5mC followed by glycosylase 
excision and BER pathway repair, or the possible hydroxy-methylation route.  
 
 
Figure.	   4.17.	   A	  working	  model	   for	   the	   role	   of	  MBD4	   in	   regulation	   of	   stability	   of	  DNA	  
methylation.	  (A.)	  MBD4	  may	  have	  a	  role	  in	  regulation	  of	  methylation	  machinery	  during	  
the	   DNA	   replication,	   through	   its	   direct	   interaction	   with	   DNMT1	   (previously	   shown),	  
UHRF1	   (novel)	   and	  USP7	   (novel).	   (B.)	   In	   addition,	  MBD4	  may	   be	   responsible	   for	   the	  
maintenance	  of	   fidelity	  of	  methylation	  marks	  at	  specific	   loci	  after	  DNA	  replication,	  by	  
its	  glycosylase	  activity	  and	  its	  ability	  of	  recruitment	  of	  the	  components	  of	  methylation	  
machinery,	  together	  with	  recruiting	  the	  co-­‐repressors	  complexes.	  
 
4.3.2.	  Role	  of	  MBD4	  in	  nuclear	  remodelling	  through	  ACF1?	  
 
ACF1 (ATP-utilizing chromatin assembly and remodelling factor 1, also known as BAZ1A) 
is the one of protein components in the complexes of ACF, WCRF and CHRAC, all of 
which are conserved in Drosophila melanogaster, Xenopus laevis and human cells (Langst 
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and Becker, 2001). ACF1 is non-catalytic, however, it can stimulate the catalytic activity of 
the other proteins in the ACF complex, the ATPase motor protein SNF2H (sucrose 
nonfermenting-2 homolog, also called SMARCA5) (Ewing et al., 2007), and may guide the 
enzymatic components to its target. The catalytic function of ACF complex is required in 
both the histone deposition and the relaxation of chromatin structure (Ewing et al., 2007, Ito 
et al., 1999, Collins et al., 2002). Nucleosome remodelling, which renders nucleosomal 
arrays dynamically driven by ATPase to disrupt histone-DNA contacts, increases the 
accessibility of nucleosomal DNA and induces histone octamer translocation on DNA 
(Narlikar et al., 2002, Eberharter et al., 2004, Becker and Horz, 2002, Lusser and Kadonaga, 
2003). It has been shown that ACF1 associates with the nucleosome remodelling ATPase 
ISWI, improves the efficiency of ISWI-induced nucleosome sliding in replication and 
transcription (Eberharter et al., 2004). Together with the other component SNF2H of the 
ACF complex, ACF1 may act as a key regulator in the nucleosome assembly and contribute 
to transcriptional repression of heterochromatic genes by maintaining the chromatin 
architecture (Ewing et al., 2007). 
A growing body of evidence suggests that remodelling factors are recruited to 
specific nucleosomes by site-specific DNA-binding proteins (Narlikar et al., 2002, Peterson 
and Logie, 2000, Li et al., 2004). One example would be the vertebrate Mi-2/NuRD 
(nucleosome remodeling and deacetylase) complex, which contains histone deacetylases 
(HDAC1/2) and methyl-CpG binding domain (MBD) proteins, in particular, MBD3 (Clapier 
and Cairns, 2009). In this chapter, I identified that MBD4 interacts and colocalise with ACF1 
at heterochromatic sites, and they exhibit concentrated enlarged heterochromatic bright dots 
in cell nucleus. This suggests another possible link between methyl-CpG binding proteins 
and chromatin remodelling factors. Interestingly, as mentioned above, MBD3 is also a 
candidate from my AP/MS screen, which potentially interacts with MBD4 directly. 
Additionally, ACF1 and its complexes have been shown to play important roles in DSBs 
repair (Lan et al., 2010). Notably, one of the DSBs repair protein MRE11 was also screened 
out in my AP/MS screen. These data suggest the interaction of MBD4 and ACF1 may be 
required for establishment of repressive environment by chromosome remodelling, for the 
effective repair including BER pathway and possibly DSBs repair pathway. These repairs 
might be involved in one of the possible demethylation pathways. One of the clues is that a 
novel regulatory role for ACF1 recently discovered in transcriptional repression of Vitamin 
D3 receptor-regulated genes (Ewing et al., 2007). This study shows that hACF1 affects the 
hormone responsiveness and the transcriptional repression of specific class II NR-regulated 
genes, and demonstrates that hACF1 is critical for the stable occupancy of the N-CoR 
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corepression complex at the target gene promoters (Ewing et al., 2007). co-incidentally 
MBD4 was reported to be involved in a possible DNA demethylation in hormone-induced 
transcriptional derepression at a specific Vitamin D responsive promoter, in a negative 
vitamin D response element (nVDRE) binding protein complex containing two DNA 
methyltransferases, DNMT1 and DNMT3B (Kim et al., 2011) (Finally this paper was 
withdrawed by some of the contents were interesting). The coincidence of the roles of ACF1 
and MBD4 at Vitamin D regulated genes suggest that ACF1 might remodel the nucleosomes 
at heterochromatin sites and make them accessible to let repair proteins such as MBD4 to 
target the specific methylated gene promoters, and subsequently switch to transcriptional 
derepression through a possible demethylation mechanism, in response to the hormone 
treatment. It is noteworthy that the other interacting partners of MBD4 including UHRF1 
and the possible partner MBD3 were implicated in the newly discovered 5-
hydroxymethylation recognition, albeit the evidence of their specificity is not strong enough 
(Yildirim et al., 2011). In theory, the 5-methylcytosine to 5-hydroxymethylcytosine 
transitions at gene promoter regions may also induce the putative demethylation, thus it is 




KAP1 ((Kruppel-associated box)-associated protein 1, also known as TRIM28; TIF1β) is a 
scaffold protein that can assemble epigenetic machinery (Iyengar and Farnham, 2011). Kap1 
has been shown to be involved in multiple cellular processes including gene silencing, cell 
growth and differentiation, pluripotency, neoplastic transformation, apoptosis, DNA repair, 
and maintenance of genomic integrity (Iyengar and Farnham, 2011). KAP1 may impact 
epigenetic patterns and chromatin compaction, and subsequently regulate the dynamic 
organization of chromatin structure, through its genomic targeting ability, protein-protein 
interactions, and specific post-translational modifications of itself and its associated histones 
(Iyengar and Farnham, 2011). Mice lacking Kap1 die prior to gastrulation, indicating that 
KAP1 is a critical regulator of normal development and differentiation (Cammas et al., 
2000). KAP1 interacts with histone methyltransferases and HDACs via a C-terminal PHD 
and bromodomain, and acts as a scaffold for various heterochromatin-inducing factors, such 
as heterochromatin protein 1 (HP1), the histone methyltransferase SETDB1 (also known as 
ESET), the nucleosome remodeling and histone deacetylation (NuRD) complex, and the 
nuclear receptor corepressor complex 1 (N-CoR1) (Quenneville et al., 2011, Schultz, 2002, 
Schultz et al., 2001). Thus it is not surprising that KAP1 mediates transcriptional repression 
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and establishes heterochromatin marks such as H3K9me3 through its binding of KRAB-
ZFPs (Groner et al., 2010). Furthermore, via its interaction with KRAB-ZNFs and other 
transcription factors, KAP1 binds to thousands of sites in the human genome, including both 
3’-coding exons of ZNF genes and promoter regions (Iyengar and Farnham, 2011). In 
addition, growing evidences demonstrated KAP1 could act as a robust transcriptional 
repressor when artificially recruited in multiple copies to promoters of reporter genes 
(Groner et al., 2010, Barde et al., 2009, Sripathy et al., 2006, Schultz, 2002, Ayyanathan, 
2003). However, it is not clear if KAP1 endogenously regulates the transcript levels or 
epigenetic profiles of target genes. (Iyengar and Farnham, 2011) 
In this chapter, I have shown that MBD4 directly interacts with KAP1 by reciprocal 
co-IP, and I have also identified the interacting domain of MBD4 responsible for the 
interaction, which further confirmed their robust association. Although my co-transfection of 
MBD4 and KAP1 in CMT93 cells is probably artificial, KAP1 indeed impacts the 
expression pattern and intensity of MBD4 in CMT93 cells, suggesting a mutual influence 
between them. Growing evidence support a link between DNA methylation and KAP1 
together with the KRAB-ZFPs during the early embryonic period (Wiznerowicz et al., 2007). 
ZFP57 and its cofactor KAP1 associates with DNA methyltransferases and the 
hemimethylated DNA-binding protein UHRF1 (Quenneville et al., 2011, Zuo et al., 2012), 
and specifically binds to the H3K9me3-bearing, DNA-methylated allele of imprinting 
control regions (ICRs) in mouse ES cells. Additionally the methylated TGCCGC 
hexanucleotide was identified as the motif that is recognized by ZFP57 in all ICRs and in 
several tens of additional loci (Quenneville et al., 2011). I have shown that MBD4 interacts 
with UHRF1 and KAP1, in addition to our previous findings of its interaction with DNMTs. 
These MBD4 interacting proteins can selectively bind to unmethylated and hemi-methylated 
DNA, and have crucial roles in maintenance of H3K9 and DNA methylation at ICRs, 
supporting the key role of ZFP57 and KAP1 and their associating factors in regulation of 
imprinted genes during early embryogenesis. In addition, MBD4 possesses its MBD domain 
which can specifically target to the methylated DNA, its glycosylase part to repair the 
mismatches and involve in the possible demethylation activity, and most importantly its 
possible regulation ability to recruit co-factors to maintain a certain level of 
methyltransferases during and after the methylation activity. The association of MBD4 and 
KAP1 together with the DNMTs and UHRF1 suggest a possible role of MBD4 for the 
protection of specific loci against the demethylation, and/or dynamically regulate the 
methylation levels at the ICRs during the global demethylation stages. However, there may 
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be redundant proteins in this system, possibly other methyl-CpG binding proteins and 
another thymine glycosylase TDG.  
Interestingly, in an assay using siRNA-mediated Kap1 knockdown, It was shown 
that endogenous KAP1 negatively regulated TNF-α-induced IL-6 production in HeLa cells, 
and subsequently negative regulatory effects of KAP1 on TNF-α-induced NF-κB 
transcriptional activity by influencing the interactions among STAT3, p300, and NF-κB/p65 
were identified. These data correlate with the possible biological significance of MBD4 in 
the inflammatory responses in rheumatoid arthritis discussed in chapter 5. Additionally the 
NF-κB associated gene transcripts are up-regulated in Mbd4-/- MEFs (chapter 5), supporting 
a possible mechanism, in which MBD4 may recruit transcriptional factors such as KAP1 to 
repress the transcription of NF-κB associating factors. In addition, KAP1 and UHRF1 have 
been implicated in systemic inflammatory disorders such as systemic lupus erythematosus 
(SLE), and the other potential MBD4 interacting partner TRIM27 from my screen has 
implicated in rheumatoid arthritis as well. Additionally both ACF1 and KAP1 have been 
found to associate with N-CoR1, the nuclear receptor corepressor complex, which may 
enable a repressive mechanism that MBD4 may be involved in. It is noteworthy that both 
ACF1 and KAP1 have the C-terminal PHD and BROMO domain, suggesting a possible 
common machinery (at least in part) to perform the transcriptional repression. KAP1 has also 
been implicated in tumor development. Increased KAP1 protein levels are found in liver, 
gastric, lung, breast, and prostate cancer, and gastric cancer patients and high levels of KAP1 
have been linked to a significantly lower survival rate (Silva et al., 2006, Beer et al., 2002, 
Yokoe et al., 2009, Iyengar and Farnham, 2011). Most of these tumours specificity coincide 
with the ones MBD4 may associate with (Bader et al., 1999). RNAi knockdown of KAP1 in 
gastric cancer cells causes dysfunction in cell growth with an accumulation of cells in the G1 
phase of the cell cycle (Wang et al., 2005, Iyengar and Farnham, 2011), and reduction of 
KAP1 stimulates p53 levels response to DNA damage, suggesting that KAP1 may be 
involved in a pathway to suppress apoptosis. Consistently, MBD4 interacts with FADD and 
DNMT1, and has the capability to induce apoptosis where the DNA damage is lethal and the 
mismatches cannot be repaired. This had led to a possible proposal that in additional to the 
putative role of transcriptional repression, the MBD4-Kap1 complex may play a critical role 






Prmt5 (Protein arginine methyltransferase 5; also known as JBP1) is an type II arginine 
methyltransferase that has multiple cytoplasmic and nuclear substrates including histones 
H2A, H3 and H4, as well as transcription factors and co-regulators, and is involved in the 
regulation of the gene expression (Cesaro et al., 2009). Mice lacking Prmt5 is early 
embryonic-lethal due to the abrogation of pluripotent cells in blastocysts (Tee et al., 2010). 
PRMT5 has multiple roles in germ cells, and as well as in pluripotency. Specifically, it has 
been shown that PRMT5 cooperates with the key regulator of unipotent primordial germ 
cells (PGCs) specification protein BLIMP1/PRDM1, to establish and propagate PGC from 
embryonic day 7.5 (E7.5) to E11.5 (Ancelin et al., 2006). In addition, PRMT5 is also 
important for the derivation and maintenance of pluripotent ES cells (Tee et al., 2010). It has 
been shown that PRMT5 is upregulated in the cytoplasm together with STAT3 during the 
derivation of ES cells, and associates with MEP50, contributing to the repression of 
differentiation genes by methylation of cytosolic histone H2A (H2AR3me2s) in ES cells 
(Tee et al., 2010). Moreover, PRMT5 is a key mediator component of the ZNF224 repressor 
complex, which interacts and depends on the corepressor KAP1 and the KRAB-A domain to 
perform the chromatic modification (Lupo et al., 2011). In the ZNF224 repressor complex, 
PRMT5 was demonstrated to methylate H4R3 on the nucleosomes surrounding the promoter 
region, which is associated with the repression of aldolase A gene expression (Lupo et al., 
2011).  
In this chapter, I have characterized the interaction between MBD4 and PRMT5 and KAP1, 
supporting a molecular model that MBD4 may recruit the corepressor KAP1 and the histone 
modifying enzymes such as PRMT5, to negatively regulate the expression of genes involved 
in the cell cycle. The formation of the ZNF224 transcriptional repression complex including 
KAP1 and PRMT5 at the human aldolase A gene as the transcriptional repressor suggests a 
possible role of MBD4 at these loci. The interacting domain of ZNF224 responsible for the 
association with PRMT5 was mapped between the second and third zinc finger motifs, 
which are conserved in several KRAB-ZFPs and are evolutionarily related. This suggests 
that the model where PRMT5 were centrally involved in together with its protein partners 
MBD4 and KAP1, may mediate the transcriptional repression of many other KRAB-ZFPs 
(Lupo et al., 2011). A recent study has also investigated the hypothesis whether Polycomb-
mediated repression requires PRMT5 and proposed a model that PAX2/GRG4 recruit 
PRMT5 and promote symmetric H4R3 dimethylation (H4R3me2s), subsequently leading to 
PRC2 recruitment and H3K27me3 (Patel et al., 2011). It is very interesting that PRMT5 was 
linked to DNA methylation, where symmetric methylation of H4R3me2s by PRMT5 can 
recruit DNMT3A to the human β-globin locus, which is required for the DNA methylation 
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and silencing of this gene, and subsequently initiate the epigenetic silencing (Zhao et al., 
2009). However, the structural basis of DNM3A does not support a direct binding to 
H4R3me2s peptide (Patel et al., 2011). My data of the direct interaction between MBD4 and 
PRMT5 provide a interesting link to support this model, suggesting an initiation of the most 
common marks H4R3me2s found in silent chromatin, followed by appropriate DNA 
methylation at designated loci.  
Most interestingly, various chromatin-modifying activities associate with each other 
through the interplay between chromatin remodelers and protein arginine methyltransferases 
such as PRMT5 (Pal and Sif, 2007). PRMT5 is stimulated by the association with both 
BRG1 and BRM-based SWI/SNF, as well as associates with the mSIN3/HDAC corepressor 
complex, the components of the multisubunit nucleosome remodeling and deacetylase 
(NURD) complex, and symmetrically methylates MBD2 and negatively regulates its DNA 
binding activity (Guezennec et al., 2006, Tan and Nakielny, 2006, Pal and Sif, 2007). In 
particular, The biochemically and functionally distinct BRG1-based SWI/SNF complex can 
form into two separate complexes (BRG1 complex I and II), which differ by the presence of 
mSIN3/HDAC and PRMT5 corepressor proteins in BRG1 complex I (Pal and Sif, 2007). My 
data of the interaction between MBD4 and PRMT5 in addition to the previous reported 
MBD4 interaction with SIN3a/HDAC provide interesting link between the two BRG1 
complexes I and II. Noticeably BRG1 interacts specifically with zinc finger containing 
transcription factors like KLF, Sp1, GATA, and type II hormone receptors like RAR and 
RXR (Kadam and Emerson, 2003), almost all of which are the putative targets that MBD4 
may regulate (Chapter 5, by gene expression analysis of Mbd4-/- MEFs). This support a role 
of MBD4 to recruit chromatin remodelers such as BRG1 (SWI2/SNF2-related chromatin 
remodeling complexes) and ACF1 (ISWI-related chromatin remodeling complexes), and 
protein arginine methyltransferases such as PRMT5, subsequently alter chromatin structure 
to regulate and/or facilitate the transcriptional repression. 
Type II arginine methyltransferases such as PRMT5 generate symmetric 
dimethylarginine, in contrast to the type I enzymes including PRMT1 and PRMT3 in the 
PRMT group that catalyze sequential formation of monomethylarginine and then asymmetric 
dimethylarginine (Aravind et al., 2011). PRMT5 and PRMT1–4 have highly conserved areas 
of sequence homology (Krause et al., 2007), thus it is not surprising that the tertiary structure 
of PRMT1 and PRMT3 are probably very similar to that of PRMT5. Consistently, PRMT1 
and PRMT3 interact with MBD4 in my reciprocal IP that are simiar to PRMT5, albeit in my 
MBD4 interacting domain characteristics, PRMT1 cannot be IPed (preliminary data), which 
need further validation. It is noteworthy that the type I enzyme such as PRMT1 is also 
 128 
implicated in diverse processes like transcription, protein localization, and signal 
transduction (Strahl et al., 2001). PRMT1 can directly associate with the p160 family of 
nuclear receptor coactivators and methylate histone H4R3 and facilitate transcription driven 
by the androgen receptor (Pal and Sif, 2007). Moreover, PRMT1 can also methylate N-
terminal arginine residues in NFAT interacting nuclear protein 45 (NIP45) to positively 
regulate cytokine production from Th cells (Mowen et al., 2004). In addition, PRMT1 can 
not only methylate and increase the DNA binding activity of the nuclear receptor HNF4, but 
also be recruited by p160 coactivators to HNF4 target genes results in H4R3 methylation and 
transcriptional activation (Barrero and Malik, 2006, Pal and Sif, 2007).  It is very interesting 
that the cluster of the orphan nuclear receptor HNF4 and its cofactor and target genes were at 
the top ranking of both MBD4 protein interaction networks (Chapter 3) and Mbd4-/- gene 
expression changes (Chapter 5), suggesting a possible role of MBD4 in transcriptional 
activation at the orphan nuclear receptors such as HNF4 cluster and their specific pathways. 
ZNF224 was demonstrated to act as a transcriptional co-activator of WT1 on VDR promoter 
(Lupo et al., 2011). Consistently a decreased expression of VDR was found in the human 
erythroleukemia cell line K562 when ZNF224 was depleted in these cells (Florio et al., 
2010), suggesting a role for ZNF224/WT1 interaction in this pathway through the 
transcriptional activation of VDR (Lupo et al., 2011). The interaction between MBD4 and 
PRMT5, the component of ZNF224, suggesting a role of MBD4 in the transcriptional 
activation of VDR through the mediation of the ZNF224 complex, possibly through the 
putative active DNA demethylation pathway that I have discussed, or a possible mechanism 
through an apoptosis pathway. In support to the latter, MBD4 has been shown to act as a 
sensor to induce apoptosis (Screaton et al., 2003, Ruzov et al., 2009), while vitamin D has 
been shown to induce apoptosis in leukemia cells (Kizildag et al., 2009), and the complex of 
ZNF224 and the cancer testis antigen DEPDC1 was identified to repress the transcription of 
the A20 gene, which is a negative regulator of the NF-κB-mediated antiapoptotic pathway 
(Lupo et al., 2011, Florio et al., 2010). Thus, it is very interesting to investigate the role of 
MBD4 in the transcriptional derepression at the type II non-steroid hormone receptors 
including adopted orphan nuclear receptors (RXR)/the RXR heterodimer receptors, and/or 
orphan receptors such as HNF4a, in the context of the pathways of putative active DNA 
demethylation and/or apoptosis. 
Last but not least, PRMT5 was identified as JAK2 interacting protein in a yeast two-
hybrid experiment (Pollack et al., 1999). JAK2 tyrosine kinase mutation JAK2-V617F is 
present in about 95% of polycythemia vera patients and about 50% of essential 
thrombocythemia and primary myelofibrosis patients (Tefferi et al., 2009, Cross, 2011), the 
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two major forms of myeloproliferative neoplasms (MPN). Mouse models that express the 
MPN-associated JAK2 mutants recapitulate the human MPN-like disorders, confirming these 
JAK2 mutations indeed pay a key role in the morphogenesis of these disorders (Cross, 2011). 
Interestingly a recent research demonstrated PRMT5 can be phosphorylated by the MPN-
associated JAK2 mutants, and subsequently inhibit the histone methyltransferase activity of 
PRMT5 (Liu et al., 2011), suggesting a link between the JAK/STAT pathway and 
transcriptional regulation through epigenetic modifications in MPN formation. My finding of 
the interaction between MBD4 and PRMT5 suggests a possible role of MBD4 in these MPN 
diseases through impairment of signaling with PRMT5 and/or its putative role in the possible 
global DNA demethylation during mouse erythropoiesis (Shearstone et al., 2011).  
 
4.3.3.	  Transcriptional	  repression	  mediated	  by	  MBD4:	  A	  role	  of	  MBD4	  that	  might	  be	  
underestimated?	  
 
Methylation at 5 position of cytosine is the most common modification in higher eukaryotes 
genomes. In mammals, the methylation modification occurs almost exclusively in CpG 
dinucleotides (Ehrlich and Wang, 1981, Riggs and Jones, 1983, Doerfler, 1983). Methylated 
CpG dinucleotides are  ~70% of total mammalian CpG, while the ~1% CG-rich regions 
called CpG islands are usually unmethylated, which mostly coincide with the promoter of 
protein-coding genes (Fraga et al., 2003). Methylation of CpG dinucleotides at promoter 
region is generally associated with transcriptional repression (Antequera et al., 1990, 
Jaenisch and Bird, 2003). In this context, the methyl-CpG binding proteins (MeCPs) that are 
capable of recognition of methylated CpG dinucleotides are proposed to play a central role in 
DNA methylation associated transcriptional repression (Ballestar and Wolffe, 2001). The 
MeCPs contain ~70-75 amino acids methyl-CpG binding domain (MBD), conserved 
between 50-70% similarity (Hendrich and Bird, 1998). As introduced in chapter 1, The 
MBD domains of MeCP2, MBD1, MBD2, and MBD4 are necessary and sufficient for DNA 
binding, and recognise and bind to single symmetrically methylated CpG dinucleotides in 
vitro (Nan et al., 1993, Hendrich and Bird, 1998, Hendrich et al., 1999). Repression by 
MeCPs can be conducted by recruitment of their associated co-repressors including histone 
deacetylases, the Mi-2 or NuRD complex, and mSin3 corepressor (Ng et al., 2000, Yu et al., 
2000, Zhang et al., 1999, Nan et al., 1998, Ng et al., 1999, Kaludov and Wolffe, 2000). 
MBD4 is the only protein that possesses a glycosylase repair function within 
MECPs, in addition to its N-terminal MBD domain. MBD4 was reported to associate with 
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the hypermethylated promoters of tumor suppressor and DNA repair genes including 
p16INK4a and hMLH1 genes, and recruit co-repressors such as Sin3A, HDAC1, and RFP 
(Fukushige et al., 2006, Kondo et al., 2005). However, globally the phenotype of Mbd4 
knockout mice was very mild, with the uplifted thymine mutation rate throughout genome 
possibly due to the lack of the thymine glycosylase repair activity in the knockouts (Millar et 
al., 2002). Mice homozygous for Mbd4-/- were viable and fertile, arguing against a major 
transcriptional repressive role of MBD4 in early development and reproductive system. In 
addition, this also suggests the transcriptional repression that MBD4 may mediate is unlikely 
the general or global repression. However, this does not exclude the possible important role 
of MBD4 in differentiated cells and/or late developmental stage to repress the specific genes 
or a specific set of genes, which shall not expressed in the specialized states. The 
transcriptional repression mechanisms may be placed but not limited into three categories, 
including inhibition of the basal transcription machinery, ablation of activator function, and 
remodeling of chromatin (Gaston and Jayaraman, 2003). In my study, I identified a cohort of 
MBD4 interacting proteins including KAP1, PRMT5, UHRF1, and USP7 (Figure. 4.18) that 
in molecular detail potentially orchestrate transcriptional repression via some of these cross-
talking mechanisms. Although the validated protein interactions of MBD4 are complicated 
in functional diversity, a common theme of these combinations of mechanisms that MBD4 
and its interacting proteins may act at is most likely the methylated promoter dependent. In 
my working model, MBD4 may recognise and bind to 5mCpGs at promoter sites of specific 
genes, and recruit its association proteins to induce/maintain a repressive chromatin state at 
downstream nucleosome (Figure. 4.18). On one hand, these include histone modifying 
complexes (HMC) such as PRMT5, UHRF1, and USP7, which has been reported to directly 
modify the status of ubiquitylation (Khoronenkova et al., 2011, Unoki et al., 2009) and 
arginine methylation (Cesaro et al., 2009) of histones in chromatin remodelling (Figure. 
4.18. upper side; A). On the other hand, KAP1 has been demonstrated as a scaffold protein 
to assemble epigenetic machinery (Iyengar and Farnham, 2011), and form repressive 
complexes with KRAB-ZFPs such as ZFP53 during the early embryonic period (Riclet et al., 
2009). In addition, PRMT5 has been found as a key mediator component of the ZNF224 
repressor complex, which interacts and depends on the corepressor KAP1 and the KRAB-A 
domain to perform the chromatic modification (Lupo et al., 2011)(Figure. 4.18. lower side; 
B). All of these complexes may be recruited by MBD4 in the context of specific tissue types 
and developmental stages, and gene-specific repressor proteins often act in a ‘short-range’ 
binding proximal to the promoter, or a ‘long-range’ at a distance from the promoter sites 
(Mannervik, 1999). The MBD domain of Mbd4 can specifically recognise methylation 
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marks at single CpG level, most of which overlap with promoter sites in the genome. In 
addition, in chapter 6 I have shown this methyl-CpG recognition ability of MBD4 is well 
conserved during the vertebrate evolution, despite of the poor conservation of its primary 
sequences. These support a general theme that MBD4 may act as a repressor mainly at the 
binding sites proximal to promoters of a set of specific genes. However, the possibility of 
‘long-range’ repression that MBD4 might involve in is not exclusive, as the two mechanisms 
are often cooperative depending on the context of its binding sites and its exact mode of 
action (Gaston and Jayaraman, 2003, Courey and Jia, 2001).  
 
 
Figure.	   4.18.	   A	   working	   model	   for	   transcriptional	   repression	   of	   MBD4	   by	   recruiting	  
histone	  modifying	  complexes	  (HMC)	  such	  as	  PRMT5,	  UHRF1,	  and	  USP7	  (Upper	  side;	  A),	  
and	   corepressor	   complex	   including	   KAP1,	   PRMT5,	   and	   specific	   zinc	   finger	   proteins	  
(lower	  side;	  B).	  5mCpG	  (Black	  dots)	  can	  be	  recognised	  and	  bound	  by	  MBD4,	  which	  can	  
recruit	  HMC	  and	  corepressors	   to	   induce/maintain	  a	   repressive	   chromatin	   state	   (dark	  
nucleosome).	  
 
4.3.4	  Concluding	  Remarks	  
 
In sum, I have validated a number of MBD4 association candidates by reciprocal co-IP and 
IF colocalisation. The significant MBD4 associations with UHRF1 and USP7 suggest that 
MBD4 might have a role in the maintenance of DNA methylation through its direct 
interaction with DNMT1 (previously shown)/UHRF1 (novel) /USP7 (novel) possibly by 
regulating the stability of DNMT1 through UHRF1 and USP7. In addition, MBD4 might 
have cross-talk to histone modification and chromatin remodelling to act as transcriptional 
repressor through partners such as KAP1, PRMT5 and/or ACF1. In general positive 
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validation by IP and IF demonstrates the robustness of the initial screens, and implies that 
MBD4 may impact several transcriptional and epigenetic networks along with a number of 
nuclear pathways that include transcriptional repression, repair survey, and regulation of 
DNA methylation machinery. In addition, the interaction between MBD4 and CFP1 and 
SETD1a may be true, as they were validated by one-side FLAG trap (Table 4.1&Figure. 4.1 
B lower) as well as partially overlap with MBD4 expression in CMT93 cells. CFP1 not only 
interact with but also dramatically influence the stability of exogenously expressed MBD4 in 
human HEK293T cells (Figure. 4.15 A&B), suggesting there might be a role of MBD4 in 
transcriptional activation by its association with CFP1 and SETD1a, which needs further 
investigation. Lastly, although the MBD4 interaction with SC35 was not validated by co-IP, 
SC35 did indeed inhibited the expression of exogenous MBD4 in HEK293T cells (Figure. 
4.15 C), suggesting there is certain connection between MBD4 and splicing factor SC35, 
which need further validation. 
However, It is noteworthy that there are a number of limitations of the experiments. 
Firstly, all the assays in this chapter were exogenous and may be artificial. This needs 
particular attention in the cases of KAP1 and PRMT5, which showed unusual condensed 
distribution in cytoplasm, and their co-localisations with MBD4 does not exist, despite of 
their robust co-IP results. Additionally the MBD4 associations with ACF1 need to be further 
validated as its immunoprecipitation was only successfully performed once, and if 
overexpressed ACF1 could resemble its endogenous distribution is unknown. Secondly, the 
IF could show the localisations between MBD4 and its association proteins at a 2D manner, 
but if they are in the same location is unknown, which requires confirmation by confocal 
microscopy. Thirdly, some MBD4 association proteins could affect the expression intensity 
and pattern of GFP-MBD4 in 293T cells. However, if MBD4 could influence them in the 
same cell system is unknown. Fourthly, I have identified the MBD4 domains responsible for 
its associations with several validated proteins. However, further investigations of the 
domains of these proteins that interact with MBD4 are needed for a better understanding of 
their associations. Finally, I could show the associations of MBD4 and KAP1, PRMT5, 
USP7, UHRF1 and ACF1. However, the biological relevance of these associations is 
unknown. Additional experiments are required. For example, luciferase based reporter assays 
can be performed to show if MBD4 indeed act as a transcriptional repressor, with 
corepressors such as KAP1, PRMT5. Another example would be using cell system like p53-/- 
MEFs to investigate what changes would happen when MBD4 expresses with USP7 or 
UHRF1, in the context of apoptosis and DNA damage responses. It was a very difficult 
question regarding the biological significance of MBD4, partially because the phenotype of 
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Mbd4 knockout mice is very mild, and other MeCPs and/or glycosylase protein might 
compensate its role in the system. However, the large number of MBD4 associations in a 
number of significant pathways especially in transcriptional repression and regulation of 
methylation suggest the role of MBD4 in the system may be indispensable. Further 
investigations are required, particularly in terms of the gene expression changes when Mbd4 
is inactivated, and/or in specific processes such as haematopoiesis and specific pathways 
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5.1.	  	  Introduction	  
 
In Chapter 3 and 4, I have identified and validated a number of MBD4 association proteins, 
suggesting that MBD4 may impact several significant pathways, particularly in terms of 
transcriptional repression, repair survey, and regulation of DNA methylation machinery. 
However, mice lacking MBD4 are both viable and fertile, arguing that the role of MBD4 
might be dispensable or compensatable (Millar et al., 2002). This might be because there are 
a number of MeCPs and/or glycosylases in the system with functional and domain structural 
similarity, suggesting their redundant roles may compensate the loss of function of 
individual proteins. For example, almost all the MeCPs have been associated with 
transcriptional repression (Ng et al., 2000, Yu et al., 2000, Zhang et al., 1999, Nan et al., 
1998, Ng et al., 1999, Kaludov and Wolffe, 2000), which are particularly important for 
stable silencing the genes that are not expressed in certain types of cells. In addition, in 
mammals MBD4 and TDG are the only two proteins that have thymine glycosylase activity 
at least in vitro (Jacobs and Schär, 2011). Mbd4-/- mice indeed showed ~3 fold enhanced 
CpG mutability but this mutation rate is far less than that resulting from the removal of all 
the thymine repair machinery (Millar et al., 2002). Consistently, genome-wide C to T 
mutagenesis has not been observed so far in either MBD4 or TDG-deficient cells (Cortázar 
et al., 2011, Jacobs and Schär, 2011), suggesting MBD4 and TDG might compensate for 
each other at least in part for thymine mismatch repair. In addition, both MBD4 and TDG 
have been reported to associate with transcriptional repression (Fukushige et al., 2006, 
Kondo et al., 2005a, Cortázar et al., 2011), and interact with DNA methyltransferases (Kim 
et al., 2009b, Métivier et al., 2008, Ruzov et al., 2009), supporting the hypothesis that they 
might be complementary in terms of these important processes in the mammalian system. 
Although catalytic inactivation of TDG in mice is embryonic lethal (Cortázar et al., 2011), 
this suggests TDG might have a developmental role for which MBD4 cannot compensate in 
early developmental stages. However, this could not exclude their compensatory roles in 
post-embryonic stage, especially in particular types of tissues. In particular, the mild 
phenotype of MBD4 knockout mice supports that TDG might have the ability to compensate 
at least in part for MBD4 inactivation.  
Moreover, although Mbd4-/- mice exhibit a very mild phenotype under normal 
conditions, this does not preclude the possibility that the loss of MBD4 function would be 
significant where the system were exposed under stress such as oxidative factors, ageing, 
and/or pro-inflammatory environment. Experimental mice are usually sacrificed within a few 
months, but the onsets of some subtypes of complex diseases in cancer, autoimmune disease, 
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and ageing related diseases are usually after several decades, thus the full effects of Mbd4 
deficiency may not have been recognised. Interestingly, inactivation of Mbd4 was reported 
to associate with increased tumour formation, but only when combined with Apc min 
oncogenic background in mice (Millar et al., 2002). In addition, the Mbd4 mutations are 
associated with several specific cancers and inflammatory disorders (Bader et al., 1999, 
Riccio et al., 1999, Abdel-Rahman et al., 2008, Saito et al., 2001, Xi et al., 2008), suggesting 
a potential value of investigation of MBD4 in understanding the pathogenesis of these 
diseases. However, the potential functional roles of MBD4 remain largely unknown.  
The independent labs of Adrain Bird and Alfonso Bellacosa generated Mbd4-
deficient mice (Cortellino et al., 2003, Millar et al., 2002). This has enabled me to analyse 
the genome-wide gene expression changes caused by MBD4 activity using mouse embryonic 
fibroblasts (MEFs) generated from these independent Mbd4-/- mice. Although the mild 
phenotypic effects of these Mbd4-/- mice have been well characterised, their changes at gene 
expression level are unclear. In this chapter, I first set out to investigate the most significant 
genes that were mis-regulated by lack of MBD4 activity. Following a clue that the 
expressions of a cohort of insulin-like growth factor-binding proteins were dramatically 
changed, I tested the possibility that MBD4 could directly interact with estrogen receptor α 
(ERα). With the long-term aim of finding possible biological significance of MBD4, I did 
pathway analysis of MBD4 in parallel with TDG, to investigate a possible role of MBD4 in 
pro-inflammatory responses in acquired conditions such as cancer and autoimmune disease. 
In response to this unexpected relationship, I focussed on the role of MBD4 in transcriptional 
regulation and identified several potential MBD4 targets including developmental genes 
Sox9, Klf2, Klf4, supporting a hypothesis that MBD4 might be responsible for stable 
expression of these developmental genes in specific types of tissues, which needs further 
investigation in the future. 
 
5.2.	  	  Results	  
5.2.1.	   Identification	   of	   gene	   candidates	   significantly	   mis-­‐regulated	   in	   two	  
independent	  Mbd4-­‐/-­‐	  MEFs	  
 
The two Mbd4-/- cell lines were the virus-transformed cell line (labelled vtWT and vtKO) 
from the Adrian Bird Lab (Millar et al., 2002) and the non-transformed cell line (labelled 




Figure.	   5.1.	   Confirmation	   of	   MBD4	   expression	   in	   Mbd4+/+	   and	   Mbd4−/−	   in	   the	   two	  
independent	  cell	  lines	  for	  Illumina’s	  whole-­‐genome	  expression	  mouse	  WG-­‐6	  BeadChip.	  
(A)	  RT-­‐PCR	  analysis	   of	  Mbd4	   transcript	   expression	   in	   the	   two	   independent	   cell	   lines.	  
Actb	  and	  Gapdh	  transcript	  expression	  are	  shown	  as	  positive	  controls.	  RT	  indicates	  the	  
reverse	   transcription	   reaction.	   The	   morphology	   of	  Mbd4+/+	   and	  Mbd4−/−	   MEFs	   were	  
visualised	  by	  light	  microscopy.	  (B)	  The	  virus	  transformed	  MEFs	  (vtWT	  &	  vtKO).	  (C)	  The	  
non-­‐transformed	  MEFs	  (nWT	  &	  nKO).	  	  
 
 
cRNA was prepared from total RNA extracted from four pairs of vtWT and vtKO 
transformed cell lines, and two pairs of nWT and nKO non-transformed cell lines. Both cell 
lines were cultured at least five days from the frozen stocks and split twice before harvesting 
using Trizol reagent. RT-PCR confirmed there were no wild type contamination and no 
expression of MBD4 in both knockout cell lines (Figure. 5.1 A). The cRNAs were then 
hybridized to the Mouse WG-6 v2.0 Expression BeadChip (Illumina, San Diego, CA). 
Differentially expressed genes were detected using the Illumina GenomeStudio Gene 
Expression Module (see methods). In general, the microarray analysis followed 
normalization of the quantile or average normalisation method, and based on gene-profiling 
(sum of several probes representing one gene) or probe-profiling, because the Illumina 
mouse WG6 system has ~45281 probe sets to represent ~19100 genes.  
Initially, most stringent criterion to identify the most significant candidates present 
in both cell lines was adopted. This criterion was that their mis-regulated expression 
alterations must be at least five fold in both cell lines and consistently overlap between both 
cell lines. In addition, their significant expression changes must be identified from either 
gene-profiling or probe-profiling approaches as well as from the profiling of both quantile 
and average normalisations. Seventeen transcripts were identified, including seven genes 





Table.	   5.1.	   Highly	   significant	   and	   confident	   genes	   mis-­‐regulated	   in	   both	   two	  
independent	  Mbd4-­‐/-­‐	  MEF	  cell	   lines.	  All	  of	  these	  candidates	  are	  at	   least	   five-­‐fold	  up-­‐	  or	  
down-­‐	   regulated,	   consistent	   in	   both	   cell	   lines	   and	   analyses	   of	   quantile	   and	   average	  
normalisation.	  
 
Quantitative reverse transcription PCR (qRT-PCR) was used to validate alterations 
in gene expression detected in Mbd4-/- MEFs using genome-wide microarray analysis. qRT-
PCR primer pairs were designed as an intron-cross manner. Firstly I tested two down-
regulated (Igfbp4 & Dio3) and two up-regulated candidates (Igfbp5 & Cry1) from the most 
significant candidate pool (seventeen candidates, see table 5.1). The cDNAs used for this 
qRT-PCR validation was the same as the ones that were put on the beadarray. The qRT-PCR 
results from all these genes were consistent with the microarray findings in both cell lines 
(Figure. 5.2 A). Additionally another four candidates from probe-profiling based analysis 
within the same candidate pool were tested in a batch of re-cultured cDNA samples. This 
time only vtKO cell line was used because the nKO cell line can only survive for limited 
passages, as they have not been virus-transfected for immortal growth. Additional qRT-PCR 
confirmed the microarray findings, with fold change slightly lower than the microarray 
results. Most of them (Lfitm1, Wnt4, and Cp) were still more than five fold changed (Figure. 
5.2 B).  Only one candidate Anxa4 was lower than five-fold change (about two fold), but it 
was still consistent and significant (Figure. 5.2 B right). Altogether, the validation of 
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microarray results showed the candidates identified by Illumina beadarrays in two 
independent knockout cell lines were robust. 
 
 
Figure.	   5.2.	   qRT-­‐PCR	  Validation	   of	   expression	  microarray	   results.	   A.	   Quantitative	  RT-­‐
PCR	  validation	  of	   four	   significant	  genes	  highly	  mis-­‐expressed	   in	  Mbd4-­‐/-­‐	  MEFs	   in	  both	  
cell	  lines.	  The	  relative	  expression	  of	  each	  genes	  were	  normalised	  to	  Gapdh.	  B.	  qRT-­‐PCR	  
confirmation	   of	   another	   four	   significant	   genes	   highly	   mis-­‐expressed	   in	   transformed	  
Mbd4-­‐/-­‐	  MEFs.	  The	  relative	  expression	  of	  each	  genes	  were	  normalised	  to	  Actb.	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5.2.2.	   	   MBD4	   might	   potentiate	   transcription	   of	   estrogen	   regulated	   genes	   via	   a	  
direct	  interaction	  with	  ERα	  
 
The high-stringent profiling strategy provided me a pool of seventeen robust candidates that 
are mis-regulated by lacking MBD4 activity. Two genes, Igfbp4 and Igfbp5 from the high-
stringent candidate pool, and two another genes Dusp4 and Runx1 at lower fold changes (not 
in the pool but consistent in two cell lines with more than two fold changed) overlap with 
genes that are mis-regulated in response to tamoxifen exposure in an ER-positive ZR-75-1 
xenograft model (Taylor et al., 2010). In response to this observation I co-transfected GFP- 
or FLAG- tagged full length MBD4 with an ERα expression vector in HEK293T cells, and 
identified a direct interaction between MBD4 and Estrogen receptor α (ERα) by co-IP 
(Figure. 5.3 A-B). Additionally, partial co-localisation of exogenous MBD4 and ERα was 
observed in murine CMT93 cells by IF microscopy (Figure. 5.3 C-D). Altogether these 
observations suggest a possible direct interaction between MBD4 and the Estrogen receptor 
α (ERα). 
 
5.2.3.	  	  Two	  paternally	  imprinted	  genes	  were	  significantly	  mis-­‐regulated	  in	  the	  two	  
Mbd4-­‐/-­‐	  cell	  lines	  
 
From the candidate pool I also observed that a paternally imprinted gene, Dio3 was 
dramatically down-regulated in the two Mbd4-/- cells lines. Therefore, all the imprinted genes 
in my microarray data were examined. Another paternally imprinted gene H19 was also 
dramatically up-regulated in both cell lines (eight fold in vtKO, three fold in nKO). The 
other one at the same imprinting cluster as Igf2 showed significant change, but its expression 
changes were not consistent across the two cell lines (~twelve fold upregulated in vtKO, 
~twenty one fold down-regulated in nKO). In contrast, all the maternally imprinted genes are 
either no significant changes or undetectable from the beadarrays. The discussion and a 
working model regarding the transcriptional regulation of these paternally imprinted genes 




Figure.	   5.3.	   Potential	   interaction	   between	   MBD4	   and	   Estrogen	   receptor	  α	   (ERα)	  
identified	   by	   co-­‐IP	   and	   IF	   co-­‐localisation.	   (A)&(B).	   Immunoprecipitation	   using	   293T	  
cells	  expressing	  GFP-­‐	  or	  FLAG-­‐	  MBD4	  and	  a	  vector	  containing	  ERα	  (HEGO	  vector,	  See	  
method),	   were	   lysed	   and	   IPed	   with	   an	   antibody	   directed	   against	   ERα.	   Association	  
between	  MBD4	  and	  ERα	  was	  analysed	  by	  sequential	  western	  blotting	  using	  indicated	  
antibodies.	   (A)	   MBD4	   confirmed	   to	   associate	   with	   ERα;	   Arrows	   indicate	   the	   ERα	  
bands	  at	  the	  correct	  size.	  (B)	  Negative	  controls	  using	  the	  same	  GFP	  trap.	  The	  IP	   lanes	  
are	   completely	   blank	   and	   negative.	   (C)&(D).	   ERα	   shows	   a	   diffused	   distribution	   in	  
nuclear,	  partially	  overlaps	  with	  MBD4	  and	  bright	  DAPI	  spots.	  (C)	  Distribution	  of	  ERα	  
was	   compared	   with	   DAPI	   counterstaining.	   Vectors	   containing	   ERα	   were	   transiently	  
transfected	   into	  mouse	  CMT93	   cells,	   and	  were	  detected	  with	   anti-­‐ERα	   antibody	   and	  
Texas	  Red-­‐conjugated	   secondary	   antibody.	   The	   overexpressed	  ERα	   exhibits	   diffused	  
general	  distribution	  in	  nuclear.	  The	  bright	  DAPI	  spots	  were	  partially	  overlap	  with	  such	  
diffused	   distribution	   of	   ERα.	   (D)	   GFP-­‐mMbd4	   and	   ERα	   were	   transiently	   expressed	  
together	  and	  compared	  with	  DAPI	  staining.	  Overexpressed	  MBD4	  colocalises	  with	  DAPI	  
bright	  spots	  that	  are	  associated	  with	  heterochromatic	  chromosomes,	  and	  ERα	  shows	  
diffused	  distribution	  in	  nuclei,	  and	  partially	  overlap	  with	  DAPI	  and	  MBD4	  bright	  spots.	  
 
 
5.2.4.	  	  Identification	  of	  a	  clue	  pointing	  to	  possible	  biological	  significance	  of	  MBD4	  
and	  TDG	  in	  pro-­‐inflammatory	  responses,	  and	  in	  acquired	  diseases	  such	  as	  cancer	  
and	  autoimmune	  disease	  
 
The most stringent criterion enabled identification of a cohort of genes with the highest fold 
changes in both cell lines, which are most likely regulated by MBD4 activity; however, it 
discarded the clues at the systemic level, thus it is hard to predict the pathways and functions 
that MBD4 may be involved in. I then used a lesser, but still significant, stringency of two-
fold expression change for MBD4 virus transformed vtKO cell line (p<0.05 according to t-
test, n = 4), and three-fold expression change for MBD4 non-transformed nKO cell line 
(p<0.05 according to Mann-Whitney, n = 2). The reason of adopting higher threshold on 
Mbd4 nKO is that only two pairs of samples were microarrayed. Thus a higher threshold 
could compensate the shortage of limited sample numbers performed and increase the 
robustness of the Mbd4 nKO results. Microarray analysis of whole genome expression in 
Mbd4-/- MEFs compared to WT identified 639 differentially expressed transcripts in Mbd4 
vtKO, as well as 583 in Mbd4 nKO (Figure. 5.4 middle). These lists are referred to the 
Mbd4vtKO and Mbd4nKO lists and can be found in full in the supplementary table 5.1 & 
5.2. The numbers for up- or down- regulated genes in both cell lines are similar (Figure 5.4 
left & right). In addition, I noticed a cohort of these perturbed transcripts overlaps between 
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both cell lines (137 transcripts in total, 75 consistent in both arrays, 32 up- and 43 down- 


























































































































































































































In order to identify the possible canonical pathways and biological functions that are 
responsive to MBD4 activity, data from the Mbd4 vtKO and nKO gene lists was analysed 
through Ingenuity Pathway Analysis (IPA) system (Ingenuity Systems, Mountain View, CA, 
USA, www.ingenuity.com). The datasets containing differently expressed genes (FDR 
adjusted P<0.05 and Fold change (FC) >2 for vtKO & FC>3 for nKO) with their values of 
fold change were uploaded to the application (see methods). A number of canonical 
pathways including the functions of several type II hormone receptors (RXR, VDR etc.) 
were implicated with significant cluster values in both two independent Mbd4-/- cell lines 
(Figure. 5.5. bold and Green colour pathway categories). These include the previous reported 
MBD4 association with Vitamin D receptors (Kim et al., 2011), suggesting the pathways 
implicated are biologically meaningful.  
Unexpectedly, several other top pathways imply a clue for possible significance of 
MBD4 in conditions such as Rheumatoid Arthritis (RA) and hepatic fibrosis (Figure. 5.5 
pathways 1, 8, 11 in vtKO line). However, most of the significance of these pathways was 
not consistent in another nKO cell line. This may be because nKO cells have high 
susceptibility to undergoing apoptosis, dying within limited numbers of passage (Figure 5.1 
C right). I then ask if the only other mammalian thymine DNA glycosylase (Tdg) could also 
be implicated in these pathways, as there might be redundant function between MBD4 and 
TDG in the system as discussed above. The microarray data of whole genome expression in 
Tdg-/- MEFs compared to Tdg+/- is available at NCBI Gene Expression Omnibus under 
accession number GSE20693 (Cortázar et al., 2011). These Tdg-/- MEFs are virus 
transformed cell lines generated from the same lab of the Mbd4 vtKO cell line, and 
microarrays were performed on the same Illumina mouse WG6 platform I used for Mbd4-/- 
cells lines, thus they are suitable for parallel comparison with my Mbd4 pathway analysis. At 
a log fold change 1.2 (p<0.05 according to T test, n = 3), 180 differentially expressed 
transcripts of Tdg vtKO MEFs were uploaded to the IPA application, and the involved 
pathways of Tdg were compared with those of Mbd4 in Figure. 5.5. Surprisingly a number of 
significant canonical pathways were implicated in both Mbd4 vtKO and Tdg vtKO cell lines, 
all of which suggest a possible biological convergence between MBD4 and TDG in pro-
inflammatory responses in acquired conditions such as cancer and autoimmune disease such 
as Rheumatoid Arthritis, and hepatic fibrosis (Figure. 5.5. bold and Red colour pathway 
categories). Specifically, 8 overlapping canonical pathways were implicated in both Mbd4 
and Tdg vtKO profiling: 1. Role of Macrophages, Fibroblasts and Endothelial Cells in 






Figure.	   5.5.	   Overlapping	   canonical	   pathways	   identified	   by	   analyses	   of	   mis-­‐regulated	  
gene	   expression	   in	   the	   two	   independent	  Mbd4-­‐/-­‐	  MEFs	   (A&B)	   and	   transformed	  Tdg-­‐/-­‐	  
MEFs	   (C).	   Up-­‐	   and	   down-­‐	   regulated	   genes	   with	   their	   expression	   fold	   changes	   were	  
functionally	   analysed	   by	   IPA	   pathway	   software.	   The	   numbers	   in	   the	   lists	   represent	  
their	   rankings	   of	   indicated	   canonical	   pathways	   in	   the	   individual	   cell	   lines,	   based	   on	  
their	  p-­‐value	  significance	  (The	  higher	  –log	  (p	  value)	  number,	  the	  more	  significant).	  The	  
top	   25	   categories	   in	   each	   ranking	   are	  most	   significant	   ones.	   The	   colour	   of	   canonical	  
pathway	   names:	   Red	   labeled:	   overlapping	   between	  Mbd4	   vtKO	   and	  Tdg	   vtKO,	  which	  
suggests	   the	   functional	   convergence	   between	   MBD4	   and	   TDG;	   Green	   labeled:	  
overlapping	   between	   two	   independent	   Mbd4	   KO	   cell	   lines,	   which	   suggests	   the	  
conserved	  and	  significant	   function	  of	  MBD4.	  Transformed	  Mbd4-­‐/-­‐	  MEFs	  (Mbd4	  vtKO):	  
fold	  change	  (FC)	  at	  two;	  Non-­‐transformed	  Mbd4-­‐/-­‐	  MEFs	  (Mbd4	  nKO):	  fold	  change	  (FC)	  
at	   three;	  Transformed	  Tdg-­‐/-­‐	  MEFs	   (Tdg	   vtKO):	   fold	  change	   (FC)	  at	   log	  1.2.	  Bar	  charts	  
represent	  the	  p-­‐value	  significance,	   in	  which	  Fisher’s	  exact	  test	  was	  used	  to	  calculate	  a	  
p-­‐value	   determining	   the	   probability	   that	   the	   association	   between	   the	   genes	   in	   the	  
dataset	  and	  the	  canonical	  pathway	  is	  explained	  by	  chance	  alone.	  (The	  bigger	  number	  at	  
the	   –log(p-­‐value)	   scale	   above	   represents	   the	   more	   significant	   category	   group	   in	   the	  
cluster,	   a	   threshold	   line	  was	   automatically	   calculated	  by	   the	   software	   labelled	  by	   the	  
yellow	   vertical	   line)	   The	   yellow	   dots	   represent	   the	   ratio	   of	   the	   number	   of	  molecules	  
from	   the	  data	   set	   that	  map	   to	   the	  pathway	  divided	  by	   the	   total	  number	  of	  molecules	  
that	  map	  to	  the	  canonical	  pathway	  whose	  scale	  is	  at	  below.	  
 
 
Hepatic Stellate Cell Activation; 4. Role of Osteoblasts, Osteoclasts and Chondrocytes in 
Rheumatoid Arthritis; 5. IGF-1 Signaling; 6. Wnt/β-catenin Signaling; 7. Glioblastoma 
Multiforme Signaling; 8. Axonal Guidance Signaling.  
The enriched biological functions of MBD4 and TDG were tested by IPA pathway 
analysis (Figure. 5.6). Seven out of ten significant biological functions of MBD4 and TDG 
overlapped in all three lists (Figure. 5.6 bold and red or blue colour categories). The top three 
biological functions identified in both Mbd4 vtKO and nKO lists were identical (red colour 
category), which were also in top ten of Tdg vtKO list. Except for the top ranking function in 
cancer, it is very interesting that there are two distinct groups within the other six 
overlapping biological functions, suggesting additional distinct roles of MBD4 and TDG at 
different developmental stages. Specifically, the two significant functions of cellular 
movement and reproductive system disease ranked in top three position in MBD4 functions, 
which fell to lower rankings, at No. six and eight, in Tdg vtKO with less significant p values. 
In contrast, the less significant biological grouping of development and functions of 
connective tissue, and skeletal and muscular system in Mbd4 vtKO were found in top 
rankings in Tdg vtKO, possibly implicating their functionally-compensatable but 




Figure.	   5.6.	   Overlapping	   biological	   functions	   identified	   by	   analysis	   of	   mis-­‐regulated	  
gene	  expression	   in	   the	   two	   independent	  Mbd4-­‐/-­‐	  MEFs	  and	  an	  additional	   transformed	  
Tdg-­‐/-­‐	  MEFs.	  Up-­‐	   and	  down-­‐	   regulated	  genes	  with	   their	   expression	   fold	   changes	  were	  
functionally	   analysed	   by	   IPA	   pathway	   software.	   The	   colours	   of	   biological	   function	  
names:	   Red	   labeled:	   overlapping	   in	   all	   three	   cell	   lines;	   Blue	   labeled:	   overlapping	  
between	  Mbd4	  vtKO	  and	  Tdg	  vtKO	  cell	   lines.	  Transformed	  Mbd4-­‐/-­‐	  MEFs	  (Mbd4	  vtKO):	  
fold	  change	  (FC)	  at	  two;	  Non-­‐transformed	  Mbd4-­‐/-­‐	  MEFs(Mbd4	  nKO):	  fold	  change	  (FC)	  at	  
three;	  Transformed	  Tdg-­‐/-­‐	  MEFs	  (Tdg	  vtKO):	  fold	  change	  (FC)	  at	  log	  1.2.	  
 
5.2.5.	   Identification	   of	   candidates	   that	   are	   most	   likely	   the	   targets	   of	  
transcriptional	  regulation	  of	  MBD4	  and	  TDG	  
 
The IPA pathway analysis provided a clue of the possible functional significance of MBD4 
and TDG. However, the knowledge bases of canonical pathways gathered by IPA have 
mixed all the known mis-regulated genes of a canonical pathway from a variety of sources of 
cell types and model systems. For example, the top canonical pathway in Mbd4 vtKO 
profiling (Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis) 
includes three biologically differential cell types. I then asked whether the overlapping gene 
sets in the 8 overlapping pathway clusters above could be the targets of MBD4 and/or TDG. 
However, a number of genes including PDGFB, PDGFRA, IL33, WNT4, SFRP1 from the 
overlapping gene sets in these possible pathway clusters are not consistent in terms of their 
up- or down- regulation in both cell lines, indicating they are unlikely the convergent targets 
of MBD4 and TDG regarding their possible function in transcriptional regulation. To 
identify the specific genes that possibly regulated by MBD4 or TDG (directly or indirectly), 
I attempted to identify the most significant and consistent gene candidates in all the 
microarray data of Mbd4-/- MEFs and Tdg-/- currently available. These include the data from 
above three cell lines and another independent Tdg-/- nKO MEFs cell line (Cortellino et al., 
2011). This led to a focus on three significant candidates, which closely correlated with the 
convergent pathways in Figure. 5.5. These three most interesting candidates are Col2a1 
(collagen, type II, alpha 1), Crabp2 (cellular retinoic acid binding protein 2), and Sdpr 







Figure.	  5.7.	  Venn	  diagram	  of	  differentially	  expressed	  genes	  in	  the	  two	  Mbd4-­‐/-­‐	  MEFs	  and	  
the	   two	  Tdg-­‐/-­‐	  MEFs.	  The	  names	  of	   the	   cell	   lines,	  number	  of	  up-­‐	  and	  down-­‐	   regulated	  
genes,	  and	   the	  overlapping	  gene	   lists	  are	   indicated.	  The	  significant	  overlapping	  genes	  
implicate	   for	   the	   functional	   convergence	   of	   MBD4	   and	   TDG	   in	   the	   pro-­‐inflammatory	  
responses	  in	  cancers	  and	  autoimmune	  diseases	  such	  as	  Rheumatoid	  Arthritis	  (collagen	  
induced,	   Col2a1),	   Sdpr	   (serum	   deprivation	   response),	   and	   lipid	   metabolism	   (RAR	  
activation,	  Crabp2).	  Red	  labeled	  gene:	  upregulated;	  Green	  labeled	  gene:	  downregulated.	  
 
In addition, to test for enrichment in MBD4 functions Gene Ontology (GO) analysis 
was undertaken with the 75 consistent overlapping genes between the two independent 
Mbd4-/- cell lines (32 up- and 43 down- regulated) (see method and Figure 5.4 middle). 
These genes were highly enriched for GO terms involved in cellular components of 
extracellular matrix, and biological functions in a number of tissue morphogenesis, and 
transcriptional regulation (Figure. 5.8 A). Most interestingly, in terms of a role of MBD4 in 
transcriptional regulation, two developmental genes Sox9 (3.12 fold in vtKO, 3.25 fold in 
nKO) and Klf2 (2.65 fold in vtKO, 4.6 fold in nKO) were identified as significantly up-
regulated (Figure. 5.8 B), which have been strongly associated with pro-inflammatory 
responses in a number of acquired conditions such as cancer and autoimmune disease. In 
contrast, Sox2, Sox11, and Klf4 were dramatically upregulated in Tdg vtKO MEFs. In 
addition to this observation, pathway analysis data previously conducted found that Klf4 
might be another target of MBD4 as it was dramatically upregulated (~16 fold) in Mbd4 
nKO cell line (Table 5.2), although no change was observed in another Mbd4 vtKO MEFs. 
This was of interest in view of the observations that the non-transformed Mbd4 nKO cell line 
exhibited a pro-apoptotic phenotype, with cells that show morphological abnormalities, grow 
more slowly and show senescent-type cell enlargement and spreading (~three or four times 
normal size) (Figure. 5.1 C), compared with their responsive wildtypes. IPA pathway 
analysis and Gene Ontology (GO) analysis with the nKO genes only was conducted, and 
identified a cluster of significant genes implicated in regulation of apoptosis. This included 
the three developmental genes referred to above, as well as a mixture of apoptosis 
suppression and induction genes (Table 5.2). Among these genes, Klf4 (~16 fold upregulated 
in nKO) and Cdkn1a (~17 fold upregulated in nKO, 1.5 fold in vtKO) are most significant, 
suggesting they might play an important role in suppressing apoptosis and inducing cell-









































































































































































































































































































































Gene	  ID	   vtKO	   nKO	   Gene	  Name	  
Cdkn1a	   1.5	   17.26	   cyclin-­‐dependent	  kinase	  inhibitor	  1A	  (P21)	  
Klf4	   1	   15.77	   Kruppel-­‐like	  factor	  4	  (gut)	  
Adrb2	   -­‐2.94	   11.74	   adrenergic	  receptor,	  beta	  2	  
Cryab	   -­‐5.88	   9.07	   crystallin,	  alpha	  B	  
Nod1	   -­‐3.85	   5.04	   nucleotide-­‐binding	  oligomerization	  domain	  containing	  1	  
Nupr1	   1.12	   4.8	   nuclear	  protein	  1	  
Klf2	   2.65	   4.6	   Kruppel-­‐like	  factor	  2	  (lung)	  
Bdnf	   x	   4.23	   brain	  derived	  neurotrophic	  factor	  
Ngfrap1	   1.2	   4.14	   nerve	  growth	  factor	  receptor	  (TNFRSF16)	  associated	  protein	  1	  
Trp53inp1	   1.44	   4.12	   transformation	  related	  protein	  53	  inducible	  nuclear	  protein	  1	  
Phlda3	   -­‐1.37	   3.88	   pleckstrin	  homology-­‐like	  domain,	  family	  A,	  member	  3	  
Gsk3b	   1.26	   3.79	   glycogen	  synthase	  kinase	  3	  beta	  
Fas	   1.08	   3.74	   Fas	  (TNF	  receptor	  superfamily	  member	  6)	  
Bax	   1.24	   3.34	   BCL2-­‐associated	  X	  protein	  
MDM2	   1.16	   3.31	   transformed	  mouse	  3T3	  cell	  double	  minute	  2	  
Hes1	   -­‐1.15	   3.28	   hairy	  and	  enhancer	  of	  split	  1	  (Drosophila)	  
Sox9	   3.12	   3.25	   SRY-­‐box	  containing	  gene	  9	  
Tle1	   -­‐1.75	   2.96	   transducin-­‐like	  enhancer	  of	  split	  1,	  homolog	  of	  Drosophila	  E(spl)	  
Kras	   1.4	   2.85	   similar	   to	   GTPase	   KRas	   precursor	   (K-­‐Ras	   2)	   (Ki-­‐Ras)	   (c-­‐K-­‐ras)	   (c-­‐Ki-­‐ras);	   v-­‐Ki-­‐ras2	  
Kirsten	  rat	  sarcoma	  viral	  oncogene	  homolog	  
Casp7	   -­‐1.09	   2.61	   caspase	  7	  
Dcun1d3	   1.13	   2.32	   DCN1,	  defective	  in	  cullin	  neddylation	  1,	  domain	  containing	  3	  (S.	  cerevisiae)	  
Tnfaip3	   -­‐2.17	   2.26	   tumor	  necrosis	  factor,	  alpha-­‐induced	  protein	  3	  
Mapk8ip1	   1.57	   -­‐3.8	   mitogen-­‐activated	  protein	  kinase	  8	  interacting	  protein	  1	  
Tle2	   1.18	   -­‐4.16	   transducin-­‐like	  enhancer	  of	  split	  2,	  homolog	  of	  Drosophila	  E(spl)	  
Bcl3	   -­‐2	   -­‐4.55	   B-­‐cell	  leukemia/lymphoma	  3	  
Bcl2l11	   -­‐1.2	   -­‐4.76	   BCL2-­‐like	  11	  (apoptosis	  facilitator)	  
Stk3	   1.21	   -­‐5	   serine/threonine	  kinase	  3	  (Ste20,	  yeast	  homolog)	  
Gch1	   -­‐1.15	   -­‐5.26	   GTP	  cyclohydrolase	  1	  




Table.	   5.2.	   Cluster	  of	   significant	   genes	   in	   terms	  of	   regulation	  of	   apoptosis	   in	  nKO	  cell	  
line.	  Fold	  changes	  of	  up-­‐	  or	  down-­‐	  regulated	  genes	  in	  Mbd4	  vtKO	  and	  nKO	  are	  labelled.	  
Red	  labelled:	  significant	  upregulated	  genes	  in	  nKO	  cell	   line;	  Green	  labelled:	  significant	  
downregulated	  genes	  in	  nKO	  cell	  line.	  Yellow	  marked:	  top	  significant	  genes.	  
 
 
5.3.	  	  Discussion	  
 
The purpose of transcriptional profiling of independent Mbd4-/- MEFs cell lines was to 
identify the possible biological relevance of MBD4 in transcriptional regulation. Illumina 
mouse WG-6 bead arrays identified a large group of genes that directly or indirectly 
regulated by MBD4 activity. Additionally, I included the currently available data of the only 
other mammalian thymine glycosylase Tdg-/- MEFs from the same platform of Illumina 
beadarray. By functional annotation and pathway analysis, I showed that MBD4 might have 
functions in the regulation of the hormone induced nuclear receptors. In addition, MBD4 and 
TDG might have convergent functions in a number of significant canonical pathways, 
possibly in collagen induced pro-inflammatory responses in Rheumatoid Arthritis (RA) and 
cancer. Finally, several developmental genes including Sox9, Klf2, and Klf4, and paternally 
imprinted genes Dio3 and H19, were identified as possible targets of transcriptional 
repression by MBD4.  
 
5.3.1.	  A	  possible	  direct	  interaction	  between	  MBD4	  and	  ERα	  	  
 
The interaction of MBD4 and ERα suggests that MBD4 might potentiate transcription of 
Estrogen regulated genes via a direct interaction with ERα, supporting a possible link 
between replication repair remodelling and steroid hormone receptor transcriptional 
regulation. Interestingly, the other mammalian G:T mismatch-specific thymine-DNA 
glycosylase TDG was also reported to potentiate transcription of Estrogen-regulated genes 
through direct interaction with Estrogen receptor α (Chen et al., 2003). The protein 
sequences responsible for the interaction with ERα lie within the glycosylase domain of 
TDG (Chen et al., 2003), suggesting a possible similar way that the C-terminal glycosylase 
domain of MBD4 might interact with ERα. However, a mutant TDG-N140A, which lacks 
glycosylase activity, can still stimulate ERα activity at the same extent of wild-type TDG, 
suggesting the DNA glycosylase activity is not required for stimulation of ERα activity by 
TDG (Chen et al., 2003). Instead, TDG may recruit co-activators such as CBP/p300 and the 
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p160 to stimulate the transcriptional activity, and to facilitate base excision repair by histone 
acetylation (Tini et al., 2002, Rai et al., 2010). In Chapter 3 &4, I identified and validated a 
large number of transcriptional co-regulators that interact with MBD4, many of them 
associated with MBD4 regardless of its glycosylase domain. Thus it is very possible that 
MBD4 acts in a similar way to TDG, regulating gene expression in a ligand-dependent 
manner in the context of steroid hormone receptors such as ERα. However, whether and how 
these steroid hormone receptors regulate DNA repair by MBD4 and/or TDG, possibly 
facilitated by the recruitment of chromatin-remodeling complexes, and/or in a context of 
DNA methylation marks including 5mC and the newly discovered 5hmC, still remain to be 
elucidated. 
Interestingly, in a number of top functional implications of canonical pathway 
annotations, MBD4 was implicated in several adopted orphan nuclear receptors (RXR)/the 
RXR heterodimer receptors pathways including VDR/RXR Activation, LPS/IL-1 Mediated 
Inhibition of RXR Function; and Metabolism of Xenobiotics by Cytochrome P450 in both 
two independent Mbd4-/- cell lines (Figure. 5.5 A). This suggests that MBD4 might act as a 
possible co-regulator at these non-steroid nuclear receptors, to facilitate the lipid 
homeostasis. Consistent with this possible significance of MBD4 from these annotations, 
Kim et al. demonstrated a phenomenon of active DNA demethylation at a specific promoter 
of the cytochrome p450 27B1 (CYP27B1) gene in vitamin-D hormone induced 
transcriptional derepression/activation (Kim et al., 2009b). It is likely that in these lipid 
metabolic processes, MBD4 might firstly directly target these adopted orphan nuclear 
receptors (RXR)/the RXR heterodimer receptors, and subsequently activate them by possible 
active demethylation routes of removal of deamination products such as thymine or the 
oxidative products such as hydroxymethylcytosine by its glycosylase repair function when 
induced by the responsive hormones. TDG might act in a similar way regarding these non-
steroid hormone receptors. The PPAR signalling was identified as the top canonical pathway 
in annotation of Tdg vtKO (Figure. 5.5 C), which concurs with previous reports that both the 
adopted orphan nuclear receptors (retinoid receptors including all-trans-retinoic acid α and 9-
cis-retinoic acid α), and the other heterodimers receptors (PPARγ, thyroid hormone α, and 




5.3.2.	   Possible	   functional	   convergence	   between	   MBD4	   and	   TDG	   in	   acquired	  
conditions	  such	  as	  Rheumatoid	  Arthritis	  (RA),	  and	  cancer.	  
 
Unexpectedly, pathway analysis implied a possible functional convergence of MBD4 and 
TDG in pro-inflammatory responses, especially in autoimmune disease such as Rheumatoid 
Arthritis (RA). In addition, it is interesting that the other overlapping pathways in this top list 
correlate with the long-term complications that clinically observed in patients with 
Rheumatoid Arthritis. For example, one of the systemic consequences of RA is the increased 
rates of cardiovascular illness, including myocardial infarction, cerebrovascular events, and 
heart failure, which are not explained by traditional risk factors, use of glucocorticoids, 
nonsteroidal anti-inflammatory drugs, or shared genetic features (McInnes and Schett, 2011). 
The significant pathway implied in Figure 5.5 such as Wnt/β-catenin Signaling, and a 
number of mis-regulated transcripts such as SOCS3, TNFSF11, PDGFB, VEGFA, are true 
cardiovascular risk factors. In addition, other systemic complications of RA including liver 
(elevated acute-phase response and anaemia of chronic disease), lungs (inflammatory and 
fibrotic disease, muscle (sarcopenia), and brain (fatigue and reduced cognitive function) 
could be associated with the identified overlapping pathways of hepatic fibrosis / hepatic 
stellate cell activation, human embryonic stem cell pluripotency, IGF-1 signaling, 
glioblastoma multiforme signaling, and axonal guidance signaling.  
Rheumatoid Arthritis (RA) is a common systemic inflammatory disorder that 
primarily affects the small diarthrodial joints of the hands and feet, and is associated with 
progressive disability, systemic complications, and early death. (Firestein, 2003, McInnes 
and Schett, 2011) The clinical features of RA include synovial inflammation and 
hyperplasia, autoantibody production, cartilage and bone destruction, and systemic features, 
including cardiovascular, pulmonary, psychological, and skeletal disorders. (McInnes and 
Schett, 2011) The underlying cause of RA is unknown, although recent studies have 
associated RA with a number of genetic and environmental factors that influence T-cell 
activation and NF-κB pathway. RA shows a complex interplay among these genetic and 
environmental factors, the drugs and therapies targeting these pathways sometimes fail or 
produce only partial responses (McInnes and Schett, 2011). The possible functional 
convergence of MBD4 and TDG in role of RA suggests they might be candidates as 
predictive biomarkers of diagnosis and prognosis of RA. The current classification of RA is 
based on the clinical phenotype (Aletaha et al., 2010). A variety of RA related canonical 
pathways have been implicated in the functional annotations of Mbd4-/- and Tdg-/- microarray 
results, suggesting it is possible that MBD4 and/or TDG might be the candidates for new 
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molecular taxonomy markers that represent subgroups within RA: this requires further 
investigation.  
In a widely used model of rheumatoid arthritis (RA), murine collagen induced 
arthritis (CIA), MBD4 was identified as one of the five top susceptibility genes controlling 
arthritis development (Yu et al., 2009). This collagen-induced arthritis (CIA) mouse model is 
the most commonly studied autoimmune model of rheumatoid arthritis and is thought to 
reflect many features of human disease pathogenesis. Autoimmune arthritis is induced in this 
model by immunization with an emulsion of complete Freund’s adjuvant and type II 
collagen (CII) (Brand et al., 2007). Yu et al. investigated six genomic regions that showed 
suggestive level of linkage to CIA in F2 mice. They used the advanced intercross line (AIL) 
mice to confirm those suggestive quantitative trait loci (QTL) and refine the positive(s) into 
a small genomic region, thus identifying MBD4 as a top candidate with the nonsynonymous 
polymorphisms and differentially expressed (Yu et al., 2009). Moreover, two polymorphism 
mutations of MBD4 were statistically associated with patients with RA in Chinese 
population (Huang et al., 2010a). It is noteworthy that the key transcripts that impact the 
collagen induced arthritis pathways were mis-regulated in the Mbd4-/- and Tdg-/- cell lines, 
including Sfrp1, Pdgfra, the Type II collagen receptor Col2a1, and a cohort of NFκB 
activating transcripts (Figure. 5.7 & supplementary Figure. 5.1 B). Therefore, it is interesting 
to validate this possible biological significance of MBD4 in RA using murine collagen 
induced arthritis (CIA) model, by treating Mbd4-/- mice with the immunization with an 
emulsion of complete Freund’s adjuvant and type II collagen (CII), to confirm if the 
depletion of Mbd4 could lower the threshold of the induction of RA. In addition, it is also 
very interesting to investigate several crucial factors in RA that were coincidently identified 
for their significance in the network analyses including NF-κB pathway associated factors, 
apoptosis resistance factors, and the interaction with stress proteins (e.g., heat-shock protein 
70). In addition, the apoptosis role of MBD4 needs to be further investigated in the context 
of RA, as a likely possibility that sustain synovial hyperplasia would be the altered resistance 
to apoptosis. Thus it will be very interesting to further study the apoptosis role of MBD4, 
regarding the link between the P53 and the NF-κB pathways. 
The biological functions of MBD4 and TDG annotated by IPA analysis reinforced 
the their possibility that their functions converged (Figure. 5.6). Interestingly, their implied 
biological role in cancer was the top association. This is perhaps unsurprising because the 
possible pro-inflammatory responses caused by lack of MBD4 or TDG activity might 
predispose the affected organs towards cancer for example in colon and lung. In addition, 
MBD4 and TDG are both thymine glycosylases that can excise DNA mismatches derived 
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from deamination or oxidative stress; loss of such repair activity increase the the risk of 
tumorigenesis when combined with other oncogenic stimuli (Millar et al., 2002). The other 
two overlapping biological functions identified were cellular movement and reproductive 
system disease (Figure. 5.6), suggesting MBD4 and TDG may have significant roles in these 
functions. Notably, although several key biological function groups were top ranked in both 
MBD4 and TDG functions, their priorities in these two glycosylase proteins were quite 
distinct. Three key developmental functions including Tissue Development, Connective 
Tissue Development and Function, and Skeletal and Muscular System Development and 
Function were ranked as very top functions in TDG list (Top No. 2, 3, 4), whereas they were 
demonstrated less significant in MBD4 list (Figure. 5.6). In contrast, the two top functions in 
MBD4 list (cellular movement and reproductive system disease) are at a much less 
significant position in the TDG list. The highly complementary but distinct prioritised 
biological functions between MBD4 and TDG might explain in part regarding the distinct 
phenotypes of knockout mice that lack MBD4 or TDG. Although MBD4 and TDG might 
compensate each other in some regards, the developmental role of TDG may be much more 
significant than that of MBD4, thus the mice lacking TDG were lethal at early 
developmental stage, whereas mice with Mbd4 deficiency were viable. Presumably when 
induced by stress factors such as arthritis inducing collagen, oxidative damage, other 
oncogenic stimuli, or aging, the Mbd4-/- mice would show a much lower threshold to develop 
overt disease. 
 
5.3.3.	   Sox9,	   Klf2,	   and	   Klf4:	   possible	   targets	   of	   MBD4	   regulation	   in	   pro-­‐
inflammatory	  responses	  and	  pro-­‐apoptotic	  responses	  in	  human	  breast	  cancer	  
 
One of the most interesting aspect of my gene expression analyses was the identification of 
several developmental genes including Sox9, Klf2, and Klf4 as possible targets of MBD4, in 
terms of its possible roles in pro-inflammatory (Sox9, Klf2, Klf4) and pro-apoptotic 
responses (Klf4 and its signalling through Cdkn1a (the gene that encodes p21)) in acquired 
conditions such as certain types of cancer and immune disease. Interestingly these possible 
targets of MBD4 have been reported to primarily expressed in certain tissues, for example 
Sox9 in testis, pancreas, intestine, brain, kidney, heart valves and derivatives of the neural 
crest (Pritchett et al., 2011), Klf2 in lung, blood vessels, lymphocytes, endothelial cells 
(Suzuki, 2005), and Klf4 in vascular smooth muscle cells, endothelial cells and gut-enriched 
(Suzuki, 2005). The expression of a vast number of target genes are regulated by SOX9, 
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KLF2 and KLF4, thus it is not surprising that they are involved in many cellular functions, 
ranging from differentiation to proliferation and apoptosis (Rowland and Peeper, 2005).  
SOX9 (Sex-determining Region Y (SRY) box 9) play crucial and diverse roles 
during development (Pritchett et al., 2011). It belongs to a group of transcription factors that 
sharing the high mobility group DNA-binding domain of SRY (Gordon et al., 2009). In 
addition to its developmental role at many sites including chondrogenesis and testis 
formation, SOX9 is also expressed and implicated in the formation and growth of cancers 
derived from several different cell types, including prostate, brain, colon, and skin (Pritchett 
et al., 2011). The roles of SOX9 in chondrogenesis and fibrosis, sclerosis and related 
disorders have been well associated with the mis-regulation of a number of extracellular 
matrix (ECM) (Pritchett et al., 2011, Leung et al., 2011), many of which coincide with the 
ECM genes identified from my GO term analysis (Figure. 5.8), including the common target 
Col2a1 (Figure. 5.7&5.8). In this context, it is very possible that Sox9 might be a key target 
of MBD4 regulation in terms of its role in autoimmune diseases such as RA implicated from 
the above pathway analysis. In addition, it is interesting that SOX9 seems to be important for 
epithelial-to-mesenchyme transition (EMT) with EMT-related transcription factor Snail2 
(Slug) in chick neural tube (Cheung et al., 2005). Most interestingly, a recent report has 
found that SOX9 and Slug suffice to convert differentiated epithelial cells into long-term 
repopulating epithelial stem cells in a human mammary cell line (Guo et al., 2012), 
indicating that SOX9 is a key transcriptional regulator in such EMT transition. This might 
underline the associations between the high expression level of SOX9 and the poor prognosis 
of a range of tumors including colon cancer, prostate cancer (Pritchett et al., 2011), and 
especially human breast cancer (Guo et al., 2012). 
KLF2 and KLF4 are Kruppel-like factors, a subclass of the zinc finger family of 
transcription factors characterised by the three Kruppel-like zinc fingers (Rowland and 
Peeper, 2005). The KLF proteins bind to common GC-rich DNA sequences, suggesting that 
their specificity depends on their co-operators and in terms of the certain tissues they 
express, and different KLFs might compensate each other to coordinately regulate the 
expression of KLF effector genes (Rowland and Peeper, 2005). Indeed, It seems the mild 
endothelial phenotype of Klf2+/- mice was due to the compensatory upregulation of Klf4 
(Atkins et al., 2008), and KLF4 strongly resembles KLF2 at least in the vascular 
endothelium (Kunes et al., 2009). Both KLF2 and KLF4 were reported to have activity in the 
vascular endothelium, and are induced by laminar shear stress that provokes the expression 
of various protective factors (Kunes et al., 2009). Interestingly these are counter-forces of 
pro-inflammatory factors induced by inflammatory stimuli such as NF-κB. In the context of 
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infection or wound healing, the pro-inflammatory responses and protective responses need to 
be fine tuned, as although the activation of inflammation helps to combat infection and 
renew organ integrity, the prolonged activation out of control may degrade into autoimmune 
diseases or cancer growth (Kunes et al., 2009). In addition to the induction of protective 
factors, KLF4 is required for induction of p21 (CDKN1A) in a p53 dependent manner in 
response to DNA damage, which results in cell-cycle arrest (Rowland and Peeper, 2005). 
This is particularly interesting considering that KLF4 overexpression was found in up to 
70% of primary human breast cancers (Rowland and Peeper, 2005), suggesting that there 
might be a oncogenic role of KLF4 through p21-dependent cell-cycle arrest at least in this 
genetic context.  
MBD4 itself is a sensor for induction of apoptosis possibly through its association 
with DNMT1 (Ruzov et al., 2009), and/or Fas pathway protein FADD (Screaton et al., 
2003). Thus it is not surprising that the removal of MBD4 might result in disruption of 
normal apoptosis, a phenomenon that is key to the imbalance of death and proliferation that 
is the hallmark of cancer and immune homeostasis. Consistent with this idea, highly 
upregulated Klf4 and CDKN1A were identified in one of the Mbd4 knockout cell line, which 
could be related to the proposed roles for the inactivation of Mbd4 in suppressing apoptosis 
and inducing cell-cycle arrest. In the certain setting that pro-inflammatory responses are out 
of control caused by the unbalance of pro-inflammatory (and/or proliferative) factors 
(regulated by SOX9) and protective factors (regulated by KLF2 and KLF4), the 
misregulation /or disruption of normal apoptosis (regulated by KLF4 and CDKN1A) might 
prolong such abnormal status. Conversely such unbalanced status of normal tissue might 
become an ‘optimal balance’ between continued proliferation and sensitization to apoptosis, 
which is beneficial for effective tumour expansion and progression of autoimmune diseases. 
These would particularly match the theme in mammary diseases such as human breast 
cancers, where the normal terminal duct lobular unit (TDLU) is a dynamic structure that 
undergoes cyclical changes including epithelial proliferation and apoptosis during the 
menstrual cycle (Rubin and Strayer, 2012), thus conceivably it is not surprising that 
unbalance of these processes could result in a ‘disease status’. Moreover, it is very 
interesting that the nuclear localisation of KLF4 has been associated with the poor outcome 
of breast cancer (Pandya, 2004), and overexpression of Klf4 is associated with the stage of 
ductal carcinoma in situ (Foster et al., 2000), an early event in breast cancer progression 
(Rowland and Peeper, 2005). This raises an immediate question that if MBD4 possesses a 
signalling role, which could switch Klf4 to an oncogenic status (possibly depending on the 
status of p21 (Rowland and Peeper, 2005)) , in certain settings such as human breast cancers. 
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It will be very interesting to know the co-incidence of nuclear localisation of MBD4 and 
KLF4, which might underline such associations of poor outcome of breast cancer. 
 
5.3.4.	   Imprinting	   control	   regions	   of	   H19	   and	   Dio3:	   possible	   targets	   that	   MBD4	  
regulates?	  
 
In higher mammals, imprinted genes are transcribed from only one parental allele, and play 
key developmental roles and are generally controlled by imprinting control regions (ICRs) 
containing CpG-rich sequences (Quenneville et al., 2011). ICRs can affect the expression of 
imprinted genes organised in clusters through various mechanisms (Quenneville et al., 2011). 
Of these mechanisms, DNA methylation is the key epigenetic modification known to mark 
the two parental chromosomes at the differentially methylated regions (DMRs) (Ferguson-
Smith, 2011). This results in an epigenetic paradigm of cis-acting mechanisms of gene 
regulation, which can act over short or long distances, and associate the epigenetic state, the 
chromatin structure to genome function (Ferguson-Smith, 2011). In particular, two 
imprinting gene clusters containing H19 and Dio3 respectively are paternally methylated 
(Ferguson-Smith, 2011) (Figure.5.9). Their DMRs are both intergenic and paternally 
methylated. This intergenic DMR is needed for normal imprinting of H19, and the DMR that 
partially overlaps with H19 promoter becomes methylated, associating with the repression of 
H19 gene (Figure. 5.9. H19). In contrast, the intergenic DMR at Dlk1-Dio3 domain is far 
from the Dio3 gene, and the methylated DMR at paternally inherited chromosome is 
generally associated with the expression of Dio3 by an unknown mechanism (Rocha et al., 
2008) (Figure. 5.9. Dio3). It is very interesting that in my microarrays profiling two 
independent Mbd4-/- MEFs, H19 was significantly upregulated (eight fold in vtKO, three fold 
in nKO), whereas Dio3 was dramatically downregulated (seven fold in vtKO, forteen fold in 
nKO) in both cell lines (All maternally imprinted genes either have no change or are 
undetectable in the assays).  Considering the methyl-CpG binding ability of MBD4, and I 
have identified a cohort of its association co-repressive complexes, it is very likely the 
silence of H19 and expression of Dio3 in wildtype MEFs may depend on the MBD4 





Figure.	   5.9.	   A	   working	   model	   of	   possible	   role	   of	   MBD4	   in	   regulation	   of	   paternally	  
imprinted	  genes.	  As	  indicated,	  H19	  has	  paternally	  methylated	  DMRs	  and	  ICRs	  that	  are	  
located	  at	  its	  promoter.	  In	  contrast,	  Dio3	  has	  paternally	  methylated	  DMRs	  and	  ICRs	  that	  
are	   located	   in	   the	   intergenic	   region	   at	   far	   upstream.	   (A)	   The	   silence	   of	   H19	   and	  
expression	   of	   Dio3	   in	   wildtype	   MEFs	   may	   depend	   on	   the	   MBD4	   association	   co-­‐
repressive	   complexes	   at	   their	   DMRs.	   (B)	   The	   deassociation	   of	   these	   repressive	  
complexes	  may	  happen	  in	  MEF	  cells	  that	  lacking	  MBD4	  activity,	  which	  may	  result	  in	  the	  
high	   expression	   of	  H19,	   and	   dramatic	   inactivation	   of	  Dio3.	   The	  methylation	   status	   at	  
their	  DMRs	  might	  largely	  keep	  unchanged,	  but	  need	  further	  investigation.	  
 
 In terms of the MBD4 association co-repressive complexes, the association of 
ZFP57/KAP1 complex and DNMTs and UHRF1 has been recently reported to recognize a 
methylated hexanucleotide of TGCCGC motif to affect chromatin and DNA methylation of 
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imprinting control regions in a parental allele-specific manner, and protect the specific loci 
against DNA demethylation in embryonic stem cells (ESCs) (Quenneville et al., 2011). 
There are several evidences in line with this mechanism. Firstly, ZFP57 gene knockout 
experiments in mice and loss-of-function mutations in human individuals affected by 
transient neonatal diabetes have recently implicated the role of ZFP57 in the establishment 
and maintenance of several imprinted loci (Mackay et al., 2008, Li et al., 2008). Secondly, 
Kap1 inactivation results in a loss of heterochromatin marks at ICRs, and in the mutants 
KRAB-ZFPs no longer mediate transcriptional repression (Li et al., 2008, Mackay et al., 
2008). Thirdly, the Kruppel-associated box repressor domain recruits KAP1 to the vicinity of 
promoters and induces their promoter methylation during mouse early embryogenesis 
(Wiznerowicz et al., 2007), whereas deletion of ZFP57 or DNMTs results in ICR DNA 
demethylation in ESCs (Quenneville et al., 2011). Last but not least, Kap1 deletion in ESCs 
results in markedly increased H3K9ac and depletion of H3K9me3 at ICRs of many 
imprinted genes, coinciding with the misregulation of similar set of imprinted genes and 
depletion of Kap1 and H3K9me3 in Zfp57-/- ES cells (Quenneville et al., 2011). 
The expression of imprinted genes, which is parental allele-specific, has been 
remarkably associated with asymmetric chromatin and DNA methylation signatures at ICRs 
(Quenneville et al., 2011). After the stage of pluripotency, these loci need to be well 
maintained in a repressed status, where the proper asymmetric histone modifications, 
heterochromatinization, and DNA methylation at these elements shall be kept by a sequence-
specific manner by repressive protein complexes. The evidence that the ZFP57-dependent 
recruitment of KAP1 at ICRs is required for the maintenance of epigenetic signatures at 
DMRs of imprinted genes in ESCs, coincides with my protein interaction findings that the 
same set of proteins including KAP1, UHRF1, and DNMTs interact directly with MBD4, 
and two of only four paternally imprinted genes H19 and Dio3 were dramatically mis-
regulated in Mbd4-/- MEFs (the other 2 paternally imprinted genes were undetectable in my 
microarrays). In addition, interestingly another MBD4 interacting protein PRMT5 has been 
reported to interacts with and depends on the corepressor KAP1 and KRAB-A domain of 
ZNF224 to perform the chromatic modification at the human aldolase A gene (Lupo et al., 
2011). It seems there might be different combinations between the same repressive complex 
containing KAP1 and its associated proteins and several KRAB-ZFPs to maintain the 
transcriptional repression at specific loci in different cellular contexts. An interesting report 
was that in mice depleted for Kap1 in the adult forebrain, deregulation of imprinted genes 
were found in the transcripts of the hippocampus, where ZFP57 is expressed (Jakobsson et 
al., 2008), suggesting a possible role of ZFP57 and KAP1 complex in controlling imprinting 
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outside of the early embryonic and germ cells. However, if this is a direct effect and if this 
really happens in adult somatic cells need further investigations. In sum, it is very likely that 
MBD4 may have a role in the maintenance of the repression status at DMRs of the paternally 
imprinted genes such as H19 and Dio3, associating with its co-repressive complexes (Figure. 
5.9). 
 
5.3.5.	  Possible	  role	  of	  MBD4	  in	  human	  cancers	  
 
The inactivation of MBD4, either by mutations (Bader et al, 1999, Riccio et al, 1999, 
Menoyo et al, 2001, Yamada et al, 2002, Bader et al., 2007) or hypermethylation at its 
promoter region (Howard et al., 2009) have been reported and proposed to associate with 
certain types of human cancers including colorectal cancers, ovarian cancers and liver 
cancers (Saito et al., 2001). All of these types of MBD4 inactivation event occur in parallel 
with the tumors exhibiting microsatellite instability (MSI), caused by inactivation of 
mismatch repair (MMR) protein. However, whether the MBD4 inactivation could affect 
early tumorigenesis, tumour progression, and/or metastasis, are largely unknown.  
In my study, I have identified a cohort of MBD4 associated proteins, including the 
three co-repressor proteins KAP1, PRMT5 and UHRF1, which interact with MBD4 at its 
intervening domain. Interestingly naturally occurring MBD4 mutations are usually a 
frameshift in two polyadenine tracts resulting in truncated MBD4 proteins at codons 310–
313 and 247–248, respectively (Bader et al., 2007, Lucci-Cordisco and Neri, 2009), which 
would reduce the ability of MBD4 to interact with the above co-repressors. This may be well 
linked to the dramatic upregulation of the possible MBD4 targets Sox9, Klf2, and Klf4 in 
Mbd4-/- MEFs, in which the inactivation of Mbd4 might result in the derepression of these 
specific genes, by dissociation of MBD4 interacting co-repressors possibly at or near their 
promoter regions. Interestingly the proximal 5’ flanking region of SOX9 contains binding 
sites for the NF-κB complex subunit RelA (Ushita et al., 2009) and CREB consensus motif 
Sp1 site (Piera-Velazquez et al., 2007), which are likely to be the potential binding sites of 
MBD4. The coupling of SOX9 and coactivators of CREB binding proteins CREB/p300 can 
transcriptionally regulate a number of specific genes including the extracellular matrix genes 
(Pritchett et al., 2011). Consistently, a common feature of some KLFs including KLF2 and 
KLF4 is that they share the same CBP/p300 (Suzuki, 2005). It is interesting that their close 
relative protein KLF5 has also been reported to be co-activated by both CBP/p300 
(Miyamoto et al., 2003, Zhang and Teng, 2003) and p50 subunit of NF-κB complex (Aizawa 
et al., 2004), suggesting a common mechanism of transcriptional regulation within the KLFs 
 168 
through these activation complexes. An oncogenic regulator SET and a histone deacetylase 
HDAC1 have been shown to negatively regulate transcriptional activity of KLF5 through 
direct interaction as well as inhibition of its interaction with p300 (Matsumura et al., 2005, 
Miyamoto et al., 2003). These observations suggest the positive activation and negative 
regulation of KLFs (possibly Sox9 as well) and their downstream genes may depend on the 
different cofactors coupled with them in different conditions. A rational explanation of the 
coincidence of the robust upregulation of Sox9, Klf2, and Klf4 in the MEF cells that lacking 
MBD4 activity would be due to the disassociation of MBD4 coupling co-repressors 
(Figure.5.10. I & II). The zinc finger domain of zinc finger transcription factors can form 
homodimers or heterodimers through protein-protein interactions with themselves as well as 
other cofactors (Suzuki, 2005, Mackay and Crossley, 1998) including two MBD4 interaction 
proteins KAP1 and PRMT5, and the different recruitment of co-factors may largely 
modulate these genes in different tissues and developmental contexts. Thus it is very likely 
the different zinc finger proteins might form heterodimers with MBD4 and its associated 
protein complexes in different contexts, to help the recruitment of the complexes to the 




Figure.	   5.10.	   A	   working	   model	   of	   possible	   role	   of	   MBD4	   in	   human	   cancers	   such	   as	  
breast	   cancers.	   (I.)	   In	   normal	   stem/progenitor	   cells,	   the	   promoter	   regions	   of	   certain	  
developmental	   genes	   including	   SOX9,	  KLF2	   and	  KLF4	   may	   be	  marked	   by	   both	   active	  
(trimethylated	   histone	   H3	   lysine	   4;	   H3K4me3)	   and	   repressive	   marks	   (trimethylated	  
histone	   H3	   lysine	   27;	   H3K27me3),	   termed	   “bivalent	   chromatin”	   (Tsai	   and	   Baylin,	  
2011).	  MBD4	  may	  recruit	  repressive	  complexes	  containing	  KAP1,	  PRMT5,	  and	  ZFPs	  as	  
well	  as	  USP7,	  UHRF1,	  and	  DNMTs,	  which	  protect	  the	  binding	  sites	  at	  promoter	  regions	  
from	  activation	  factors	  such	  as	  NF-­‐kB,	  cbp/p300,	  and	  RNAPII	  to	  hold	  these	  genes	  in	  a	  
low,	  poised	  transcription	  state.	  (II.)	  In	  certain	  types	  of	  cancer	  cells,	  inactivation	  and/or	  
downregulation	  of	  MBD4	  might	  cause	  deassociation	  of	  the	  repressive	  complexes.	  This	  
might	  expose	  the	  binding	  sites	  at	  promoter	  regions	  to	  activation	  factors,	  and	  results	  in	  
a	  high	   transcription	  state	  of	   these	  developmental	  genes.	  Meanwhile,	   the	  derepression	  
at	  these	  promoter	  regions	  may	  be	  accompanied	  with	  open	  chromatin	  marked	  by	  active	  
marks	  of	  H3K4me3.	  These	  schematic	  processes	  may	  be	  induced	  by	  a	  number	  of	  chronic	  
stress	  signals	  including	  collagen	  antibody	  induced	  stress,	  reactive	  oxygen	  species,	  DNA	  
damage,	  inflammation,	  and/or	  ER	  stress	  (A).	  Multiple	  signaling	  pathways	  including	  NF-­‐
kB,	  TGFb,	  EGF,	  and	  WNT	  may	  conduct	   these	  stress	   signals	   into	  nuclear	   (B).	  Repeated	  
environmental	   stress	   would	   accumulate	   to	   a	   certain	   threshold,	   especially	   when	   the	  
repression	  machinery	   has	   defects	   such	   as	   inactivation	   of	  MBD4	   and/or	   other	  MeCPs	  
and	   glycosylases	   like	  TDG,	   and/or	  when	   combined	  with	   other	   oncogenic	   background	  
such	  as	  APC	  min	  or	  HRAS.	  This	  may	  promote	   the	  cell	   renewal	  system	  with	  genetic	  or	  
epigenetic	   abnormalities	   (C).	   These	   abnormalities	   may	   include	   a	   high	   transcription	  
state	   of	   certain	   developmental	   genes	   discussed,	   and	   the	   activation	   of	   stem	   cell	  
pathways	  in	  these	  tumor	  cells.	  The	  consequences	  of	  such	  abnormalities	  may	  manifest	  a	  
number	  of	  changes	  at	  gene	  expression	  level,	  including	  the	  upregulation	  of	  extracellular	  
matrix	  genes	  Col2a1	  and	  Col8a1;	  the	  downregulation	  of	  WNT	  signaling	  pathway	  genes	  
Wnt4	   and	  Wnt5	   (D).	   In	   addition,	   this	   may	   also	   cause	   defects	   of	   apoptotic	   signaling	  
pathways	   (impaired	   programmed	   cell	   death),	   and	   prolonged	   proliferative	   and	  
apoptotic	   responses,	  which	   contribute	   to	   tumor	   initiation	  and	  progression	   (D).	  These	  
changes	   may	   alter	   the	   existing	   signaling	   pathways	   (E),	   and	   form	   abnormal	   loops	   to	  
auto-­‐activate	   these	   ‘disease’	   processes	   (F),	   as	   well	   as	   lower	   the	   threshold	   to	   the	  
repeated	  chronic	  stress	  signals	  (G).	  This	  model	  might	  also	  apply	  in	  the	  possible	  role	  of	  
MBD4	  in	  autoimmune	  diseases	  such	  as	  rheumatoid	  arthritis.	  
 
Why are Mbd4 knockout mice viable, while MBD4 has so many important 
interaction proteins especially in transcriptional regulation? And why are a number of 
developmental and imprinted genes misregulated when MBD4 is inactivated, but only a mild 
phenotype was observed from these mice? My interpretation is that this might be due to the 
multiple transcriptional repression machineries available in the system, including other 
MeCPs such as MBD1, MBD2, UHRF1 and their associated co-repressors, which may well 
compensate the potential role of MBD4 in transcriptional repression. They might work like 
multiple locks that share a cohort of co-repressive components, to secure an ‘optimal’ 
expression of certain developmental genes in specific types of tissues. Lack of an individual 
component of the lock might only lower the threshold, but has only a mild phenotype, as 
these developmental genes express during early developmental stages anyway, thus their 
increased expressions may not cause severe phenotypes that were observed where 
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inactivated. In contrast, in certain types of differentiated tissues, especially at the location or 
tissue types that are usually exposed to chronic stresses, the upregulation of these 
developmental genes may result in positive feedbacks or loops to reinforce and/or amplify 
the systemic burden when combined on other oncogenic background, and transit the cell 
status and behavior to cancer proliferation or a worse prognosis (Figure. 5.10). This would 
be particularly the case in certain process such as epithelial-to-mesenchyme transition 
(EMT). Consistent with this speculation, an unpublished work demonstrated some 
interesting data that in gene expression level, a number of MeCPs including MBD1, MBD2, 
MBD4, and UHRF1, and a number of co-repressive complexes containing HDAC1, PRMT5 
etc. were dramatically downregulated in transformed human mammary epithelial cells (by 
induce hRAS to undergo a neoplastic transformation) (Deangelis, 2010). Moreover, as 
mentioned in above discussion section, Sox9 has been shown to cooperatively determine the 
mammary stem cell state with Slug, and elevate the tumorigenic and metastasis-seeding 
abilities of human breast cancer cells, likely in concert with the EMT program (Guo et al., 
2012).  
Although it is very possible that MBD4 might act as a tumor suppressor through 
transcriptional repression, it does not preclude that MBD4 might also exert its influence 
through signaling. Actually the signaling pathways that MBD4 is involved in may link the 
opposing forces in certain cancers. In my gene expression study, a cohort of genes from 
wingless-type MMTV integration factor (WNT) signaling pathway, insulin growth factor 
(IGF) and insulin signaling pathway, and retinoic acid (RA) signaling pathway were 
dramatically misregulated in MEF cell lines that lack MBD4 activity. Interestingly, SOX9 
has been shown to potentially act downstream of both WNT (in the hair follicle and 
intestinal crypt) (Wang et al., 2007), IGF (in the putative intestinal crypt stem cell region) 
(Ramocki et al., 2007) and RA (breast cancer cell lines) (Muller et al., 2009, Afonja et al., 
2002) signaling pathways. However, the downstream effects of these pathways caused by 
MBD4 inactivation seem to differentially regulate the transcriptional factors, including 
SOX9, depending on the developmental stages and tissue types. For example, the WNT 
pathway gene Wnt5 can differentially signal through noncanonical pathways to upregulate 
Sox9 during early stages of chondrogenesis and downregulate it during chondrocyte 
maturation (Pritchett et al., 2011). In this context, it may warrant caution that not all the data 
are concordant with the paradigm model that derepression of Sox9 by MBD4 inactivation 
promotes proliferation and advances certain cancer growth. For example, xenografts of 
LNCaP cells (Prostate cancer) containing SOX9 overexpression enhanced tumor growth 
(Wang et al., 2008), whereas the stably transfected M12 prostate cancer cells highly 
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expressing SOX9 suppressed growth and tumorigenicity (Drivdahl et al., 2004). In addition 
to the tissue specificity, one clue that might cause these contradictory outcomes is the 
differential status of a cell cycle arrest protein p21. In a report that SOX9 was observed 
absent from nearly all examined melanomas, overexpressing SOX9 in melanoma cell lines or 
in xenografts reduced cell proliferation and tumor growth, which coincided with the p21 
upregulation (Passeron et al., 2009). In contrast, the lung adenocarcinoma that highly express 
SOX9 exhibited enhanced tumor cell proliferation, which coincided with significant lower 
p21 expression (Jiang et al., 2010). In addition, SOX9 was detected in over 80% of 
melanomas in another report (Rao et al., 2010), and I observed high nuclear expression of 
SOX9 as well as MBD4, and also their cytoplasmic expression (much more nuclear than 
cytoplasmic) in primary human breast cancer tissues (Supplementary figure 7.1). It seems 
that the switches of some transcriptional factors from a tumor-suppressor gene to an 
oncogene, depend on the status of the cell cycle arrest protein p21 (Rowland and Peeper, 
2005). These include above described SOX9 (Pritchett et al., 2011) and the Kruppel-like 
factor KLF4. In this context, MBD4 may also act as an apoptotic signaling sensor, while 
derepressing and cooperating with p21 (CDKN1A) and/or KLF4, and the inactivation of 
MBD4 may cause cell cycle arrest and suppression of apoptosis signaling, which also 
facilitate its function at DNA-damage repair. 
 Last but not least, it is very interesting that MBD4 potentially has a direct interaction 
with ERα identified in my co-IP and IF, which indicate MBD4 might involve in the cellular 
responses under hormone stress such as Estradiol (E2 or 17β-estradiol, also oestradiol). 
MBD4 has been reported to be involved in transcriptional derepression of a vitamin D 
hormone receptor that responses to parathyroid hormone (Kim et al., 2009). Interestingly 
when ERα was induced and bound by estradiol and recruited to target promoters, an ordered 
and cyclical recruitment of DNMTs and cofactors has been reported (Métivier et al., 2008, 
Métivier et al., 2003). Estrogen receptor and vitamin D hormone receptor belong to the 
nuclear receptor superfamily of transcription factors (Chawla, 2001). This superfamily 
includes not only the classic endocrine receptors type I steroid hormones, type II retinoic 
acid receptor, retinoid X receptor and thyroid hormone receptor, and the fat-soluble vitamins 
A and D, but also a large cohort of ‘orphan’ nuclear receptors (Chawla, 2001). It is 
interesting that one of such ‘orphan’ nuclear receptors HNF4a was implicated in my MBD4 
pathway analysis of both protein interactions and gene expressions (Supplementary figures 
3.1 D & 5.1 F). Despite the variations of their ligand sensitivities, the structural organization 
of these nuclear receptors is similar (Chawla, 2001). It seems MBD4 may have a universal 
role in the regulation of all these classes of nuclear receptors in response to the responsive 
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hormone stress or inductions. This might depend on the association co-factors and/or the 
glycosylase activity of MBD4, which may also relevant to my model in Figure. 5.10, and 
need further investigation. 
 
5.3.6.	  Concluding	  remarks	  
 
It is noteworthy that all these transcriptional aberrations by lack of MBD4 were observed in 
MEFs, a mixture of different types of cells and before end of developmental stage. 
Considering the mild phenotype of Mbd4 knockout mice, the significant phenotype caused 
by lack of MBD4, however, might emerge in differentiated tissues and at a late onset or 
under certain stress. Thus it is required to choose more relevant cells or tissues to validate the 
possible roles of Mbd4 following these clues. In addition, it will be of interest to investigate 
the expression level and pattern of MBD4 in line with its possible targets identified such as 
Sox9, Klf2, Klf4, and the possible compensators such as TDG (and/or other MeCPs) in terms 
of its roles in transcriptional repression and/or glycosylase activity, in some relevant normal 
and diseased tissues including breast and synovium. Lastly, MBD4 rescue experiments are 































Chapter	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6.1.	  	  Introduction	  
 
It has been previously determined that the MBD domain of human and mouse MBD4 can 
recognise and bind to single symmetrically methylated CpG dinucleotides in test substrates 
in vitro (Hendrich and Bird, 1998, Bellacosa et al., 1999). In addition, the G:T mismatches 
derived from deamination of methylated CpG dinucleotides can be both bound by the N 
terminus of MBD4 and processed by its glycosylase domain in vitro (Hendrich et al., 1999). 
However, it is unknown if the binding specificity of MBD domain of MBD4 is conserved 
between species in vertebrate. While the phenotype of Mbd4 knockout in mice is viable, the 
Mbd4 morpholino knockdown in frog results in late lethal phenotype, and they fail to 
develop from tadpole to adult frog (Ruzov et al., 2009), indicating a central role of MBD4 in 
the early development of lower vertebrates. However, a pertinent question would be if 
MBD4 in lower vertebrates like frog and/or fish also possesses a similar binding specificity 
to methylated CpG dinucleotides. 
In general the MBD domain of MBD4 is most similar to that of MeCP2 within the 
methy-CpG binding domain proteins (Hendrich and Tweedie, 2003). The glycosylase 
domain of MBD4 is very conserved between species (77.9% pairwise identical primary 
sequences between human and Xenopus, 79.6% between human and Medaka fish). 
However, unlike MeCP2 whose MBD domain is very conserved between species (94.7% 
pairwise identical primary sequences between human and Xenopus, 86.8% between human 
and Medaka fish) (Figure. 6.1.1. B), the MBD domain of MBD4 is poorly conserved (44.7% 
pairwise identical primary sequences between human and Xenopus, 49.2% between human 
and Medaka fish, in contrast to 46.1% pairwise identical primary sequences between human 
MBD4 and MeCP2) (Figure. 6.1.1. A). The primary sequences within the MBD domain are 
important to the binding specificities of methyl-CpG binding proteins (MeCPs). One 
example is that the mammalian MBD3 protein has a very complete MBD domain, which is 
very similar to that of MBD1 and MBD2, but it was poor recognition of methylated DNA 
due to point substitutions in its MBD domain (Ballestar and Wolffe, 2001). The solution 
structures of MBD domains of MeCP2 and MBD1 have been solved (Ohki et al., 1999, 
Wakefield et al., 1999, Ohki et al., 2001) (Figure. 6.1.2 structure and loops indicated). Key 
amino acids responsible for their methyl-CpG recognition, DNA binding conservation, 
interaction with DNA bases, MeCP2 mutations, and structure and loop have been identified 
(Free et al., 2001, Ohki et al., 1999, Wakefield et al., 1999, Ohki et al., 2001) (Figure. 6.1.2 
red dots above). These key functional and structural amino acids are well conserved within 
MBD domain of MBD4, despite its poorly conserved primary sequences between species 
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(Figure. 6.1.2 The lanes where grey vertical lines indicated). Thus it is very possible that 
MBD domains of MBD4 in lower vertebrates like Xenopus frog and Medaka fish still 
possess the binding specificity to the methylation marks despite of their poor conserved 
primary sequences within MBD domain. 
Given their common MBD domains, different MeCPs may possess special binding 
specificities of the context of upstream or downstream signature sequences in addition to the 
methyl-CpGs. For example, MeCP2 cannot occupy the loci vacated by MBD2 (Klose et al., 
2005). In addition, in two cancer cell lines of MCF7 and MDA- MB-231, while many genes 
are associated with multiple MeCPs, there are a number of genes regulated only by MeCP2, 
other than MBD1 or MBD2 (Ballestar et al., 2003), such that ~9% of MeCP2 binding sites 
were not IPed by MBD1 or MBD2 chromatin immunoprecitation (ChIP) (Klose et al., 2005). 
These suggest there might be recognition differences between MeCP2 and MBD1 or MBD2 
in addition to their common object; methyl-CpG. MeCP2 is the closest relative of MBD4 
within the group, while other MeCPs may share another common ancestor (Albalat, 2008). 
The family tree of the MBD domain of MeCPs supports the hypothesis that in addition to the 
necessary methyl-CpG, different MeCPs might have distinct binding ability to some special 
context sequences. Their intrinsic primary sequences within or outside of MBD domain 
might be responsible for such binding specificity. For example, MeCP2 may require the ~13 
amino acids upstream in addition to MBD domain for its high-affinity binding to the special 
DNA bases of A/T runs adjacent to methyl-CpG (Klose et al., 2005). 
DNA bases in the CpG context in cellular environment are vulnerable to chemical 
reactions. One of the most frequent DNA damages affecting the base-pairing properties at 
CpG dinucleotides is the hydrolytic deamination of cytosine and 5-methylcytosine (5-meC), 
which results in uracil and thymine mispaired with guanine, the G:U and G:T mismatches 
respectively (Jacobs and Schär, 2011). If these mismatches are not repaired before DNA 
replication, the cells would acquiesce them and it may cause C:G to T:A transition 
mutations. In mammals, MBD4 is one of the four uracil glycosylases, and one of only two 
thymine glycosylases in the system (Jacobs and Schär, 2011). Unlike other glycosylases, it 
has a MBD domain that potentially recognise deamination products at CpG context in a 
specific manner. While it has been shown that MBD4 can process a wide range of G-
mispaired base lesions including thymine, uracil, 5-FU, and 3,N4-ethenocytosine (Jacobs 
and Schär, 2011, Petronzelli et al., 2000), the binding affinities of the MBD domain of 
MBD4 to deamination mismatches in different methylation contexts such as opposite to 
unmethylated, fully methylated or hemimethylated CpGs are not clear. In addition, all the 




Figure.	   6.1.1	   The	   domain	   structure	   of	   MBD4	   vary	   in	   their	   sequence	   conservation.	   A.	  
Schematic	   domain	   structure	   of	   xenopus	   lavis	   Mbd4	   is	   shown,	   with	   amino	   acids	  
indicated	   showing	   the	   beginning	   and	   end	   of	   the	   significant	   domains.	   The	   percentage	  
above	  the	  domain	   is	   the	  conservations	  between	  the	  species	  of	  human	  and	  stickleback	  
Mbd4.	   The	   alignment	   of	   MBD	   domain	   of	   MBD4	   is	   shown.	   The	   red	   circle	   indicates	   3	  
amino	  acids	  missing	   in	   the	  primary	  sequence	  of	  xenopus	  lavis	  Mbd4.	  The	   table	  shows	  
the	   conservation	   between	   the	   selected	   species	   for	   the	   MBD	   domain	   of	   MBD4.	   The	  
numbers	   in	   the	   table	   are	   the	   percentage	   of	   pairwise	   identical	   sites	   between	   the	   two	  
indicated	  species.	  B.	  The	  alignment	  and	  conservation	  of	  primary	  sequences	  of	  MeCP2.	  
The	  MBD	   from	  MeCP2	   is	  more	   highly	   conserved.	   But	   note	   that	   the	  MBD	   domains	   of	  
MeCP2	   and	  MBD4	   are	  most	   conserved	   between	  MBD	   proteins	   (cf	   MBD1,	   MBD2	   and	  
MBD3).	   The	   species	   in	   the	   alignments	   are	   human	   sapiens	   (h);	   Mus	   musculus	   (m);	  





Figure.	  6.1.2	  Key	  functional	  and	  structural	  amino	  acids	  are	  well	  conserved	  within	  MBD	  
domain	   of	   MBD4.	   The	   MBD	   domain	   alignment	   is	   shown.	   A	   solution	   structure	   of	   the	  
MBDs	  from	  MeCP2	  and	  MBD1	  has	  been	  determined,	  consisting	  of	   four	  anti-­‐parallel	  β-­‐
strands,	  two	  of	  which	  were	  proposed	  to	  interact	  with	  the	  major	  groove	  of	  DNA,	  where	  a	  
methyl	   group	   would	   be	   located.	   In	   addition,	   a	   number	   of	   conserved	   residues	  
throughout	  the	  MBD	  domains	  of	  MeCP2	  and	  MBD1	  can	  be	  easily	  revealed	  by	  alignment,	  
despite	   their	   full-­‐length	   sequences	   sharing	   only	   moderate	   homology.	   The	   MBDs	   of	  
MBD4,	   MBD1	   and	   MeCP2	   were	   aligned	   and	   compared	   to	   indicate	   essential	   residues	  
within	   the	   MBD	   of	   MBD4	   that	   are	   responsible	   for	   binding	   to	   methylated	   DNA	  
sequences.	   Essential	   Residues	   are	   well	   conserved	   in	   the	   MBD	   of	   MBD4.	   In	   addition,	  
amino	   acids	  within	   the	  MBD	   of	  MBD4	   that	   are	   important	   for	   DNA	   binding	   found	   by	  
mutational	   analyses	   and	   associated	   with	   Rett	   syndrome	   in	   MeCP2	   are	   also	   well	  




while such promoter associated sites conceivably need careful surveillance, implicating 
possible unknown machinery to specifically distinguish this deamination mismatches at CpG 
sites from the base damages of vast genomes. 
In this chapter, I first performed a comparison of MBD domain DNA binding 
activity with distant MBD4 homologues from the Medaka fish (Oryzias latipes) and the 
amphibian, Xenopus laevis to probes containing 5mCpG. I then checked the DNA binding 
specificity of MBD4 and MeCP2 to the probes containing the newly discovered 
hydroxymethylated mark. Lastly, their binding affinities to the G:U mismatches in a serial of 
unmethylated, fully methylated and hemimethylated context were tested. The surprising 
results suggest a previous unknown contribution to efficient repair of this deamination 
product at CpG dinucleotides by MeCP2, as well as a well conserved binding specificity of 
MBD4 to 5mCpG dinucleotides. 
 
6.2.	  	  Results	  
6.2.1.	  	  Generation	  of	  6HIS-­‐	  tagged	  TF-­‐UB-­‐MBD	  fusion	  proteins	  	  
 
I chose a vector system called 6HIS-TF-UB (Figure. 6.2. A) for productions of MBD domain 
peptides of Mbd4 homologues from the Medaka fish (Oryzias latipes) and the amphibian 
frog (Xenopus laevis) (Figure. 6.2 B). This vector system contains Escherichia coli 
thermostable protein trigger factor (TF), which shows high expression and stability, and is 
capable of helping the proteins cloned next to TF express to be in a soluble state (Thapa et 
al., 2008). It also engineered the minimum ubiquitin sequences downstream of TF, linking to 
the targeting proteins, such that the TF-UB fusion proteins can be cleavaged by specific 
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ubiquitin cleavage enzymes (Thapa et al., 2008, Baker et al., 2005) (Figure. 6.2. A). 
However, the empty TF-UB vector I received from the Park lab (Thapa et al., 2008) only has 
a 6HIS tag at its downstream (Figure. 6.2. A upper), and there is a stop codon within its 
multiple cloning site (MCS), which results in a control TF-UB protein without the 6HIS tag. 
In addition, the fusion proteins containing the target MBDs cannot be observed after 
cleavage under western blotting. Thus I decided to insert another 6HIS tag upstream of the 
TF by site-directed mutagenesis (the QuikChange® II XL Site-Directed Mutagenesis Kit 
(Stratagene)) (see Chapter 2. Method) (Figure. 6.2. A lower). I then cloned the MBD domain 
of Mbd4 of Xenopus laevis (xl.Mbd4), Oryzias latipes (ol.Mbd4) and MBD domain of 
MeCP2 of Xenopus laevis (xl.MeCP2), into the 6HIS-TF-UB system (Figure. 6.2 B). 
Specifically, amino acids 49-134 of ol.Mbd4,  44-135 of xl.Mbd4,  and 90-177 of xl.MeCP2 
(Figure. 6.2. B (1) red bracket) were cloned downstream of TF-UB, followed by 6his-tag at 
their C-terminal. In addition, I also made another batch of these proteins, which included the 
~13 amino acids upstream of their MBD domains (Figure. 6.2. B (2) green bracket, labeled 
*), which were suggested to confer high-affinity binding of MeCP2 to the special DNA bases 
of A/T runs adjacent to methyl-CpG (Klose et al., 2005). These fusion proteins were 
produced in E.coli, and then purified by HIS-tagged Ni-NTA columns (see methods). The 
fusion MBD proteins were very soluble, and can be cleaved by ubiquitin specific enzyme 
USP2cc (Baker et al., 2005), suggesting they are suitable for the following EMSA assays 








Figure.	  6.2.	  Generation	  of	  6HIS-­‐	  tagged	  pET21b-­‐TF-­‐UB-­‐MBDs	  fusion	  proteins.	  (A.)	  The	  
schematic	   representation	   of	   the	   fusion	   protein	   of	   MBD	   domain	   of	   MBD4.	   (B.)	   The	  
alignment	  of	  MBD	  domain	  of	  MBD4	  and	  MeCP2	  of	  human	  (h),	  mouse	  (m),	  the	  Medaka	  
fish	  (Oryzias	  latipes,	  labeled	  med	  or	  ol)	  and	  the	  amphibian,	  Xenopus	  laevis	  (labeled	  x	  or	  
xl).	  The	  differences	  of	  ~	  20	  amino	  acids	  (AAs)	  at	  upstream	  between	  the	  green	  bracket	  
(1)	  and	  the	  red	  bracket	  (2)	  are	  those	  reported	  crucial	  AAs	  for	  specific	  binding	  to	  mCpG	  
with	  A/T	  run	   in	  hMeCP2	  (Klose	  et	  al.,	  2005).	  The	  fusion	  proteins	  with	  these	  ~20	  AAs	  
are	   labeled	   with	   *.	   (C-­‐D)	   Cleavage	   of	   recombinant	   proteins	   expressed	   in	   E.	   coli	   at	  
ubiquitin	   site.	   (C.)	  SDS–PAGE	  analysis	  of	  protein	   fractions	  with	  and	  without	   cleavage.	  
The	  corresponding	  fusion	  proteins	  were	  indicated	  with	  bracket;	  Lane	  1,	  4,	  7,	  10,	  13,	  16	  
were	   purified	   soluble	   fusion	   proteins;	   lane	   2,	   5,	   8,	   11,	   14,	   17	   were	   same	   proteins	  
treated	  at	  37°C	  for	  1	  hour	  without	  cleavage	  protein	  enzyme;	  lane	  3,	  6,	  9,	  12,	  15,	  18	  were	  
reactions	  where	  excess	  ubiquitin	  specific	   cleavage	  protein	  enzyme,	  6HIS-­‐Usp2-­‐cc	  was	  
added	  and	  incubated	  at	  37°C	  for	  1	  hour.	  (D)	  Western	  Blotting	  (WB)	  analysis	  of	  protein	  
fractions	  with	  and	  without	  cleavage.	  Lane	  1,	  3,	  5,	  7,	  9,	  11	  were	  purified	  soluble	  fusion	  
proteins;	  lane	  2,	  4,	  6,	  8,	  10,	  12	  were	  reactions	  where	  excess	  ubiquitin	  specific	  cleavage	  
protein	  enzyme,	  6HIS-­‐Usp2-­‐cc	  was	  added	  and	  incubated	  at	  37°C	  for	  1	  hour.	  
 
6.2.2.	   The	   binding	   specificity	   of	   MBD4	   to	   methylated	   probes	   is	   well	   conserved	  
between	  species,	  regardless	  of	  its	  poor	  sequence	  conservation	  
 
The MBD fusion proteins were assayed for their binding affinities to methylated and 
unmethylated 39-mer duplex oligonucleotides containing a single, symmetrically methylated 
CpG dinucleotide (Figure. 6.3. labeled color green) with A/T runs (Figure. 6.3. labeled color 
orange) adjacent to the CpG dinucleotide (Probe S1 and S2) at increment amount of 
respective proteins and fixed amount of DNA probe concentrations, and I optimised the 
assays with and without competitors, to ensure the binding specificities were specific (see 
method). Both fusion proteins of MBD domains of ol.Mbd4 and xl.Mbd4 exhibited a range 
of binding preferences to methylated probes (Figure. 6.3. A&B left) compared to 
unmethylated probes under the experimental conditions (Figure. 6.3. A&B right). In 
addition, the binding specificities of the MBD domain of ol.Mbd4 and xl.Mbd4 to the 
methylated probes with adjacent AT runs are similar to those of their responsive fusion 
proteins that have additional upstream ~13 amino acids (AAs) (Figure. 6.3 A&B left 
ol.MBD4vs*ol.MBD4 & xl.MBD4vs*xl.MBD4), suggesting in this condition, these 
upstream AAs do not affect the binding affinities of MBD domains of ol.Mbd4 and xl.Mbd4 
to the probes containing the methylated CpG with adjacent A/T runs. It is noteworthy that I 
did not observe the binding specificities of the MBD domain of ol.MeCP2 and xl.MeCP2 to 
the methylated probes with adjacent AT runs described in Klose’s report (Klose et al., 2005) 




Figure.	  6.3.	  The	  binding	  specificity	  of	  MBD4	  with	  methylated	  probes	  is	  well	  conserved	  
between	   species,	   regardless	   of	   its	   poor	   sequence	   conservation.	  Binding	  of	   the	   duplex	  
probes	   containing	   5-­‐methylcytosine	   (5mC)(left)	   or	   the	   responsive	   unmethylated	  
cytosines	  (right)	  in	  the	  context	  of	  CpG	  to	  varying	  concentrations	  of	  the	  methyl-­‐binding	  
domain	  (MBD)	  of	  (A.	  ol.-­‐	  Oryzias	  latipes)	  and	  (B.	  xl-­‐	  Xenopus	  laevis)	  MBD4	  from	  	  100	  to	  
800nM;	   sequence	  of	   duplex	   is	   seen	   in	   the	  Figure.	  The	   correct	   bands	   are	   indicated	  by	  
black	  arrows.	  The	  procedure	  of	  radioactive	  EMSAs	  is	  in	  methods.	  
 
 
without the ~13aa upstream has very clear binding specificity to the U6 probe (Figure. 2.1), 
which doesn’t contain the AT runs and was claim to have no detectable binding with MeCP2 
in Klose’s report (Klose et al., 2005), suggesting at least in xenopus lavis and under my 
experimental condition, the ~13 amino acids (AAs) upstream of MeCP2 and the AT runs 
downstream of the probes do not affect the binding specificity of MeCP2. 
 
6.2.3.	   	   ol.Mbd4,	   xl.Mbd4	   and	   xl.MeCP2	   have	   no	   binding	   specificity	   with	  
hydroxymethylated	  probes	  by	  themselves.	  
 
Among the methylated-CpG binding domain (MBD) family of proteins, MBD4 has affinity 
to mCpG sites with a subsequent ability for glycosylase repair. 5-hydroxymethylcytosines 
(5hmCs) are the oxidative products of 5-methylcytosines recently suggested as a potential 
substrate in the context of active DNA demethylation (Wu and Zhang, 2011). Thus I 
proceeded to test the binding affinities of MBD domains of xl.Mbd4 and xl.MeCP2 to 
5hmC-containing probes. Using the fusion 6HIS-tagged TF-UB-MBD of ol.Mbd4 and 
xl.Mbd4 proteins, I tested the affinity of these proteins to fluorescent-end-labeled 36-mers 
probe S2CpG containing unmethylated, methylated or hydroxymethylated cytosines at two 
separated CpG sites (Figure. 6.4). EMSA assays using a 6% non-denaturing polyacrylamide 
gel were performed. As seen in Figure 6.4 A&B&C, all of these fusion proteins can only 
bind to methylated but none of them bind to unmethylated or hydroxymethylated probes by 




Figure.	   6.4.	   ol.Mbd4,	   xl.Mbd4	   and	   	   xl.MeCP2	   have	   no	   binding	   specificity	   with	  
hydroxymethylated	  probes.	  Affinity	  of	  MBD	  domains	  of	  ol.Mbd4	  (A),	  xl.Mbd4	  (B),	  and	  
xl.MeCP2	   (C)	   towards	   unmethylated	   cytosine,	   5mC-­‐	   and	   5hmC-­‐containing	   oligomers	  
are	  shown.	  These	  proteins	  by	  themselves	  bind	  effectively	  to	  methylated	  CpG	  sequences	  
but	  do	  not	  bind	  to	  the	  same	  sequences	  containing	  5hmC	  in	  place	  of	  5mC.	  The	  lanes	  with	  
a	   *	   below	   on	   the	   left	   are	   corresponsive	   to	   the	   separated	   lanes	   on	   the	   right.	   The	  
procedure	  of	  fluorescent	  EMSAs	  is	  in	  methods.	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6.2.4.	   ol.Mbd4	   and	   xl.Mbd4	   can	   not	   distinguish	   the	   uracil	   mismatches	   at	   CpG	  
dinucleotide	  context.	  In	  contrast,	  xl.MeCP2	  shows	  a	  significant	  binding	  preference	  
to	  semi-­‐methylated	  probe	  with	  uracil	  mismatches.	  
 
MBD4 is one of the glycosylases that can excise the uracil mismatches in vitro. However, its 
binding affinity to G:U mismatches in unmethylated, fully methylated, and hemimethylated 
context is not clear. Pierre-Antoine Defossez lab at CNRS of Universite Paris-Diderot 
generated a series of G:U probes. These probes are double-stranded oligonucleotides that 
have five separated CpGs. One of the CpG dinucleotides in the center is either unmethylated 
(Figure. 6.5. A. Probes A.C.I.K.), or mutated to G:U mismatches (Probes B.D.J.L.), which 
are opposite to an unmethylated (Probes A.B.I.J.) or methylated CpG (Probes C.D.K.L.). The 
other four CpG dinucleotides are either unmethylated (Probes A.B.C.D.), or fully methylated 
(Probes I.J.K.L.). I tested the binding affinity of MBD domain of xl.Mbd4 and ol.Mbd4 to 
these G:U containing probes. Not surprisingly, both fusion proteins bind to the probes 
containing four fully methylated symmetrically CpGs (Figure. 6.5. B&C probes I.J.K.L), 
while none of them bind to the responsive unmethylated ones (Figure. 6.5. B&C probes 
A.B.) or the probes containing one hemimethylated CpG (Figure. 6.5. B&C probes C.D.). 
However, both ol.Mbd4 and xl.Mbd4 do not bind the G:U mismatches probes with greater 
affinity (Figure. 6.5. B&C). 
Surprisingly, the MBD domain of xl.MeCP2 showed very strong binding preference 
to the probe containing one G:U mismatch opposite to a methylated CpG (Figure. 6.5. D. 
Probe CvsD & KvsL). The binding affinity of xl.MeCP2 is approximately ~30-~50 fold 
higher than that of xl.Mbd4,  and ~70-~100 fold than that of ol.Mbd4, based on my 
estimation of their binding affinity to the same methylated probe by their fusion protein 
titrations. The G:U binding affinity of xl.MeCP2 is even much stronger than its binding to 
the fully methylated probes (Figure. 6.5 D. Probe D vs I.J.K.L.), and the methylation at 
adjacent CpGs inhibited such binding affinity (Figure. 6.5 D. Probe D vs L), suggesting a 
unique role of MeCP2 to recognise such special G:U mismatches, especially in a context of 










Figure.	   6.5.	   ol.Mbd4	   and	   xl.Mbd4	   can	   not	   distinguish	   the	   uracil	   mismatches	   at	   CpG	  
dinucleotide	   context.	   In	   contrast,	   xl.MeCP2	   shows	   a	   significant	   binding	   preference	   to	  
hemi-­‐methylated	  probe	  with	  uracil	  mismatches.	   (A.)	  The	   schematic	   representation	  of	  
the	  G:U	  probes.	  The	  fluorescent	  probes	  are	  60	  mer	  with	  5	  CpGs.	  The	  CpG	  dinucleotides	  
are	   unmethylated	   (white	   square),	   methylated	   (black	   square),	   or	   substituted	   with	   a	  
uracil	  mismatch	  (pink	  triangle).	  (B-­‐C)	  The	  MBD	  domains	  of	  ol.Mbd4	  and	  xl.Mbd4	  bind	  
to	  fully	  methylated	  probes	  (I,	   J,	  K,	  L),	  but	  can	  not	  distinguish	  the	  uracil	  mismatches	  at	  
CpG	   dinucleotide	   context.	   (D.)	   The	   MBD	   domain	   of	   xl.MeCP2	   preferentially	   binds	   to	  
hemi-­‐methylated	  probe	  with	  uracil	  mismatches	  (probe	  D	  and	  L).	  The	  odd	  number	  lanes	  
in	  (B.	  C.	  and	  lower	  D)	  are	  free	  probes	  only	  and	  have	  no	  proteins	  added.	  
 
 
6.3.	  	  Discussion	  
 
In this chapter I have investigated the binding affinities of ol.Mbd4, xl.Mbd4 and xl.MeCP2 
to a variety of probes containing modified bases at CpG sites. In sum, the binding specificity 
of MBD4 to methylated CpG dinucleotides is well conserved in lower vertebrates like 
medaka fish and xenopus frog. In addition, none of my fusion proteins of MBD domains of 
MBD4 and MeCP2 by themselves showed binding affinity to the probes containing 
hydroxymethylated CpGs. Lastly, the MBD domains of ol.Mbd4 and xl.Mbd4 did not 
distinguish the probes containing G:U, whereas the MBD domain of xl.MeCP2 showed a 
striking binding affinity to the G:U mismatch at a single hemimethylated CpG context. 
  
6.3.1.	  The	  binding	  conservation	  of	  MBD4	  suggests	  a	  general	  machinery	  in	  terms	  of	  
MBD4	  function	  during	  vertebrate	  evolution	  
 
I started my PhD from the EMSA assays to ask if MBD4 in lower vertebrates like Xenopus 
frog and Medaka fish possesses the binding affinity to methylated CpG dinucleotides in the 
same extent of those in mammals. Initially we addressed this as we previously identified a 
indispensable role of xl.Mbd4 with MLH1 for apoptotic induction in xDnmt1-depleted 
embryos (Ruzov et al., 2009). Partial depletion of xDnmt1 in Xenopus is sufficient to induce 
apoptosis without general hypo-methylation (Ruzov et al., 2009). However, If xl.Mbd4 could 
recognise mCpG dinucleotides was unknown. Thus it was interesting to investigate this 
point. Moreover, later I reasoned MBD4 might have a key role in Xenopus development, 
possibly in the context of active demethylation at thyroid hormone receptors and/or other 
hormone receptors. There are several piece of evidence supporting this point. While mice 
lacking Mbd4 are viable, the morpholino knockdowns of Mbd4 in Xenopus result in a lethal 
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phenotype in their early development, which fail to develop to tadpole stages (Ruzov et al., 
2009). This is a potential precise phenotype to study the biological role of MBD4. A clue is 
that the thyroid hormone (T3) is essential to control the anuran amphibian metamorphosis 
including the development of tadpole-specific organs and the limb development (Matsuda et 
al., 2009). This involves gene regulation by the T3 receptor (TR). TRs form heterodimmers 
with 9-cis retinoic acid receptors (RXRs), the type II hormone receptors. One of the other 
heterodimmer-forming hormone receptors with RXRs is the nuclear vitamin D receptor, 
which is parathyroid (PTH) hormone-induced (Lee and Lee Kraus, 2001). These dimers bind 
to the response element (RE), most of which coincide with the promoters of target genes, 
negatively regulating their transcriptional repression (Kim et al., 2009). Recently a 
demethylation role of MBD4 at promoter of this specific vitamin D receptor has been 
reported (Kim et al., 2009). Coincidentally a study in zebrafish embryos has suggested 
zMbd4 could excise the G:T mismatches derived from deamination of 5mC, implicating its 
possible role in demethylation in this lower vertebrate organism (Rai et al., 2008). However, 
whether MBD4 of low vertebrates could efficiently recognise 5mC was unknown, especially 
there is a noticeable poor conservation of the primary sequences of its MBD domain. My 
results show the binding affinities of MBD4 in the lower Vertebrates of xenopus frog and 
Medaka fish are well conserved, suggesting that a possible role of Mbd4 in recognition of 
5mC in the vertebrate genomes to act as a component of the machinery in, but not limited to 
the apoptosis signaling and the possible demethylation. Actually the role of MBD4 in 
binding methylation marks and inducing transcriptional repression might be underestimated, 
thus these results answered a prerequisite question for confirming its evolutionary binding 
affinity. 
  
6.3.2.	   Maintenance	   of	   fidelity	   and	   regulation	   of	   stability	   of	   DNA	  methylation:	   a	  
possible	  role	  of	  MBD4	  and	  MeCP2	  
 
At the time of implantation of the early stage of mouse embryonic development, the initial 
pattern of DNA methylation are established by the DNMT3 enzymes (Popp et al., 2010, 
Sasaki and Matsui, 2008, Lees-Murdock and Walsh, 2008, Morgan, 2005, Reik, 2001). Once 
the DNA methylation patterns are established, they must be maintained and replicated with 
fidelity. DNMT1 prefers hemimethylated DNA over an unmethylated counterpart 
(Figure.6.6 A), and reproduces the methylation pattern according to the hemimethylated 
template after each round of replication (Jurkowska et al., 2010). In addition, UHRF1 has 
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been shown to bind specifically to hemimethylated DNA through its SRA domain 
(Hashimoto et al., 2008, Bostick et al., 2007, Arita et al., 2008, Avvakumov et al., 2008), and 
target DNMT1 to these specific sites (Sharif et al., 2007, Bostick et al., 2007) (Figure. 6.6 
A). DNMT1 and its association with UHRF1 perform a central role in maintenance of the 
patterns of DNA methylation after the synthesis of the new DNA double strands. 
Additionally MBD4 may regulate their activity by direct association with them, and/or 
through regulation of their ubiquitination by its interactions with USP7 and UHRF1 (Figure. 
6.6 A and Chapter 4). One of the factors affecting the fidelity of the methylation marks at 
CpG sites is the spontaneous deamination of methylated cytosines. The 5-methyl-cytosine is 
prone to the spontaneous deamination (Figure. 6.6 lower left diagram), the most common 
single nucleotide mutation, which removes ammonia from the 5-methylcytosine, and results 
in thymine (Figure. 6.6 lower left diagram, process on the right). In contrast, deamination of 
unmethylated cytosine generates uracil (Figure. 6.6 lower left diagram, process on the left).  
MBD4 is one of the only two mammalian thymine glycosylases, and one of four uracil 
glycosylases. MBD4 has the MBD domain that has a preferential binding affinity to G:T 
context (Figure. 6.6 C1&C2), and its glycosylase domain specifically recognise and excise 
the thymine mismatches (Hendrich et al., 1999). Where thymine mismatches occur at CpG 
dinucleotides, thymine glycosylases like MBD4 may repair the mismatches, with the help of 
component proteins of BER pathway, and mismatch repair pathway proteins such as MLH1 
(Figure. 6.6 C1&C2). In addition, the cytosine bases restored may be unmethylated. Thus 
these unmethylated cytosines at CpG context need to be remethylated faithfully to maintain 
the fidelity of the methylation information. This may be performed by a precise machinery in 
which MBD4 may be involved through its associations with DNMT1 and/or DNMT3b 




Figure	  6.6.	  A	  working	  model	  for	  the	  role	  of	  MBD4	  and	  MeCP2	  in	  maintenance	  of	  fidelity	  
and	   regulation	   of	   stability	   of	   DNA	   methylation.	   (A.)	   DNMT1	   and	   UHRF1	   can	  
preferentially	   bind	   to	   hemi-­‐methylated	   CpG	   dinucleotides.	   DNMT1	   is	   present	   at	   the	  
replication	  fork,	  and	  functions	  with	  the	  help	  of	  partner	  proteins	  including	  UHRF1	  and	  
PCNA	   (Proliferating	   cell	   nuclear	   antigen).	  MBD4	  may	   regulate	   their	   activity	   by	   direct	  
association	   with	   them,	   and/or	   through	   regulation	   of	   their	   ubiquitination	   by	   its	  
interactions	   with	   USP7	   and	   UHRF1.	   (B.)	   MeCP2	   has	   binding	   preferences	   to	   a	  
deamination	   mismatch	   product	   of	   uracil	   in	   the	   context	   of	   hemimethylated	   CpG	  
dinucleotide.	  Other	  glycosylases	   (possibly	  TDG)	  might	   follow	   to	  excise	  and	   repair	   the	  
uracil	   mismatches.	   The	   restored	   cytosine	   bases	   can	   be	   remethylated	   by	   their	  
association	  proteins	  DNMT1	  and/or	  DNMT3b.	  (C1&C2)	  The	  5mC	  deamination	  product	  
G:T	   mismatch	   can	   be	   preferentially	   recognized	   by	   MBD4,	   followed	   by	   excision	   and	  
repair	   with	   the	   help	   of	   BER	   pathway	   and/or	   MMR	   pathway	   protein	   MLH1.	   MBD4	  
interacts	   directly	   with	   both	   DNMT1	   (and/or	   DNMT3b)	   and	   MLH1	   leading	   to	  
recruitment	   of	   all	   of	   them	   at	   DNA	   damage	   sites.	   (D)	   Both	  MBD4	   and	  MeCP2	   are	   not	  
capable	   of	   recognition	   of	   5-­‐hydroxymethylcytosine	   (5hmC)	   by	   themselves.	   However,	  
this	   does	   not	   exclude	   they	  may	   involve	   in	   such	   processes	   where	   forming	   complexes	  
with	   other	   capable	   proteins.	   Lower	   left	   diagram:	   components	   and	   processes	   of	  
deamination	  of	  unmethylated	  and	  methylated	  cytosines.	  
 
I tested ol.Mbd4, xl.Mbd4 and  xl.MeCP2 with hydroxymethylated (hmC) probes, 
and none of them showed binding specificity with hmC (Figure. 6.6 D), suggesting at least 
the MBD domains of these proteins could not distinguish this newly discovered epigenetic 
mark, while this does not exclude the possibility they might involve in recognition or 
excision of 5hmC in a complex with other possible 5hmC binding proteins. However, 
surprisingly I identified that the MBD domain of xl.MeCP2 has binding preferences to a 
deamination mismatch product of uracil in the context of hemimethylated CpG dinucleotide 
(Figure. 6.6 B). As far as I am aware, no published work has reported such binding 
specificity to deamination products like G:U by the MeCPs other than MBD4 and other 
glycosylase. The finding of this G:U mismatch affinity of MeCP2 with hemimethylated 
context has a very important implication that the MeCPs may involve in the efficient 
recognition of the deamination mismatches at CpG dinucleotides, to ensure the replication 
fidelity at the promoter-coincidence regions. There are a number of possible mechanisms 
proposed regarding how DNA glycosylases manage to efficiently search for and recognise 
the lesions including sliding-scan, tracking-diffusion-hopping, and forming a iron–sulfur 
cluster (Jacobs and Schär, 2011). However, if there is a preference repair to protect the most 
crucial sites like CpG dinucleotides and how this will work is unclear. In terms of hydrolytic 
deamination, MBD4 has demonstrated a binding preference to G:T mutation at CpG 
dinucleotides, and we have shown this is also true in Xenopus, suggesting a possible 
efficient repair mechanisms for this deamination product of 5mC (Figure. 6.6 C1&C2). This 
also in another way implicates a biological relevance of the special property of MBD4 in 
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possessing a MBD domain in addition to its glycosylase domain. Similarly, I have shown the 
G:U binding affinity of xl.MeCP2 is much stronger than its binding to the fully methylated 
probes, providing a preferential role of G:U recognision by MeCp2. Thus for the 
deamination product of unmethylated cytosine G:U at hemimethylated CpG sites, my results 
suggest a previously unknown machinery, in which G:U mismatches generated during DNA 
replication might be firstly recognised by MeCP2, and a uracil glycosylase such as TDG 
might follow, and induce BER repair for an unmethylated cytosine. Both MeCP2 and TDG 
have been reported to associate with DNA methyltransferases like DNMT1 or DNMT3b 
(Kimura, 2002, Boland and Christman, 2008), suggesting this speculation might be true. This 
also ensures the repaired cytosine at CpG sites can be remethylated subsequently to maintain 

























Chapter	  7:	  General	  Discussion	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My overall aim for this project was to identify new possible roles for MBD4, and the 
underlining mechanisms. I began by screening for MBD4 associated protein partners in two 
complementary high-throughput approaches of Y2H and AP/MS. Surprisingly a large 
number of protein candidates were identified from both screens. This led me to choose and 
validate a cohort of most interesting candidates by reciprocal co-IP and IF, followed by an 
identification of MBD4 domains responsible for their interactions. Almost all these 
identified MBD4 association proteins including UHRF1, PRMT5, KAP1, ACF1, and USP7 
are known transcriptional co-repressors as histone modifiers and/or chromatin remodellers. 
This led me to investigate the role of MBD4 in transcriptional repression (TR) in the context 
of two independent Mbd4-/- MEF cell lines by performing microarrays and bioinformatic 
analysis to identify the possible MBD4 targets. Last but not least, I tested the binding 
specificity of MBD4 and its closest relative protein homologue MeCP2 against a variety of 
DNA probes containing unmethylated, methylated, hydroxymethylated, and mismatched 
cytosine bases at CpG dinucleotides. The main findings of this work are as follows: 
• A large number of proteins (~380) potentially interact with MBD4, many of which 
are involved in the functional groups of signalling, transcriptional regulation, DNA 
repair and RNA processing. 
• Majority of chosen candidates were validated by reciprocal co-IP of expressed 
partners and by immunofluorescence (IF) microscopy to determine their potential 
co-localisation in mouse and human cell lines, including UHRF1, PRMT5, KAP1, 
ACF1, and USP7. 
• The intervening domain of MBD4 is a novel protein interaction region for tested 
candidates including UHRF1, PRMT5, and KAP1. 
• The transcription regulatory components KAP1 and CFP1 not only interact with but 
also dramatically influence the stability of exogenously expressed MBD4 in human 
cells. 
• A cohort of genes were identified that are significantly up- or down- regulated in 
both Mbd4-/- MEFs. This included mis-expression of insulin-like growth factor-
binding proteins and two paternally imprinted genes Dio3 and H19. In response to 
this observation, I identified a potential interaction between MBD4 and estrogen 
receptor α (ERα) by co-IP and IF co-localisation. 
• By pathway analysis, several developmental genes including Sox9, Klf2 and Klf4, 
were prioritised as possible MBD4 targets. On this basis I propose a role for MBD4 
in acquired diseases such as cancers and autoimmune diseases via transcriptional 
regulation. 
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• DNA binding specificity to a series of methylated and mismatched probes is 
conserved regardless of the poor sequence conservation of the MBD domain of 
Mbd4 between the species.  
Based on above findings, I conclude that MBD4 is integrated in multiple pathways in the 
nucleus that includes DNA repair, chromatin remodelling, transcriptional regulation and 
genome stability. It is noteworthy that although MBD4 has a functionally conserved methyl-
CpG binding domain, this is unlikely to be major methyl-CpG associated machinery. 
Because in both MEFs or normal and cancer cells from human and mouse, the methylation 
statuses of the promoter regions of the developmental genes that are potential MBD4 targets 
are usually low (Supplementary table 7.1). This may indicate indirect targeting by MBD4 
and link with discussed protein interactors that are involved in transcriptional regulation. It is 
very likely that potential targeting at these promoters rely on the protein association complex 
including MBD4 and its co-repressors including KAP1, PRMT5, USP7 and UHRF1. The 
only exception is the two paternally imprinted genes Dio3 and H19, whose differentially 




In terms of immediate future work I think it will be interesting to check the endogenous 
MBD4 expression in human primary cancer tissues such as breast, colorectal and ovarian 
cancers. One of the limitations of my PhD work was the lack of a good MBD4 antibody that 
could check endogenous MBD4 expression. At the very end of this thesis writing, I noticed 
that there is a new human MBD4 antibody now available at Sigma. I have tried this new 
antibody, and observed both nuclear and cytoplasmic expression of MBD4 in human primary 
cancer tissues (Supplementary figure 7.1). In response to this observation, right before the 
writing of this general discussion chapter, I have performed immunofluorescent Aquanalysis 
to examine the association of expressions of MBD4 in line with TDG and SOX9, on tissue 
microarrays containing primary human cancer specimens of 182 breast cancers, 130 
colorectal cancer, and 247 ovarian cancers (for breast cancers tissue microarray, we also 
have ERα and PgR expression data). This will be important to test the working model of the 
role of MBD4 in cancers regarding the possible mechanism of transcriptional repression 
and/or apoptosis signaling. These expression results need to be classed by their pathologic 
subtypes and/or tumour grades and/or prognosis and metastasis history. In addition, it is also 
very interesting to check my MBD4 association findings using this MBD4 antibody by 
endogenous co-IP in primary tissues. 
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It is very interesting to knockdown MBD4 in relevant cell lines such as MCF7 to 
further investigate transcriptional changes according to the Mbd4-/- MEFs microarray results. 
And as mentioned in above chapter, MBD4 rescue experiment is necessary to confirm the 
direct targets of MBD4. Importantly, repression assays for MBD4 need to be set up to ask if 
MBD4 and the identified co-repressive complexes indeed act on target genes in a manner of 
transcriptional repression. A Gal4 based vector system together with CREB and KAP1 
vectors can be used as a system for transcriptional reporter assays. If this system could work 
for MBD4, it will be very interesting to see if the different combinations of MBD4 
association proteins including KAP1, PRMT5, UHRF1 and ACF1 could differentially 
regulate the transcriptional level. In terms of the reporters that would be suitable for the 
assay, it is interesting to try the promoter regions of the developmental genes discussed 
including SOX9, KLF2, and KLF4, which have either NF-kB or cbp/p300 binding sites. This 
may accompany with EMSAs (electrophoretic mobility shift assay) using purified MBD4 
with fluorescent or radioactive labeled probes of NF-kB and/or CREB binding sites within 
their promoters containing differential CpG dinucleotides. In addition, methylation status of 
the promoters of a number of potential MBD4 targets including the above-mentioned 
developmental genes and paternally imprinted genes need to be investigated by bisulfate 
sequencing and/or methyl-DIP.  
In the longer term, it will be necessary to check the MBD4 binding sites in the 
genome by CHIP-seq in both cultured cells and primary tissues. The new MBD4 antibody 
may be suited for this task. Ideally it should be done in a more biologically relevant system 
such as certain cancer cell lines such as MCF7 and chondrocytes, and primary tissues such as 
breast cancers and/or synovial joints tissues from rheumatoid arthritis patients. Moreover, the 
effects of chronic stress on mice models that lacking MBD4 need to be re-evaluated, 
especially for the collagen antibody stress and estradiol stress, to test the hypothesis 
described in Figure. 5.10. In addition, it will be interesting to test DNA damage responses on 
MBD4-/- cells or MBD4 knockdown cells for the role of MBD4 in apoptotic responses, while 
keeping an eye on the status of p21 and KLF4 expression. Last but not least, it will be 
interesting to knockout multiple MeCPs to see if this would cause more severe phenotype. A 
multiple knockout of MeCP2, Mbd2 and Kaiso in mice has been reported but the phenotype 
observed was very similar to the single knockout of MeCP2 (Martin Caballero et al., 2009). 
One of the possibilities would be other MeCPs existing in the system compensated their 
roles of transcriptional regulation, including MBD4. Thus more multiple knockouts of 
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Panther molecular function 
  
mRNA transcription regulation 
E4f1 E4F transcription factor 1; May function as a transcriptional repressor. May 
also function as a ubiquitin ligase mediating ubiquitination of chromatin-
associated TP53. Functions in cell survival and proliferation through control of 
the cell cycle. Functions in the p53 and pRB tumor suppressor pathways and 
regulates the cyclin CCNA2 transcription (782 aa) 
10 Transcription factor 
    Zinc finger transcription factor 
           KRAB box transcription factor 
 
Zscan22 Zinc finger and SCAN domain-containing protein 22 (Zinc finger protein 50) 
(Krueppel-related zinc finger protein 2) (Protein HKR2); May be involved in 
transcriptional regulation (491 aa)(Homo sapiens) 
2 Transcription factor 
    Zinc finger transcription factor 
           KRAB box transcription factor 
Zfp748 zinc finger protein 748 (888 aa) 1 Transcription factor 
    Zinc finger transcription factor 
           KRAB box transcription factor 
Ring1 ring finger protein 1; Constitutes one of the E3 ubiquitin-protein ligases that 
mediate monoubiquitination of 'Lys-119' of histone H2A, thereby playing a 
central role in histone code and gene regulation. H2A 'Lys-119' ubiquitination 
gives a specific tag for epigenetic transcriptional repression and participates in 
X chromosome inactivation of female mammals. Essential component of the 
Polycomb group (PcG) multiprotein PRC1 complex, a complex required to 
maintain the transcriptionally repressive state of many genes, including Hox 
genes, throughout development. PcG PRC1 complex act via c [...] (406 aa) 
3 Transcription factor 
    Zinc finger transcription factor 
Pcgf6 polycomb group ring finger 6; Transcriptional repressor. May modulate the 
levels of histone H3K4Me3 by activating JARID1D histone demethylase (By 
similarity) (353 aa) 
2 Transcription factor 
    Zinc finger transcription factor 
Rnf2 ring finger protein 2; E3 ubiquitin-protein ligase that mediates 
monoubiquitination of 'Lys-119' of histone H2A, thereby playing a central role 
in histone code and gene regulation. H2A 'Lys-119' ubiquitination gives a 
specific tag for epigenetic transcriptional repression and participates in X 
chromosome inactivation of female mammals. May be involved in the initiation 
of both imprinted and random X inactivation. Essential component of the 
Polycomb group (PcG) multiprotein PRC1 complex, a complex required to 
maintain the transcriptionally repressive state of many genes, including Hox g 
[...] (336 aa) 
2 Transcription factor 
    Zinc finger transcription factor 
Zfp161 zinc finger protein 161; Transcriptional repressor of c-Myc and thymidine 
kinase promoters (448 aa) 
1 Transcription factor 
    Zinc finger transcription factor 
Mysm1 myb-like, SWIRM and MPN domains 1 (819 aa) 1 Transcription factor 
    Transcription cofactor 
 Nucleic acid binding 
Hoxb9 homeo box B9; Sequence-specific transcription factor which is part of a 
developmental regulatory system that provides cells with specific positional 
identities on the anterior-posterior axis (250 aa) 
1 Transcription factor 
    Homeobox transcription factor 
 Nucleic acid binding 
    Other DNA-binding protein 
Lhx1 LIM homeobox protein 1; Potential transcription factor. May play a role in 
early mesoderm formation and later in lateral mesoderm differentiation and 
neurogenesis (406 aa) 
2 Transcription factor 
    Homeobox transcription factor 
    Zinc finger transcription factor 
           Other zinc finger transcription 
factor 
 Nucleic acid binding 
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Hes6 hairy and enhancer of split 6 (Drosophila); Does not bind DNA itself but 
suppresses both HES1- mediated N box-dependent transcriptional repression 
and binding of HES1 to E box sequences. Also suppresses HES1-mediated 
inhibition of the heterodimer formed by ASCL1/MASH1 and TCF3/E47, 
allowing ASCL1 and TCF3 to up-regulate transcription in its presence. 
Promotes cell differentation (224 aa) 
1 Transcription factor 
    Basic helix-loop-helix transcription 
factor 
 Nucleic acid binding 
Pja2 praja 2, RING-H2 motif containing; Has E2-dependent E3 ubiquitin-protein 
ligase activity (707 aa) 
2 Transcription factor 
mycn v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) 
(462 aa) 
3 Transcription factor 
    Basic helix-loop-helix transcription 
factor 
 Nucleic acid binding 
Ewsr1 RNA-binding protein EWS (EWS oncogene) (Ewing sarcoma breakpoint 
region 1 protein); Might normally function as a repressor. EWS-fusion- proteins 
(EFPS) may play a role in the tumorigenic process. They may disturb gene 
expression by mimicking, or interfering with the normal function of CTD-
POLII within the transcription initiation complex. They may also contribute to 
an aberrant activation of the fusion protein target genes (656 aa)(Homo sapiens) 
1 Nucleic acid binding 
    Other RNA-binding protein 
Crebzf CREB/ATF bZIP transcription factor; Strongly activates transcription when 
bound to HCFC1. Suppresses the expression of HSV proteins in cells infected 
with the virus in a HCFC1-dependent manner. Also suppresses the HCFC1- 
dependent transcriptional activation by CREB3 and reduces the amount of 
CREB3 in the cell. Able to down-regulate expression of some cellular genes in 
CREBZF-expressing cells (By similarity) (273 aa) 
  Transcription factor 
    CREB transcription factor 
 Nucleic acid binding 
Lsm14b LSM14 protein homolog B (Protein FAM61B) (385 aa)   Nucleic acid binding 
    Other RNA-binding protein 
Cir1 corepressor interacting with RBPJ, 1   Transcription factor 
    Transcription cofactor 
Ttc3 Tetratricopeptide repeat protein 3 (TPR repeat protein 3) (TPR repeat protein 
D) (RING finger protein 105) (2025 aa)Ttc3 tetratricopeptide repeat domain 3; 
contain RING-finger (Really Interesting New Gene) domain, a specialized type 
of Zn-finger of 40 to 60 residues that binds two atoms of zinc; defined by the 
'cross-brace' motif C-X2-C-X(9-39)-C-X(1-3)- H-X(2-3)-(N/C/H)-X2-C-X(4-
48)C-X2-C; probably involved in mediating protein-protein interactions; 
identified in a proteins with a wide range of functions such as viral replication, 
signal transduction, and development; has two variants, the C3HC4-type and a 
C3H2C3-type (RING-H2 finger), which have different cysteine/histidine 
pattern; a subset of RINGs are associated with B-Boxes (C-X2-H-X7-C-X7-C-
X2-C-H-X2-H) 
3 Molecular function unclassified 
Cenpv proline-rich polypeptide 6; Required for distribution of pericentromeric 
heterochromatin in interphase nuclei and for centromere formation and 
organization, chromosome alignment and cytokinesis (By similarity) (252 aa) 
1 Molecular function unclassified 
Uimc1 ubiquitin interaction motif containing 1; Acts as a transcriptional repressor. 
Inhibits the interaction of NR6A1 with the corepressor NCOR1 (By similarity) 
(729 aa) 
1  Molecular function unclassified 
Signaling, Transporter & Receptor 
Plcd1 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase delta 1 (EC 
3.1.4.11) (Phosphoinositide phospholipase C) (PLC-delta-1) (Phospholipase C-
delta-1) (PLC-III); The production of the second messenger molecules 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by 
activated phosphatidylinositol-specific phospholipase C enzymes. Essential for 
trophoblast and placental development (777 aa)(Homo sapiens) 
2 Hydrolase 
    Lipase 
           Phospholipase 
 Select calcium binding protein 
Fbn2 fibrillin 2; Fibrillins are structural components of 10-12 nm extracellular 
calcium-binding microfibrils, which occur either in association with elastin or 
in elastin-free bundles. Fibrillin-2- containing microfibrils regulate the early 
process of elastic fiber assembly (2909 aa) 
1 Signaling molecule 
 Cell adhesion molecule 
 Extracellular matrix 
    Extracellular matrix structural protein 
    Extracellular matrix glycoprotein 
 Select calcium binding protein 
    Annexin 
Hba-a1 hemoglobin alpha, adult chain 1 (Hba-a1) 2 Transfer/carrier protein 
    Other transfer/carrier protein 
Slc25a37 solute carrier family 25, member 37; Mitochondrial iron transporter that 
specifically mediates iron uptake in developing erythroid cells, thereby playing 
an essential role in heme biosynthesis. The iron delivered into the mitochondria, 
2 Transfer/carrier protein 
    Mitochondrial carrier protein 
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presumably as Fe(2+), is then probably delivered to ferrochelatase to catalyze 
Fe(2+) incorporation into protoprophyrin IX to make heme (338 aa) 
G3bp2 Ras GTPase activating protein (SH3 domain) binding protein 2; Probable 
scaffold protein that may be involved in mRNA transport (Potential) (482 aa) 
1 Signaling molecule 
    Other signaling molecule 
 Nucleic acid binding 
    Other RNA-binding protein 
Nck2 non-catalytic region of tyrosine kinase adaptor protein 2 (380 aa) 1 Signaling molecule 
    Other signaling molecule 
 Miscellaneous function 
    Other miscellaneous function protein 
    Transmembrane receptor 
regulatory/adaptor protein 
Marcks myristoylated alanine rich protein kinase C substrate; MARCKS is the most 
prominent cellular substrate for protein kinase C. This protein binds 
calmodulin, actin, and synapsin. MARCKS is a filamentous (F) actin cross-
linking protein (309 aa) 
2 Signaling molecule 
    Other signaling molecule 
 Cytoskeletal protein 
    Actin binding cytoskeletal protein 
           Non-motor actin binding protein 
 Miscellaneous function 
    Structural protein 
Lgals2 lectin, galactose-binding, soluble 2; This protein binds beta-galactoside. Its 
physiological function is not yet known (130 aa) 
1 Signaling molecule 
    Other signaling molecule 
 Cell adhesion molecule 
    Other cell adhesion molecule 
Rab11fip3 RAB11 family interacting protein 3 (class II) (907 aa) 1  Signaling molecule 
    Other signaling molecule 
 Select regulatory molecule 
    Other enzyme regulator 
 Select calcium binding protein 
    Calmodulin related protein 
 Miscellaneous function 
Vps16 vacuolar protein sorting 16 (yeast); May play a role in vesicle-mediated protein 
trafficking to lysosomal compartments and in membrane docking/fusion 
reactions of late endosomes/lysosomes (By similarity) (839 aa) 
6 Molecular function unclassified 
Stx8 syntaxin 8; Vesicle trafficking protein that functions in the early secretory 
pathway, possibly by mediating retrograde transport from cis-Golgi membranes 
to the ER (By similarity) (236 aa) 
1  Membrane traffic protein 
    SNARE protein 
Arf6 ADP-ribosylation factor 6; GTP-binding protein that functions as an allosteric 
activator of the cholera toxin catalytic subunit, an ADP- ribosyltransferase. 
Involved in protein trafficking; may modulate vesicle budding and uncoating 
within the Golgi apparatus (By similarity) (175 aa) 
1 Select regulatory molecule 
    G-protein 
           Small GTPase 
Lrrn1 Leucine-rich repeat neuronal protein 1 precursor (Neuronal leucine- rich repeat 
protein 1) (NLRR-1)(Homo sapiens) 
1 Receptor 
 Extracellular matrix 
Kit kit oncogene; This is the receptor for stem cell factor (mast cell growth factor). 
It has a tyrosine-protein kinase activity. Binding of the ligands leads to the 
autophosphorylation of KIT and its association with substrates such as 
phosphatidylinositol 3-kinase (Pi3K) (979 aa) 
1 Receptor 
    Protein kinase receptor 
           Tyrosine protein kinase receptor 
 Kinase 
    Protein kinase 
Loxl1 lysyl oxidase-like 1; Active on elastin and collagen substrates (By similarity) 
(607 aa) 
2 Receptor 
    Other receptor 
 Oxidoreductase 
    Oxidase 
Nr1h3 nuclear receptor subfamily 1, group H, member 3; Orphan receptor. Interaction 
with RXR shifts RXR from its role as a silent DNA-binding partner to an active 
ligand- binding subunit in mediating retinoid responses through target genes 
defined by LXRES. LXRES are DR4-type response elements characterized by 
direct repeats of two similar hexanuclotide half- sites spaced by four 
nucleotides. Plays an important role in the regulation of cholesterol homeostasis 
(445 aa) 
1 Receptor 
    Nuclear hormone receptor 
 Transcription factor 
 Nucleic acid binding 
Pth1r parathyroid hormone receptor 1; This is a receptor for parathyroid hormone and 
for parathyroid hormone-related peptide. The activity of this receptor is 
mediated by G proteins which activate adenylyl cyclase and also a 
phosphatidylinositol-calcium second messenger system (591 aa) 
2 Receptor 
    G-protein coupled receptor 
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Rhoa ras homolog gene family, member A; Regulates a signal transduction pathway 
linking plasma membrane receptors to the assembly of focal adhesions and 
actin stress fibers. May be an activator of PLCE1 (By similarity) (193 aa) 
1 Select regulatory molecule 
    G-protein 
           Small GTPase 
Ran RAN, member RAS oncogene family (Ran) 1 Select regulatory molecule 
    G-protein 
           Small GTPase 
Dcaf8 DDB1 and CUL4 associated factor 8 (Dcaf8) 1 Select regulatory molecule 
    G-protein 
 Miscellaneous function 
    Other miscellaneous function protein 
Gnb2 guanine nucleotide binding protein, beta 2; Guanine nucleotide-binding proteins 
(G proteins) are involved as a modulator or transducer in various 
transmembrane signaling systems. The beta and gamma chains are required for 
the GTPase activity, for replacement of GDP by GTP, and for G protein- 
effector interaction (340 aa) 
1 Select regulatory molecule 
    G-protein 
           Large G-protein 
 Hydrolase 
Atl3 atlastin GTPase 3 (Atl3) 1 Select regulatory molecule 
    G-protein 
           Large G-protein 
Atp1b2 ATPase, Na+/K+ transporting, beta 2 polypeptide; This is the non-catalytic 
component of the active enzyme, which catalyzes the hydrolysis of ATP 
coupled with the exchange of Na(+) and K(+) ions across the plasma 
membrane. The exact function of the beta-2 subunit is not known (290 aa) 
  Transporter 
    Cation transporter 
Atp1b3 ATPase, Na+/K+ transporting, beta 3 polypeptide; This is the non-catalytic 
component of the active enzyme, which catalyzes the hydrolysis of ATP 
coupled with the exchange of Na(+) and K(+) ions across the plasma 
membrane. The exact function of the beta-3 subunit is not known (278 aa) 
   Transporter 
    Cation transporter 
Exoc5 exocyst complex component 5; Component of the exocyst complex involved in 
the docking of exocystic vesicles with fusion sites on the plasma membrane (By 
similarity) (709 aa) 
  Membrane traffic protein 
    Membrane traffic regulatory protein 
    Other membrane traffic protein 
Mapkapk5 MAP kinase-activated protein kinase 5 (EC 2.7.11.1) (MAPK-activated protein 
kinase 5) (MAPKAP kinase 5) (p38-regulated/activated protein kinase); 
Mediates stress-induced small heat shock protein 27 phosphorylation (461 aa) 
  Kinase 
    Protein kinase 
           Non-receptor serine/threonine 
protein kinase 
Odz3 Teneurin-3 (Ten-3) (Tenascin-M3) (Ten-m3) (Protein Odd Oz/ten-m homolog 
3); May function as a cellular signal transducer (2715 aa) 
  Receptor 
    Other receptor 
 Signaling molecule 
    Other signaling molecule 
    Membrane-bound signaling molecule 
Hba-a2 hemoglobin alpha, adult chain 2; Involved in oxygen transport from the lung to 
the various peripheral tissues (142 aa) 
  Transfer/carrier protein 
    Other transfer/carrier protein 
Slc35b4 solute carrier family 35, member B4; Sugar transporter that specifically 
mediates the transport of UDP-xylose (UDP-Xyl) and UDP-N-
acetylglucosamine (UDP-GlcNAc) from cytosol into Golgi (By similarity) 
(331 aa) 
  Transporter 
    Carbohydrate transporter 
    Other transporter 
Tmed2 transmembrane emp24 domain trafficking protein 2; Could have a role in the 
budding of coatomer-coated and other species of coated vesicles. Could bind 
cargo molecules to collect them into budding vesicles (By similarity) (201 aa) 
  Membrane traffic protein 
    Vesicle coat protein 
Efcab7 Efcab7 EF-hand calcium binding domain 7; EF-hand, calcium binding motif; A 
diverse superfamily of calcium sensors and calcium signal modulators; most 
examples in this alignment model have 2 active canonical EF hands. Ca2+ 
binding induces a conformational change in the EF-hand motif, leading to the 
activation or inactivation of target proteins. EF-hands tend to occur in pairs or 
higher copy numbers. 
4 Molecular function unclassified 
Gpr149 Probable G-protein coupled receptor 149 (G-protein coupled receptor PGR10); 
Orphan receptor (730 aa) 
1 Molecular function unclassified 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) (GAPDH); 
Independent of its glycolytic activity it is also involved in membrane trafficking 
in the early secretory pathway (335 aa) 
2  Molecular function unclassified 
Hmmr hyaluronan mediated motility receptor (RHAMM); Involved in cell motility. 
When hyaluronan binds to HMMR, the phosphorylation of a number of 
proteins, including the focal adhesion kinase occurs. May also be involved in 
cellular transformation and metastasis formation, and in regulating 
extracellular-regulated kinase (ERK) activity (794 aa) 
2  Molecular function unclassified 
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Protein synthesis regulation, modification & Proteolysis 
Eif3a eukaryotic translation initiation factor 3, subunit 10 (theta); Binds to the 40S 
ribosome and promotes the binding of methionyl-tRNAi and mRNA. May act 
as an adapter molecule between the translation initiation apparatus and the 
cytoskeleton structure in the cell (By similarity) (1344 aa) 
15 Nucleic acid binding 
    Translation factor 
           Translation initiation factor 
Eef1a1 eukaryotic translation elongation factor 1 alpha 1; This protein promotes the 
GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during 
protein biosynthesis (By similarity) (468 aa) 
5  Nucleic acid binding 
    Translation factor 
           Translation elongation factor 
Cacybp calcyclin binding protein; May be involved in calcium-dependent ubiquitination 
and subsequent proteosomal degradation of target proteins. Probably serves as a 
molecular bridge in ubiquitin E3 complexes. Participates in the ubiquitin-
mediated degradation of beta-catenin (CTNNB1) (By similarity) (229 aa) 
1 Ligase 
    Ubiquitin-protein ligase 
Prmt10 protein arginine methyltransferase 10 (putative) (Prmt10) 1  Transferase 
    Methyltransferase 
Sephs1 selenophosphate synthetase 1; Synthesizes selenophosphate from selenide and 
ATP (392 aa) 
2 Transferase 
    Other transferase 
Tpp2 tripeptidyl peptidase II; Component of the proteolytic cascade acting 
downstream of the 26S proteasome in the ubiquitin-proteasome pathway. May 
be able to complement the 26S proteasome function to some extent under 
conditions in which the latter is inhibited (By similarity) (1262 aa) 
3 Protease 
    Serine protease 
Psma5 proteasome (prosome, macropain) subunit, alpha type 5; The proteasome is a 
multicatalytic proteinase complex which is characterized by its ability to cleave 
peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at 
neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic 
activity (By similarity) (241 aa) 
2 Protease 
    Other proteases 
Bmp1 bone morphogenetic protein 1; Cleaves the C-terminal propeptides of 
procollagen I, II and III. Induces cartilage and bone formation. May participate 
in dorsoventral patterning during early development by cleaving chordin 
(CHRD) (By similarity) (991 aa) 
5 Protease 
    Metalloprotease 
Usp7 Ubiquitin carboxyl-terminal hydrolase 7 (EC 3.1.2.15) (Ubiquitin thioesterase 
7) (Ubiquitin-specific-processing protease 7) (Deubiquitinating enzyme 7) 
(Herpesvirus-associated ubiquitin-specific protease); Cleaves ubiquitin fusion 
protein substrates. Deubiquitinates TP53/p53 and MDM2 and strongly 
stabilizes TP53 even in the presence of excess MDM2, and also induces TP53- 
dependent cell growth repression and apoptosis (1110 aa)(Homo sapiens) 
1 Protease 
    Cysteine protease 
Phf21b PHD finger protein 21B (505 aa) 3  Ligase 
    Ubiquitin-protein ligase 
Anapc2 anaphase promoting complex subunit 2; Component of the anaphase promoting 
complex/cyclosome (APC/C), a cell cycle-regulated ubiquitin ligase that 
controls progression through mitosis and the G1 phase of the cell cycle (By 
similarity) (837 aa) 
1 Ligase 
    Ubiquitin-protein ligase 
Anapc10 anaphase promoting complex subunit 10; Component of the anaphase 
promoting complex/cyclosome (APC/C), a cell cycle-regulated ubiquitin ligase 
that controls progression through mitosis and the G1 phase of the cell cycle (By 
similarity) (185 aa) 
2 Select regulatory molecule 
 Ligase 
    Other ligase 
Cul1 cullin 1; Core component of multiple cullin-RING-based SCF (SKP1- CUL1-F-
box protein) E3 ubiquitin-protein ligase complexes, which mediate the 
ubiquitination of proteins involved in cell cycle progression, signal transduction 
and transcription. In the SCF complex, serves as a rigid scaffold that organizes 
the SKP1-F-box protein and RBX1 subunits. May contribute to catalysis 
through positioning of the substrate and the ubiquitin-conjugating enzyme. The 
E3 ubiquitin-protein ligase activity of the complex is dependent on the 
neddylation of the cullin subunit and is inhibited by the associ [...] (776 aa) 
2  Molecular function unclassified 
Skp1a S-phase kinase-associated protein 1A; Essential component of the SCF (SKP1-
CUL1-F-box protein) ubiquitin ligase complex, which mediates the 
ubiquitination of proteins involved in cell cycle progression, signal transduction 
and transcription. In the SCF complex, serves as an adapter that links the F-box 
protein to CUL1 (By similarity) (163 aa) 
1 Ligase 
    Ubiquitin-protein ligase 
Nedd8 neural precursor cell expressed, developmentally down-regulated gene 8; 
Ubiquitin-like protein which plays an important role in cell cycle control and 
embryogenesis. Covalent attachment to its substrates requires prior activation 
by the E1 complex UBE1C- APPBP1 and linkage to the E2 enzyme UBE2M. 
Attachment of NEDD8 to cullins activates their associated E3 ubiquitin ligase 
1 Nucleic acid binding 
    Ribosomal protein 
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activity, and thus promotes polyubiquitination and proteasomal degradation of 
cyclins and other regulatory proteins (75 aa) 
Ube2e1 ubiquitin-conjugating enzyme E2E 1, UBC4/5 homolog (yeast); Catalyzes the 
covalent attachment of ubiquitin to other proteins. Mediates the selective 
degradation of short-lived and abnormal proteins (193 aa) 
2 Ligase 
    Other ligase 
Papss1 3'-phosphoadenosine 5'-phosphosulfate synthase 1; Bifunctional enzyme with 
both ATP sulfurylase and APS kinase activity, which mediates two steps in the 
sulfate activation pathway. The first step is the transfer of a sulfate group to 
ATP to yield adenosine 5'-phosphosulfate (APS), and the second step is the 
transfer of a phosphate group from ATP to APS yielding 3'-
phosphoadenylylsulfate (PAPS- activated sulfate donor used by 
sulfotransferase). In mammals, PAPS is the sole source of sulfate; APS appears 
to be only an intermediate in the sulfate- activation pathway. Also involved in 
the [...] (627 aa) 
1 Kinase 
    Other kinase 
 Transferase 
    Nucleotidyltransferase 
Cndp2 CNDP dipeptidase 2 (metallopeptidase M20 family) (475 aa)   Protease 
    Metalloprotease 
Pcbp2 poly(rC) binding protein 2; Single-stranded nucleic acid binding protein that 
binds preferentially to oligo dC (362 aa) 
  Select regulatory molecule 
Pias1 protein inhibitor of activated STAT 1; Functions as an E3-type small ubiquitin-
like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the 
substrate, and as a SUMO-tethering factor. Plays a crucial role as a 
transcriptional coregulation in various cellular pathways, including the STAT 
pathway, the p53 pathway and the steroid hormone signaling pathway. The 
effects of this transcriptional coregulation, transactivation or silencing, may 
vary depending upon the biological context (644 aa) 
  Ligase 
Ptpn2 Tyrosine-protein phosphatase non-receptor type 2 (EC 3.1.3.48) (T-cell protein-
tyrosine phosphatase) (TCPTP) (415 aa) 
  Phosphatase 
    Protein phosphatase 
Trim27 tripartite motif protein 27; Has a transcriptional repressor activity. Induces 
apoptosis by activating Jun N-terminal kinase and p38 kinase and also increases 
caspase-3-like activity independently of mitochondrial events. May function in 
male germ cell development. Has DNA-binding activity and preferentially 
bound to double- stranded DNA (By similarity) (521 aa) 
  Ligase 
    Ubiquitin-protein ligase 
Ube2m ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast); Accepts the 
ubiquitin-like protein NEDD8 from the UBA3- NAE1 E1 complex and 
catalyzes its covalent attachment to other proteins. Involved in cell proliferation 
(By similarity) (183 aa) 
  Ligase 
    Other ligase 
Cstb Cystatin-B (Stefin-B) (Liver thiol proteinase inhibitor) (CPI-B); This is an 
intracellular thiol proteinase inhibitor. Tightly binding reversible inhibitor of 
cathepsins L, H and B (98 aa) 
  Select regulatory molecule 
    Protease inhibitor 
           Cysteine protease inhibitor 
Naa50 N(alpha)-acetyltransferase 50, NatE catalytic subunit   Transferase 
    Acetyltransferase 
Sugt1 Suppressor of G2 allele of SKP1 homolog (Sgt1) (Putative 40-6-3 protein); 
May play a role in ubiquitination and subsequent proteosomal degradation of 
target proteins (365 aa) 
2 Molecular function unclassified 
Zc3hc1 zinc finger, C3HC type 1; Essential component of an SCF-type E3 ligase 
complex, SCF(NIPA), a complex that controls mitotic entry by mediating 
ubiquitination and subsequent degradation of cyclin B1 (CCNB1). Its cell-
cycle-dependent phosphorylation regulates the assembly of the SCF(NIPA) 
complex, restricting CCNB1 ubiquitination activity to interphase. Its 
inactivation results in nuclear accumulation of CCNB1 in interphase and 
premature mitotic entry (By similarity). Overexpression may be able to protect 
from apoptosis induced by IL-3 withdrawal (502 aa) 
2 Molecular function unclassified 
Ribosomal protein 
Rpl12 ribosomal protein (Rpl12) 32 Nucleic acid binding 
    Ribosomal protein 
Ubc ubiquitin C; Protein modifier which can be covalently attached to target lysines 
either as a monomer or as a lysine-linked polymer. Attachment to proteins as a 
Lys-48-linked polymer usually leads to their degradation by proteasome. 
Attachment to proteins as a monomer or as an alternatively linked polymer does 
not lead to proteasomal degradation and may be required for numerous 
functions, including maintenance of chromatin structure, regulation of gene 
expression, stress response, ribosome biogenesis and DNA repair (By 
28 Nucleic acid binding 
    Ribosomal protein 
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similarity) (886 aa) 
Rps20 ribosomal protein S20 (Rps20) 8 Nucleic acid binding 
    Ribosomal protein 
Ubb ubiquitin B (Ubb) 3 Nucleic acid binding 
    Ribosomal protein 
Brix1 BRX1, biogenesis of ribosomes, homolog (S. cerevisiae) (Brix1) 1 Nucleic acid binding 
    Ribosomal protein 
Rpl5 ribosomal protein L5 (Rpl5) 1 Nucleic acid binding 
    Ribosomal protein 
Rpl7a ribosomal protein L7A (Rpl7a) 1 Nucleic acid binding 
    Ribosomal protein 
Rps6 ribosomal protein S6; May play an important role in controlling cell growth and 
proliferation through the selective translation of particular classes of mRNA 
(249 aa) 
1 Molecular function unclassified 
      Pre-mRNA processing 
Cpsf3 cleavage and polyadenylation specificity factor 3; Component of the cleavage 
and polyadenylation specificity factor (CPSF) complex that play a key role in 
pre-mRNA 3'-end formation, recognizing the AAUAAA signal sequence and 
interacting with poly(A) polymerase and other factors to bring about cleavage 
and poly(A) addition. Has endonuclease activity, and functions as mRNA 3'-
end-processing endonuclease (By similarity) (684 aa) 
1 Nucleic acid binding 
    Nuclease 
           Endoribonuclease 
    mRNA processing factor 
           mRNA polyadenylation factor 
Sfrs2 splicing factor, arginine/serine-rich 2 (SC-35); Necessary for the splicing of 
pre-mRNA. It is required for formation of the earliest ATP-dependent splicing 
complex and interacts with spliceosomal components bound to both the 5'- and 
3'-splice sites during spliceosome assembly. It also is required for ATP-
dependent interactions of both U1 and U2 snRNPs with pre- mRNA (By 
similarity). Can bind to the myelin basic protein (MBP) gene MB3 regulatory 
region and increase transcription of the mbp promoter in cells derived from the 
CNS (277 aa) 
116 Nucleic acid binding 
    mRNA processing factor 
           mRNA splicing factor 
Sfrs5 splicing factor, arginine/serine-rich 5 (SRp40, HRS); May be required for 
progression through G1 and entry into S phase of cell growth. May play a 
regulatory role in pre- mRNA splicing. Autoregulates its own expression. Plays 
a role in constitutive splicing and can modulate the selection of alternative 
splice sites (By similarity) (269 aa) 
24  Nucleic acid binding 
    mRNA processing factor 
           mRNA splicing factor 
Sfrs7 splicing factor, arginine/serine-rich 7; Required for pre-mRNA splicing (By 
similarity) (266 aa) 
3 Nucleic acid binding 
    mRNA processing factor 
           mRNA splicing factor 
Sfrs15 splicing factor, arginine/serine-rich 15 (1199 aa) 7 Nucleic acid binding 
    mRNA processing factor 
Sfrs18 Splicing factor, arginine/serine-rich 130 (Serine-arginine-rich- splicing 
regulatory protein 130) (SRrp130) (SR-rich protein) (SR- related protein) 
(805 aa) 
1 Molecular function unclassified 
Fip1l1 FIP1_MOUSE Isoform 2 of Q9D824 - Mus musculus (Mouse); Component of 
the cleavage and polyadenylation specificity factor (CPSF) complex that plays 
a key role in pre- mRNA 3'-end formation, recognizing the AAUAAA signal 
sequence and interacting with poly(A) polymerase and other factors to bring 
about cleavage and poly(A) addition. FIP1L1 contributes to poly(A) site 
recognition and stimulates poly(A) addition. Binds to U-rich RNA sequence 
elements surrounding the poly(A) site. May act to tether poly(A) polymerase to 
the CPSF complex (By similarity) (545 aa) 
17 Molecular function unclassified 
Ints7 integrator complex subunit 7; Component of the Integrator complex, a complex 
involved in the small nuclear RNAs (snRNA) U1 and U2 transcription and in 
their 3'-box-dependent processing. The Integrator complex is associated with 
the C-terminal domain (CTD) of RNA polymerase II largest subunit (POLR2A) 
and is recruited to the U1 and U2 snRNAs genes (By similarity) (965 aa) 
6 Molecular function unclassified 
DNA binding, replication, repair & Chromatin binding 
 208 
Taf1 TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor; 
Largest component and core scaffold of the TFIID basal transcription factor 
complex. Contains novel N- and C-terminal Ser/Thr kinase domains which can 
autophosphorylate or transphosphorylate other transcription factors. 
Phosphorylates TP53 on 'Thr-55' which leads to MDM2-mediated degradation 
of TP53. Phosphorylates GTF2A1 and GTF2F1 on Ser residues. Possesses 
DNA- binding activity. Essential for progression of the G1 phase of the cell 
cycle (By similarity) (1891 aa) 
1 Transcription factor 
 Nucleic acid binding 
    Nuclease 
 Kinase 
    Protein kinase 
 Transferase 
    Acetyltransferase 
    Acyltransferase 
Setd2 Histone-lysine N-methyltransferase SETD2 (EC 2.1.1.43) (SET domain- 
containing protein 2) (hSET2) (Huntingtin-interacting protein HYPB) 
(Huntingtin yeast partner B) (Huntingtin-interacting protein 1) (HIF- 1) 
(p231HBP); Histone methyltransferase that methylates 'Lys-36' of histone H3. 
H3 'Lys-36' methylation represents a specific tag for epigenetic transcriptional 
activation. Probably plays a role in chromatin structure modulation during 
elongation via its interaction with hyperphosphorylated POLR2A. Binds DNA 
at promoters. May also act as a transcription activator that binds to promot [...] 
(2061 aa)(Homo sapiens) 
1  Nucleic acid binding 
    Other DNA-binding protein 
 Transferase 
    Methyltransferase 
G2e3 G2/M-phase specific E3 ubiquitin ligase (G2e3) 1 Nucleic acid binding 
    Double-stranded DNA binding protein 
Polr1d DNA-directed RNA polymerase I subunit D (EC 2.7.7.6) (DNA-directed RNA 
polymerase I 16 kDa polypeptide) (RPA16); DNA-dependent RNA polymerase 
catalyzes the transcription of DNA into RNA using the four ribonucleoside 
triphosphates as substrates. Common core component of RNA polymerases I 
and III which synthesize ribosomal RNA precursors and small RNAs, such as 
5S rRNA and tRNAs, respectively (133 aa)(Homo sapiens) 
1 Nucleic acid binding 
    DNA-directed RNA polymerase 
 Transferase 
    Nucleotidyltransferase 
Top2b DNA topoisomerase 2-beta (EC 5.99.1.3) (DNA topoisomerase II, beta 
isozyme); Control of topological states of DNA by transient breakage and 
subsequent rejoining of DNA strands. Topoisomerase II makes double-strand 
breaks (By similarity) (1626 aa) 
2 Nucleic acid binding 
    DNA topoisomerase 
 Select regulatory molecule 
 Isomerase 
Pcna proliferating cell nuclear antigen; This protein is an auxiliary protein of DNA 
polymerase delta and is involved in the control of eukaryotic DNA replication 
by increasing the polymerase's processibility during elongation of the leading 
strand (By similarity) (261 aa) 
22 Nucleic acid binding 
    DNA polymerase processivity factor 
Sec61b Sec61 beta subunit; Necessary for protein translocation in the endoplasmic 
reticulum (By similarity) (122 aa) 
2 Nucleic acid binding 
    DNA ligase 
 Ligase 
Hmgn2 Nonhistone chromosomal protein HMG-17 (High-mobility group nucleosome- 
binding domain-containing protein 2); Binds to the inner side of the 
nucleosomal DNA thus altering the interaction between the DNA and the 
histone octamer. May be involved in the process which maintains transcribable 
genes in an unique chromatin conformation (By similarity) (90 aa)(Homo 
sapiens) 
1 Nucleic acid binding 
    Chromatin/chromatin-binding protein 
Sap18 Histone deacetylase complex subunit SAP18 (Sin3-associated polypeptide, 18 
kDa) (Sin3-associated polypeptide p18) (2HOR0202); Component of the SIN3-
repressing complex. Enhances the ability of SIN3-HDAC1-mediated 
transcriptional repression. When tethered to the promoter, it can direct the 
formation of a repressive complex to core histone proteins (153 aa)(Homo 
sapiens) 
1 Nucleic acid binding 
    Chromatin/chromatin-binding protein 
Fus RNA-binding protein FUS (Oncogene FUS) (Oncogene TLS) (Translocated in 
liposarcoma protein) (POMp75) (75 kDa DNA-pairing protein); Binds both 
single-stranded and double-stranded DNA and promotes ATP-independent 
annealing of complementary single- stranded DNAs and D-loop formation in 
superhelical double-stranded DNA. May play a role in maintenance of genomic 
integrity (526 aa)(Homo sapiens) 
1 Transcription factor 
    Other transcription factor 
 Nucleic acid binding 
    mRNA processing factor 
           mRNA splicing factor 
    Other DNA-binding protein 
Pcbp1 poly(rC) binding protein 1; Single-stranded nucleic acid binding protein that 
binds preferentially to oligo dC (By similarity) (356 aa) 
2 Select regulatory molecule 
Ctbp1 C-terminal binding protein 1; Involved in controlling the equilibrium between 
tubular and stacked structures in the Golgi complex (By similarity). Co- 
repressor targeting diverse transcription regulators such as GLIS2. Has 
dehydrogenase activity (441 aa) 
  Transcription factor 
    Transcription cofactor 
 Oxidoreductase 
    Dehydrogenase 
Dek DEK oncogene (DNA binding); May have a function in the nucleus (380 aa)   Nucleic acid binding 
    DNA ligase 
 Ligase 
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Rpa1 Replication protein A 70 kDa DNA-binding subunit (RP-A) (RF-A) 
(Replication factor-A protein 1) (Single-stranded DNA-binding protein) (p70); 
It participates in a very early step in initiation. RP-A is a single-stranded DNA-
binding protein. Absolutely required for simian virus 40 DNA replication in 
vitro (616 aa) 
  Nucleic acid binding 
    Single-stranded DNA-binding protein 
Setd1a Histone-lysine N-methyltransferase, H3 lysine-4 specific SET1 (EC 2.1.1.43) 
(Set1/Ash2 histone methyltransferase complex subunit SET1) (SET domain-
containing protein 1A); Histone methyltransferase that specifically methylates 
'Lys-4' of histone H3, when part of the SET1 histone methyltransferase (HMT) 
complex, but not if the neighboring 'Lys- 9' residue is already methylated. H3 
'Lys-4' methylation represents a specific tag for epigenetic transcriptional 
activation. The non-overalpping localization with SETD1B suggests that 
SETD1A and SETD1B make non-redundant contributions to the epig [...] 
(1709 aa) 
  Nucleic acid binding 
    Other DNA-binding protein 
 Transferase 
    Methyltransferase 
Zfand5 Mus musculus zinc finger, AN1-type domain 5 (Zfand5), mRNA   Nucleic acid binding 
 Miscellaneous function 
    Other miscellaneous function protein 
Zfp280b suppressor of hairy wing homolog 2 (Drosophila) (534 aa)   Transcription factor 
    Zinc finger transcription factor 
Ss18 SSXT protein (Synovial sarcoma, translocated to X chromosome) (SYT 
protein) (418 aa) 
  Nucleic acid binding 
    Chromatin/chromatin-binding protein 
Xrcc1 X-ray repair complementing defective repair in Chinese hamster cells 1; 
Corrects defective DNA strand-break repair and sister chromatid exchange 
following treatment with ionizing radiation and alkylating agents (631 aa) 
  Nucleic acid binding 
Aplf aprataxin and PNKP like factor; Involved in single-strand and double-strand 
DNA break repair (By similarity) (499 aa) 
1 Molecular function unclassified 
Men1 multiple endocrine neoplasia 1; May be involved in DNA repair. Component of 
MLL- containing complexes (named MLL, ASCOM, MLL2/MLL3 or 
MLL3/MLL4 complex)- at least composed ASH2L, RBBP5, DPY30, WDR5, 
one or several histone methyltransferases (MLL, MLL2, MLL3 and/or MLL4), 
and the facultative components MEN1, HCFC1, HCFC2, NCOA6, UTX, 
PAXIP1/PTIP and C16orf53/PA1 (616 aa) 
  Molecular function unclassified 
Cell skeleton, adhesion & Chaperone 
Emilin1 elastin microfibril interfacer 1; May be responsible for anchoring smooth 
muscle cells to elastic fibers, and may be involved not only in the formation of 
the elastic fiber, but also in the processes that regulate vessel assembly. Has cell 
adhesive capacity (By similarity). May have a function in placenta formation 
and initial organogenesis and a later role in interstitial connective tissue 
(1017 aa) 
1 Extracellular matrix 
    Extracellular matrix glycoprotein 
Fcho2 FCH domain only 2; May play a role in membrane remodeling by imposing and 
stabilizing particular membrane curvatures (By similarity) (781 aa) 
1 Cytoskeletal protein 
    Actin binding cytoskeletal protein 
           Other actin family cytoskeletal 
protein 
 Membrane traffic protein 
    Membrane traffic regulatory protein 
Flna filamin, alpha; Promotes orthogonal branching of actin filaments and links actin 
filaments to membrane glycoproteins. Anchors various transmembrane proteins 
to the actin cytoskeleton and serves as a scaffold for a wide range of 
cytoplasmic signaling proteins (By similarity). Interaction with FLNA may 
allow neuroblast migration from the ventricular zone into the cortical plate. 
Tethers cell surface-localized furin, modulates its rate of internalization and 
directs its intracellular trafficking (2647 aa) 
6 Cytoskeletal protein 
    Actin binding cytoskeletal protein 
           Non-motor actin binding protein 
Flnb Filamin-B (FLN-B) (Beta-filamin) (Actin-binding-like protein) (Thyroid 
autoantigen) (Truncated actin-binding protein) (Truncated ABP) (ABP- 280 
homolog) (ABP-278) (Filamin 3) (Filamin homolog 1) (Fh1); Connects cell 
membrane constituents to the actin cytoskeleton. May promote orthogonal 
branching of actin filaments and links actin filaments to membrane 
glycoproteins. Anchors various transmembrane proteins to the actin 
cytoskeleton. Interaction with FLNA may allow neuroblast migration from the 
ventricular zone into the cortical plate. Various interactions and localizations of 
isoforms a [...] (2602 aa)(Homo sapiens) 
2  Cytoskeletal protein 
    Actin binding cytoskeletal protein 
           Non-motor actin binding protein 
Fhod1 formin homology 2 domain containing 1; Required for the assembly of F-actin 
structures, such as stress fibers. Depends on the Rho-ROCK cascade for its 
activity. Contributes to the coordination of microtubules with actin fibers and 
1 Cytoskeletal protein 
    Actin binding cytoskeletal protein 
           Non-motor actin binding protein 
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plays a role in cell elongation (By similarity) (1197 aa) 
Whrn whirlin; Necessary for elongation and maintenance of inner and outer hair cell 
stereocilia in the organ of Corti in the inner ear (918 aa) 
1 Cytoskeletal protein 
Gypa Glycophorin A precursor (PAS-2) (Sialoglycoprotein alpha) (MN 
sialoglycoprotein) (CD235a antigen); Glycophorin A is the major intrinsic 
membrane protein of the erythrocyte. The N-terminal glycosylated segment, 
which lies outside the erythrocyte membrane, has MN blood group receptors 
and also binds influenza virus (150 aa)(Homo sapiens) 
1 Molecular function unclassified 
Cdh11 cadherin 11; Cadherins are calcium dependent cell adhesion proteins. They 
preferentially interact with themselves in a homophilic manner in connecting 
cells; cadherins may thus contribute to the sorting of heterogeneous cell types 
(796 aa) 
4 Cell adhesion molecule 
    Cadherin 
Pcdhgb6 protocadherin gamma subfamily C, 3 (944 aa) 1 Cell adhesion molecule 
    Cadherin 
Pcdhgb7 protocadherin gamma subfamily B, 7 (Pcdhgb7) 2 Cell adhesion molecule 
    Cadherin 
Ahsa1 AHA1, activator of heat shock protein ATPase homolog 1 (yeast); Cochaperone 
that stimulates HSP90 ATPase activity. May affect a step in the endoplasmic 
reticulum to Golgi trafficking (By similarity) (338 aa) 
1 Chaperone 
    Other chaperones 
 Select regulatory molecule 
    Other enzyme regulator 
           Other enzyme activator 
Fkbp3 FK506 binding protein 3; FK506- and rapamycin-binding proteins (FKBPs) 
constitute a family of receptors for the two immunosuppressants which inhibit 
T-cell proliferation by arresting two distinct cytoplasmic signal transmission 
pathways. PPIases accelerate the folding of proteins (By similarity) (224 aa) 
4 Chaperone 
    Other chaperones 
 Isomerase 
    Other isomerase 
Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1; Interacts with HSP70 and can 
stimulate its ATPase activity. Stimulates the association between HSC70 and 
HIP (By similarity) (340 aa) 
2 Chaperone 
    Other chaperones 
Dnaja3 DnaJ (Hsp40) homolog, subfamily A, member 3; Modulates apoptotic signal 
transduction or effector structures within the mitochondrial matrix. Affect 
cytochrome C release from the mitochondria and caspase 3 activation, but not 
caspase 8 activation. Isoform 1 increases apoptosis triggered by both TNF and 
the DNA-damaging agent mytomycin C; in sharp contrast, isoform 2 suppresses 
apoptosis. Can modulate IFN-gamma- mediated transcriptional activity (By 
similarity) (480 aa) 
1 Chaperone 
    Other chaperones 
Dnajb4 DnaJ homolog subfamily B member 4 (Heat shock 40 kDa protein 1 homolog) 
(Heat shock protein 40 homolog) (HSP40 homolog) (337 aa)(Homo sapiens) 
1 Chaperone 
    Other chaperones 
Dnajc18 DnaJ (Hsp40) homolog, subfamily C, member 18 (Dnajc18) 1 Chaperone 
    Other chaperones 
Grp94 Endoplasmin precursor (Heat shock protein 90 kDa beta member 1) (94 kDa 
glucose-regulated protein) (GRP94) (gp96 homolog) (Tumor rejection antigen 
1); Molecular chaperone that functions in the processing and transport of 
secreted proteins. Has ATPase activity (By similarity) (803 aa)(Homo sapiens) 
1 Chaperone 
    Hsp 90 family chaperone 
Hspa5 heat shock 70kD protein 5 (glucose-regulated protein); Probably plays a role in 
facilitating the assembly of multimeric protein complexes inside the ER, AND 
MASS SPECTROMETRY (655 aa) 
1 Chaperone 
    Hsp 70 family chaperone 
Hspa8 Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8); Chaperone. 
Isoform 2 may function as an endogenous inhibitory regulator of HSC70 by 
competing the co-chaperones (646 aa)(Homo sapiens) 
2 Chaperone 
    Hsp 70 family chaperone 
Hspa12b heat shock protein 12B 1 Chaperone 
    Hsp 70 family chaperone 
Fnbp4 formin binding protein 4 (1077 aa)   Cytoskeletal protein 
    Actin binding cytoskeletal protein 
           Non-motor actin binding protein 
Mtap1b microtubule-associated protein 1 B; The function of brain MAPS is essentially 
unknown. Phosphorylated MAP1B may play a role in the cytoskeletal changes 
that accompany neurite extension. Possibly MAP1B Binds to at least two 
tubulin subunits in the polymer, and this bridging of subunits might be involved 
in nucleating microtubule polymerization and in stabilizing microtubules 
(2464 aa) 
   Cytoskeletal protein 
    Microtubule family cytoskeletal 
protein 
           Non-motor microtubule binding 
protein 
Fermt3 Fermt3 fermitin family homolog 3 (Drosophila) [ Mus musculus ]; Probably 
involved in cell adhesion (By similarity) (665 aa) 
1 Molecular function unclassified 
Hspa14 heat shock 70kDa protein 14 isoform 1 (509 aa) 2  Molecular function unclassified 
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Others 
Qars glutaminyl-tRNA synthetase (775 aa) 1 Synthase and synthetase 
    Synthetase 
           Aminoacyl-tRNA synthetase 
Paics Multifunctional protein ADE2 [Includes- Phosphoribosylaminoimidazole- 
succinocarboxamide synthase (EC 6.3.2.6) (SAICAR synthetase); 
Phosphoribosylaminoimidazole carboxylase (EC 4.1.1.21) (AIR carboxylase) 
(AIRC)] (451 aa)(Homo sapiens) 
8 Synthase and synthetase 
    Synthase 
 Ligase 
Pop7 processing of precursor 7, ribonuclease P family, (S. cerevisiae) (Pop7) 1 Nucleic acid binding 
    Nuclease 
           Endoribonuclease 
 Hydrolase 
Cmpk1 cytidylate kinase; Catalyzes specific phosphoryl transfer from ATP to UMP and 
CMP (By similarity) (227 aa) 
6 Kinase 
    Nucleotide kinase 
Pgm2 Phosphoglucomutase-2 (EC 5.4.2.2) (Glucose phosphomutase 2) (PGM 2); This 
enzyme participates in both the breakdown and synthesis of glucose (By 
similarity) (612 aa)(Homo sapiens) 
7 Isomerase 
    Mutase 
Eno1 179aa 6 Carbohydrate metabolism 
    Glycolysis 
Bpgm 2,3-bisphosphoglycerate mutase; Plays a major role in regulating hemoglobin 
oxygen affinity as a consequence of controlling 2,3-BPG concentration. Can 
also catalyze the reaction of EC 5.4.2.1 (mutase) and EC 3.1.3.13 
(phosphatase), but with a reduced activity (259 aa) 
5 Isomerase 
    Mutase 
Lactb Serine beta-lactamase-like protein LACTB, mitochondrial precursor (EC 3.4.-.-
) (547 aa)(Homo sapiens) 
1 Hydrolase 
    Other hydrolase 
 Protease 
    Serine protease 
Crmp1 collapsin response mediator protein 1; Necessary for signaling by class 3 
semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in 
axon guidance, invasive growth and cell migration (574 aa)(Mus musculus) 
1 Hydrolase 
    Other hydrolase 
Obsl1 Obscurin-like protein 1 precursor 1 Hydrolase 
    Other hydrolase 
Txnl1 thioredoxin-like 1 (289 aa) 1 Oxidoreductase 
    Other oxidoreductase 
R3hdm1 R3H domain 1 (binds single-stranded nucleic acids) (R3hdm1) 2 Molecular function unclassified 
Sms spermine synthase; Required for normal viability, growth and fertility (366 aa) 1 Synthase and synthetase 
    Synthase 
Npc2 Niemann Pick type C2; May be involved in the regulation of the lipid 
composition of sperm membranes during the maturation in the epididymis (By 
similarity) (149 aa) 
4 Molecular function unclassified 
Aldh9a1 4-trimethylaminobutyraldehyde dehydrogenase (EC 1.2.1.47) (TMABADH) 
(Aldehyde dehydrogenase 9A1) (EC 1.2.1.3) (Aldehyde dehydrogenase E3 
isozyme) (Gamma-aminobutyraldehyde dehydrogenase) (EC 1.2.1.19) (R- 
aminobutyraldehyde dehydrogenase); Converts gamma-
trimethylaminobutyraldehyde into gamma- butyrobetaine. Catalyzes the 
irreversible oxidation of a broad range of aldehydes to the corresponding acids 
in an NAD-dependent reaction (518 aa) 
  Oxidoreductase 
    Dehydrogenase 
Cyb5r4 cytochrome b5 reductase 4; NADH-cytochrome b5 reductase involved in 
endolasmic reticulum stress response pathway. Plays a critical role in protecting 
pancreatic beta-cells against oxidant stress, possibly by protecting the cell from 
excess buildup of reactive oxygen species (ROS) (497 aa) 
  Oxidoreductase 
    Reductase 
Fech Ferrochelatase, mitochondrial precursor (EC 4.99.1.1) (Protoheme ferro-lyase) 
(Heme synthetase); Catalyzes the ferrous insertion into protoporphyrin IX (By 
similarity) (429 aa) 
  Lyase 
    Other lyase 
RNASEH2A ribonuclease H2, large subunit; Catalytic subunit of RNase HII, an 
endonuclease that specifically degrades the RNA of RNA-DNA hybrids. 
Participates in DNA replication, possibly by mediating the removal of lagging- 
strand Okazaki fragment RNA primers during DNA replication. Mediates the 
excision of single ribonucleotides from DNA-RNA duplexes (By similarity) 
(301 aa) 
  Nucleic acid binding 
    Nuclease 
           Endoribonuclease 
 Hydrolase 
Exosc5 exosome component 5; Component of the exosome 3'->5' exoribonuclease 
complex, a complex that degrades inherently unstable mRNAs containing AU- 
rich elements (AREs) within their 3'-untranslated regions. Required for the 3'-
  Nucleic acid binding 
    Nuclease 
           Exoribonuclease 
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processing of the 7S pre-RNA to the mature 5.8S rRNA. Has a 3'-5' 
exonuclease activity (By similarity) (235 aa) 
 Transferase 
    Nucleotidyltransferase 
 Hydrolase 
Pgm1 phosphoglucomutase 2; This enzyme participates in both the breakdown and 
synthesis of glucose (By similarity) (562 aa) 
  Isomerase 
    Mutase 
Mybpc1 Myosin-binding protein C, slow-type (Slow MyBP-C) (C-protein, skeletal 
muscle slow isoform); Thick filament-associated protein located in the 
crossbridge region of vertebrate striated muscle a bands. In vitro it binds MHC, 
F-actin and native thin filaments, and modifies the activity of actin-activated 
myosin ATPase. It may modulate muscle contraction or may play a more 
structural role (1171 aa) 
3 Molecular function unclassified 
Poldip2 Polymerase delta-interacting protein 2 (38 kDa DNA polymerase delta 
interaction protein) (p38) 
2 Molecular function unclassified 
Golga1 golgi autoantigen, golgin subfamily a, 1; Probably involved in maintaining 
Golgi structure. May play a role in acrosome formation and spermatogenesis 
(758 aa) 
1 Molecular function unclassified 
Ngly1 N-glycanase 1; Specifically deglycosylates the denatured form of N- linked 
glycoproteins in the cytoplasm and assists their proteasome-mediated 
degradation. Cleaves the beta-aspartyl- glucosamine (GlcNAc) of the glycan 
and the amide side chain of Asn, converting Asn to Asp. Prefers proteins 
containing high- mannose over those bearing complex type oligosaccharides. 
Can recognize misfolded proteins in the endoplasmic reticulun that are exported 
in the cytosol to be destroyed and deglycosylate them, while it has no activity 
toward native proteins. Deglycosylation is prerequisite for subse [...] (651 aa) 
1   
Tmem55a transmembrane protein 55A; Catalyzes the hydrolysis of the 4-position 
phosphate of phosphatidylinositol 4,5-bisphosphate. Does not hydrolyze 
phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-bisphosphate, 
inositol 3,5-bisphosphate, inositol 3,4- bisphosphate, phosphatidylinositol 5-
monophosphate, phosphatidylinositol 4-monophosphate and 
phosphatidylinositol 3- monophosphate (By similarity) (257 aa) 
  Molecular function unclassified 
Peli2 pellino 2; Scaffold protein which probably links Toll-like receptors (TLRs) to 
basic cellular processes via its interaction with the complex containing IRAK 
kinases and TRAF6. Can activate the MAP (mitogen activated protein) kinase 
pathway leading to activation of ELK1. Not required for NF-kappa-B activation 
(419 aa) 
  Molecular function unclassified 
Cenpc1 centromere protein C1; Component of the CENPA-NAC (nucleosome-
associated) complex, a complex that plays a central role in assembly of 
kinetochore proteins, mitotic progression and chromosome segregation. The 
CENPA-NAC complex recruits the CENPA-CAD (nucleosome distal) complex 
and may be involved in incorporation of newly synthesized CENPA into 
centromeres (By similarity) (904 aa) 
  Molecular function unclassified 
      Molecular function unclassified 
Fam96b Fam96b family with sequence similarity 96, member B [ Mus musculus ] 10 Molecular function unclassified 
Fam128b Fam128b family with sequence similarity 128, member B [ Mus musculus ] 3 Molecular function unclassified 
Cep192 CEP192 centrosomal protein 192kDa [ Homo sapiens ] 2 Molecular function unclassified 
N4bp2l2 N4bp2l2 NEDD4 binding protein 2-like 2 [ Mus musculus ]; contain NK; 
Nucleoside/nucleotide kinase (NK) is a protein superfamily consisting of 
multiple families of enzymes that share structural similarity and are 
functionally related to the catalysis of the reversible phosphate group transfer 
from nucleoside... 
2 Molecular function unclassified 
Phf13 PHD finger protein 13 2 Molecular function unclassified 
Ehbp1l1 EH domain binding protein 1-like 1 (1718 aa); contain Calponin homology 
domain; actin-binding domain which may be present as a single copy or in 
tandem repeats (which increases binding affinity). The CH domain is found in 
cytoskeletal and signal transduction proteins, including actin-binding proteins 
like spectrin, alpha-actinin, dystrophin, utrophin, and fimbrin, proteins essential 
for regulation of cell shape (cortexillins), and signaling proteins (Vav). 
1 Molecular function unclassified 
Fndc3c1 Fndc3c1 fibronectin type III domain containing 3C1 [ Mus musculus ]; contain 
Fibronectin type 3 domain; One of three types of internal repeats found in the 
plasma protein fibronectin. Its tenth fibronectin type III repeat contains an RGD 
cell recognition sequence in a flexible loop between 2 strands. Approximately 
2% of all animal proteins contain the FN3 repeat; including extracellular and 
intracellular proteins, membrane spanning cytokine receptors, growth hormone 
1 Molecular function unclassified 
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receptors, tyrosine phosphatase receptors, and adhesion molecules. FN3-like 
domains are also found in bacterial glycosyl hydrolases. 
Lrrc61 Leucine-rich repeat-containing protein 61 (259 aa) 1 Molecular function unclassified 
Igsf3 immunoglobulin superfamily, member 3 isoform 2 (1214 aa) 5  Molecular function unclassified 
Gm15450 Gm15450 predicted gene 15450 [ Mus musculus ]; contain Ribosomal_S23; 
S12-like family, 40S ribosomal protein S23 subfamily; S23 is located at the 
interface of the large and small ribosomal subunits of eukaryotes, adjacent to 
the decoding center. It interacts with domain III of the eukaryotic elongation 
factor 2 (eEF2),... 
1  Molecular function unclassified 
Zc4h2 Mus musculus zinc finger, C4H2 domain containing (Zc4h2), mRNA 
>gi|51261758|gb|BC079862.1| Mus musculus zinc finger, C4H2 domain 
containing, mRNA (cDNA clone MGC:105164 IMAGE:6807437), complete 
cds 
  Molecular function unclassified 
Rsbn1 rosbin, round spermatid basic protein 1 (795 aa)    Molecular function unclassified 
No Known Names 
AB114630 1 gene (Pcdha6: protocadherin alpha 6) 1   
AC007995 2 genes (Arhgap26: Rho GTPase activating protein 26; Nr3c1: nuclear receptor 
subfamily 3, group C, member 1. ) 
1   
AC083890 3 genes (Cutl1:  cut-like 1 (Drosophila); Sh2b2: SH2B adaptor protein 2; 
Rpl7a: ribosomal protein L7a) 
2   
AC098731 1 gene (Rbms3: RNA binding motif, single stranded interacting protein) 3   
AC112979 1 gene (EGF-like domain-containing protein C3orf50 homolog isoform b 
precursor) 
1   
AC121523 1 gene (Dcc: deleted in colorectal carcinoma) 2   
AC122343 2 genes (Dkk3: dickkopf homolog 3 (Xenopus laevis); Usp47: ubiquitin specific 
peptidase 47 ) 
2   
AC122903 1 gene (Ptprc: protein tyrosine phosphatase, receptor type, C ) 1   
AC123954 7 genes (Bicd2: bicaudal D homolog 2 (Drosophila); Dcun1d1: DCUN1D1 
DCN1, defective in cullin neddylation 1, domain containing 1 (S. cerevisiae); 
Ecm2: extracellular matrix protein 2, female organ and adipocyte specific; 
Ippk: inositol 1,3,4,5,6-pentakisphosphate 2-kinase; Cenpp: centromere protein 
P;  Aspn: asporin; Dcun1d2: DCN1, defective in cullin neddylation 1, domain 
containing 2 (S. cerevisiae)) 
1   
AC125466 2 genes (Crb1: crumbs homolog 1 (Drosophila); Rbms3: RNA binding motif, 
single stranded interacting protein) 
1   
AC130843 1 gene (Akt3: thymoma viral proto-oncogene 3 ) 1   
AC132370 1 gene (Dach1: dachshund 1 (Drosophila)) 1   
AC151264 5 genes (Ube2c: ubiquitin-conjugating enzyme E2C; Heatr5b: HEAT repeat 
containing 5B; Strn: striatin, calmodulin binding protein; Mtap7: microtubule-
associated protein 7; Ccdc75: coiled-coil domain containing 75 ) 
1   
AC152164 no novel gene 1   
AC153508 3 genes (Appl2: adaptor protein, phosphotyrosine interaction, PH domain and 
leucine zipper containing 2; Aldh1l2: aldehyde dehydrogenase 1 family, 
member L2; WASH complex subunit 7) 
2   
AC154436 4 genes (Rft1: RFT1 homolog (S. cerevisiae) ; Sfrs10: splicing factor, 
arginine/serine-rich 10; Tmem110: transmembrane protein 110; Sfmbt1: Scm-
like with four mbt domains 1 ) 
1   
AC154438 2 gene (Opa1: optic atrophy 1 homolog (human); Crxos1: Crx opposite strand 
transcript 1) 
1   
AC157557 2 genes (Rps4x: ribosomal protein S4, X-linked; Nox4: NADPH oxidase 4 ) 1   
AC161812 1 gene (Acvr1b: activin A receptor, type 1B) 1   
AC164550 2 genes (Pnpla8: patatin-like phospholipase domain containing 8; Nrcam: 
neuron-glia-CAM-related cell adhesion molecule) 
1   
AC164576 1 gene (Slc35f1: solute carrier family 35, member F1) 1   
AC165266 1 gene (Txndc10: thioredoxin domain containing 10) 1   
AC166834 4 genes (Dkk3: dickkopf homolog 3 (Xenopus laevis); Usp47: ubiquitin specific 
peptidase 47; Tra2a: transformer 2 alpha homolog (Drosophila); Mical2: 
microtubule associated monoxygenase, calponin and LIM domain containing 2 
)  
3   
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AC167464 4 genes (Fam134a: family with sequence similarity 134, member A; Atg9a: 
Mus musculus autophagy-related 9A (yeast); Abcb6: ATP-binding cassette, 
sub-family B (MDR/TAP), member 6; Zfand2b: zinc finger, AN1 type domain 
2B ) 
1   
AF220294 10 genes (Hn1l: hematological and neurological expressed 1-like; Igfals: 
insulin-like growth factor binding protein, acid labile subunit; Mapk8ip3: 
mitogen-activated protein kinase 8 interacting protein 3; Spsb3: splA/ryanodine 
receptor domain and SOCS box containing 3; Nubp2: nucleotide binding 
protein 2; Mrps34: mitochondrial ribosomal protein S34; Nme3: expressed in 
non-metastatic cells 3; Hagh: hydroxyacyl glutathione hydrolase; Ift140: 
intraflagellar transport 140 homolog (Chlamydomonas); HN1-like protein 
mRNA) 
1   
AF285162 1 gene (Ubc: ubiquitin C) 1   
AF483216 1 gene (H13: histocompatibility 13) 1   
AJ132592 1 gene (ZNF281: zinc finger protein 281) 1   
AL589651 Olfr1361; Olfr1359; Olfr11; Olfr1362; Olfr1360; Hist1h1b; Hist1h3h; Hist1h3i; 
Hist1h2bg; Hist1h2be; Hist1h3g; Hist1h3d; Hist1h2an; Hist1h2ak; Hist1h2ai; 
Hist1h3a; Hist1h3b; Hist1h3c; Hist1h3e; Hist1h2ae; Hist1h2ag; Hist1h3f; 
Hist1h2ad; Hist1h2bl; Hist1h2bn; Hist1h2bm; Hist1h2bp; Hist1h2ah; 
Hist1h2ao; Hist1h2ac; Hist1h2af; Hist1h2ab; Hist1h2bc;  
1   
AL596384 9 genes (Nfe2l1: nuclear factor, erythroid derived 2,-like 1; Pnpo: pyridoxine 
5'-phosphate oxidase; Sp2: Sp2 transcription factor; Atad4: ATPase family, 
AAA domain containing 4; Cbx1: chromobox homolog 1 (Drosophila HP1 
beta); Rps2:  ribosomal protein S2; Uba52:  ubiquitin A-52 residue ribosomal 
protein fusion product 1; Copz2: coatomer protein complex, subunit zeta 2; 
Cdk5rap3: CDK5 regulatory subunit associated protein 3) 
1   
AL671671 5 genes (Zswim5: zinc finger, SWIM domain containing 5; Hectd3: HECT 
domain containing 3; Urod: uroporphyrinogen decarboxylase; Gtf2b: general 
transcription factor IIB; Zswim4: zinc finger, SWIM domain containing 4) 
1   
AL845162 12 genes (H13: histocompatibility 13; Mcts2: malignant T cell amplified 
sequence 2; Rem1: rad and gem related GTP binding protein 1; Mcts1: 
malignant T cell amplified sequence 1; Defb29: defensin beta 29; Tmem167: 
transmembrane protein 167; Defb19: defensin beta 19; Defb21: defensin beta 
21; Defb36: defensin beta 36; Defb45: defensin beta 45; Defb25: defensin beta 
25; Defb28: defensin beta 28) 
1   
BC017141 hypothetical protein LOC75964 1   
BC032970 no novel gene 3   
BC059832 1 gene (Acvr1b: activin A receptor, type 1B) 1   
BC086760 1 gene (Cdh11: cadherin 11) 1   
NM_020616 proline-rich protein BCA3 2   
NR_015554 no novel gene 1   
X82564 1 gene (Lars2:leucyl-tRNA synthetase, mitochondrial) 1   
1500001M20Ri
k 
1 gene (MMP37-like protein, mitochondrial precursor)     
2510012J08Rik 1 gene (hypothetical protein LOC70312)     
AC113050 1 gene (Rgs7:regulator of G protein signaling 7;      
AC158964 2 genes (Scyl3: SCY1-like 3 (S. cerevisiae); Kifap3: kinesin-associated protein 
3) 
    
AC160932 3 genes (Acp1: acid phosphatase 1, soluble; Sh3yl1: Sh3 domain YSC-like 1; 
Zfp120: zinc finger protein 120. ) 
    
AC161177 1 gene (Dcc: deleted in colorectal carcinoma)     
AC099643 2 genes (Rps4x: ribosomal protein S4, X-linked; Nox4: NADPH oxidase 4. )     
AC133198 1 gene (Zdhhc14:zinc finger, DHHC domain containing 14 )     
D930014E17Rik 1 Gene (proline-rich protein BCA3)     
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  Signaling, Transporter & Receptor 34   
  Cell skeleton, adhesion & Chaperone 24   
  Protein synthesis regulation, modification & Proteolysis 27   
  mRNA transcription regulation 20   
  DNA binding, replication, repair & Chromatin binding 21   
  Ribosomal protein 8   
  Pre-mRNA processing 8   
  Others 27   
  Molecular function unclassified 13   
  No known Names 48   
  Total 230   
        
 
 





(The proteins without the colony PCR hit number are the 











mRNA transcription regulation 
Ash2l ash2 (absent, small, or homeotic)-like (Drosophila); Component of the Set1/Ash2 
histone methyltransferase (HMT) complex, a complex that specifically methylates 
'Lys-4' of histone H3, but not if the neighboring 'Lys-9' residue is already 
methylated (By similarity). May function as a transcriptional regulator. May play a 
role in hematopoiesis (631 aa) 
1 n Transcription factor 
    Zinc finger 
transcription factor 
           Other zinc finger 
transcription factor 
Ring1 ring finger protein 1; Constitutes one of the E3 ubiquitin-protein ligases that 
mediate monoubiquitination of 'Lys-119' of histone H2A, thereby playing a central 
role in histone code and gene regulation. H2A 'Lys-119' ubiquitination gives a 
specific tag for epigenetic transcriptional repression and participates in X 
chromosome inactivation of female mammals. Essential component of the 
Polycomb group (PcG) multiprotein PRC1 complex, a complex required to 
maintain the transcriptionally repressive state of many genes, including Hox genes, 
throughout development. PcG PRC1 complex act via c [...] (406 aa) 
4 y Transcription factor 
    Zinc finger 
transcription factor 
Mycn v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) 
(462 aa) 
2 y Transcription factor 
    Basic helix-loop-helix 
transcription factor 
 Nucleic acid binding 
Pja2 praja 2, RING-H2 motif containing; Has E2-dependent E3 ubiquitin-protein ligase 
activity (707 aa) 
1 y Transcription factor 
Protein synthesis regulation, modification & Proteolysis 
Eif3a eukaryotic translation initiation factor 3, subunit 10 (theta); Binds to the 40S 
ribosome and promotes the binding of methionyl-tRNAi and mRNA. May act as an 
adapter molecule between the translation initiation apparatus and the cytoskeleton 
structure in the cell (By similarity) (1344 aa) 
13 y Nucleic acid binding 
    Translation factor 
           Translation 
initiation factor 
Cacybp calcyclin binding protein; May be involved in calcium-dependent ubiquitination 
and subsequent proteosomal degradation of target proteins. Probably serves as a 
molecular bridge in ubiquitin E3 complexes. Participates in the ubiquitin-mediated 
degradation of beta-catenin (CTNNB1) (By similarity) (229 aa) 
2 y Ligase 
    Ubiquitin-protein 
ligase 
Cell skeleton, adhesion & Chaperone 
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Emilin1 elastin microfibril interfacer 1; May be responsible for anchoring smooth muscle 
cells to elastic fibers, and may be involved not only in the formation of the elastic 
fiber, but also in the processes that regulate vessel assembly. Has cell adhesive 
capacity (By similarity). May have a function in placenta formation and initial 
organogenesis and a later role in interstitial connective tissue (1017 aa) 
1 y Extracellular matrix 
    Extracellular matrix 
glycoprotein 
Tyro3 Tyrosine-protein kinase receptor TYRO3 precursor (EC 2.7.10.1) (Tyrosine-protein 
kinase RSE) (Tyrosine-protein kinase SKY) (Tyrosine- protein kinase DTK) 
(Protein-tyrosine kinase byk); May be involved in cell adhesion processes, 
particularly in the central nervous system. In case of filovirus infection, seems to 
function as a cell entry factor (890 aa)(Homo sapiens) 
2 n  Receptor 
    Protein kinase 
receptor 
           Tyrosine protein 
kinase receptor 
 Kinase 
    Protein kinase 
Tbcb tubulin folding cofactor B; Binds to alpha-tubulin folding intermediates after their 
interaction with cytosolic chaperonin in the pathway leading from newly 
synthesized tubulin to properly folded heterodimer (By similarity). Involved in 
regulation of tubulin heterodimer dissociation. May function as a negative regulator 
of axonal growth (244 aa) 
1 n Chaperone 
    Other chaperones 
 Cytoskeletal protein 
    Microtubule family 
cytoskeletal protein 
           Non-motor 
microtubule binding 
protein 
Signaling, Transporter & Receptor 
Marcks myristoylated alanine rich protein kinase C substrate; MARCKS is the most 
prominent cellular substrate for protein kinase C. This protein binds calmodulin, 
actin, and synapsin. MARCKS is a filamentous (F) actin cross-linking protein 
(309 aa) 
3 y Signaling molecule 
    Other signaling 
molecule 
 Cytoskeletal protein 
    Actin binding 
cytoskeletal protein 
           Non-motor actin 
binding protein 
 Miscellaneous function 
    Structural protein 
Frem1 FRAS1-related extracellular matrix protein 1 precursor (Protein QBRICK); 
Extracellular matrix protein that plays a role in epidermal differentiation and is 
required for epidermal adhesion during embryonic development (By similarity) 
(2181 aa) 
1 n Receptor 
    Other receptor 
Nr1h3 nuclear receptor subfamily 1, group H, member 3; Orphan receptor. Interaction 
with RXR shifts RXR from its role as a silent DNA-binding partner to an active 
ligand- binding subunit in mediating retinoid responses through target genes 
defined by LXRES. LXRES are DR4-type response elements characterized by 
direct repeats of two similar hexanuclotide half- sites spaced by four nucleotides. 
Plays an important role in the regulation of cholesterol homeostasis (445 aa) 
1 y Receptor 
    Nuclear hormone 
receptor 
 Transcription factor 
 Nucleic acid binding 
Arcn1 archain 1; The coatomer is a cytosolic protein complex that binds to dilysine motifs 
and reversibly associates with Golgi non- clathrin-coated vesicles, which further 
mediate biosynthetic protein transport from the ER, via the Golgi up to the trans 
Golgi network. Coatomer complex is required for budding from Golgi membranes, 
and is essential for the retrograde Golgi-to-ER transport of dilysine-tagged proteins. 
In mammals, the coatomer can only be recruited by membranes associated to ADP-
ribosylation factors (ARFs), which are small GTP-binding proteins; the complex 
also influences the G [...] (510 aa) 
1 n Membrane traffic 
protein 
    Vesicle coat protein 
Efcab7 Efcab7 EF-hand calcium binding domain 7; EF-hand, calcium binding motif; A 
diverse superfamily of calcium sensors and calcium signal modulators; most 
examples in this alignment model have 2 active canonical EF hands. Ca2+ binding 
induces a conformational change in the EF-hand motif, leading to the activation or 
inactivation of target proteins. EF-hands tend to occur in pairs or higher copy 
numbers. 
3 y Molecular function 
unclassified 
Ribosomal protein 
Rps20 ribosomal protein S20 (Rps20) 5 y Nucleic acid binding 
    Ribosomal protein 
Ubc ubiquitin C; Protein modifier which can be covalently attached to target lysines 
either as a monomer or as a lysine-linked polymer. Attachment to proteins as a Lys-
48-linked polymer usually leads to their degradation by proteasome. Attachment to 
proteins as a monomer or as an alternatively linked polymer does not lead to 
proteasomal degradation and may be required for numerous functions, including 
maintenance of chromatin structure, regulation of gene expression, stress response, 
3 y Nucleic acid binding 
    Ribosomal protein 
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ribosome biogenesis and DNA repair (By similarity) (886 aa) 
Pre-mRNA processing 
Sfrs2 splicing factor, arginine/serine-rich 2 (SC-35); Necessary for the splicing of pre-
mRNA. It is required for formation of the earliest ATP-dependent splicing complex 
and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites 
during spliceosome assembly. It also is required for ATP-dependent interactions of 
both U1 and U2 snRNPs with pre- mRNA (By similarity). Can bind to the myelin 
basic protein (MBP) gene MB3 regulatory region and increase transcription of the 
mbp promoter in cells derived from the CNS (277 aa) 
41 y Nucleic acid binding 
    mRNA processing 
factor 
           mRNA splicing 
factor 
Sfrs5 splicing factor, arginine/serine-rich 5 (SRp40, HRS) (Sfrs5) 2 y  Nucleic acid binding 
    mRNA processing 
factor 
           mRNA splicing 
factor 
Sfrs7 splicing factor, arginine/serine-rich 7 (Sfrs7) 1 y Nucleic acid binding 
    mRNA processing 
factor 
           mRNA splicing 
factor 
Fip1l1 FIP1_MOUSE Isoform 2 of Q9D824 - Mus musculus (Mouse); Component of the 
cleavage and polyadenylation specificity factor (CPSF) complex that plays a key 
role in pre- mRNA 3'-end formation, recognizing the AAUAAA signal sequence 
and interacting with poly(A) polymerase and other factors to bring about cleavage 
and poly(A) addition. FIP1L1 contributes to poly(A) site recognition and stimulates 
poly(A) addition. Binds to U-rich RNA sequence elements surrounding the poly(A) 
site. May act to tether poly(A) polymerase to the CPSF complex (By similarity) 
(545 aa) 
2 y Molecular function 
unclassified 
DNA binding, replication, repair & Chromatin binding 
Pcna proliferating cell nuclear antigen; This protein is an auxiliary protein of DNA 
polymerase delta and is involved in the control of eukaryotic DNA replication by 
increasing the polymerase's processibility during elongation of the leading strand 
(By similarity) (261 aa) 
2 y Nucleic acid binding 
    DNA polymerase 
processivity factor 
Hmgn2 Nonhistone chromosomal protein HMG-17 (High-mobility group nucleosome- 
binding domain-containing protein 2); Binds to the inner side of the nucleosomal 
DNA thus altering the interaction between the DNA and the histone octamer. May 
be involved in the process which maintains transcribable genes in an unique 
chromatin conformation (By similarity) (90 aa)(Homo sapiens) 
5 y Nucleic acid binding 
    Chromatin/chromatin-
binding protein 
Pcbp1 poly(rC) binding protein 1; Single-stranded nucleic acid binding protein that binds 
preferentially to oligo dC (By similarity) (356 aa) 
2 y Select regulatory 
molecule 
Others 
Acbd3 acyl-Coenzyme A binding domain containing 3; Involved in the maintenance of 
Golgi structure by interacting with giantin, affecting protein transport between the 
endoplasmic reticulum and Golgi (By similarity). Involved in hormone-induced 
steroid biosynthesis in testicular Leydig cells (525 aa) 
1 n Molecular function 
unclassified 
Cdca2 cell division cycle associated 2; Regulator of chromosome structure during mitosis 
required for condensin-depleted chromosomes to retain their compact architecture 
through anaphase. Acts by mediating the recruitment of phopsphatase PP1-gamma 
subunit (PPP1CC) to chromatin at anaphase and into the following interphase. At 
anaphase onset, its association with chromatin targets a pool of PPP1CC to 
dephosphorylate substrates (By similarity) (823 aa) 
1 n Molecular function 
unclassified 
Molecular function unclassified 
Fam96b family with sequence similarity 96, member B 1 y Molecular function 
unclassified 
        No Known Names 
9130401
M01Rik 




1 gene (Rbms3: RNA binding motif, single stranded interacting protein) 1 y   
AL92868 1 gene (Ttn: titin) 1 n   
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TRIM28 FIP2  gi|1699027 
gi|31544959 
in Y2H is TRIM27. nuclear corepressor KAP-1 [Homo sapiens] 
TRIM28 protein [Homo sapiens] 
80621 221 20 
USP9X 2A  gi|1666075  ubiquitin hydrolase [Homo sapiens]ubiquitin specific peptidase 9, X-
linked [Homo sapiens] 
292860 209 11 
CDKN2A FIP5  gi|4502709  cell division cycle 2 isoform 1 [Homo sapiens] 34131 205 14 
Top2 FIP1   gi|37231  In control as well. DNA topoisomerase II [Homo sapiens] 183548 191 23 
SAE1 FIP2  gi|35830  ubiquitin activating enzyme E1 [Homo sapiens] 118799 181 8 
ZMAT3 FIP2  gi|21626466  matrin 3 [Homo sapiens] 95078 178 19 
SRRT FIP2  gi|46812675  serrate RNA effector molecule homolog (Arabidopsis) [Homo sapiens] 
arsenate resistance protein ARS2 [Homo sapiens] 
90650 163 14 
DARS2 FIP3  gi|40789249  aspartyl-tRNA synthetase 2, mitochondrial precursor [Homo sapiens] 74086 162 13 
MBD3 FIP5  gi|4505119  methyl-CpG binding domain protein 3 [Homo sapiens] 33051 161 10 
ELAVL1 FIP5  gi|119589356  ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu 
antigen R), isoform CRA_b [Homo sapiens] 
50732 155 10 
SMCHD1 FIP1   gi|148839305  structural maintenance of chromosomes flexible hinge domain 
containing 1 [Homo sapiens] 
227942 154 12 
THOC2 FIP1   gi|125656165  THO complex 2 [Homo sapiens] 184541 152 10 
HDAC2 FIP3  gi|1667394 
gi|116284376 
histone deacetylase 2 [Homo sapiens] 66294 150 11 
ACAT1 FIP4  gi|499158  mitochondrial acetoacetyl-CoA thiolase [Homo sapiens] 45537 140 8 
SMC2 FIP1   gi|3851584  chromosome-associated protein-E [Homo sapiens] 136266 136 13 
SLC25A6 FIP5  gi|15928608   Slc25a37 and Slc35b4 in Y2H. Solute carrier family 25 (mitochondrial 
carrier; adenine nucleotide translocator), member 6 [Homo sapiens] 
33133 130 14 
CANX FIP3  gi|180631  calnexin [Homo sapiens] 41096 129 5 
V_region EP2  gi|619430  This CDS feature is included to show the translation of the 
corresponding V_region. Presently translation qualifiers on V_region 
features are illegal [Homo sapiens] in SC2 as well 
13370 127 6 
MCM6 FIP2  gi|7427519  minichromosome maintenance complex component 6 [Homo sapiens] 93801 123 5 
SET 2D  gi|338039 SET translocation (myeloid leukemia-associated) isoform 1 [Homo 
sapiens] 
32115 118 8 
SNRNP200 FIP1   gi|20521660 
gi|40217847 
activating signal cointegrator 1 complex subunit 3-like 1 [Homo 
sapiens] 
246006 117 17 
USP48 FIP1   gi|52630449  ubiquitin specific protease 48 isoform a [Homo sapiens] 121066 117 7 
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SLC25A5 FIP5  gi|119610275   Slc25a37 and Slc35b4 in Y2H. solute carrier family 25 (mitochondrial 
carrier; adenine nucleotide translocator), member 5, isoform CRA_b 
[Homo sapiens] 
27843 116 17 
GTF2B FIP5  gi|338043 tat-associated protein (Transcription factor IIB serves as a bridge 
between IID, the factor which initially recognizes the promoter 
sequence, and RNA polymerase II.) 
31364 112 4 
USP9Y 2A  gi|2181867  DFFRY [Homo sapiens] ubiquitin specific protease 9 , Y-linked 
[Homo sapiens] 
294468 107 6 
VDAC3 FIP5  gi|25188179  voltage-dependent anion channel 3 isoform b [Homo sapiens] 30981 105 4 
PRPF6 FIP2  gi|4103604 
gi|40807485 
 putative mitochondrial outer membrane protein import receptor [Homo 
sapiens] PRP6 pre-mRNA processing factor 6 homolog [Homo sapiens] 
107656 103 7 
EIF3A FIP1   gi|116283747  In control as well. EIF3A protein [Homo sapiens] 75019 101 11 
RANBP2 FIP1   gi|857368 
gi|1009337 
RanBP2 (Ran-binding protein 2) [Homo sapiens] 362337 100 18 
NCL 2B  gi|189306  nucleolin [Homo sapiens] 76355 100 6 
LRRC15 FIP5  gi|288541297  in y2h is lrrc6. leucine rich repeat containing 15 isoform b [Homo 
sapiens] 
65238 99 15 
HADHA FIP3  gi|862457  mitochondrial trifunctional protein, alpha subunit precursor [Homo 
sapiens] enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase 
alpha-subunit of trifunctional protein [Homo sapiens] 
83688 98 8 
RARS FIP3  gi|1217668  arginyl-tRNA synthetase [Homo sapiens] 75614 96 7 
SLC25A4 FIP5  gi|339920  Slc25a37 and Slc35b4 in Y2H. ADP/ADT translocator protein [Homo 
sapiens]solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 4 [Homo sapiens] 
33355 94 13 
SFRS15 FIP1   gi|4102967 
gi|40789229 
 pre-mRNA splicing SR protein rA4 [Homo sapiens] (splicing factor, 
arginine/serine-rich 15 isoform 1) 
126132 91 7 
DNM2 FIP2  gi|56549123  dynamin 2 isoform 2 [Homo sapiens] 98190 90 13 
SF3A1 FIP2  gi|5032087  splicing factor 3b in control. splicing factor 3a, subunit 1, 120kDa 
isoform 1 [Homo sapiens] 
88888 90 9 
SRP68 FIP3  gi|6690741  signal recognition particle 68 [Homo sapiens] 70712 87 3 
VDAC2 FIP5  gi|119574954  voltage-dependent anion channel 2, isoform CRA_a [Homo sapiens] 35029 85 7 
CHD1L FIP2  gi|50418184 CHD4 in control. chromodomain helicase DNA binding protein 1-like [ 
Homo sapiens ] 
77878 85 6 
SYMPK FIP1   gi|124028529  symplekin [Homo sapiens] 141915 84 13 
CYB5R3 FIP5  gi|4503327  cytochrome b5 reductase 3 isoform 1 [Homo sapiens] 34441 84 3 
MTHFD1 FIP2  gi|115206 
gi|14602585 
Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate 
synthetase [Homo sapiens] 
102152 83 9 
CSTF3 FIP2  gi|4557495  cleavage stimulation factor subunit 3 isoform 1 [Homo sapiens] 83325 83 6 
BAZ1A FIP1   gi|6683494  bromodomain adjacent to zinc finger domain 1A [Homo sapiens] 192610 79 14 
EXOC2 FIP2  gi|7023436 Exoc5 in Y2H list. EXOC2 protein [Homo sapiens] Sec5 protein 
[Homo sapiens] 
92115 78 1 
NUMA1 FIP1   gi|35121  NuMA protein [Homo sapiens] 237523 77 13 
DNMT1 FIP1   gi|4503351  In control as well. DNA (cytosine-5-)-methyltransferase 1 isoform b 
[Homo sapiens]  
185388 77 11 
MSH2 FIP2  gi|4557761  mutS homolog 2 [Homo sapiens] Chain A, Human Mutsalpha 
(Msh2MSH6) BOUND TO A G T MISPAIR, WITH Adp Bound To 
Msh2 Only 
105418 77 10 
IARS FIP1   gi|440799  isoleucyl-tRNA synthetase [Homo sapiens] 145700 76 10 
SMC4 FIP1   gi|6807671 
gi|50658063  
SMC4 structural maintenance of chromosomes 4-like 1 [Homo sapiens] 147775 75 8 
TFRC FIP2  gi|37433 
gi|189458817 
transferrin receptor [Homo sapiens] 85274 75 5 
MOGS FIP2  gi|2344810  a-glucosidase I [Homo sapiens] 91955 75 3 
HADH FIP5  gi|5107725  Chain A, Biochemical Characterization And Structure Determination 
Of Human Heart Short Chain L-3-Hydroxyacyl Coa Dehydrogenase 
Provide Insight Into Catalytic Mechanism  hydroxyacyl-CoA 
dehydrogenase [Homo sapiens] 
31848 74 9 
AIMP2 FIP5  gi|1215669 aminoacyl tRNA synthetase complex-interacting multifunctional 
protein 2 [Homo sapiens] 
35668 73 3 
GTF3C5 FIP3  gi|5281316 
gi|170763508 
general transcription factor IIIC, polypeptide 5 isoform 1 [Homo 
sapiens] 
60787 72 6 
CHD3 FIP1   gi|2645433 CHD4 in control. CHD3 [Homo sapiens]chromodomain helicase DNA 
binding protein 3 
222036 71 14 
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SMC1 FIP1   gi|158257274 
gi|999380 
mitosis-specific chromosome segregation protein SMC1 homolog 
[Homo sapiens] 
143743 71 12 
PDS5 FIP1   gi|21951802 
gi|155030216 
PDS5, regulator of cohesion maintenance, homolog A isoform 1 [Homo 
sapiens] 
152274 71 11 
RIF1 FIP1   gi|55418562 RAP1 interacting factor homolog (yeast) [ Homo sapiens ] 273726 71 6 
ESYT1 FIP1   gi|3882215 
gi|3882215 
extended synaptotagmin-like protein 1 [Homo sapiens] 123293 71 3 
HEATR1 FIP1   gi|55959427  HEAT repeat containing 1 [Homo sapiens] 235294 70 7 
C4A EP2  gi|179674  complement component C4A [Homo sapiens] 194337 70 2 
COBRA1 FIP3  gi|10434169 
gi|20070260 
cofactor of BRCA1 [Homo sapiens] 66283 70 1 
PTPLAD1 FIP5  gi|6735452  B-ind1 protein [Homo sapiens] protein tyrosine phosphatase-like A 
domain containing 1 [Homo sapiens] 
43800 69 5 
RFC4 FIP5  gi|4506491  replication factor C 4 [Homo sapiens] 40170 68 7 
GTF3C3 FIP2  gi|6808030 
gi|28175202 
General transcription factor IIIC, polypeptide 3, 102kDa [Homo 
sapiens] 
101979 67 5 
ANXA2 FIP5  gi|4757756  annexin A2 isoform 2 [Homo sapiens] 38808 66 1 
USP7 FIP1   gi|1545952  herpesvirus associated ubiquitin-specific protease (HAUSP) [Homo 
sapiens] double hits gi|34851150 ubiquitin-specific protease 7 isoform 
[Homo sapiens] 
129274 65 10 
p67 FIP2  gi|603225  p67 [Homo sapiens] 65401 65 2 
MTHFD2 FIP5  gi|35071 methylenetetrahydrofolate dehydrogenase 2 precursor variant [Homo 
sapiens] 
37440 64 3 
NR2F2 FIP4  gi|30140 nuclear receptor subfamily 2, group F, member 1 [Homo sapiens] 47095 63 1 
TBL3 FIP2  gi|19913369  transducin beta-like 3 [Homo sapiens] 90347 62 5 
RFC5 FIP4  gi|6677723  replication factor C 5 isoform 1 [Homo sapiens] 38757 60 1 
ATP5C1 FIP5  gi|4885079  ATP synthase, H+ transporting, mitochondrial F1 complex, gamma 
subunit isoform H (heart) precursor [Homo sapiens] 
32917 59 4 
GTF3C1 FIP1   gi|50978466 
gi|101943240   
general transcription factor IIIC, polypeptide 1, alpha 220kDa [Homo 
sapiens] 
241062 58 12 
LBP1d FIP3  gi|476099 LBP-1d=transcription factor binding to initiation site of HIV-1 
alternatively spliced [human, Namalwa cells, Peptide Partial, 391 
aa]  transcription factor LSF [Homo sapiens]  
51618 58 9 
MCM2 FIP2  gi|434753 
gi|33356547 
minichromosome maintenance complex component 2 [Homo sapiens] 102516 57 4 
EXOC4 FIP2  gi|12697943 
gi|82546830 
Exoc5 in Y2H list. exocyst complex component 4 [ Homo sapiens ] 111170 57 3 
MPG FIP5  gi|178654  alkyl-N-purine-DNA glycosylasee [Homo sapiens] 25777 57 3 
hMre11 FIP2  gi|3912938  MRE11 homologue hMre11 [Homo sapiens] 77908 55 7 
OSBPL9 FIP2  gi|14042588 
gi|22547165 
oxysterol binding protein-like 9 isoform a [Homo sapiens] 63059 55 2 
LMAN2 FIP5  gi|5803023  lectin, mannose-binding 2 precursor [Homo sapiens] 40545 55 1 
KIF4A FIP1   gi|5802957  kinesin family member 4A [Homo sapiens] 141402 54 22 
PRMT5 2C  gi|20070220 in Y2H is PRMT10. protein arginine methyltransferase 5 isoform a 
[Homo sapiens] 
73322 54 6 
GTF2IRD1 FIP2  gi|10047171 
gi|122937295 
BEN domain containing 3 [Homo sapiens] 95556 54 3 
SHCBP1 FIP1   gi|7661950  SH2 domain binding protein 1 [Homo sapiens] 134332 54 1 
USP10 FIP3  gi|3098601  Ras-GAP SH3 binding protein [Homo sapiens] 50795 54 1 
LRRC59 FIP5  gi|40254924  leucine rich repeat containing 59 [Homo sapiens] 35308 53 7 
RUVBL2 FIP4  gi|5730023  RuvB-like 2 [Homo sapiens] 51296 53 3 
ORC5L FIP4  gi|3033526  origin recognition complex subunit 5 [Homo sapiens] 50864 53 2 
OTUD4 SC1  gi|118572680  RecName: Full=OTU domain-containing protein 4; AltName: 
Full=HIV-1-induced protein HIN-1 
124823 52 6 
UHRF1 FIP2  gi|6815251 
gi|116138198 
Ubiquitin-like with PHD and ring finger domains 1 [Homo sapiens] 92598 51 6 
GTF3C4 FIP2  gi|6175593 
gi|156119605 
general transcription factor IIIC 4 [Homo sapiens] 93235 51 4 
TP53 FIP4  gi|189479  p53 cellular tumor antigen [Homo sapiens] double hits  gi|116668388 
Chain A, Human P53 Core Domain Mutant M133l-V203a-N239y-
N268d-R282w 
44177 51 3 
DPM1 FIP5  gi|2258418  dolichol monophosphate mannose synthase [Homo sapiens] 28857 51 1 
EXOSC7 FIP5  gi|473949 Exoc5 in Y2H list. exosome component 7 [Homo sapiens] 32428 51 1 
DNM3 FIP2  gi|42544243  dynamin 3 isoform a [Homo sapiens] 97434 50 10 
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DNM3 FIP2  gi|20521666 
gi|209915561 
dynamin 3 isoform b [Homo sapiens] 97021 50 9 
ATP1B1 FIP4  gi|4502281  in Y2H is ATP1b2. Na+/K+ -ATPase beta 3 subunit [Homo sapiens] 31834 50 1 
COPG FIP2  gi|7023756 
gi|11559929 
coatomer protein complex, subunit gamma 1 [Homo sapiens] 98967 49 1 
PPPIA FIP5  gi|190281  protein phosphatase I alpha subunit (PPPIA) (EC 3.1.3.16) [Homo 
sapiens] 
35844 48 2 
CSNK2A1 FIP4  gi|599778  casein kinase II alpha subunit [Homo sapiens] 45242 48 1 
STOML2 FIP4  gi|2984585 stomatin (EPB72)-like 2 [Homo sapiens] 38624 47 3 
DEK FIP4  gi|4503249  DEK oncogene isoform 1 [Homo sapiens] 42933 46 6 
PSPC1 FIP3  gi|7023323 paraspeckle protein 1 [Homo sapiens] 58820 45 5 
GNAS FIP4  gi|4504047  GNAS complex locus GNASL [Homo sapiens]   45 2 
PICALM FIP3  gi|1373146  phosphatidylinositol binding clathrin assembly protein [Homo sapiens] 70879 45 2 
CDK2 FIP5  gi|34809859  Chain A, Cdk2 In Complex With A Disubstituted 2, 4-Bis Anilino 
Pyrimidine Cdk4 Inhibitor 
34062 44 6 
DNAH5 FIP4  gi|19115954  dynein, axonemal, heavy chain 5 [Homo sapiens] 532504 44 5 
FAT2 FIP4  gi|13787217  FAT tumor suppressor 2 precursor [Homo sapiens]   44 5 
XPNPEP3 FIP2  gi|11559925  X-prolyl aminopeptidase (aminopeptidase P) 3, putative [Homo 
sapiens] 
57624 44 4 
CHGB FIP4  gi|134461  RecName: Full=Secretogranin-1; AltName: Full=Secretogranin I; 
Short=SgI; AltName: Full=Chromogranin-B; Short=CgB; Contains: 
RecName: Full=GAWK peptide; Contains: RecName: Full=CCB 
peptide; Flags: Precursor 
  44 3 
DNAH8 FIP4  gi|14335444  axonemal dynein heavy chain 8 [Homo sapiens] 518134 44 3 
ZC3H8 FIP4  gi|21618936  ZC3H8 protein [Homo sapiens]   44 3 
CLPX FIP3  gi|7242140  ClpX caseinolytic protease X homolog precursor [Homo sapiens] 69922 44 2 
LAS1L FIP2  gi|13654270  LAS1-like isoform 1 [Homo sapiens] 83982 44 2 
STRAP FIP4  gi|4519417  WD-40 repeat protein [Homo sapiens] unr-interacting protein [Homo 
sapiens]serine-threonine kinase receptor-associated protein [Homo 
sapiens] 
38814 44 2 
HADHB FIP4  gi|4504327  mitochondrial trifunctional protein, beta subunit precursor [Homo 
sapiens] 
51547 43 4 
MAPRE2 FIP4  gi|10346135  microtubule-associated protein, RP/EB family, member 2 isoform 1 
[Homo sapiens] 
37236 43 4 
MARS FIP2  gi|1702932  yeast methionyl-tRNA synthetase homolog [Homo sapiens] 102262 42 5 
PTBP1 FIP3  gi|4506243  polypyrimidine tract-binding protein 1 isoform a [Homo sapiens] 59767 42 3 
ORC4L FIP4  gi|2736149  putative replication initiator origin recognition complex subunit 
Orc4Lp [Homo sapiens]origin recognition complex subunit 4 
50717 42 2 
ANXA6 FIP3  gi|35218 calelectrin [Homo sapiens] 76199 42 1 
LBP1a FIP3  gi|545524  LBP-1a=transcription factor binding to initiation site of HIV-1 
alternatively spliced [human, Namalwa cells, Peptide, 504 aa] 
56846 41 5 
SRPRB FIP5  gi|284795266  signal recognition particle receptor, beta subunit [Homo sapiens] 29912 41 3 
DAP3 FIP4  gi|4758118  death-associated protein 3 [Homo sapiens] 45880 41 2 
H2A.2 2F  gi|31979  In control is histone cluster 1(H1d), histone H2A.2 [Homo sapiens] 13898 41 1 
LARP4 FIP2  gi|15053987  c-Mpl binding protein [Homo sapiens]La ribonucleoprotein domain 
family, member 4 
42820 41 1 
RBBP4 FIP4  gi|5032027  retinoblastoma binding protein 4 isoform a [Homo sapiens] 47911 40 13 
CTNNBL1 FIP3  gi|18644734  beta catenin-like 1 [Homo sapiens] 65588 40 4 
DPF2 FIP4  gi|5454004  D4, zinc and double PHD fingers family 2 [Homo sapiens] 45268 40 2 
GCN1L1 FIP1   gi|3970973 
gi|54607053 
GCN1 general control of amino-acid synthesis 1-like 1 [Homo sapiens] 294919 40 2 
LEPRE1 FIP2  gi|11127636 
gi|119627549 
leucine proline-enriched proteoglycan (leprecan) 1, isoform CRA_c 91681 40 2 
FUBP3 FIP3  gi|1575609  In control is fuse binding protein 2. FUSE binding protein 3 [Homo 
sapiens]far upstream element (FUSE) binding protein 3 
64239 40 1 
PWP2 FIP2  gi|1438062 PWP2 periodic tryptophan protein homolog (yeast) [ Homo sapiens ] 103342 39 6 
Setd1a FIP1   gi|6683126 
gi|55741677  
SET domain containing 1A [Homo sapiens] 186918 39 3 
CSDE1 FIP2  gi|3387902 
gi|16356661  
NRAS-related protein [Homo sapiens] 80046 39 2 
NOP56 FIP3  gi|2230878  NOP56 ribonucleoprotein homolog (yeast) NOP56 ribonucleoprotein 
homolog (yeast) [Homo sapiens] 
67206 39 1 
SMC3 FIP1   gi|4885399 chondroitin sulfate proteoglycan 6 (bamacan), isoform CRA_b [Homo 
sapiens] 
141853 38 8 
 222 
LIG3 FIP2  gi|860963  DNA ligase III [Homo sapiens] 103937 38 6 
PPP2R4 FIP3  gi|178663  medium tumor antigen-associated 61-kD protein [Homo sapiens] 
phosphatase 2A regulatory subunit [Homo sapiens] 
65980 38 4 
EXOSC10 FIP2  gi|4505917 Exoc5 in Y2H list. exosome component 10 isoform 2 [Homo sapiens] 98826 38 3 
MED4 FIP1   gi|4826626 
gi|4884564 
vitamin D3 receptor interacting protein [Homo sapiens]mediator 
complex subunit 4 
158212 38 3 
MARCKSL1 FIP5  gi|13491174 MARCKS in Y2H. MARCKS-like 1 [Homo sapiens] 19574 38 1 
IDH3A FIP5  gi|5031777  isocitrate dehydrogenase 3 (NAD+) alpha precursor [Homo sapiens] 12397 37 16 
IFT172 FIP3  gi|46358428  selective LIM binding factor homolog [Homo sapiens] intraflagellar 
transport 172 homolog (Chlamydomonas), isoform CRA_a [Homo 
sapiens] 
199175 37 9 
PSMD3 FIP3  gi|2656092  proteasome subunit p58 [Homo sapiens]proteasome (prosome, 
macropain) 26S subunit, non-ATPase, 3 [ Homo sapiens ] 
61082 37 3 
CCNB1 FIP4  gi|14327896  cyclin B1 [Homo sapiens] 48591 37 1 
RBM10 FIP2  gi|34785044  RBM10 protein [Homo sapiens] 59274 37 1 
ABCF2 FIP3  gi|3005931  ABC transporter [Homo sapiens] ATP-binding cassette, sub-family F, 
member 2 isoform a [Homo sapiens] 














Supplementary	  Figure.	  3.1.	  Significant	  protein	  clusters	  from	  the	  IPA	  network	  analysis.	  
(A)	   DNA	   repair,	   recombination,	   and	   replication.	   (B)	   Histone	   modification,	   and	  
chromatin	  remodeling.	  (C)	  Lipid	  Metabolism,	  and	  Endocrine	  System	  Development	  and	  
Function.	   (D)	   Genetic	   Disorder,	   Respiratory	   Disease,	   and	   Lipid	   Metabolism	   (Orphan	  
nuclear	  receptor)	   	   (E)	  Cellular	  Growth	  and	  Proliferation	  (RXR	  activation,	  retinoic	  acid	  
associated,	  much	  less	  significant).	  Note	  the	  proteins	  with	  gray	  filling	  are	  the	  candidates	  
from	   my	   screens;	   the	   ones	   without	   gray	   filling	   are	   those	   involved	   in	   the	   indicated	  
pathway	  but	  not	   in	  my	  candidate	   list.	  The	  solid	   lines	  are	  direct	  relationships;	  and	  the	  


















Supplementary	  Figures	  for	  Chapter	  4.	  	  
More	  pictures	  for	  each	  IF	  microscopy	  of	  single	  and	  double	  transfections	  of	  Mbd4	  and	  its	  
protein	   association	   candidates	   are	   shown.	   The	   cell	   sizes	   between	   single	   and	   double	  
transfections	  of	  Mbd4	  with	  respective	  protein	  candidate	  were	  zoomed	   in	  at	   the	  same	  



















Supplementary	   Table	   5.1	   Transcripts	   significantly	  misregulated	   in	   virus	   transformed	  
Mbd4-­‐/-­‐	   cells	   (vtKO).	   Shown	   are	   all	   transcripts	  mis-­‐regulated	   >2-­‐fold	   in	  Mbd4-­‐/-­‐	   cells	  
(relative	  to	  wildtype	  cells)	  and	  their	  average	  signals	  on	  the	  BeadChips.	  Positive	  number	  
in	   the	   fold	   change	   column	   indicates	   upregulation	   in	   knockout	   cells;	   negative	   number	  
means	  downregulation.	  
 
Gene	  Name	   Wildtype_AVG_Signal	   Knockout_AVG_Signal	   Fold	  
Change	  
SEARCH_KEY	  
LOC666403	   232.6723	   6684.256	   28.7	   ILMN_199173	  
2310014G06Rik	   39.19115	   895.7907	   22.9	   ILMN_187083	  
Slc1a3	   148.3591	   3347.447	   22.6	   ILMN_213165	  
Slc2a10	   8.122583	   119.9356	   14.8	   ILMN_211721	  
Ebf3	   36.31731	   460.7043	   12.7	   ILMN_184911	  
Sncg	   13.27798	   154.2386	   11.6	   ILMN_209715	  
Igf2	   288.1348	   3343.976	   11.6	   ILMN_209642	  
Enpp1	   11.85449	   136.6972	   11.5	   ILMN_210635	  
Gpx7	   19.21198	   218.149	   11.4	   ILMN_220603	  
Prss35	   24.10223	   268.3559	   11.1	   ILMN_210857	  
Igfbp5	   28.2518	   314.4135	   11.1	   ILMN_190841	  
scl0002702.1_3805	   44.66982	   482.2918	   10.8	   ILMN_195541	  
Serpine2	   248.5313	   2652.274	   10.7	   ILMN_204512	  
AI467606	   11.2887	   107.6597	   9.5	   ILMN_220903	  
Chst7	   11.97757	   108.344	   9.0	   ILMN_211189	  
Mmp23	   26.13883	   236.3173	   9.0	   ILMN_215522	  
Ccdc3	   15.60841	   139.2129	   8.9	   ILMN_210971	  
Kcnab2	   9.48685	   84.29489	   8.9	   ILMN_220644	  
Cln3	   17.22556	   148.4376	   8.6	   ILMN_220100	  
Pygo1	   13.37353	   112.8549	   8.4	   ILMN_217089	  
H19	   165.1176	   1341.726	   8.1	   ILMN_219881	  
Flywch2	   14.01056	   110.8243	   7.9	   ILMN_213672	  
Col2a1	   33.20084	   248.082	   7.5	   ILMN_188506	  
Lrrc17	   23.63244	   173.2555	   7.3	   ILMN_194980	  
LOC381230	   918.942	   6690.498	   7.3	   ILMN_198449	  
Clip4	   16.34958	   112.6116	   6.9	   ILMN_193898	  
Tspyl3	   13.15097	   90.25643	   6.9	   ILMN_196361	  
Slc2a3	   8.877837	   59.52139	   6.7	   ILMN_211512	  
Rgs16	   44.74363	   291.8918	   6.5	   ILMN_209950	  
BC011487	   20.86034	   135.8858	   6.5	   ILMN_211661	  
Mest	   33.584	   216.8244	   6.5	   ILMN_212378	  
Foxc1	   87.86136	   565.3849	   6.4	   ILMN_214651	  
Diras2	   19.5947	   124.2857	   6.3	   ILMN_194373	  
Irx3	   105.5247	   664.3024	   6.3	   ILMN_224225	  
Stmn2	   17.19265	   105.9531	   6.2	   ILMN_210469	  
Cryl1	   44.49581	   271.6955	   6.1	   ILMN_217939	  
Sdpr	   300.0698	   1805.715	   6.0	   ILMN_217783	  
C1qtnf3	   228.1418	   1352.817	   5.9	   ILMN_209151	  
Larp6	   13.91039	   79.45901	   5.7	   ILMN_209330	  
LOC100045780	   61.27566	   341.5616	   5.6	   ILMN_223951	  
Runx1t1	   40.25037	   215.7801	   5.4	   ILMN_210856	  
Adamtsl1	   12.63175	   67.65624	   5.4	   ILMN_219541	  
Rab15	   60.80197	   324.8687	   5.3	   ILMN_218127	  
Nfatc4	   181.6671	   960.3871	   5.3	   ILMN_214372	  
E330009F12Rik	   16.25993	   83.07156	   5.1	   ILMN_206616	  
Usp13	   10.46358	   53.01886	   5.1	   ILMN_184877	  
Gata2	   147.2167	   726.5109	   4.9	   ILMN_211079	  
Unc5c	   29.39423	   144.2213	   4.9	   ILMN_188618	  
Pcdh17	   16.36931	   80.18647	   4.9	   ILMN_236878	  
Bglap2	   20.78012	   100.8721	   4.9	   ILMN_226483	  
 234 
Tnfsf11	   16.5336	   79.48047	   4.8	   ILMN_194367	  
Capn6	   279.4984	   1335.438	   4.8	   ILMN_218388	  
Ldoc1l	   23.38252	   110.4228	   4.7	   ILMN_209512	  
Osbpl6	   9.936504	   46.62185	   4.7	   ILMN_190013	  
Creb5	   12.42477	   58.25422	   4.7	   ILMN_217830	  
LOC100048376	   16.8174	   78.63554	   4.7	   ILMN_206536	  
Hgf	   6.179766	   28.1847	   4.6	   ILMN_220957	  
Arc	   16.43672	   74.95475	   4.6	   ILMN_209647	  
Magohb	   22.80122	   102.447	   4.5	   ILMN_216019	  
Aoc3	   15.15454	   67.85607	   4.5	   ILMN_203969	  
Dleu2	   21.33905	   95.08724	   4.5	   ILMN_184991	  
1810031K17Rik	   12.81047	   57.03035	   4.5	   ILMN_209092	  
Pappa	   17.03749	   75.28543	   4.4	   ILMN_212814	  
Sgsm1	   16.92474	   74.51131	   4.4	   ILMN_218133	  
D130017D19Rik	   40.73962	   179.0964	   4.4	   ILMN_206166	  
Thg1l	   35.37402	   154.4858	   4.4	   ILMN_246881	  
Sorcs2	   24.21794	   104.6961	   4.3	   ILMN_218384	  
D130032J17Rik	   39.63448	   170.6335	   4.3	   ILMN_205501	  
Arsj	   21.59859	   91.52135	   4.2	   ILMN_217748	  
Aatk	   13.00303	   54.81442	   4.2	   ILMN_221321	  
Hebp1	   50.2327	   211.4887	   4.2	   ILMN_218714	  
Fxyd5	   93.2799	   392.0496	   4.2	   ILMN_221977	  
Tuba4a	   9.227804	   38.28577	   4.1	   ILMN_195615	  
2410075B13Rik	   12.92626	   53.01389	   4.1	   ILMN_217814	  
Fez1	   136.397	   553.4005	   4.1	   ILMN_214033	  
Limch1	   19.47171	   78.83987	   4.0	   ILMN_212627	  
Acta1	   8.152735	   32.77879	   4.0	   ILMN_221671	  
B4galnt1	   34.55429	   138.5764	   4.0	   ILMN_220892	  
Stag3	   21.0913	   84.57735	   4.0	   ILMN_212542	  
Itga11	   62.65017	   250.8298	   4.0	   ILMN_210182	  
C030003D03Rik	   10.38529	   41.37816	   4.0	   ILMN_184855	  
Flrt2	   30.90172	   122.905	   4.0	   ILMN_215172	  
Apol7a	   11.07717	   43.34136	   3.9	   ILMN_211553	  
2310046K01Rik	   11.45495	   44.0897	   3.8	   ILMN_216823	  
6330406I15Rik	   313.1269	   1202.792	   3.8	   ILMN_213942	  
Slc17a5	   49.25476	   188.8229	   3.8	   ILMN_222093	  
AI747699	   32.90839	   125.62	   3.8	   ILMN_258552	  
Foxg1	   49.37395	   187.9115	   3.8	   ILMN_209777	  
Anxa4	   86.26463	   327.9602	   3.8	   ILMN_223968	  
Aqp1	   110.8348	   420.5979	   3.8	   ILMN_216314	  
Cap1	   313.7124	   1185.877	   3.8	   ILMN_214505	  
Pdgfra	   236.6705	   887.0174	   3.7	   ILMN_212227	  
Mlf1	   57.1548	   213.8385	   3.7	   ILMN_246637	  
D730042P09Rik	   34.11002	   127.5683	   3.7	   ILMN_202674	  
Cbr2	   78.7692	   294.0188	   3.7	   ILMN_222912	  
Farsa	   19.9718	   74.40858	   3.7	   ILMN_184453	  
Lrp11	   44.14596	   164.1566	   3.7	   ILMN_216574	  
Tro	   17.24827	   63.76163	   3.7	   ILMN_227694	  
Scara3	   513.7833	   1897.084	   3.7	   ILMN_219254	  
Cpe	   1367.751	   5022.34	   3.7	   ILMN_223071	  
5430433G21Rik	   22.12658	   81.14508	   3.7	   ILMN_220885	  
Mcf2l	   8.850212	   32.45078	   3.7	   ILMN_207033	  
1810062O18Rik	   15.32137	   55.84475	   3.6	   ILMN_192867	  
Endod1	   55.65228	   202.0621	   3.6	   ILMN_221277	  
Ripk4	   17.5804	   63.78962	   3.6	   ILMN_231082	  
Gstm4	   9.989587	   36.12521	   3.6	   ILMN_220200	  
LOC665032	   1900.742	   6861.591	   3.6	   ILMN_196998	  
1810014F10Rik	   24.02255	   85.23515	   3.5	   ILMN_209922	  
Fabp3	   75.98491	   269.3723	   3.5	   ILMN_210798	  
Rnf130	   289.5708	   1022.093	   3.5	   ILMN_218606	  
Ddr2	   16.0882	   56.76863	   3.5	   ILMN_217700	  
 235 
Thsd1	   9.372628	   33.04095	   3.5	   ILMN_192069	  
1600021P15Rik	   90.49725	   318.0388	   3.5	   ILMN_185891	  
Fahd2a	   13.73765	   48.05991	   3.5	   ILMN_210830	  
A730096C04Rik	   34.90505	   121.8205	   3.5	   ILMN_204109	  
3830406C13Rik	   46.446	   161.0942	   3.5	   ILMN_207451	  
A730020E08Rik	   7.588012	   26.14706	   3.4	   ILMN_192463	  
6230400G14Rik	   68.36479	   235.4947	   3.4	   ILMN_193477	  
Ocel1	   15.97345	   54.55274	   3.4	   ILMN_216109	  
Ppbp	   32.97945	   111.7722	   3.4	   ILMN_209889	  
Prkd1	   15.0822	   50.47045	   3.3	   ILMN_214388	  
AI428936	   53.84797	   179.8416	   3.3	   ILMN_211797	  
Mrgprf	   59.72216	   198.023	   3.3	   ILMN_223171	  
Cpxm1	   56.12373	   185.0691	   3.3	   ILMN_214237	  
4833431P16Rik	   41.60565	   136.9423	   3.3	   ILMN_204798	  
scl0002540.1_6	   19.93278	   65.41423	   3.3	   ILMN_196212	  
Ly6a	   630.8228	   2052.006	   3.3	   ILMN_209150	  
1500009L16Rik	   38.73602	   125.9192	   3.3	   ILMN_187731	  
AA467197	   10.92054	   35.3493	   3.2	   ILMN_236731	  
Hbegf	   198.2778	   641.2649	   3.2	   ILMN_218639	  
Cxxc6	   11.26261	   36.35355	   3.2	   ILMN_209685	  
Glipr1	   33.70589	   108.0936	   3.2	   ILMN_217063	  
9030013K10Rik	   41.52975	   132.8418	   3.2	   ILMN_207071	  
2900016J09Rik	   11.79499	   37.67979	   3.2	   ILMN_202127	  
Ssh3	   31.16196	   98.67797	   3.2	   ILMN_214682	  
Nicn1	   186.5011	   588.7534	   3.2	   ILMN_209291	  
Npr3	   28.55296	   89.73986	   3.1	   ILMN_206823	  
Tnpo2	   21.43903	   67.03648	   3.1	   ILMN_189809	  
Sox9	   318.6924	   992.889	   3.1	   ILMN_261259	  
LOC100044736	   25.83275	   80.30547	   3.1	   ILMN_198762	  
Snf1lk2	   14.53984	   45.19496	   3.1	   ILMN_211380	  
Ebf1	   8.861051	   27.51272	   3.1	   ILMN_191261	  
Xylb	   9.435558	   29.28097	   3.1	   ILMN_187649	  
Gas6	   75.23415	   232.8612	   3.1	   ILMN_217682	  
Rgs4	   41.13184	   127.2028	   3.1	   ILMN_209130	  
Irak3	   19.7384	   60.54045	   3.1	   ILMN_222700	  
Ndufs6	   894.5782	   2738.651	   3.1	   ILMN_197367	  
Mfap2	   40.4502	   122.9058	   3.0	   ILMN_209358	  
Dlx2	   33.78724	   101.2805	   3.0	   ILMN_239308	  
Paip1	   40.83055	   121.2337	   3.0	   ILMN_222633	  
Naprt1	   20.79523	   61.41785	   3.0	   ILMN_217024	  
G630019A19Rik	   21.8438	   64.49814	   3.0	   ILMN_207404	  
Col8a1	   176.0184	   519.6152	   3.0	   ILMN_194118	  
Eng	   21.82842	   64.33217	   2.9	   ILMN_193131	  
Rgma	   33.76603	   98.832	   2.9	   ILMN_212164	  
Adra2a	   11.91381	   34.825	   2.9	   ILMN_190996	  
Rarb	   46.7001	   136.2455	   2.9	   ILMN_195865	  
9630009N10Rik	   27.24883	   79.26035	   2.9	   ILMN_205004	  
Hoxd9	   9.394702	   27.19967	   2.9	   ILMN_223278	  
Prkar1b	   27.11168	   78.22446	   2.9	   ILMN_212314	  
LOC668631	   123.3728	   353.5466	   2.9	   ILMN_204532	  
Mgst2	   121.8022	   348.8108	   2.9	   ILMN_211231	  
Galnt11	   210.2867	   602.1761	   2.9	   ILMN_218803	  
Hoxa4	   80.69389	   229.8069	   2.8	   ILMN_222859	  
Fosb	   13.25606	   37.65029	   2.8	   ILMN_192812	  
Socs2	   128.9201	   364.4951	   2.8	   ILMN_212590	  
Uchl1	   81.98615	   231.1058	   2.8	   ILMN_190011	  
Itgb7	   57.49219	   162.0092	   2.8	   ILMN_216930	  
Hyou1	   41.41079	   116.6316	   2.8	   ILMN_215592	  
Pbx1	   59.45525	   167.3667	   2.8	   ILMN_206010	  
Npr2	   79.7575	   224.3988	   2.8	   ILMN_218454	  
9530050F08Rik	   13.24299	   37.24749	   2.8	   ILMN_203683	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Mustn1	   39.40601	   109.074	   2.8	   ILMN_215350	  
Leprel2	   94.27553	   260.4487	   2.8	   ILMN_214406	  
Ifit3	   18.29643	   50.42126	   2.8	   ILMN_214979	  
Tbc1d9	   4.971491	   13.65993	   2.7	   ILMN_213352	  
D230007K08Rik	   22.13857	   60.65035	   2.7	   ILMN_196597	  
LOC384344	   19.6266	   53.612	   2.7	   ILMN_200542	  
B430305P08Rik	   93.89063	   253.1376	   2.7	   ILMN_196622	  
6230427J02Rik	   28.16925	   75.88644	   2.7	   ILMN_234696	  
5930418K15Rik	   314.4155	   844.5696	   2.7	   ILMN_184478	  
Rap1gap	   6.885259	   18.45432	   2.7	   ILMN_201583	  
Sema4f	   5.613576	   15.01651	   2.7	   ILMN_235029	  
scl0015365.1_6	   35.12809	   93.76427	   2.7	   ILMN_196128	  
Spry3	   29.26513	   77.88371	   2.7	   ILMN_253053	  
Klf2	   144.532	   383.1184	   2.7	   ILMN_210280	  
D14Ertd500e	   12.69582	   33.64906	   2.7	   ILMN_211056	  
Hyi	   163.4672	   432.8415	   2.6	   ILMN_218094	  
Car12	   135.7726	   358.8157	   2.6	   ILMN_233734	  
H2-­‐DMa	   18.12323	   47.67715	   2.6	   ILMN_224639	  
1700038P13Rik	   49.55024	   130.3037	   2.6	   ILMN_196167	  
5730437N04Rik	   640.7289	   1675.853	   2.6	   ILMN_216779	  
Plau	   304.2441	   795.5578	   2.6	   ILMN_212726	  
Fetub	   11.11528	   28.87808	   2.6	   ILMN_223266	  
6330444G18Rik	   51.74722	   134.1408	   2.6	   ILMN_206187	  
2600001B17Rik	   167.2629	   432.6639	   2.6	   ILMN_193322	  
Hemk1	   157.5149	   404.6358	   2.6	   ILMN_216005	  
Ramp2	   22.14312	   56.55408	   2.6	   ILMN_215597	  
Pde1a	   40.85752	   104.273	   2.6	   ILMN_202741	  
Dlx1	   174.8717	   444.464	   2.5	   ILMN_210579	  
D14Ertd449e	   178.3184	   451.9613	   2.5	   ILMN_184960	  
D930046M13Rik	   13.07281	   33.09542	   2.5	   ILMN_191508	  
Npal1	   27.16578	   68.61846	   2.5	   ILMN_222626	  
Zfhx2	   50.62733	   127.5678	   2.5	   ILMN_197499	  
Icam1	   12.53678	   31.56981	   2.5	   ILMN_221313	  
BC034090	   26.3971	   66.3407	   2.5	   ILMN_211522	  
Crabp1	   71.50598	   179.4944	   2.5	   ILMN_218661	  
Gstk1	   15.46747	   38.75112	   2.5	   ILMN_213974	  
Thbd	   96.77809	   241.8538	   2.5	   ILMN_223542	  
Elovl4	   133.1449	   330.7346	   2.5	   ILMN_223323	  
Gng2	   36.52029	   90.54585	   2.5	   ILMN_222219	  
Ndrg2	   5.3967	   13.31886	   2.5	   ILMN_214204	  
Ogn	   245.1254	   602.8912	   2.5	   ILMN_220162	  
LOC433955	   898.34	   2203.803	   2.5	   ILMN_200277	  
BC066028	   42.17014	   103.2892	   2.4	   ILMN_225896	  
Arhgef3	   120.2757	   294.5768	   2.4	   ILMN_214179	  
St3gal6	   108.6663	   265.5305	   2.4	   ILMN_187032	  
BC017612	   73.74236	   179.9507	   2.4	   ILMN_212906	  
E030025L23Rik	   13.01494	   31.72122	   2.4	   ILMN_206889	  
Oaf	   24.63974	   59.98651	   2.4	   ILMN_222394	  
Cyp4v3	   23.30914	   56.7099	   2.4	   ILMN_222960	  
Armcx6	   16.58153	   40.2494	   2.4	   ILMN_249108	  
Arhgdig	   100.9985	   244.8166	   2.4	   ILMN_220986	  
Fbxl16	   14.27613	   34.5073	   2.4	   ILMN_214895	  
Atg9b	   46.27785	   111.6558	   2.4	   ILMN_249271	  
Ripk3	   11.63392	   28.01658	   2.4	   ILMN_222495	  
Zdhhc3	   60.33446	   145.1022	   2.4	   ILMN_184449	  
4930513E20Rik	   28.38401	   67.70391	   2.4	   ILMN_220780	  
Abhd14a	   61.3405	   145.8852	   2.4	   ILMN_252670	  
LOC100045019	   78.12558	   184.8972	   2.4	   ILMN_195453	  
Gdf1	   80.18184	   189.3237	   2.4	   ILMN_214494	  
Tnc	   248.6555	   585.5164	   2.4	   ILMN_185280	  
1700012H17Rik	   138.6384	   326.3513	   2.4	   ILMN_188924	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Sdc2	   637.5183	   1500.019	   2.4	   ILMN_211837	  
Galm	   28.16032	   66.15855	   2.3	   ILMN_217755	  
Smpdl3a	   18.20438	   42.67522	   2.3	   ILMN_209738	  
LOC382050	   15.72106	   36.77679	   2.3	   ILMN_201166	  
Fbxo2	   60.16906	   140.4765	   2.3	   ILMN_212537	  
3110001A05Rik	   95.39771	   221.7077	   2.3	   ILMN_202154	  
Abhd1	   42.46539	   98.59059	   2.3	   ILMN_216579	  
Lrig3	   586.4861	   1361.595	   2.3	   ILMN_220870	  
Rab27a	   41.87727	   96.96421	   2.3	   ILMN_211354	  
1700029G01Rik	   29.96721	   69.35058	   2.3	   ILMN_221884	  
LOC100044683	   54.02951	   125.0313	   2.3	   ILMN_184844	  
Car13	   274.284	   631.3511	   2.3	   ILMN_219489	  
Cbr3	   330.6771	   755.8992	   2.3	   ILMN_210755	  
Ccl5	   26.22889	   59.6003	   2.3	   ILMN_212715	  
Ank	   790.2815	   1795.097	   2.3	   ILMN_210121	  
B130051A04Rik	   11.42203	   25.8662	   2.3	   ILMN_206009	  
3202002H23Rik	   47.31332	   107.0751	   2.3	   ILMN_206575	  
Tdrkh	   77.96048	   176.2869	   2.3	   ILMN_219057	  
LOC100047427	   39.78378	   89.79955	   2.3	   ILMN_218228	  
D630004B07Rik	   12.16109	   27.44156	   2.3	   ILMN_205082	  
C130045I22Rik	   42.02686	   94.58928	   2.3	   ILMN_192205	  
BC028528	   55.06386	   123.8616	   2.2	   ILMN_215178	  
Mxd4	   45.16882	   101.6006	   2.2	   ILMN_223182	  
LOC100047264	   20.02926	   44.98558	   2.2	   ILMN_194238	  
Phf19	   93.99767	   210.584	   2.2	   ILMN_210062	  
Inha	   12.66026	   28.27518	   2.2	   ILMN_210068	  
6530401I16Rik	   10.33348	   23.05144	   2.2	   ILMN_207046	  
9530062G19Rik	   11.81631	   26.35743	   2.2	   ILMN_203679	  
Myl9	   214.8979	   479.1199	   2.2	   ILMN_214832	  
H2-­‐D1	   147.1148	   327.5954	   2.2	   ILMN_196741	  
LOC223672	   20.99286	   46.71019	   2.2	   ILMN_216469	  
LOC333744	   46.88903	   104.3195	   2.2	   ILMN_198234	  
C230080E09Rik	   18.11628	   40.21581	   2.2	   ILMN_207443	  
LOC100047082	   9.676561	   21.47702	   2.2	   ILMN_220663	  
Adora2b	   127.0244	   281.7839	   2.2	   ILMN_222330	  
Gfer	   1210.959	   2686.2	   2.2	   ILMN_217434	  
A130021C14Rik	   13.72513	   30.34787	   2.2	   ILMN_204839	  
Plcl2	   29.05411	   64.10551	   2.2	   ILMN_187236	  
Slc26a6	   42.79084	   94.14424	   2.2	   ILMN_216189	  
Arid3a	   51.33039	   112.6834	   2.2	   ILMN_217809	  
Ccdc80	   222.9575	   489.375	   2.2	   ILMN_186636	  
A730040I05Rik	   39.32325	   85.9285	   2.2	   ILMN_205840	  
D9Wsu20e	   140.6607	   305.8981	   2.2	   ILMN_186315	  
LOC675899	   1233.75	   2683.046	   2.2	   ILMN_222997	  
Csgalnact1	   7.597406	   16.51687	   2.2	   ILMN_204811	  
4930546H06Rik	   17.08434	   37.1077	   2.2	   ILMN_220063	  
Dgat2	   109.8296	   237.8404	   2.2	   ILMN_211789	  
LOC100046744	   179.8641	   388.7363	   2.2	   ILMN_217084	  
Ccdc92	   127.7451	   275.0344	   2.2	   ILMN_185720	  
Wnt10a	   67.33057	   144.8134	   2.2	   ILMN_189304	  
Gsta4	   56.02418	   120.4891	   2.2	   ILMN_216097	  
C030027H14Rik	   90.48592	   194.2234	   2.1	   ILMN_195794	  
A930026I22Rik	   35.41186	   75.57338	   2.1	   ILMN_188757	  
Pvrl3	   100.2871	   213.5925	   2.1	   ILMN_190689	  
Cxx1a	   21.36272	   45.49716	   2.1	   ILMN_226958	  
scl0002069.1_48	   40.70155	   86.62703	   2.1	   ILMN_187328	  
Prkg1	   48.01555	   101.9183	   2.1	   ILMN_198467	  
E130010O04Rik	   7.984832	   16.89067	   2.1	   ILMN_205411	  
Arhgap28	   12.20895	   25.7356	   2.1	   ILMN_208859	  
Ngfb	   130.6328	   274.4039	   2.1	   ILMN_215493	  
Gadd45gip1	   8.402637	   17.63996	   2.1	   ILMN_213437	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D5Wsu178e	   342.1687	   717.3511	   2.1	   ILMN_215613	  
Loxl4	   38.04776	   79.75448	   2.1	   ILMN_212724	  
Vgll3	   182.9765	   382.511	   2.1	   ILMN_189588	  
LOC245892	   337.4286	   705.3447	   2.1	   ILMN_198932	  
Mtrf1	   36.89901	   77.09094	   2.1	   ILMN_199371	  
Dnm3os	   67.99136	   141.8683	   2.1	   ILMN_191797	  
5730410E15Rik	   19.07853	   39.80537	   2.1	   ILMN_222288	  
Tnnc1	   86.37764	   179.9406	   2.1	   ILMN_194064	  
6430526O11Rik	   10.06878	   20.95958	   2.1	   ILMN_219257	  
Atp10d	   54.81351	   114.0972	   2.1	   ILMN_210812	  
2610034E13Rik	   10.92902	   22.72379	   2.1	   ILMN_185860	  
Prrx1	   89.05343	   185.1128	   2.1	   ILMN_252720	  
Camkk1	   34.80649	   72.3487	   2.1	   ILMN_216860	  
1810049O03Rik	   15.70355	   32.61583	   2.1	   ILMN_222449	  
6330404C01Rik	   142.181	   294.8482	   2.1	   ILMN_201857	  
Sepm	   58.18999	   120.1749	   2.1	   ILMN_219316	  
Mlkl	   115.1545	   237.7563	   2.1	   ILMN_194213	  
Slc25a42	   25.68548	   52.77723	   2.1	   ILMN_239705	  
4930481F22Rik	   6.107635	   12.51629	   2.0	   ILMN_196062	  
Dock5	   8.200668	   16.79367	   2.0	   ILMN_189346	  
A930005H10Rik	   118.0345	   241.512	   2.0	   ILMN_194765	  
Atp10a	   114.1721	   233.4588	   2.0	   ILMN_220676	  
Ptafr	   6.031271	   12.32963	   2.0	   ILMN_201584	  
G630038I01Rik	   11.37447	   23.24307	   2.0	   ILMN_207278	  
4930406P12Rik	   15.60108	   31.84407	   2.0	   ILMN_202345	  
E330016A19Rik	   401.6247	   814.797	   2.0	   ILMN_207189	  
Dbp	   151.3446	   306.3671	   2.0	   ILMN_211471	  
A530079D03Rik	   13.44146	   27.009	   2.0	   ILMN_204718	  
Dusp1	   514.8914	   1034.062	   2.0	   ILMN_212121	  
Thsd7a	   22.42929	   45.03861	   2.0	   ILMN_200561	  
Lrrc8	   17.54469	   35.20151	   2.0	   ILMN_222070	  
C230004H03Rik	   26.1807	   52.47404	   2.0	   ILMN_205949	  
2210411K11Rik	   386.9212	   775.1173	   2.0	   ILMN_221521	  
Fhl1	   953.698	   1907.582	   2.0	   ILMN_245416	  
Adamts4	   246.6198	   123.3096	   -­‐2.0	   ILMN_214117	  
Smarcd3	   199.396	   99.65034	   -­‐2.0	   ILMN_215257	  
E030017M08Rik	   24.562	   12.25078	   -­‐2.0	   ILMN_205683	  
Slc7a2	   17.1946	   8.56276	   -­‐2.0	   ILMN_191970	  
Bcl3	   133.9487	   66.69832	   -­‐2.0	   ILMN_222447	  
2610019N19Rik	   51.93466	   25.8384	   -­‐2.0	   ILMN_196256	  
7030401E22Rik	   90.36264	   44.93195	   -­‐2.0	   ILMN_206630	  
C230048N02Rik	   28.02898	   13.9333	   -­‐2.0	   ILMN_206433	  
Fbln1	   592.9532	   294.4361	   -­‐2.0	   ILMN_188080	  
Map4k3	   1280.42	   635.2591	   -­‐2.0	   ILMN_215807	  
LOC100046963	   31.92482	   15.83429	   -­‐2.0	   ILMN_194113	  
Ccdc57	   31.05096	   15.38112	   -­‐2.0	   ILMN_223765	  
LOC100038894	   822.5236	   407.257	   -­‐2.0	   ILMN_196719	  
Usp21	   307.9538	   152.0818	   -­‐2.0	   ILMN_193302	  
Tmem119	   661.7032	   326.0667	   -­‐2.0	   ILMN_219443	  
Slc25a29	   26.05035	   12.82704	   -­‐2.0	   ILMN_209032	  
Sec16b	   90.3781	   44.43853	   -­‐2.0	   ILMN_211545	  
Eif4e	   53.90336	   26.47637	   -­‐2.0	   ILMN_210783	  
Dcamkl1	   46.82301	   22.92971	   -­‐2.0	   ILMN_204046	  
Gramd4	   63.78131	   31.20813	   -­‐2.0	   ILMN_208963	  
Fkbp11	   1473.775	   720.4687	   -­‐2.0	   ILMN_210599	  
Ccng2	   129.3723	   63.00871	   -­‐2.1	   ILMN_218789	  
Atpbd1b	   836.7203	   406.5232	   -­‐2.1	   ILMN_214811	  
A130039H09Rik	   74.8169	   36.30077	   -­‐2.1	   ILMN_204052	  
Pex19	   516.311	   249.1191	   -­‐2.1	   ILMN_209858	  
9530064J02	   3120.009	   1505.023	   -­‐2.1	   ILMN_213325	  
Pyroxd1	   353.7421	   170.2215	   -­‐2.1	   ILMN_223861	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scl0002507.1_236	   1151.946	   552.4913	   -­‐2.1	   ILMN_193522	  
A530023B05Rik	   25.63301	   12.28669	   -­‐2.1	   ILMN_204882	  
1810043M20Rik	   38.80471	   18.59451	   -­‐2.1	   ILMN_201764	  
Snapc2	   25.83515	   12.36306	   -­‐2.1	   ILMN_217540	  
Rai3	   389.9095	   186.2403	   -­‐2.1	   ILMN_223863	  
Slc9a3r1	   1531.305	   730.4385	   -­‐2.1	   ILMN_212760	  
Dusp28	   74.64001	   35.35544	   -­‐2.1	   ILMN_194314	  
Clstn1	   87.25806	   41.21202	   -­‐2.1	   ILMN_187140	  
Wnt5b	   26.95174	   12.65898	   -­‐2.1	   ILMN_191856	  
Hr	   55.96965	   26.25727	   -­‐2.1	   ILMN_218559	  
Notum	   20.99659	   9.824379	   -­‐2.1	   ILMN_194267	  
Mical2	   119.61	   55.68366	   -­‐2.1	   ILMN_221807	  
E530017G24Rik	   27.42919	   12.75811	   -­‐2.1	   ILMN_206095	  
Prl2c2	   389.9386	   180.6848	   -­‐2.2	   ILMN_201515	  
Wwc1	   194.3236	   89.99316	   -­‐2.2	   ILMN_229795	  
Ppargc1b	   74.8576	   34.58081	   -­‐2.2	   ILMN_223929	  
7330410H16Rik	   82.26654	   37.94758	   -­‐2.2	   ILMN_189986	  
C230055K05Rik	   69.46963	   32.02577	   -­‐2.2	   ILMN_229958	  
Kctd1	   254.0371	   117.0958	   -­‐2.2	   ILMN_222835	  
Mnt	   28.73423	   13.19558	   -­‐2.2	   ILMN_230843	  
Swap70	   474.0649	   217.4255	   -­‐2.2	   ILMN_206014	  
Ppl	   74.84332	   34.3091	   -­‐2.2	   ILMN_194079	  
Tnfaip3	   177.1985	   81.0732	   -­‐2.2	   ILMN_187343	  
Cyb5	   1183.336	   540.9611	   -­‐2.2	   ILMN_224117	  
Aqp5	   171.8436	   78.49655	   -­‐2.2	   ILMN_217154	  
Spsb4	   108.8479	   49.59155	   -­‐2.2	   ILMN_212461	  
Ndg2	   141.2222	   64.31139	   -­‐2.2	   ILMN_222397	  
9630007E23Rik	   93.64247	   42.37317	   -­‐2.2	   ILMN_204282	  
Sobp	   50.12623	   22.60043	   -­‐2.2	   ILMN_192584	  
6330414G02Rik	   506.1029	   228.1077	   -­‐2.2	   ILMN_193331	  
BC064033	   108.7913	   48.99652	   -­‐2.2	   ILMN_213776	  
Prl2c3	   832.8683	   373.8724	   -­‐2.2	   ILMN_201546	  
Hmgcr	   68.96626	   30.95217	   -­‐2.2	   ILMN_220196	  
Tinagl	   576.2538	   258.4109	   -­‐2.2	   ILMN_223197	  
Ybx3	   2141.43	   956.9924	   -­‐2.2	   ILMN_203309	  
B230334I05Rik	   130.5165	   58.22475	   -­‐2.2	   ILMN_204518	  
Dhrs7	   296.9062	   132.3158	   -­‐2.2	   ILMN_213586	  
Serpina3g	   932.218	   415.089	   -­‐2.2	   ILMN_220729	  
9630009A08Rik	   29.33263	   13.01438	   -­‐2.3	   ILMN_204210	  
Man1c1	   41.40658	   18.35849	   -­‐2.3	   ILMN_211041	  
D230017C05Rik	   98.99113	   43.86392	   -­‐2.3	   ILMN_205625	  
5430435G22Rik	   157.4943	   69.73066	   -­‐2.3	   ILMN_223803	  
Trim37	   31.42459	   13.90569	   -­‐2.3	   ILMN_194081	  
Spata7	   18.21226	   8.057454	   -­‐2.3	   ILMN_210281	  
Tmc4	   69.59656	   30.79008	   -­‐2.3	   ILMN_186472	  
4632415K11Rik	   95.61253	   42.19706	   -­‐2.3	   ILMN_214381	  
3110021A11Rik	   72.25201	   31.84795	   -­‐2.3	   ILMN_189769	  
Prl2c4	   575.0294	   253.4433	   -­‐2.3	   ILMN_199380	  
Pdlim2	   295.9025	   130.3903	   -­‐2.3	   ILMN_211617	  
Lgals2	   26.40362	   11.62195	   -­‐2.3	   ILMN_213844	  
2010011I20Rik	   40.96349	   17.9658	   -­‐2.3	   ILMN_218925	  
Mapkapk3	   211.5999	   92.72988	   -­‐2.3	   ILMN_224132	  
Coq3	   44.89563	   19.56421	   -­‐2.3	   ILMN_219194	  
Socs3	   1053.615	   458.2059	   -­‐2.3	   ILMN_211651	  
Capns2	   33.79014	   14.6572	   -­‐2.3	   ILMN_185539	  
2610044O15Rik	   48.87528	   21.14706	   -­‐2.3	   ILMN_217556	  
D17H6S56E-­‐5	   150.9485	   65.00861	   -­‐2.3	   ILMN_196579	  
Gata6	   701.6214	   301.7988	   -­‐2.3	   ILMN_209474	  
2410051C13Rik	   64.07466	   27.42427	   -­‐2.3	   ILMN_202217	  
Edn2	   29.23084	   12.44106	   -­‐2.3	   ILMN_220576	  
Hoxb6	   500.6657	   212.9976	   -­‐2.4	   ILMN_216818	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Ifi35	   195.0465	   82.46265	   -­‐2.4	   ILMN_212338	  
Vegfa	   402.8679	   169.9742	   -­‐2.4	   ILMN_224512	  
5830411K21Rik	   83.54332	   35.24244	   -­‐2.4	   ILMN_186422	  
Ctsc	   296.5959	   125.0957	   -­‐2.4	   ILMN_214875	  
Agtrap	   112.0101	   47.22925	   -­‐2.4	   ILMN_208935	  
Runx1	   77.90806	   32.84678	   -­‐2.4	   ILMN_192279	  
Lbh	   1467.945	   618.3139	   -­‐2.4	   ILMN_215742	  
LOC100047645	   29.81422	   12.51626	   -­‐2.4	   ILMN_196644	  
Zfp593	   25.38135	   10.5977	   -­‐2.4	   ILMN_190772	  
1190002H23Rik	   504.4489	   210.4599	   -­‐2.4	   ILMN_209224	  
Heg1	   43.15241	   17.97368	   -­‐2.4	   ILMN_235037	  
Itpk1	   215.241	   89.33578	   -­‐2.4	   ILMN_220572	  
2200002D01Rik	   160.0353	   66.30216	   -­‐2.4	   ILMN_184461	  
Ralgps2	   133.6022	   55.19207	   -­‐2.4	   ILMN_238709	  
Manba	   256.1089	   105.703	   -­‐2.4	   ILMN_219952	  
Oxr1	   107.5049	   44.09302	   -­‐2.4	   ILMN_213669	  
EG632802	   67.85917	   27.80243	   -­‐2.4	   ILMN_196874	  
scl0002775.1_4	   95.30786	   38.99197	   -­‐2.4	   ILMN_186200	  
Mkx	   200.8846	   82.07319	   -­‐2.4	   ILMN_219001	  
C130023A14Rik	   150.7899	   61.24025	   -­‐2.5	   ILMN_195997	  
Areg	   223.8034	   90.41296	   -­‐2.5	   ILMN_217903	  
Slc7a11	   65.43837	   26.43497	   -­‐2.5	   ILMN_205646	  
Asgr1	   293.6649	   118.2188	   -­‐2.5	   ILMN_210744	  
Ddr1	   551.9943	   221.9004	   -­‐2.5	   ILMN_219438	  
Nek6	   35.23449	   14.15863	   -­‐2.5	   ILMN_217629	  
Bnc1	   156.6407	   62.88671	   -­‐2.5	   ILMN_223056	  
Omp	   21.2088	   8.514393	   -­‐2.5	   ILMN_184266	  
Leprel1	   42.21786	   16.90505	   -­‐2.5	   ILMN_184387	  
A730017D01Rik	   204.0831	   81.47868	   -­‐2.5	   ILMN_187956	  
AI646023	   172.9942	   68.7208	   -­‐2.5	   ILMN_210462	  
Aste1	   138.311	   54.71539	   -­‐2.5	   ILMN_212823	  
Paqr7	   135.6327	   53.37876	   -­‐2.5	   ILMN_216225	  
En1	   151.9833	   59.76232	   -­‐2.5	   ILMN_261544	  
Ttc23	   17.04704	   6.698587	   -­‐2.5	   ILMN_215477	  
Nt5e	   51.74896	   20.27041	   -­‐2.6	   ILMN_213360	  
Tcf7	   51.18078	   20.02527	   -­‐2.6	   ILMN_215616	  
LOC100046616	   43.50359	   17.00677	   -­‐2.6	   ILMN_217154	  
Map3k6	   99.42783	   38.86625	   -­‐2.6	   ILMN_233949	  
Kif26b	   79.52576	   31.08009	   -­‐2.6	   ILMN_211222	  
Ccdc109b	   52.51559	   20.51011	   -­‐2.6	   ILMN_209057	  
Sult2b1	   17.55362	   6.797498	   -­‐2.6	   ILMN_217684	  
Osgin1	   133.4348	   51.14267	   -­‐2.6	   ILMN_214233	  
Pld1	   268.6967	   102.951	   -­‐2.6	   ILMN_209394	  
Wisp2	   881.7182	   337.7096	   -­‐2.6	   ILMN_192308	  
Arfl4	   33.94349	   13.00025	   -­‐2.6	   ILMN_212066	  
Gmpr	   383.1645	   146.1067	   -­‐2.6	   ILMN_210136	  
F11r	   166.077	   63.19294	   -­‐2.6	   ILMN_219759	  
Niban	   52.58195	   19.93658	   -­‐2.6	   ILMN_191711	  
Apobec3	   89.72931	   33.95382	   -­‐2.6	   ILMN_218267	  
Rab3b	   23.92311	   9.017391	   -­‐2.7	   ILMN_193861	  
4930404F20Rik	   45.86389	   17.25426	   -­‐2.7	   ILMN_202239	  
2210408F11Rik	   380.9002	   143.28	   -­‐2.7	   ILMN_191967	  
Khk	   433.3749	   162.9312	   -­‐2.7	   ILMN_218651	  
Amigo2	   69.83593	   26.17855	   -­‐2.7	   ILMN_193798	  
6330509M05Rik	   54.60982	   20.45814	   -­‐2.7	   ILMN_187875	  
LOC100048436	   491.1138	   183.2299	   -­‐2.7	   ILMN_220948	  
Plvap	   42.7189	   15.89207	   -­‐2.7	   ILMN_216938	  
1600002H07Rik	   44.77868	   16.64469	   -­‐2.7	   ILMN_214668	  
Ckb	   2722.313	   1011.862	   -­‐2.7	   ILMN_193661	  
LOC676640	   245.3346	   91.02916	   -­‐2.7	   ILMN_184785	  
Adamts7	   37.53836	   13.90093	   -­‐2.7	   ILMN_212242	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A130038J17Rik	   96.7347	   35.78524	   -­‐2.7	   ILMN_195241	  
6720422M22Rik	   327.0119	   120.5923	   -­‐2.7	   ILMN_195056	  
Tmem106a	   52.39495	   19.20371	   -­‐2.7	   ILMN_220104	  
Dcp1b	   48.90105	   17.88965	   -­‐2.7	   ILMN_237203	  
Sulf2	   377.8372	   137.9805	   -­‐2.7	   ILMN_191187	  
Them4	   34.08429	   12.44703	   -­‐2.7	   ILMN_218844	  
Cdh3	   97.0977	   34.89893	   -­‐2.8	   ILMN_228163	  
Pla1a	   19.4513	   6.989331	   -­‐2.8	   ILMN_236152	  
Lonrf3	   45.82985	   16.43044	   -­‐2.8	   ILMN_222854	  
Bckdhb	   65.47566	   23.4725	   -­‐2.8	   ILMN_215543	  
Rbpms	   121.3852	   43.4986	   -­‐2.8	   ILMN_190688	  
2810003C17Rik	   2016.479	   721.0569	   -­‐2.8	   ILMN_221837	  
Zfp52	   58.79827	   21.00913	   -­‐2.8	   ILMN_196018	  
Wnt6	   73.08739	   25.97512	   -­‐2.8	   ILMN_185059	  
A330021E22Rik	   49.08216	   17.42338	   -­‐2.8	   ILMN_212595	  
Crabp2	   542.6907	   192.396	   -­‐2.8	   ILMN_223221	  
Glrx1	   672.1139	   238.1391	   -­‐2.8	   ILMN_224227	  
LOC229810	   288.1544	   101.7644	   -­‐2.8	   ILMN_197643	  
2810408P10Rik	   88.46747	   31.04037	   -­‐2.9	   ILMN_209085	  
LOC100044177	   553.576	   192.6378	   -­‐2.9	   ILMN_185055	  
Plekha6	   70.95644	   24.63108	   -­‐2.9	   ILMN_211786	  
Gpr146	   25.43071	   8.813067	   -­‐2.9	   ILMN_258519	  
Dusp4	   137.0223	   47.35087	   -­‐2.9	   ILMN_188216	  
Rdh10	   36.47513	   12.51385	   -­‐2.9	   ILMN_221783	  
B230343A10Rik	   284.5547	   96.58751	   -­‐2.9	   ILMN_190249	  
Csdc2	   39.26384	   13.32289	   -­‐2.9	   ILMN_221533	  
Tspan12	   36.40434	   12.34344	   -­‐2.9	   ILMN_190691	  
Adrb2	   147.343	   49.75607	   -­‐3.0	   ILMN_217517	  
Rin3	   186.6556	   62.76797	   -­‐3.0	   ILMN_215946	  
Ptgs1	   49.90517	   16.76317	   -­‐3.0	   ILMN_213920	  
Chd7	   33.62745	   11.20729	   -­‐3.0	   ILMN_215704	  
Hoxb9	   40.16719	   13.34236	   -­‐3.0	   ILMN_224060	  
Sphk1	   244.0817	   80.86204	   -­‐3.0	   ILMN_221190	  
C030014I23Rik	   36.79984	   12.16953	   -­‐3.0	   ILMN_196060	  
Pcdh21	   198.6133	   65.67675	   -­‐3.0	   ILMN_216921	  
2410146L05Rik	   33.01647	   10.83134	   -­‐3.0	   ILMN_214200	  
Sfrp1	   583.1172	   190.8084	   -­‐3.1	   ILMN_210306	  
Atp7a	   55.86957	   18.26951	   -­‐3.1	   ILMN_219616	  
3300005D01Rik	   91.3115	   29.8568	   -­‐3.1	   ILMN_210819	  
Vdr	   208.1276	   67.82571	   -­‐3.1	   ILMN_187559	  
A730054J21Rik	   857.3325	   277.4537	   -­‐3.1	   ILMN_187889	  
Epb4.1l4a	   415.7589	   133.9888	   -­‐3.1	   ILMN_194065	  
Gdpd3	   49.96845	   16.10321	   -­‐3.1	   ILMN_217647	  
Spp1	   3260.93	   1048.658	   -­‐3.1	   ILMN_218026	  
Eme2	   48.53425	   15.54953	   -­‐3.1	   ILMN_216685	  
LOC674427	   220.9294	   70.69267	   -­‐3.1	   ILMN_207028	  
Sv2a	   178.8575	   57.06665	   -­‐3.1	   ILMN_218994	  
9030611O19Rik	   193.7802	   61.0526	   -­‐3.2	   ILMN_222981	  
Sox11	   719.3066	   225.6198	   -­‐3.2	   ILMN_214025	  
Aldh3b1	   180.7815	   56.64622	   -­‐3.2	   ILMN_214234	  
Cacna2d1	   127.6848	   39.73623	   -­‐3.2	   ILMN_204931	  
Anpep	   163.685	   50.72736	   -­‐3.2	   ILMN_208800	  
Mgat3	   228.6955	   69.61978	   -­‐3.3	   ILMN_215046	  
LOC100047651	   2867.046	   866.6475	   -­‐3.3	   ILMN_187579	  
Mylk	   413.6839	   124.0413	   -­‐3.3	   ILMN_190234	  
Clmn	   40.52944	   12.10616	   -­‐3.3	   ILMN_208976	  
Atpbd3	   61.59446	   18.35896	   -­‐3.4	   ILMN_222461	  
Nme5	   59.95346	   17.84005	   -­‐3.4	   ILMN_184565	  
Nudt6	   164.3049	   48.66026	   -­‐3.4	   ILMN_210970	  
St6galnac2	   822.9109	   242.3379	   -­‐3.4	   ILMN_201528	  
Rapgefl1	   117.5419	   34.44387	   -­‐3.4	   ILMN_212357	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Camk2n1	   301.7679	   87.75297	   -­‐3.4	   ILMN_254160	  
Cdon	   344.0735	   99.95779	   -­‐3.4	   ILMN_203979	  
Ndrl	   916.241	   264.6656	   -­‐3.5	   ILMN_214267	  
Dlx3	   56.78472	   16.26912	   -­‐3.5	   ILMN_216829	  
Gsdmdc1	   204.9081	   58.67153	   -­‐3.5	   ILMN_222389	  
Arrdc3	   209.5952	   59.96544	   -­‐3.5	   ILMN_216006	  
Slpi	   60.99187	   17.08165	   -­‐3.6	   ILMN_219640	  
Parp3	   191.5368	   53.56898	   -­‐3.6	   ILMN_211968	  
E530016P10Rik	   49.73941	   13.90828	   -­‐3.6	   ILMN_206561	  
Ptpn6	   73.65567	   20.50577	   -­‐3.6	   ILMN_222531	  
Stard6	   54.5612	   15.12968	   -­‐3.6	   ILMN_220243	  
BC032265	   32.06116	   8.880066	   -­‐3.6	   ILMN_224038	  
Prkag2	   125.9228	   34.82687	   -­‐3.6	   ILMN_221101	  
1200016E24Rik	   177.6524	   48.86094	   -­‐3.6	   ILMN_191167	  
Otx1	   728.431	   200.1859	   -­‐3.6	   ILMN_217984	  
4732435K05Rik	   80.65807	   22.01444	   -­‐3.7	   ILMN_203523	  
Megf10	   108.0106	   28.55141	   -­‐3.8	   ILMN_198326	  
Grem1	   2915.548	   767.2842	   -­‐3.8	   ILMN_213216	  
OTTMUSG00000010673	   310.0212	   81.18607	   -­‐3.8	   ILMN_228043	  
Cotl1	   1548.189	   403.7357	   -­‐3.8	   ILMN_219070	  
Raet1b	   409.9851	   105.9697	   -­‐3.9	   ILMN_201542	  
Il11	   126.6849	   32.71162	   -­‐3.9	   ILMN_215774	  
G430005B15Rik	   85.06609	   21.81089	   -­‐3.9	   ILMN_207399	  
Nod1	   537.3145	   137.3481	   -­‐3.9	   ILMN_222316	  
1810015C04Rik	   210.8496	   53.74314	   -­‐3.9	   ILMN_222164	  
Pdgfb	   273.1614	   69.51267	   -­‐3.9	   ILMN_211703	  
Lama5	   606.1924	   154.05	   -­‐3.9	   ILMN_213736	  
Epm2aip1	   88.64892	   22.38274	   -­‐4.0	   ILMN_218771	  
Cd59a	   119.8463	   30.1365	   -­‐4.0	   ILMN_214646	  
Adssl1	   164.0222	   40.9008	   -­‐4.0	   ILMN_210075	  
Podxl	   77.34526	   19.2795	   -­‐4.0	   ILMN_210330	  
2610024M03Rik	   601.1432	   148.653	   -­‐4.0	   ILMN_189885	  
1190007F08Rik	   368.3851	   90.46323	   -­‐4.1	   ILMN_232083	  
Col4a5	   455.1432	   110.848	   -­‐4.1	   ILMN_186711	  
2700017A04Rik	   23.9494	   5.805688	   -­‐4.1	   ILMN_221682	  
Rgs17	   673.4044	   162.6912	   -­‐4.1	   ILMN_187084	  
Trim56	   156.6218	   36.83594	   -­‐4.3	   ILMN_187187	  
Rpl29	   2543.357	   573.9031	   -­‐4.4	   ILMN_221019	  
Hpse	   127.0154	   28.63137	   -­‐4.4	   ILMN_216095	  
Ndrg1	   564.7465	   125.8694	   -­‐4.5	   ILMN_223174	  
Spon2	   1450.617	   320.2812	   -­‐4.5	   ILMN_223108	  
Cyp2s1	   72.52116	   15.9488	   -­‐4.5	   ILMN_223026	  
LOC100047870	   172.2172	   37.54394	   -­‐4.6	   ILMN_213638	  
Ncald	   67.49866	   14.67383	   -­‐4.6	   ILMN_214828	  
Rapgef3	   92.61622	   19.93019	   -­‐4.6	   ILMN_213815	  
Kcnab1	   150.6522	   31.77479	   -­‐4.7	   ILMN_211650	  
Rpp25	   263.8009	   55.43745	   -­‐4.8	   ILMN_222749	  
Parp8	   102.1306	   21.12031	   -­‐4.8	   ILMN_209706	  
Centd3	   82.13421	   16.65382	   -­‐4.9	   ILMN_211864	  
Mgst1	   580.4053	   113.1717	   -­‐5.1	   ILMN_216289	  
Hoxc9	   944.6088	   182.5156	   -­‐5.2	   ILMN_223992	  
Smoc1	   64.23833	   12.37951	   -­‐5.2	   ILMN_211655	  
Cox7a2l	   1226.658	   234.3773	   -­‐5.2	   ILMN_223726	  
8030402P03Rik	   434.4914	   82.38298	   -­‐5.3	   ILMN_207113	  
Il33	   82.16874	   15.34694	   -­‐5.4	   ILMN_213496	  
Cxadr	   574.4451	   105.16	   -­‐5.5	   ILMN_227636	  
Scube3	   225.8754	   40.23154	   -­‐5.6	   ILMN_249967	  
Hs3st1	   188.8531	   33.59804	   -­‐5.6	   ILMN_209971	  
Cxcl15	   131.9494	   23.34883	   -­‐5.7	   ILMN_213274	  
Odz4	   207.1419	   35.81351	   -­‐5.8	   ILMN_194814	  
Cryab	   294.8189	   50.81403	   -­‐5.8	   ILMN_217805	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Adh7	   518.7874	   86.74728	   -­‐6.0	   ILMN_211984	  
Galntl4	   171.061	   27.80354	   -­‐6.2	   ILMN_221507	  
Msln	   234.4364	   37.39478	   -­‐6.3	   ILMN_211608	  
Kcnh2	   117.686	   18.31039	   -­‐6.4	   ILMN_213233	  
Zbtb7c	   108.8779	   16.83062	   -­‐6.5	   ILMN_212080	  
1110059G02Rik	   120.9926	   18.07338	   -­‐6.7	   ILMN_190837	  
Aim1	   915.7984	   136.606	   -­‐6.7	   ILMN_208931	  
Baiap2l1	   206.5662	   29.47513	   -­‐7.0	   ILMN_215954	  
Dio3	   128.2648	   18.16983	   -­‐7.1	   ILMN_223923	  
2810423A18Rik	   1375.56	   182.5468	   -­‐7.5	   ILMN_186667	  
Igfbp2	   158.5099	   20.07263	   -­‐7.9	   ILMN_222264	  
Cdh26	   261.5187	   32.75253	   -­‐8.0	   ILMN_219271	  
Axud1	   269.8358	   33.10211	   -­‐8.2	   ILMN_213373	  
Etl4	   96.33768	   11.37184	   -­‐8.5	   ILMN_192240	  
Wnt4	   128.3642	   14.94104	   -­‐8.6	   ILMN_195108	  
Mmp10	   109.9946	   12.6962	   -­‐8.7	   ILMN_211834	  
Smpd3	   297.9785	   33.24168	   -­‐9.0	   ILMN_220010	  
Mmp13	   52.81427	   5.718719	   -­‐9.2	   ILMN_210384	  
Kcnmb4	   82.58699	   8.850835	   -­‐9.3	   ILMN_213638	  
Hmha1	   257.1252	   23.94753	   -­‐10.7	   ILMN_217580	  
Igfbp4	   4144.354	   351.4114	   -­‐11.8	   ILMN_210225	  
Elfn1	   178.3773	   13.59004	   -­‐13.1	   ILMN_210519	  
Lars2	   231.2172	   16.64084	   -­‐13.9	   ILMN_221567	  
Uap1	   1112.49	   72.77073	   -­‐15.3	   ILMN_194014	  
Cp	   180.4986	   10.43172	   -­‐17.3	   ILMN_203167	  
D1Ertd471e	   562.78	   31.32249	   -­‐18.0	   ILMN_187044	  
Mrps27	   276.6797	   15.28519	   -­‐18.1	   ILMN_208650	  
1110018J23Rik	   606.5533	   30.06133	   -­‐20.2	   ILMN_213005	  
Sprr2k	   266.1004	   13.09267	   -­‐20.3	   ILMN_258141	  
Igsf4a	   1275.006	   44.73253	   -­‐28.5	   ILMN_194372	  
Ptgis	   1588.106	   44.51039	   -­‐35.7	   ILMN_220660	  
LOC383308	   2168.66	   33.4696	   -­‐64.8	   ILMN_200537	  
 
Supplementary	   Table	   5.2	   Transcripts	   significantly	   mis-­‐regulated	   in	   Non-­‐transformed	  
(nko)	  Mbd4-­‐/-­‐	   cells.	   Shown	  are	   all	   transcripts	  mis-­‐regulated	  >3-­‐fold	   in	  ntMbd4-­‐/-­‐	   cells	  
(relative	  to	  wildtype	  cells)	  and	  their	  average	  signals	  on	  the	  BeadChips.	  Positive	  number	  
in	   the	   fold	   change	   column	   indicates	   upregulation	   in	   knockout	   cells;	   negative	   number	  
means	  downregulation.	  
 
Gene	  Name	   Wildtype_AVG_Signal	   Knockout_AVG_Signal	   Fold	  
Change	  
SEARCH_KEY	  
C1qtnf3	   10.34066	   3475.413	   336.1	   ILMN_209151	  
Fhl1	   46.74125	   5953.684	   127.4	   ILMN_245416	  
Ptgis	   34.74647	   4075.586	   117.3	   ILMN_220660	  
Igfbp2	   80.54948	   8795.384	   109.2	   ILMN_222264	  
Col8a1	   53.97717	   1955.796	   36.2	   ILMN_194118	  
1110032E23Rik	   65.62099	   2363.884	   36.0	   ILMN_187154	  
Pappa	   32.79083	   781.3681	   23.8	   ILMN_212814	  
Inhba	   77.75533	   1510.099	   19.4	   ILMN_209192	  
Sdpr	   240.0267	   4613.933	   19.2	   ILMN_217783	  
Hebp1	   24.20243	   464.4074	   19.2	   ILMN_218714	  
Tiam1	   102.4417	   1920.403	   18.7	   ILMN_221605	  
Cdkn1a	   65.35168	   1128.013	   17.3	   ILMN_209664	  
Rai3	   35.60147	   562.067	   15.8	   ILMN_223863	  
Klf4	   9.76973	   154.0405	   15.8	   ILMN_209216	  
Tspan2	   21.27343	   328.587	   15.4	   ILMN_186229	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Mcam	   86.23905	   1289.41	   15.0	   ILMN_211310	  
Gprc5a	   59.87022	   892.6079	   14.9	   ILMN_239682	  
5033414K04Rik	   67.74311	   961.5439	   14.2	   ILMN_210073	  
9130213B05Rik	   95.78693	   1242.969	   13.0	   ILMN_216760	  
Eng	   32.9481	   396.9045	   12.0	   ILMN_193131	  
Adrb2	   30.69232	   360.1751	   11.7	   ILMN_217517	  
Npy1r	   29.65161	   318.9252	   10.8	   ILMN_211592	  
Chrd	   33.40907	   357.5493	   10.7	   ILMN_223518	  
Mgll	   48.96025	   517.6797	   10.6	   ILMN_209140	  
Dennd2a	   69.15369	   678.6058	   9.8	   ILMN_218566	  
scl0003073.1_164	   37.92841	   354.0112	   9.3	   ILMN_186746	  
Limch1	   163.2591	   1512.866	   9.3	   ILMN_212627	  
Zcchc5	   33.84047	   310.5942	   9.2	   ILMN_187122	  
Tnc	   186.2198	   1706.848	   9.2	   ILMN_185280	  
Cryab	   254.9966	   2314.04	   9.1	   ILMN_217805	  
Rspo3	   126.0854	   1138.259	   9.0	   ILMN_221501	  
Pkp1	   17.66537	   146.3172	   8.3	   ILMN_223293	  
Sulf1	   184.4747	   1490.345	   8.1	   ILMN_193870	  
Tspan12	   39.25039	   312.4616	   8.0	   ILMN_190691	  
2200002D01Rik	   60.42404	   468.2123	   7.7	   ILMN_184461	  
Fyb	   13.86576	   107.092	   7.7	   ILMN_222124	  
Snurf	   84.76928	   651.1382	   7.7	   ILMN_221855	  
Gdf15	   146.5044	   1119.177	   7.6	   ILMN_221419	  
Uchl1	   34.47517	   263.1922	   7.6	   ILMN_190011	  
Thbs1	   23.68723	   179.5712	   7.6	   ILMN_215409	  
Rasl11b	   142.6339	   1058.608	   7.4	   ILMN_200046	  
LOC100048332	   232.5773	   1680.558	   7.2	   ILMN_193758	  
D730042P09Rik	   16.70375	   116.1017	   7.0	   ILMN_202674	  
Dusp4	   36.55875	   245.4398	   6.7	   ILMN_188216	  
Ccng1	   287.1877	   1900.458	   6.6	   ILMN_193770	  
2810003C17Rik	   278.8297	   1797.36	   6.4	   ILMN_221837	  
Epb4.1l4b	   67.34761	   429.5949	   6.4	   ILMN_224014	  
Prelp	   349.159	   2159.948	   6.2	   ILMN_221743	  
Osbpl3	   278.8793	   1725.145	   6.2	   ILMN_214782	  
Dcxr	   158.7735	   958.6804	   6.0	   ILMN_223082	  
Dgkg	   155.7137	   935.0571	   6.0	   ILMN_188868	  
Il17d	   21.43921	   128.6117	   6.0	   ILMN_248374	  
2210015K02Rik	   30.57849	   177.7166	   5.8	   ILMN_202282	  
LOC227393	   27.35723	   157.4897	   5.8	   ILMN_197084	  
3110082D06Rik	   47.2532	   267.1554	   5.7	   ILMN_195121	  
LOC100043986	   39.69152	   221.5186	   5.6	   ILMN_219654	  
5031436O03Rik	   169.1642	   934.8342	   5.5	   ILMN_189777	  
Cryl1	   85.18723	   467.1452	   5.5	   ILMN_217939	  
Arsj	   28.17718	   153.8121	   5.5	   ILMN_217748	  
Mical2	   69.74276	   372.9203	   5.3	   ILMN_221807	  
Fgfrl1	   166.3217	   880.064	   5.3	   ILMN_211983	  
Tspan18	   28.42294	   149.8678	   5.3	   ILMN_210130	  
6230400G14Rik	   81.13354	   423.0014	   5.2	   ILMN_193477	  
Ccl17	   17.206	   89.6376	   5.2	   ILMN_220052	  
Anxa4	   119.6601	   618.8853	   5.2	   ILMN_223968	  
Raet1b	   77.2205	   397.822	   5.2	   ILMN_201542	  
Upk3b	   11.51574	   59.31396	   5.2	   ILMN_188123	  
Slc19a2	   86.88435	   441.0793	   5.1	   ILMN_223225	  
Myom1	   86.27552	   437.7882	   5.1	   ILMN_241505	  
Nod1	   105.4804	   531.3724	   5.0	   ILMN_222316	  
LOC381860	   16.40346	   82.07124	   5.0	   ILMN_200791	  
Efnb2	   20.39202	   101.7812	   5.0	   ILMN_219995	  
Slc7a2	   14.31631	   71.37851	   5.0	   ILMN_191970	  
Sort1	   63.70035	   316.7707	   5.0	   ILMN_212031	  
Bmper	   51.59573	   256.5308	   5.0	   ILMN_223608	  
Zmat3	   211.7886	   1042.415	   4.9	   ILMN_184413	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Pkia	   236.4293	   1155.107	   4.9	   ILMN_216692	  
Nupr1	   1175.275	   5636.806	   4.8	   ILMN_221920	  
BC064033	   39.56429	   189.1685	   4.8	   ILMN_213776	  
LOC100048169	   24.88584	   117.1807	   4.7	   ILMN_185828	  
LOC100040657	   17.47009	   81.3749	   4.7	   ILMN_199303	  
Papss2	   172.6139	   795.1919	   4.6	   ILMN_184209	  
Klf2	   225.2548	   1035.931	   4.6	   ILMN_210280	  
Igfbp5	   17.48514	   80.13703	   4.6	   ILMN_190841	  
Nuak1	   962.6436	   4407.984	   4.6	   ILMN_234029	  
Tes	   426.914	   1934.907	   4.5	   ILMN_216487	  
E230020D15Rik	   82.30367	   370.571	   4.5	   ILMN_184584	  
Ndn	   438.6167	   1946.532	   4.4	   ILMN_212068	  
Lims2	   159.8899	   708.5914	   4.4	   ILMN_221324	  
Llgl2	   236.2876	   1040.838	   4.4	   ILMN_223065	  
Acta1	   125.4867	   551.6194	   4.4	   ILMN_221671	  
Dner	   171.9009	   751.3356	   4.4	   ILMN_219944	  
Tead4	   28.05703	   122.1389	   4.4	   ILMN_192395	  
Creb5	   17.32844	   75.17724	   4.3	   ILMN_217830	  
Crim1	   15.10852	   65.38578	   4.3	   ILMN_195784	  
AW146242	   216.4223	   919.8475	   4.3	   ILMN_221426	  
Bdnf	   98.04885	   415.0121	   4.2	   ILMN_216070	  
4933427D14Rik	   19.6879	   83.27302	   4.2	   ILMN_220964	  
Ctgf	   3573.182	   15098.79	   4.2	   ILMN_223979	  
LOC100043822	   39.72166	   167.7831	   4.2	   ILMN_188198	  
E130308A19Rik	   11.58619	   48.87088	   4.2	   ILMN_207120	  
Tbxa2r	   28.6958	   120.9408	   4.2	   ILMN_219522	  
BC022687	   51.94145	   218.6448	   4.2	   ILMN_212921	  
Flrt3	   127.707	   535.0834	   4.2	   ILMN_210479	  
Picalm	   118.2471	   493.0108	   4.2	   ILMN_209744	  
Snx30	   51.28943	   213.0861	   4.2	   ILMN_185019	  
AI646023	   235.9839	   979.0677	   4.1	   ILMN_210462	  
Ngfrap1	   3500.679	   14478.04	   4.1	   ILMN_211730	  
Col4a5	   175.5711	   725.7273	   4.1	   ILMN_186711	  
9930004G02Rik	   28.35655	   117.1744	   4.1	   ILMN_204385	  
Nxn	   164.6491	   679.738	   4.1	   ILMN_190874	  
Trp53inp1	   120.6186	   497.4815	   4.1	   ILMN_194391	  
Slit2	   84.78352	   349.5049	   4.1	   ILMN_186672	  
D4Bwg0951e	   816.8505	   3354.776	   4.1	   ILMN_214279	  
2900027G03Rik	   21.30311	   87.19423	   4.1	   ILMN_214582	  
Hbegf	   255.0348	   1043.609	   4.1	   ILMN_218639	  
1110006E14Rik	   37.05984	   151.6167	   4.1	   ILMN_188726	  
Whrn	   48.62869	   196.9041	   4.0	   ILMN_229647	  
Raet1c	   12.95481	   52.16194	   4.0	   ILMN_201541	  
4632401N01Rik	   92.09451	   369.8586	   4.0	   ILMN_202709	  
3110013H01Rik	   60.08421	   240.5877	   4.0	   ILMN_215880	  
1110036O03Rik	   645.123	   2555.411	   4.0	   ILMN_214424	  
Sephs2	   31.15468	   122.7231	   3.9	   ILMN_209348	  
D0H4S114	   1071.905	   4200.065	   3.9	   ILMN_217188	  
scl000171.1_4	   38.25821	   149.1599	   3.9	   ILMN_195535	  
Phlda3	   472.6763	   1831.998	   3.9	   ILMN_212624	  
Gcap27	   3259.445	   12627.13	   3.9	   ILMN_186123	  
Exoc4	   63.48079	   243.6419	   3.8	   ILMN_209872	  
Glipr1	   661.6081	   2512.467	   3.8	   ILMN_217063	  
Gsk3b	   64.48595	   244.3067	   3.8	   ILMN_191246	  
6030400N17Rik	   27.90663	   105.5988	   3.8	   ILMN_203014	  
Mtap6	   32.27213	   121.9607	   3.8	   ILMN_206927	  
scl0003781.1_22	   86.64725	   326.4056	   3.8	   ILMN_196280	  
1700038P13Rik	   89.6554	   336.2522	   3.8	   ILMN_196167	  
Fas	   99.92044	   373.4239	   3.7	   ILMN_188640	  
Creg1	   25.9222	   94.55373	   3.6	   ILMN_211269	  
2510022D24Rik	   26.56856	   96.71023	   3.6	   ILMN_185937	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Pcgf3	   48.53363	   176.631	   3.6	   ILMN_190917	  
A930010I20Rik	   17.69053	   64.05283	   3.6	   ILMN_211923	  
Garnl3	   92.3194	   331.1686	   3.6	   ILMN_217308	  
E230025E14Rik	   18.1512	   65.03798	   3.6	   ILMN_195795	  
C920027I18Rik	   62.2155	   222.883	   3.6	   ILMN_191962	  
A130028J20Rik	   49.53832	   176.6129	   3.6	   ILMN_195564	  
Gmfg	   8.721038	   31.07448	   3.6	   ILMN_217353	  
Vgll3	   299.5761	   1067.052	   3.6	   ILMN_189588	  
Magi1	   11.85661	   41.76398	   3.5	   ILMN_195326	  
Tpd52	   115.0247	   404.6506	   3.5	   ILMN_188233	  
Gas6	   896.6461	   3142.542	   3.5	   ILMN_217682	  
C330023J09Rik	   55.25688	   193.5969	   3.5	   ILMN_207088	  
Pmepa1	   57.57077	   200.8496	   3.5	   ILMN_186309	  
2900026A02Rik	   134.7628	   470.1495	   3.5	   ILMN_187380	  
Rspo2	   532.2729	   1839.279	   3.5	   ILMN_215554	  
A230106J09Rik	   25.20563	   85.5309	   3.4	   ILMN_202683	  
Tceal8	   1826.084	   6179.885	   3.4	   ILMN_223469	  
Dpysl3	   189.3699	   638.8594	   3.4	   ILMN_218073	  
Bax	   184.0618	   615.2999	   3.3	   ILMN_211762	  
Ostm1	   726.2676	   2424.744	   3.3	   ILMN_212196	  
Chrnb1	   54.42599	   180.3282	   3.3	   ILMN_217651	  
Mdm2	   823.8137	   2724.952	   3.3	   ILMN_220130	  
Tmed8	   12.65355	   41.70699	   3.3	   ILMN_261943	  
Trim11	   31.97846	   104.9074	   3.3	   ILMN_186471	  
Hes1	   153.5354	   503.4648	   3.3	   ILMN_210390	  
Ncam1	   71.89225	   235.3249	   3.3	   ILMN_184370	  
C230060E24	   39.44452	   128.8912	   3.3	   ILMN_219479	  
Npr3	   221.5217	   723.5316	   3.3	   ILMN_206823	  
9530081N05Rik	   81.99737	   266.8964	   3.3	   ILMN_205593	  
Sox9	   850.7388	   2765.737	   3.3	   ILMN_261259	  
Lmod1	   142.6916	   463.5367	   3.2	   ILMN_210366	  
Rgs4	   228.0729	   737.4663	   3.2	   ILMN_209130	  
Pkp2	   83.91284	   270.9414	   3.2	   ILMN_213446	  
Ctsh	   213.0318	   686.6871	   3.2	   ILMN_241653	  
D830014B20Rik	   116.8066	   375.7643	   3.2	   ILMN_206756	  
F630107L03Rik	   46.90493	   150.4308	   3.2	   ILMN_207418	  
LOC100044736	   28.32229	   90.70721	   3.2	   ILMN_198762	  
Psrc1	   21.84832	   69.66103	   3.2	   ILMN_218163	  
Cap1	   330.7706	   1054.483	   3.2	   ILMN_214505	  
Endod1	   163.0493	   514.6422	   3.2	   ILMN_221277	  
Csdc2	   20.70249	   64.75287	   3.1	   ILMN_221533	  
A230021I18Rik	   31.0249	   96.96757	   3.1	   ILMN_204870	  
Serpinb1a	   127.0207	   395.6677	   3.1	   ILMN_218572	  
Dysf	   130.7893	   406.6433	   3.1	   ILMN_184715	  
AW123240	   57.65371	   179.0297	   3.1	   ILMN_195216	  
Reck	   80.15815	   248.8711	   3.1	   ILMN_223820	  
4933421H10Rik	   111.2033	   344.9431	   3.1	   ILMN_221469	  
Plscr3	   23.54509	   72.93366	   3.1	   ILMN_218814	  
Gpr23	   270.6616	   835.2703	   3.1	   ILMN_223959	  
Rusc2	   398.6543	   1228.811	   3.1	   ILMN_214316	  
BB146404	   98.15958	   301.51	   3.1	   ILMN_184649	  
Ptrh1	   215.5212	   654.2502	   3.0	   ILMN_208796	  
B930083E23Rik	   71.27987	   215.3564	   3.0	   ILMN_205609	  
1500015O10Rik	   44.01895	   132.7568	   3.0	   ILMN_222808	  
B230312A22Rik	   161.0088	   484.5546	   3.0	   ILMN_210245	  
Evi1	   15.02089	   45.08184	   3.0	   ILMN_214877	  
D230005E09Rik	   88.69312	   266.1036	   3.0	   ILMN_204935	  
H19	   26.42925	   79.26706	   3.0	   ILMN_219881	  
Psmb5	   721.7653	   240.4372	   -­‐3.0	   ILMN_211192	  
Hic2	   201.6055	   67.10759	   -­‐3.0	   ILMN_194097	  
9830002I17Rik	   50.6334	   16.83948	   -­‐3.0	   ILMN_221228	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B830017H08Rik	   61.35537	   20.37897	   -­‐3.0	   ILMN_203494	  
Matn2	   95.43671	   31.69371	   -­‐3.0	   ILMN_220046	  
Mkx	   306.1007	   101.5028	   -­‐3.0	   ILMN_219001	  
BC021381	   279.3847	   92.3955	   -­‐3.0	   ILMN_223208	  
Slco1a5	   76.1471	   25.17623	   -­‐3.0	   ILMN_221283	  
4833409N03Rik	   506.1417	   167.3305	   -­‐3.0	   ILMN_195376	  
A930005H10Rik	   389.5107	   128.7569	   -­‐3.0	   ILMN_194765	  
4930445K14Rik	   451.5424	   149.0859	   -­‐3.0	   ILMN_189952	  
9330188B09Rik	   96.36654	   31.80994	   -­‐3.0	   ILMN_204370	  
Sphk1	   261.9549	   85.98535	   -­‐3.0	   ILMN_221190	  
Rnf213	   1798.633	   590.383	   -­‐3.0	   ILMN_213503	  
Sesn3	   41.1235	   13.49722	   -­‐3.0	   ILMN_184128	  
Zfp41	   607.1316	   198.9374	   -­‐3.1	   ILMN_189448	  
Tmem55b	   1350.659	   441.6316	   -­‐3.1	   ILMN_221957	  
Hoxa4	   268.5713	   87.64173	   -­‐3.1	   ILMN_222859	  
Aprin	   1006.914	   328.5021	   -­‐3.1	   ILMN_216438	  
AA409316	   338.2637	   110.2374	   -­‐3.1	   ILMN_221994	  
B430201A12Rik	   274.7596	   89.42561	   -­‐3.1	   ILMN_192167	  
8030467N07Rik	   105.9939	   34.47438	   -­‐3.1	   ILMN_207056	  
AI413782	   37.92953	   12.33626	   -­‐3.1	   ILMN_214512	  
9130004J05Rik	   189.9596	   61.74068	   -­‐3.1	   ILMN_193459	  
1110031I02Rik	   110.9074	   36.0303	   -­‐3.1	   ILMN_222011	  
4831403C07Rik	   180.3356	   58.55266	   -­‐3.1	   ILMN_188701	  
4930550C14Rik	   145.0882	   47.0752	   -­‐3.1	   ILMN_213960	  
Fgd6	   242.289	   78.60153	   -­‐3.1	   ILMN_224288	  
Pcyt2	   328.9428	   106.6649	   -­‐3.1	   ILMN_209615	  
scl0002624.1_576	   95.85807	   31.07387	   -­‐3.1	   ILMN_184713	  
Sdc3	   2006.668	   648.0548	   -­‐3.1	   ILMN_219906	  
Elfn1	   250.0585	   80.70979	   -­‐3.1	   ILMN_210519	  
2310040C09Rik	   84.39429	   27.21946	   -­‐3.1	   ILMN_186638	  
Glt8d2	   165.4777	   53.35516	   -­‐3.1	   ILMN_203977	  
Zfp820	   82.39539	   26.5363	   -­‐3.1	   ILMN_204952	  
6230425C21Rik	   500.8293	   161.2033	   -­‐3.1	   ILMN_202500	  
Sqrdl	   118.4931	   38.1079	   -­‐3.1	   ILMN_223305	  
Runx1t1	   229.0862	   73.61584	   -­‐3.1	   ILMN_210856	  
Slc23a3	   62.98718	   20.23257	   -­‐3.1	   ILMN_219791	  
8030481K01Rik	   134.5237	   43.18512	   -­‐3.1	   ILMN_207013	  
Clec11a	   347.7948	   111.5976	   -­‐3.1	   ILMN_189820	  
Samd4	   114.8198	   36.83779	   -­‐3.1	   ILMN_221466	  
AI256775	   166.9932	   53.46572	   -­‐3.1	   ILMN_185879	  
Eno3	   2266.861	   724.3914	   -­‐3.1	   ILMN_222979	  
Phf13	   355.161	   113.2705	   -­‐3.1	   ILMN_214014	  
2310005L22Rik	   1581.353	   503.5748	   -­‐3.1	   ILMN_192733	  
Mccc2	   95.26058	   30.23473	   -­‐3.2	   ILMN_219661	  
LOC100044683	   202.0879	   63.97835	   -­‐3.2	   ILMN_184844	  
1110049F12Rik	   434.6578	   137.4501	   -­‐3.2	   ILMN_212471	  
Npff	   81.31773	   25.70894	   -­‐3.2	   ILMN_216935	  
Tnrc6b	   36.78185	   11.62456	   -­‐3.2	   ILMN_204914	  
Glrx	   4128.174	   1303.683	   -­‐3.2	   ILMN_238781	  
Scnn1a	   49.29381	   15.55668	   -­‐3.2	   ILMN_220993	  
Errfi1	   2069.818	   653.1835	   -­‐3.2	   ILMN_190042	  
Snta1	   243.7582	   76.92226	   -­‐3.2	   ILMN_221335	  
B330002M01Rik	   56.29587	   17.75134	   -­‐3.2	   ILMN_203490	  
Cdkn2c	   489.1868	   154.0961	   -­‐3.2	   ILMN_213040	  
Nanos1	   162.3268	   50.7773	   -­‐3.2	   ILMN_218879	  
Steap1	   362.5601	   113.2835	   -­‐3.2	   ILMN_210027	  
1700021C14Rik	   220.056	   68.62109	   -­‐3.2	   ILMN_221114	  
C230009C22Rik	   55.37031	   17.25932	   -­‐3.2	   ILMN_207368	  
Mme	   301.0988	   93.7514	   -­‐3.2	   ILMN_206056	  
BC038925	   96.06147	   29.88059	   -­‐3.2	   ILMN_213504	  
C030003A18Rik	   302.6373	   93.59549	   -­‐3.2	   ILMN_203064	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Pogz	   29.03939	   8.978961	   -­‐3.2	   ILMN_229041	  
scl0002007.1_97	   175.2955	   54.08537	   -­‐3.2	   ILMN_191549	  
ENSMUSG00000074822	   36.00861	   11.10246	   -­‐3.2	   ILMN_206176	  
Pdk1	   111.1515	   34.23186	   -­‐3.2	   ILMN_214993	  
P2rx5	   164.3631	   50.51679	   -­‐3.3	   ILMN_221894	  
Dlk2	   427.0789	   131.1975	   -­‐3.3	   ILMN_218738	  
2310014F06Rik	   72.20573	   22.17144	   -­‐3.3	   ILMN_192976	  
Bicc1	   2458.86	   754.8414	   -­‐3.3	   ILMN_215610	  
Col6a1	   7706.899	   2365.454	   -­‐3.3	   ILMN_208779	  
5430414B19Rik	   53.47944	   16.41045	   -­‐3.3	   ILMN_196359	  
Sipa1l2	   166.2525	   50.96694	   -­‐3.3	   ILMN_223616	  
Tlcd1	   380.4151	   116.6059	   -­‐3.3	   ILMN_212241	  
Zhx2	   193.4011	   59.15037	   -­‐3.3	   ILMN_195577	  
Slc24a3	   1891.465	   578.3742	   -­‐3.3	   ILMN_220855	  
Prrx1	   126.8333	   38.78068	   -­‐3.3	   ILMN_252720	  
Klhl17	   834.7981	   254.4461	   -­‐3.3	   ILMN_209660	  
Thbs2	   3580.359	   1088.005	   -­‐3.3	   ILMN_213253	  
Otx1	   710.0976	   215.7306	   -­‐3.3	   ILMN_217984	  
C130057N11Rik	   179.8773	   54.62923	   -­‐3.3	   ILMN_190624	  
2700063P19Rik	   226.4756	   68.57703	   -­‐3.3	   ILMN_202082	  
B230312E02Rik	   180.925	   54.76945	   -­‐3.3	   ILMN_206789	  
Itgb4	   58.42581	   17.64483	   -­‐3.3	   ILMN_213200	  
Hlx	   313.1851	   94.50337	   -­‐3.3	   ILMN_213507	  
Hist1h2ae	   57.19297	   17.21672	   -­‐3.3	   ILMN_196748	  
6430407L02Rik	   282.5469	   84.88407	   -­‐3.3	   ILMN_203250	  
1700025G04Rik	   269.3204	   80.72125	   -­‐3.3	   ILMN_216343	  
Zfp316	   103.5618	   31.0323	   -­‐3.3	   ILMN_184408	  
Hexdc	   303.8002	   90.96548	   -­‐3.3	   ILMN_241904	  
Map3k1	   285.8687	   85.50298	   -­‐3.3	   ILMN_211294	  
Esco2	   359.0276	   107.1411	   -­‐3.4	   ILMN_208759	  
9330177P20Rik	   358.2766	   106.8308	   -­‐3.4	   ILMN_195505	  
Tapbp	   71.2259	   21.22718	   -­‐3.4	   ILMN_213284	  
Pltp	   105.1166	   31.30003	   -­‐3.4	   ILMN_208776	  
Spry3	   120.7332	   35.88885	   -­‐3.4	   ILMN_253053	  
C130040J23Rik	   277.2737	   82.07254	   -­‐3.4	   ILMN_192554	  
D930007N19Rik	   75.41334	   22.29677	   -­‐3.4	   ILMN_195777	  
Tnfrsf4	   62.56816	   18.49527	   -­‐3.4	   ILMN_187722	  
Scube3	   334.1714	   98.56088	   -­‐3.4	   ILMN_249967	  
Aak1	   41.24004	   12.14643	   -­‐3.4	   ILMN_254339	  
Rpl22	   2970.654	   874.1182	   -­‐3.4	   ILMN_215417	  
Dok3	   126.6829	   37.20255	   -­‐3.4	   ILMN_217284	  
Polg2	   119.163	   34.95186	   -­‐3.4	   ILMN_228682	  
LOC100039623	   49.54964	   14.53228	   -­‐3.4	   ILMN_196792	  
Letmd1	   740.5508	   217.1092	   -­‐3.4	   ILMN_211469	  
Sbsn	   67.79766	   19.62374	   -­‐3.5	   ILMN_216457	  
Tuba4a	   50.09013	   14.47289	   -­‐3.5	   ILMN_195615	  
Cxcr7	   109.6363	   31.66273	   -­‐3.5	   ILMN_217785	  
Clip4	   154.9312	   44.6416	   -­‐3.5	   ILMN_193898	  
2610029K11Rik	   71.20475	   20.46325	   -­‐3.5	   ILMN_189412	  
Rab28	   4764.253	   1369.139	   -­‐3.5	   ILMN_196462	  
Arhgdig	   487.7996	   139.3873	   -­‐3.5	   ILMN_220986	  
EG433229	   6663.32	   1903.48	   -­‐3.5	   ILMN_215511	  
Suv420h1	   240.3018	   68.48883	   -­‐3.5	   ILMN_186777	  
Mboat1	   1030.688	   292.6428	   -­‐3.5	   ILMN_209663	  
Pdxp	   893.0643	   253.4111	   -­‐3.5	   ILMN_219636	  
Ramp2	   302.8783	   85.91326	   -­‐3.5	   ILMN_215597	  
Lnx2	   396.9727	   112.3743	   -­‐3.5	   ILMN_209763	  
Rnf207	   38.87628	   11.0043	   -­‐3.5	   ILMN_196652	  
Ankrd28	   389.287	   109.8226	   -­‐3.5	   ILMN_187988	  
Sfrp1	   2983.888	   839.7314	   -­‐3.6	   ILMN_210306	  
Tmem53	   416.5225	   117.0727	   -­‐3.6	   ILMN_215216	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4922503N01Rik	   150.7895	   42.37249	   -­‐3.6	   ILMN_210268	  
5430426F23Rik	   64.01309	   17.91711	   -­‐3.6	   ILMN_205677	  
Samd1	   83.52781	   23.26606	   -­‐3.6	   ILMN_211130	  
BC016495	   88.67927	   24.68978	   -­‐3.6	   ILMN_216548	  
D17H6S56E-­‐5	   78.48188	   21.82955	   -­‐3.6	   ILMN_196579	  
Shd	   44.71228	   12.38441	   -­‐3.6	   ILMN_236512	  
scl0003799.1_2	   1751.105	   483.5699	   -­‐3.6	   ILMN_186828	  
Tmem179b	   709.0638	   195.7274	   -­‐3.6	   ILMN_215148	  
Ccdc9	   39.60387	   10.90828	   -­‐3.6	   ILMN_216266	  
Csf2ra	   72.7596	   20.0078	   -­‐3.6	   ILMN_211976	  
Mreg	   51.29582	   14.06098	   -­‐3.6	   ILMN_253687	  
Grem1	   383.5378	   105.0664	   -­‐3.7	   ILMN_213216	  
LOC333331	   80.17326	   21.9444	   -­‐3.7	   ILMN_215850	  
Itga2b	   96.77187	   26.40188	   -­‐3.7	   ILMN_221217	  
C130002N06	   73.85911	   20.10927	   -­‐3.7	   ILMN_186859	  
Lrrc17	   286.5811	   78.02413	   -­‐3.7	   ILMN_194980	  
Col17a1	   52.21601	   14.13935	   -­‐3.7	   ILMN_221356	  
Slc43a1	   167.063	   45.18572	   -­‐3.7	   ILMN_193227	  
Ccl27	   151.1404	   40.78555	   -­‐3.7	   ILMN_216432	  
Tmem119	   438.8438	   117.817	   -­‐3.7	   ILMN_219443	  
Tasp1	   54.61119	   14.65575	   -­‐3.7	   ILMN_219832	  
Emp2	   1888.514	   505.6946	   -­‐3.7	   ILMN_209674	  
2810021B07Rik	   211.2101	   56.50565	   -­‐3.7	   ILMN_210854	  
Il1rn	   662.9731	   176.613	   -­‐3.8	   ILMN_217380	  
Slc27a6	   52.67462	   14.02646	   -­‐3.8	   ILMN_214291	  
Hsf4	   61.30737	   16.32078	   -­‐3.8	   ILMN_222242	  
Zfp825	   49.34717	   13.02571	   -­‐3.8	   ILMN_220879	  
Map3k6	   131.917	   34.81593	   -­‐3.8	   ILMN_233949	  
Nme3	   316.575	   83.4649	   -­‐3.8	   ILMN_222087	  
Tlr2	   375.3636	   98.61851	   -­‐3.8	   ILMN_221308	  
B430305P08Rik	   212.8502	   55.8018	   -­‐3.8	   ILMN_196622	  
Acss2	   175.2679	   45.83664	   -­‐3.8	   ILMN_216644	  
D730003I15Rik	   46.2605	   12.06949	   -­‐3.8	   ILMN_195420	  
Epdr1	   3530.29	   919.6412	   -­‐3.8	   ILMN_214840	  
Map4k2	   202.8405	   52.68924	   -­‐3.8	   ILMN_188020	  
Samd10	   107.2754	   27.76465	   -­‐3.9	   ILMN_215170	  
4932408C11Rik	   216.0285	   55.87397	   -­‐3.9	   ILMN_203468	  
Mapk8ip1	   127.7168	   33.00172	   -­‐3.9	   ILMN_223186	  
LOC226017	   954.3906	   246.1977	   -­‐3.9	   ILMN_198408	  
Rgs17	   550.531	   141.7143	   -­‐3.9	   ILMN_187084	  
Tap2	   94.12442	   24.12951	   -­‐3.9	   ILMN_217715	  
LOC433943	   255.2281	   65.26745	   -­‐3.9	   ILMN_198112	  
C230043G09Rik	   915.9519	   233.9937	   -­‐3.9	   ILMN_205959	  
D930042A21Rik	   69.27411	   17.68757	   -­‐3.9	   ILMN_206876	  
Zfp817	   71.65195	   18.29189	   -­‐3.9	   ILMN_243422	  
Ppm2c	   117.0272	   29.82523	   -­‐3.9	   ILMN_261727	  
0610040B10Rik	   104.2708	   26.44995	   -­‐3.9	   ILMN_215673	  
D230048P18Rik	   110.7031	   28.06521	   -­‐3.9	   ILMN_206055	  
Cd248	   1559.326	   395.1964	   -­‐3.9	   ILMN_216345	  
2410008K03Rik	   259.9987	   65.70718	   -­‐4.0	   ILMN_223117	  
Itpk1	   88.74877	   22.33282	   -­‐4.0	   ILMN_220572	  
E130014J05Rik	   71.25277	   17.89008	   -­‐4.0	   ILMN_189509	  
Stmn2	   65.94501	   16.52906	   -­‐4.0	   ILMN_210469	  
Rpgrip1l	   189.9234	   47.56342	   -­‐4.0	   ILMN_221013	  
Glrx1	   2839.261	   709.8499	   -­‐4.0	   ILMN_224227	  
AI747699	   96.80217	   24.0925	   -­‐4.0	   ILMN_258552	  
2310001H17Rik	   102.5508	   25.52005	   -­‐4.0	   ILMN_213451	  
Hps6	   192.1075	   47.74895	   -­‐4.0	   ILMN_223360	  
Syn1	   252.9124	   62.79257	   -­‐4.0	   ILMN_222720	  
Recql4	   199.7906	   49.37078	   -­‐4.0	   ILMN_211352	  
Cfi	   59.32181	   14.64562	   -­‐4.1	   ILMN_212927	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8030402P03Rik	   703.345	   173.1073	   -­‐4.1	   ILMN_207113	  
C1qtnf6	   128.8834	   31.67092	   -­‐4.1	   ILMN_221628	  
C920004C08Rik	   220.3085	   54.055	   -­‐4.1	   ILMN_190891	  
Sobp	   145.8139	   35.56796	   -­‐4.1	   ILMN_192584	  
Mustn1	   424.0905	   103.2088	   -­‐4.1	   ILMN_215350	  
Ifi27	   69.35394	   16.84204	   -­‐4.1	   ILMN_184190	  
Tle2	   1280.361	   310.7886	   -­‐4.1	   ILMN_184889	  
Sv2a	   38.79099	   9.414949	   -­‐4.1	   ILMN_218994	  
Angptl6	   53.96983	   13.05633	   -­‐4.1	   ILMN_214036	  
Pcdhb22	   333.9556	   80.32935	   -­‐4.2	   ILMN_213754	  
Ltbp4	   562.2674	   135.1103	   -­‐4.2	   ILMN_208840	  
Sepp1	   164.1141	   39.32566	   -­‐4.2	   ILMN_217349	  
Cml1	   63.8477	   15.29464	   -­‐4.2	   ILMN_221685	  
Ptp4a3	   136.8153	   32.74582	   -­‐4.2	   ILMN_213418	  
D15Bwg0759e	   303.4806	   72.23535	   -­‐4.2	   ILMN_195654	  
1810062O18Rik	   80.02505	   19.02348	   -­‐4.2	   ILMN_192867	  
D930015E06Rik	   357.1513	   84.12836	   -­‐4.2	   ILMN_208662	  
S100a4	   492.1362	   115.6567	   -­‐4.3	   ILMN_221174	  
A430106B04Rik	   106.5604	   24.95858	   -­‐4.3	   ILMN_203048	  
EG638695	   118.4819	   27.4859	   -­‐4.3	   ILMN_257853	  
Nt5dc2	   3195.979	   736.9973	   -­‐4.3	   ILMN_215517	  
Acadm	   6587.83	   1506.211	   -­‐4.4	   ILMN_227083	  
4933436C20Rik	   164.0848	   37.40826	   -­‐4.4	   ILMN_210320	  
Lgals3bp	   2344.197	   533.7465	   -­‐4.4	   ILMN_209135	  
1200016E24Rik	   92.13522	   20.97804	   -­‐4.4	   ILMN_191167	  
LOC223672	   88.5661	   20.02322	   -­‐4.4	   ILMN_216469	  
2610307O08Rik	   196.201	   44.13772	   -­‐4.4	   ILMN_221480	  
Ift80	   121.3162	   27.2909	   -­‐4.4	   ILMN_220633	  
1700027N10Rik	   133.2828	   29.94068	   -­‐4.5	   ILMN_242897	  
Bcl3	   176.5321	   39.59875	   -­‐4.5	   ILMN_222447	  
Fbln1	   591.2425	   132.433	   -­‐4.5	   ILMN_188080	  
LOC380844	   215.6401	   48.17661	   -­‐4.5	   ILMN_197188	  
Trpc2	   100.2522	   22.37511	   -­‐4.5	   ILMN_192626	  
Hoxb7	   1917.568	   427.6057	   -­‐4.5	   ILMN_211288	  
1810062G17Rik	   198.0838	   43.70291	   -­‐4.5	   ILMN_208903	  
Sult2b1	   51.21893	   11.29793	   -­‐4.5	   ILMN_217684	  
LOC100038894	   585.8642	   128.6927	   -­‐4.6	   ILMN_196719	  
Irx3	   1654.412	   363.0829	   -­‐4.6	   ILMN_224225	  
Slc2a6	   127.9485	   28.07224	   -­‐4.6	   ILMN_211726	  
Slpi	   292.1718	   64.00404	   -­‐4.6	   ILMN_219640	  
9030425E11Rik	   190.2837	   41.6839	   -­‐4.6	   ILMN_189630	  
5430411C19Rik	   88.68565	   19.18629	   -­‐4.6	   ILMN_193294	  
Cd9	   3428.769	   734.9481	   -­‐4.7	   ILMN_220691	  
Spon2	   1440.58	   307.9263	   -­‐4.7	   ILMN_223108	  
5730409K12Rik	   94.96428	   20.10878	   -­‐4.7	   ILMN_193516	  
HIP-­‐1	   54.45347	   11.51115	   -­‐4.7	   ILMN_206964	  
Zfpm2	   493.7007	   103.8086	   -­‐4.8	   ILMN_195765	  
A930026I22Rik	   140.8073	   29.59997	   -­‐4.8	   ILMN_188757	  
Cnksr3	   152.7074	   32.09559	   -­‐4.8	   ILMN_222298	  
Sord	   331.1094	   69.54982	   -­‐4.8	   ILMN_223021	  
Supt16h	   928.9438	   194.0957	   -­‐4.8	   ILMN_223539	  
Wnt5b	   311.056	   64.8243	   -­‐4.8	   ILMN_191856	  
1700081H05Rik	   109.4135	   22.76836	   -­‐4.8	   ILMN_196392	  
Gstm1	   643.9881	   133.9432	   -­‐4.8	   ILMN_212441	  
Bcl2l11	   300.0225	   61.96204	   -­‐4.8	   ILMN_208904	  
AB112350	   101.7023	   20.98958	   -­‐4.8	   ILMN_211687	  
Angpt4	   74.65689	   15.36233	   -­‐4.9	   ILMN_222129	  
Cd14	   181.7816	   37.22334	   -­‐4.9	   ILMN_221922	  
Ntn2l	   148.5249	   30.34522	   -­‐4.9	   ILMN_210119	  
Exoc3l	   119.4873	   24.35279	   -­‐4.9	   ILMN_218843	  
Sema5a	   42.51192	   8.663857	   -­‐4.9	   ILMN_204130	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Stk3	   49.79597	   10.1136	   -­‐4.9	   ILMN_206738	  
Mlkl	   178.1503	   35.9819	   -­‐5.0	   ILMN_194213	  
Ssh3	   266.1504	   53.6825	   -­‐5.0	   ILMN_214682	  
4632417K18Rik	   918.9	   185.114	   -­‐5.0	   ILMN_220188	  
Mycl1	   222.6399	   44.67434	   -­‐5.0	   ILMN_213909	  
Ppm1l	   162.824	   32.45504	   -­‐5.0	   ILMN_184575	  
Hoxb5	   405.5818	   80.26199	   -­‐5.1	   ILMN_213971	  
Ankrd47	   132.1799	   26.12701	   -­‐5.1	   ILMN_221468	  
Muc1	   57.11061	   11.27767	   -­‐5.1	   ILMN_208888	  
5031425E22Rik	   236.1068	   46.07572	   -­‐5.1	   ILMN_222309	  
S3-­‐12	   1460.003	   284.779	   -­‐5.1	   ILMN_208656	  
4930572J05Rik	   289.8939	   55.32214	   -­‐5.2	   ILMN_219117	  
2310076O14Rik	   154.1566	   29.28517	   -­‐5.3	   ILMN_221888	  
C230098O21Rik	   84.13457	   15.91922	   -­‐5.3	   ILMN_184645	  
Gch1	   49.68622	   9.39511	   -­‐5.3	   ILMN_210506	  
Tmem35	   95.53104	   17.98076	   -­‐5.3	   ILMN_188922	  
Abi3bp	   504.459	   94.72248	   -­‐5.3	   ILMN_212813	  
Lrp4	   564.1052	   105.4323	   -­‐5.4	   ILMN_213961	  
3110070M22Rik	   73.05151	   13.64733	   -­‐5.4	   ILMN_218458	  
5730593F17Rik	   136.6469	   25.4998	   -­‐5.4	   ILMN_223419	  
Pcsk4	   44.60275	   8.322991	   -­‐5.4	   ILMN_212743	  
Gdf1	   314.7358	   58.42004	   -­‐5.4	   ILMN_214494	  
Slc7a7	   44.15223	   8.125346	   -­‐5.4	   ILMN_217989	  
S100a1	   2225.106	   407.0105	   -­‐5.5	   ILMN_214542	  
OTTMUSG00000010673	   293.4787	   53.36362	   -­‐5.5	   ILMN_228043	  
Vit	   633.0846	   113.7882	   -­‐5.6	   ILMN_191294	  
1500005N04Rik	   283.4388	   50.68332	   -­‐5.6	   ILMN_202497	  
Lbp	   466.5725	   82.02612	   -­‐5.7	   ILMN_223901	  
Il13ra1	   823.1803	   144.6002	   -­‐5.7	   ILMN_216227	  
Fmnl2	   1005.092	   175.9994	   -­‐5.7	   ILMN_215164	  
3110021A11Rik	   136.0923	   23.69496	   -­‐5.7	   ILMN_189769	  
H2-­‐DMa	   182.8962	   31.70216	   -­‐5.8	   ILMN_224639	  
Aldh3b1	   636.8285	   109.9207	   -­‐5.8	   ILMN_214234	  
Cln3	   199.2089	   34.11724	   -­‐5.8	   ILMN_220100	  
Rbm14	   99.4691	   17.0183	   -­‐5.8	   ILMN_204298	  
Cyp4v3	   456.1019	   77.36152	   -­‐5.9	   ILMN_222960	  
Aoc3	   774.609	   130.758	   -­‐5.9	   ILMN_203969	  
A730040I05Rik	   174.1803	   29.34691	   -­‐5.9	   ILMN_205840	  
Cenpp	   567.4822	   95.17678	   -­‐6.0	   ILMN_222261	  
Rgs9bp	   73.8065	   12.24271	   -­‐6.0	   ILMN_217635	  
Ager	   183.1248	   30.2821	   -­‐6.0	   ILMN_210862	  
Map3k8	   103.0053	   17.02335	   -­‐6.1	   ILMN_204712	  
Mad2l2	   199.2484	   32.72016	   -­‐6.1	   ILMN_219303	  
Ppargc1b	   104.2315	   17.06873	   -­‐6.1	   ILMN_223929	  
Mylk	   789.2093	   128.524	   -­‐6.1	   ILMN_190234	  
EG623230	   1474.634	   239.2042	   -­‐6.2	   ILMN_186051	  
Clec2d	   484.4626	   77.99601	   -­‐6.2	   ILMN_210243	  
9430064K01Rik	   256.6933	   41.17949	   -­‐6.2	   ILMN_192598	  
C230066H01Rik	   67.49267	   10.8124	   -­‐6.2	   ILMN_206723	  
Kcnh2	   116.1785	   18.55562	   -­‐6.3	   ILMN_213233	  
Entpd2	   123.2936	   19.69098	   -­‐6.3	   ILMN_215332	  
Egr3	   323.6744	   51.49716	   -­‐6.3	   ILMN_195299	  
Smarca1	   1148.928	   182.7624	   -­‐6.3	   ILMN_209637	  
Dlg7	   284.9103	   45.2245	   -­‐6.3	   ILMN_214861	  
Vcam1	   121.1164	   19.12282	   -­‐6.3	   ILMN_202787	  
6720477C19Rik	   540.2004	   84.75518	   -­‐6.4	   ILMN_185354	  
Ccl7	   1192.973	   187.1649	   -­‐6.4	   ILMN_223895	  
Aldh3a1	   544.4032	   84.92189	   -­‐6.4	   ILMN_223471	  
1190007F08Rik	   464.1748	   72.40321	   -­‐6.4	   ILMN_232083	  
Phf21b	   105.7302	   16.4435	   -­‐6.4	   ILMN_214807	  
LOC381739	   1506.708	   230.8535	   -­‐6.5	   ILMN_200488	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Rhou	   1064.165	   163.0326	   -­‐6.5	   ILMN_215476	  
Lrrc8d	   659.3508	   100.7718	   -­‐6.5	   ILMN_223609	  
Cda	   237.0583	   36.12019	   -­‐6.6	   ILMN_220880	  
2810423A18Rik	   1661.572	   252.6184	   -­‐6.6	   ILMN_186667	  
Susd2	   160.2677	   24.12811	   -­‐6.6	   ILMN_219457	  
Rasl11a	   1649.947	   247.4422	   -­‐6.7	   ILMN_225258	  
Ccl2	   160.9719	   24.10948	   -­‐6.7	   ILMN_211411	  
Calml4	   232.4484	   34.68931	   -­‐6.7	   ILMN_212718	  
D830050E09Rik	   103.7771	   15.4724	   -­‐6.7	   ILMN_205110	  
Gsdmdc1	   233.5528	   34.74226	   -­‐6.7	   ILMN_222389	  
Cables1	   391.4229	   57.35958	   -­‐6.8	   ILMN_216355	  
Slc1a3	   1467.349	   214.9821	   -­‐6.8	   ILMN_213165	  
Ang	   350.5417	   51.157	   -­‐6.9	   ILMN_244375	  
Psmb8	   143.7287	   20.80076	   -­‐6.9	   ILMN_185344	  
Socs3	   1826.607	   263.8726	   -­‐6.9	   ILMN_211651	  
Slc25a45	   490.2873	   70.34534	   -­‐7.0	   ILMN_220462	  
Pacs1	   218.8533	   31.26811	   -­‐7.0	   ILMN_220552	  
Twist2	   1197.49	   170.6341	   -­‐7.0	   ILMN_186022	  
Dkk3	   1015.621	   144.5972	   -­‐7.0	   ILMN_219132	  
6330414G02Rik	   1288.185	   182.0019	   -­‐7.1	   ILMN_193331	  
Cdkl2	   171.6058	   24.16768	   -­‐7.1	   ILMN_211931	  
Mapk13	   103.4825	   14.52988	   -­‐7.1	   ILMN_209546	  
Mt1	   12416.66	   1725.369	   -­‐7.2	   ILMN_209514	  
Tgfbi	   2841.483	   394.0177	   -­‐7.2	   ILMN_192154	  
Igsf10	   291.3417	   40.38636	   -­‐7.2	   ILMN_187617	  
A230005G17Rik	   139.6336	   19.16831	   -­‐7.3	   ILMN_205324	  
Gstm4	   140.2984	   19.24629	   -­‐7.3	   ILMN_220200	  
LOC638301	   199.7959	   27.34194	   -­‐7.3	   ILMN_186725	  
Tspan17	   1277.231	   174.4811	   -­‐7.3	   ILMN_208788	  
Aatk	   126.6958	   17.30565	   -­‐7.3	   ILMN_221321	  
Tshz3	   871.5295	   118.3936	   -­‐7.4	   ILMN_194436	  
Edg2	   253.0988	   33.93119	   -­‐7.5	   ILMN_224105	  
Parp8	   279.3118	   37.18604	   -­‐7.5	   ILMN_209706	  
Brp17	   715.2197	   94.842	   -­‐7.5	   ILMN_213275	  
H1f0	   143.9181	   18.5612	   -­‐7.8	   ILMN_222971	  
Net1	   116.2877	   14.72615	   -­‐7.9	   ILMN_187922	  
1700029G01Rik	   195.8975	   24.67467	   -­‐7.9	   ILMN_221884	  
Serpina3n	   1408.404	   176.5648	   -­‐8.0	   ILMN_222516	  
Sncg	   79.90771	   9.994639	   -­‐8.0	   ILMN_209715	  
Elovl4	   129.0072	   16.01648	   -­‐8.1	   ILMN_223323	  
Fbxo44	   116.8509	   14.50542	   -­‐8.1	   ILMN_223033	  
Ube1l	   341.9855	   42.31841	   -­‐8.1	   ILMN_192098	  
scl0002507.1_236	   967.5753	   119.2388	   -­‐8.1	   ILMN_193522	  
Scd1	   1710.462	   209.7351	   -­‐8.2	   ILMN_218062	  
2600010E01Rik	   103.2605	   12.602	   -­‐8.2	   ILMN_222950	  
H2-­‐Q7	   42.77068	   5.219112	   -­‐8.2	   ILMN_196751	  
Itih2	   409.1718	   49.86595	   -­‐8.2	   ILMN_216672	  
Htra1	   1517.907	   183.1698	   -­‐8.3	   ILMN_222238	  
D630040I23Rik	   255.7581	   30.80201	   -­‐8.3	   ILMN_193224	  
Col6a2	   3466.582	   414.9943	   -­‐8.4	   ILMN_216544	  
Acy3	   178.3488	   21.1849	   -­‐8.4	   ILMN_220901	  
E130102H24Rik	   129.4637	   15.03233	   -­‐8.6	   ILMN_214408	  
Odz4	   124.4277	   14.38235	   -­‐8.7	   ILMN_194814	  
Gchfr	   243.5134	   27.7866	   -­‐8.8	   ILMN_215064	  
Ndrl	   1494.107	   168.7862	   -­‐8.9	   ILMN_214267	  
Lyz	   333.0328	   37.26352	   -­‐8.9	   ILMN_218930	  
Gpha2	   117.2885	   12.80067	   -­‐9.2	   ILMN_211491	  
Olfm1	   127.7846	   13.83351	   -­‐9.2	   ILMN_212106	  
Ogn	   2323.883	   250.3238	   -­‐9.3	   ILMN_220162	  
Rnf144a	   250.3409	   26.52234	   -­‐9.4	   ILMN_217013	  
LOC100046518	   190.1332	   20.13372	   -­‐9.4	   ILMN_221629	  
 253 
Icam1	   203.987	   20.73097	   -­‐9.8	   ILMN_221313	  
2310039E09Rik	   163.7812	   16.57272	   -­‐9.9	   ILMN_211197	  
Pcp4l1	   656.2724	   66.22733	   -­‐9.9	   ILMN_203100	  
St6galnac2	   1688.984	   167.5566	   -­‐10.1	   ILMN_201528	  
Hapln4	   440.497	   43.46132	   -­‐10.1	   ILMN_208828	  
2810405K02Rik	   219.7994	   20.9408	   -­‐10.5	   ILMN_220895	  
5330431K02Rik	   939.2208	   88.20355	   -­‐10.6	   ILMN_219563	  
C1qdc2	   738.8486	   68.31789	   -­‐10.8	   ILMN_214190	  
Cbx7	   170.1508	   15.60744	   -­‐10.9	   ILMN_219110	  
6720458D17Rik	   459.7479	   41.88677	   -­‐11.0	   ILMN_187288	  
Col14a1	   426.9518	   38.45116	   -­‐11.1	   ILMN_203320	  
Ccno	   229.3811	   20.56048	   -­‐11.2	   ILMN_221503	  
Arhgef3	   473.7351	   42.0942	   -­‐11.3	   ILMN_214179	  
Wnt4	   173.0376	   14.91518	   -­‐11.6	   ILMN_195108	  
LOC268828	   203.6957	   17.31733	   -­‐11.8	   ILMN_197760	  
Plekhg4	   420.4597	   33.63264	   -­‐12.5	   ILMN_220732	  
Gstt1	   1954.227	   150.2489	   -­‐13.0	   ILMN_217226	  
2210016F16Rik	   174.9863	   13.3278	   -­‐13.1	   ILMN_218530	  
Ppp1r3c	   1909.399	   144.8433	   -­‐13.2	   ILMN_216078	  
Scara5	   3424.242	   257.0929	   -­‐13.3	   ILMN_222294	  
Slc27a3	   256.2712	   18.31193	   -­‐14.0	   ILMN_222312	  
Crip2	   2657.361	   187.6231	   -­‐14.2	   ILMN_219558	  
Dio3	   353.993	   24.98933	   -­‐14.2	   ILMN_223923	  
Camk2n1	   302.0564	   20.83071	   -­‐14.5	   ILMN_254160	  
Wif1	   460.5247	   31.27604	   -­‐14.7	   ILMN_194714	  
H2-­‐K1	   102.4962	   6.769175	   -­‐15.1	   ILMN_208622	  
Olfml3	   1562.581	   99.81375	   -­‐15.7	   ILMN_219432	  
scl0002702.1_3805	   574.9486	   35.83515	   -­‐16.0	   ILMN_195541	  
Lgals3	   4300.176	   264.7988	   -­‐16.2	   ILMN_222956	  
Tnnt1	   438.6359	   26.73763	   -­‐16.4	   ILMN_189308	  
Ndrg1	   757.7451	   46.11279	   -­‐16.4	   ILMN_223174	  
Anpep	   368.9018	   22.38591	   -­‐16.5	   ILMN_208800	  
Chi3l1	   1127.408	   67.26659	   -­‐16.8	   ILMN_210847	  
Nnmt	   896.3633	   53.12735	   -­‐16.9	   ILMN_201751	  
Oplah	   287.9391	   17.04069	   -­‐16.9	   ILMN_215664	  
BC028528	   438.6346	   25.89315	   -­‐16.9	   ILMN_215178	  
Smpdl3b	   1608.293	   88.98137	   -­‐18.1	   ILMN_210171	  
Ggt7	   347.264	   19.15092	   -­‐18.1	   ILMN_210362	  
LOC674135	   481.4417	   24.97606	   -­‐19.3	   ILMN_220727	  
Gng13	   590.0897	   30.56078	   -­‐19.3	   ILMN_211395	  
Mmp23	   494.2267	   24.70391	   -­‐20.0	   ILMN_215522	  
Avil	   221.6535	   11.06891	   -­‐20.0	   ILMN_222666	  
Macrod1	   567.7158	   28.2387	   -­‐20.1	   ILMN_217502	  
Pla1a	   163.5443	   7.981448	   -­‐20.5	   ILMN_236152	  
Igf2	   1182.897	   56.26129	   -­‐21.0	   ILMN_209642	  
Egfl7	   835.6354	   38.93021	   -­‐21.5	   ILMN_207457	  
Cd59a	   570.6747	   26.14909	   -­‐21.8	   ILMN_214646	  
Akp2	   653.2094	   29.12788	   -­‐22.4	   ILMN_215583	  
Cd82	   989.0947	   39.5298	   -­‐25.0	   ILMN_222273	  
Pdlim4	   3915.495	   146.2634	   -­‐26.8	   ILMN_210491	  
Hp	   1439.596	   50.07777	   -­‐28.7	   ILMN_214144	  
Smoc1	   753.7094	   25.70373	   -­‐29.3	   ILMN_211655	  
C3	   1176.613	   39.85423	   -­‐29.5	   ILMN_223109	  
Lcn2	   1287.872	   41.67941	   -­‐30.9	   ILMN_219674	  
Mfap2	   270.3965	   8.334862	   -­‐32.4	   ILMN_209358	  
Aqp1	   2872.172	   85.4954	   -­‐33.6	   ILMN_216314	  
Pdgfra	   455.4812	   13.14808	   -­‐34.6	   ILMN_212227	  
LOC100045864	   3981.891	   111.8958	   -­‐35.6	   ILMN_196741	  
Capn6	   1363.685	   37.21738	   -­‐36.6	   ILMN_218388	  
Hoxb6	   979.7885	   22.98364	   -­‐42.6	   ILMN_216818	  
H2-­‐D1	   1887.698	   44.122	   -­‐42.8	   ILMN_196741	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Emilin2	   1951.222	   42.77086	   -­‐45.6	   ILMN_250777	  
Gsta4	   528.7911	   11.1307	   -­‐47.5	   ILMN_216097	  
Fbxo2	   1691.625	   33.10698	   -­‐51.1	   ILMN_212537	  
5430433G21Rik	   2827.351	   46.44001	   -­‐60.9	   ILMN_220885	  
Mgst2	   1925.706	   31.26836	   -­‐61.6	   ILMN_211231	  
Serping1	   1084.449	   14.94927	   -­‐72.5	   ILMN_256713	  
Igfbp4	   5869.105	   79.47958	   -­‐73.8	   ILMN_210225	  
Cpxm1	   1485.039	   17.4844	   -­‐84.9	   ILMN_214237	  
Chst1	   1483.803	   17.43739	   -­‐85.1	   ILMN_222161	  
Pcdh21	   1577.516	   17.22009	   -­‐91.6	   ILMN_216921	  


























Supplementary	  Figure.	  5.1.	  Significant	  protein	  clusters	  of	  misregulated	  transcripts	  from	  
the	  virus	   transformed	  Mbd4-­‐/-­‐	  MEFs	  by	   IPA	  network	  analysis.	   (A)	  Cellular	  Movement,	  
DNA	   Replication	   (Growth	   hormones	   related	   transcriptional	   regulation).	   (B)	   Cellular	  
Movement,	  Cellular	  Growth	  and	  Proliferation	  (Collagen	  induced	  and	  NFkB	  associated).	  
(C)	   Endocrine	   System	  Development	   and	   Function	   (Type	   II	   nuclear	   receptor	   RXR	   and	  
retinoic	   acid	   associated).	   (D)	   Cellular	   Development,	   Cellular	   Assembly	   and	  
Organization	   (Type	   II	   non-­‐steroid	   nuclear	   receptor	   VDR	   related)	   	   (E)	   Cancer,	  
Reproductive	  System	  Disease,	  Renal	   and	  Urological	  Disease	   (Steroid	  nuclear	   receptor	  
ERα	   related).	   (F)	   Cellular	   Assembly	   and	   Organization,	   Cellular	   Function	   and	  
Maintenance	   (orphan	   nuclear	   receptor	   HNF4a	   related).	   Note	   the	   proteins	   with	   red	  
(upregulation)	   or	   green	   (downregulation)	   filling	   are	   the	   candidates	   from	   my	   mis-­‐
regulation	  gene	   list;	   the	  ones	  without	   color	   filling	  are	   those	   involved	   in	   the	   indicated	  
pathway	  but	  not	   in	  my	  candidate	   list.	  The	  solid	   lines	  are	  direct	  relationships;	  and	  the	  
dotted	   lines	   are	   indirect	   relationships.	   The	   arrows	   generally	   indicate	   the	   positive	  






Supplementary	  Figure.	  6.1.	  The	  binding	   specificity	  of	   xl.MeCP2.	  Binding	  of	   the	  duplex	  
probes	   containing	   5-­‐methylcytosine	   (5mC)(left)	   or	   the	   responsive	   unmethylated	  
cytosines	  (right)	  in	  the	  context	  of	  CpG	  to	  varying	  concentrations	  of	  the	  methyl-­‐binding	  
domain	  (MBD)	  of	  (A.	  probe	  S1)	  and	  (B.	  probe	  S2)	  MeCP2	  from	  100	  to	  800	  nM;	  sequence	  
of	  duplex	   is	   seen	   in	   the	  Figure.	  The	  correct	  bands	  are	   indicated	  by	  black	  arrows.	  The	  
procedure	  of	  radioactive	  EMSAs	  is	  in	  methods.	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Sox9 y low low n y y 
Sox2 y low low y y (low) n 
Sox11 y low low n y y 
Klf4 y low low n y y 
Klf2 y low low n y y 
 
Supplementary Table 7.1 B  
SYMBOL RNAPII H3me3K9 H3me3K27 meC ACCESSION GENE_ID Species 
SOX9	   0.8625	   0.315	   1.8125	   0.3075	   NM_000346.2	   6662	   human	  
KLF4	   1.12	   0.36	   1.75	   0.435	   NM_004235.3	   9314	   human	  
KLF2	   0.3175	   0.215	   0.825	   0.6775	   NM_016270.2	   10365	   human	  
CDKN1A	   1.7925	   0.485	   1.2975	   0.515	   NM_078467.1	   1026	   human	  
SOX2	   3.3125	   	   	   0.4	   0.9575	   0.255	   NM_003106.2	   6657	   human	  
SOX11	   1.605	   0.5325	   0.5075	   0.4825	   NM_003108.3	   6664	   human	  
	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  
Sox9	   1.5775	   0.2425	   0.045	   0.34	   NM_011448	   20682	   mouse	  
Klf4	   1.66	   0.15	   0.0475	   0.2275	   NM_010637	   16600	   mouse	  
Klf2	   0.6725	   0.1075	   0.5275	   0.18	   NM_008452	   16598	   mouse	  
Cdkn1a	   1.7925	   0.2375	   0.1875	   0.445	   NM_007669	   12575	   mouse	  
Sox2	   0.055	   0.35	   0.5625	   0.9525	   NM_011443	   20674	   mouse	  
Sox11	   0.225	   0.2525	   	   0.6225	   0.4225	   Z18960	   20666	   mouse	  
	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  
Median 0.4825 0.36 0.425 0.415 	   	   human	  
0.3975	   0.2725	   0.17	   0.235	   	   	   mouse	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Supplementary	  Table	  7.1.	  The	  methylation	  statuses	  of	  some	  developmental	  genes	  that	  
are	   potential	   MBD4	   targets	   are	   usually	   low	   (yellow	   labeled).	   A.	   DNA	  methylation	   at	  
promoters	   of	   selected	   genes.	   The	   promoter	   CGIs	   were	   checked	   from	   UCSC	   browser.	  
Other	  Data	  from	  (Meissner	  et	  al.,	  2008a)	  (DNA	  methy	  meissner	  MEF)	  and	  all	  the	  others	  
are	   from	   unpublished	   data	   of	   James	   Reddington	   Thesis	   (Reddington,	   2011).	   MEF:	  
mouse	  embryonix	  fibrast;	  HELP:	  HpaII	  tiny	  fragment	  Enrichment	  by	  Ligation-­‐mediated	  
PCR.	  B.	  DNA	  methylation	  statuses	  of	  promoters	  of	  selected	  genes	  using	  (Komashko	  et	  
al.,	   2008)‘s	   data	   (Max4	   enrichment	   values	   for	   all	  marks	   in	   all	   human	   and	  mouse	   cell	  
lines).	  Briefly,	  Max4	   is	  peak	   calling	  method	   (Komashko	  et	   al.,	   2008)	   that	   a	   value	  was	  
assigned	  based	  on	  the	  highest	  mean	  of	  four	  consecutive	  probes	  in	  each	  promoter,	  then	  
obtained	   results	   were	   combined	   if	   two-­‐array	   designs	   were	   used	   (Komashko	   et	   al.,	  
2008).	  Medians	  based	  on	  all	   the	  genes	   in	  Komashko’s	  Max4	  human	  and	  mouse	   tables	  
were	  calculated,	  based	  on	  which	   low	  (yellow)	  or	  high	   (red)	  values	  were	  estimated.	   It	  
worth	  noting	  that	  almost	  all	  the	  methylated	  cytosine	  value	  at	  the	  promoter	  regions	  of	  





Supplementary	   Figure.	   7.1.	   MBD4	   and	   SOX9	   expression	   in	   primary	   breast	   tumor	  
tissues.	   (A)	   Immunohistochemistry	  using	  brown	  staining	   for	  MBD4	   in	  primary	  breast	  
tumor	   tissues	   are	   shown.	  MBD4	   is	   clearly	   expressing	   in	   both	   nuclear	   and	   cytoplasm	  
(with	   approximate	   ratio	   at	   2:1	   for	   Nuclear:cytoplasm	   expression	   in	   most	   cases,	  
unpublished	  data).	  The	  stroma	  area	   is	  clean.	   (B&C)	  AQUA	  quantitative	   image	  analysis	  
for	   (B)	  MBD4	  and	   (C)	   SOX9.	  DAPI	   counterstain	  was	  used	   to	   identify	  nuclei	   (B&C,	   top	  
left),	  pan-­‐cytokeratin	  antibody	  (epithelial	  marker)	   to	   identify	   infiltrating	   tumour	  cells	  
(B&C,	  top	  right),	  and	  Cy-­‐5–tyramide	  for	  detection	  of	  targets	  of	  (B)	  MBD4	  and	  (C)	  SOX9	  
(B&C,	  bottom	  left)	   for	  compartmentalised	  analysis	  of	   tissue	  sections.	  The	  merge	  of	  all	  
three	  stainings	  are	  shown	   in	  (B&C	  bottom	  right)	  Representative	   immunofluorescence	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